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Abstract
The principal objective o f  this research concerned the production, characterisation and 
application o f  antibodies for the specific detection o f  Listeria monocytogenes.
Monoclonal antibodies were generated against various L. monocytogenes-derived 
antigens. Initially, a panel o f  antibodies was produced against a 60 kDa extracellular 
protein isolated from exponentially growing L. monocytogenes culture supernatants. 
Subsequently, the L. monocytogenes-speclfic surface pathogenicity protein, Intemalin B 
(InlB), was biochemically isolated and used to generate InlB-specific monoclonal 
antibodies. The specific reactivity o f  these antibodies was demonstrated using purified 
recombinant InlB (rlnlB) and p60 (rp60) proteins, respectively. However, the anti-p60 
antibody was cross-reactive with certain non-pathogenic members o f  the Listeria  genus 
and the anti-InlB monoclonal antibody was not capable o f  efficiently binding InlB on the 
L. monocytogenes cell surface.
Thus, a third panel o f  monoclonal antibodies was generated using intact, formalin- 
inactivated L. monocytogenes cells as the immunogen. From this panel, a promising 
antibody was selected and shown to demonstrate improved specificity for the L. 
monocytogenes species. This antibody was further examined in order to demonstrate its 
potential application in traditional immunoassay and SPR-based biosensor formats.
The L. monocytogenes inlA gene was cloned into a compatible expression vector and 
recombinant InlA protein (rlnlA) was heterologously expressed in Escherischia coli. This 
was then used to confirm that the antibody was indeed specific for the L. monocytogenes 
pathogenicity marker, InlA. The results indicated that the anti-InlA monoclonal antibody 
produced was capable o f  specifically binding to intact L. monocytogenes cells and 
therefore, it was concluded that it could potentially be employed to facilitate more rapid, 
reliable and specific detection o f  L. monocytogenes cells.
xxvii

C h a p t e r  1
I n t r o d u c t i o n
i

1.1 Listeria monocytogenes: discovery and history
The original identification and description o f  Listeria monocytogenes is accredited to E.G.D. 
Murray, R.A Webb and M.B.R. Swann. While working in the pathology laboratories at 
Cambridge University in May 1924 Murray and co-workers undertook to investigate the 
cause o f  an outbreak o f  severe septicemic illness occurring in their laboratory rabbit 
population (Murray et ah, 1926). Post-mortem  examination revealed localised hepatic lesions 
and systemic monocytosis. A  small Gram-positive rod-shaped bacterium, (ATCC 4428, 
ATCC 15313 and NCTC 10357), was isolated from the infected rabbits and this was 
concluded to be the etiological agent. A s a result o f  the monocytotic effect o f  the disease, the 
infected hosts were observed to compensate for this by initiating a rapid and significant up- 
regulation in their monocyte gene rating activity, thus, the bacterium was named Bacterium  
monocytogenes. One year later, in Johannesburg, a similar bacterium was isolated from wild  
gerbils displaying septicemic illness, by J.H Pirie. The bacterium was named Listerella  
hepatolytica, reflecting the pathogens necrotic effect on the liver. It soon became apparent 
that the organism isolated in both the rabbit and gerbil outbreaks was one and the same. This 
prompted Pirie to re-name the bacterium Listerella monocytogenes. However, the name 
Listerella had previously been used to classify a metazoan that was frequently isolated from 
both human and animal hosts suffering from “Listerellosis” and, thus, in 1940 the genus 
Listerella was re-classified as Listeria  and the species Listerella monocytogenes was re­
named Listeria monocytogenes (Pirie, 1940).
Although only identified in 1926, the first recorded culture o f  what w e now know as L. 
monocytogenes, was actually documented in a soldier suffering from meningitis in France at 
the end o f  World War I (Dumont and Cotoni, 1921; Seeliger, 1988; McLaughlin, 1997). In 
fact, records suggest a very similar disease to listeriosis was recorded in 1891 (Gray and 
Kil linger, 1966). The first reported cases o f  human listeriosis occurred in Denmark, three 
years after Murray’s identification o f  the causal bacterium (Nyfelt, 1929).
L. monocytogenes is one o f  six species within the genus Listeria. The remainder comprise L. 
innocua, L. ivanovii, L. welshimeri, L. grayi and L. seeligeri (Seeliger and Jones, 1986). The 
genus classification has been subject to regular revision and updating. For instance, in the 
early 1970’s a new species, L. murrayi, was putatively added to the genus (Stuart and 
Welshimer, 1974). However, it was subsequently designated a subspecies o f  L. grayi (Rocourt 
et al., 1992). In addition, when L. ivanovii was first isolated in 1955, from congenitally 
infected lambs, it was classified as L. monocytogenes serotype 5 (Ivanov, 1962). It is now  
considered to comprise two divergent subspecies, L. ivanovii subsp. ivanovii and L. ivanovii
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subsp. londiensis (Boerlin el al., 1992). These are differentiated on the basis o f  the latter 
strains inability to ferment ribose.
Although it was earlier classified within the family Corynebacteriaceae, 16S rRNA 
sequencing has confirmed the genus Listeria to be taxonomically situated in the Clostridium  
sub-branch, along with Staphylococcus, Streptococcus, Lactobacillus and Brochothrix 
(Collins et al., 1991; Sallen et al., 1996). The latter o f  these is phylogenetically closest to 
Listeria  (Seeliger and Jones, 1986). Indeed this phylogenetic position o f  Listeria  is consistant 
with its low G+C content (Allerberger et al., 2002).
1.2 Bacteriology and biochemistry of Listeria
Listeria  are Gram-positive, regular short rods ranging in size from 0.4 - 0.5 |im in diameter 
and 0.5 - 2 [im in length (Seeliger and Jones, 1986). They generally exhibit motility between 
20 and 28 °C by means o f  one to five peritrichous flagella and this can be demonstrated by 
performing a hanging drop experiment at room temperature or by inoculating semi-solid 
‘motility agar’ containing 0.2 -  0.4 %  agar (Allerberger, 2002). They are both aerobic and 
facultatively aerobic (Seeliger and Jones, 1986) and when grown in motility agar, disseminate 
and demonstrate localised increased growth just below the agar surface. It appears that in this 
zone o f reduced oxygen tension, Listeria shows a better development than under either 
aerobic or strictly anaerobic conditions (Allerberger, 2002). The optimal growth temperature 
is between 30 and 37 °C although growth can occur temperatures between 1 and 45 °C, at pH 
6 - 9  and in the presence o f  up to 10 % (w/v) salt (Seeliger and Jones, 1986).
All members o f  the genus Listeria  are catalase positive. However, only L. monocytogenes, L. 
ivanovii and L. seeligeri are haemolytic. The CAMP (Christie, Atkins, Munch-Petersen) test 
(Schuchat et al., 1991a) is commonly employed to assess haemolytic patterns in Listeria. It 
uses a P-haemolysin-producing Staphylococcus aureus, and a Rhodococcus equi strain 
streaked in one direction on a sheep blood agar plate and test cultures o f  Listeria  spp. streaked 
at right angles to (but not touching), the S. aureus and R  equi lines. Haemolysis o f  L. 
monocytogenes (and to a lesser extent L. seeligeri) is enhanced in the vicinity o f  the S. aureus 
streak and L. ivanovii haemolysis is enhanced in the vicinity o f  R. equi (Allerberger, 2002). 
Problems have been described in the interpretation o f  haemolytic reactions (McLaughlin,
1997), particularly when using the CAMP test (Schuchat e t al., 1991b; Vazquez-Boland et al., 
1992; McKellar, 1994; Femandez-Garayzabal et a l ,  1996). These problems have been
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attributed to the occasional synergistic haemolytic activity between L. monocytogenes and R  
equi (Bille et al., 1999; Allerberger, 2002). In addition to the characteristic haemolytic 
patterns, each species’ ability or inability to ferment selected sugars has formed the basis for 
biochemical identification to the species level using the ‘Analytical Profile Index’, or API test 
(bioMerieux, France). The fermentation patterns exhibited by each species are outlined in 
Table 1.1. However, despite it’s widespread use, occasional discrepant results have been 
reported with the API test (Bille, 1992).
Table 1.1: Biochemical differentiation across the genus Listeria. (Adaptedfrom  Seeliger and  
Jones, 1986; Allerberger, 2002).
L. L. L. L. L. L.
monocytogenes innocua welshimeri seeligeri ivanovii1 grayi
Haemolysis + - - + + -
L-rhamose + V V - - -
D-xylose - - + + + -
a-methyl-
D-
mannoside
+ + + - - +
D-mannitol - - - - - +
CAM P test 
(S. aureus)
+ +
CAM P test 
(R. equi)
+
+: positive  
negative 
V: variable
Ribose fermenting
The L. monocytogenes species is further sub-classified by serotyping with antisera derived 
from immunised rabbits (Seeliger and Hohne, 1979). This discriminates on the basis o f  
reactivity patterns towards defined somatic (O) and flagellar (H) antigens. There are thirteen 
serotypes in total: l/2a, l/2b, l/2c, 3a, 3b, 3c, 4a, 4ab, 4b, 4c, 4d, 4e and 7 (Table 1.2). The 
serogroups 1/2 and 3 are subdivided into serovars according to their H-antigen profile, while 
the serogroup 4 serovars all contain similar H-antigen profiles and are, thus, divided into
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serovars according to their O-antigen profile (Schonberg el al., 1996). Unfortunately, certain 
serotyping antigens are also present in L. innocua, L. seeligeri and L. Welshmen. This 
significantly compromises the discriminatory power o f  serotyping, by preventing species- 
level identification. Nonetheless, serotyping serves a useful purpose for confirming the genus 
diagnosis o f  Listeria  and for allowing first-level subtyping for epidemiological purposes 
(Allerberger, 2002).
Table 1.2: Serotyping o f  L. monocytogenes according to O and H antigens. (Adapted from  
Seeliger andHdhne, 1979 and Allerberger 2003).
Serotype O-Antigens H-Antigens
I n in IV V VI VII VIII IX X XI XII XIII A B C D
l/2a • • (•) • •
l/2b • • (•) • • •
l/2c • • (•) • •
3a • (•) • • •
3b • (•) • (•) (•) • • •
3c • (•) • (•) (•) • •
4a (•) (•) • • • • •
4ab (•) • • • • • • • •
4b (•) • • • • •
4c (•) • • • • •
4d (•) (•) • • • • •
4e (•) • • (•) (•) • • •
7 (•) • • • • •
The brackets, '() ’ indicate variable interpretation o f  reactivity.
1.3 Listeriosis: pathophysiology and incidence
Listeria monocytogenes is ubiquitous in the natural environment and is frequently isolated 
from both domestic (Duggan and Phillips, 1998), and food processing (Blackman and Frank, 
1996; Gravani, 1999; Senczek et al., 2000; Silva, et al., 2003) environments. The associated 
potential for significant contamination is exacerbated by virtue o f  the organism’s ability to 
tolerate high salt concentrations (Marth, 1993; Esvan et al., 2000), acidic media (Dykes and
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Moorhead, 2000; Scott Merrel and Camili, 2002), modified atmosphere packaging (Beuchat 
and Brackett, 1990), in addition to its capacity to multiply at refrigeration temperatures 
(Walker el al., 1990).
In 2000, the Centres for Disease Control (CDC) reported that all o f  all the foodbome 
pathogens tracked by the CDC, L. monocytogenes had the second highest case fatality rate (21 
%) and the highest hospitalisation rate (90.5 %) (Anon., 2003a).
In fact, because listeriosis so often results in medical intervention, the CDC postulate that its 
‘Foodbome Active Surveillance Network’ (FoodNet) misses only half o f  all listeriosis cases, 
compared with 97 % in the case o f  other pathogens (Mead et al., 1999). Thus, when the data 
in Table 1.3 is considered, pathogens such as Cam pylobacter spp. and Salmonella spp. may 
account for as many as 50 times the number o f  Listeria infections, yet the latter still accounts 
for one third o f  the total deaths due to foodbome pathogens. It has even been suggested hat 
salmonellae may account for 500 times as many cases o f  foodbome illness, annually, with an 
associated fatality rate o f  just 0.04 % (Mead et al., 1999; Doyle, 2001). A  similar scenario is 
depicted in the UK and Denmark, where, despite the incidence o f  listeriosis between 1995 and 
1999 remaining quite low, at 1.7-2.4 cases per million head o f  population (Smeardon et al.,
2001), and 6-7 per million head o f  population (Slutsker and Schuchat, 1999), respectively, 
mortality rates were consistantly above 20 %. A recent review o f selected cases from around 
the world puts the mean incidence o f  non-pregnancy associated listeriosis at 0.1-1.1 per one 
hundred thousand head o f  population with an associated mortality o f  36 %. While, for 
pregnancy-associated listeriosis, incidence is estimated to be 0.6-4.1 per ten thousand births, 
with an associated mortality o f  33 % (Siegman-Igra e t al., 2001). This emphasises the 
alarming clinical severity o f  the pathophysiological effects o f  listeriosis.
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Table 1.3: Incidence offoodborne pathogens in USA, 2000 (Anon., 2003b).
Pathogen Infections 
(Cases per l x l 0 6 population)
Vibrio 2.1
Listeria 3.4
Yershina 4.4
E. coli 0157 .H 7 21
Shigella 79
Salmonella 144
Campylobacter 157
Total pathogens 411.6
Infection with L. monocytogenes can be categorised as invasive or non-invasive (Figure 1.1). 
Cases can be further defined as either non-pregnancy-associated, which refers to all cases in 
patients aged over one month and un-associated with pregnancy, or pregnancy-associated 
(Duggan and Phillips, 1998). The principal transmission route for infection with L. 
monocytogenes is the consumption o f  contaminated food (McLaughhlin, 1996; Schlech, 
2000). In a healthy population, consumption o f  foods contaminated with L. monocytogenes 
may cause self-limiting gastrointestinal symptoms that include fever, nausea, vomiting and 
diarrhoea (DiMaio, 2000). Gastrointestinal symptoms are observed in approximately one third 
o f documented cases o f  listeriosis (Donnelly, 2001). It is likely, however, that a significant 
proportion o f  sporadic cases o f  gastrointestinal illness due to L. monocytogenes infection go 
unreported and, are thus, unaccounted for in the epidemiological statistics. The oral bacterial 
load required to cause infection has been estimated to be greater than 1 x  104 cells (DiMaio,
2000). The relatively short median incubation time (typically 18-20 hours) between 
consumption o f contaminated food and noticeable gastrointestinal symptoms in healthy, 
immunocompetent individuals suggests that the etiologic dose is significantly higher than this 
conservative estimate. Available epidemiological data have indicated levels ranging from 106 
cells/g o f  food, to 1011 cells/ml o f  milk (Azadian et al., 1989; Juntilla and Brander, 1989; 
Dalton et al., 1997) may be necessary, which is in agreement with experimental and risk 
assessment estimates (Golnazarian et al., 1989; Farber and Peterkin, 1991; Buchanan et al., 
1997; Notermans et al., 1998; Haas et al., 1999; Lindqvist and Westoo, 2000, Anon 
WHO/FAO, 2002). It would appear from recent outbreaks that gastrointestinal symptoms 
might, in fact, represent the principal pathophysiological manifestation o f  listeriosis 
(Salamina et a l ,  1996; Miettinen et al., 1999; Aureli et al., 2000). This is acknowledged by
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calls for L. monocytogenes infection to be specifically investigated in patients presenting with 
acute gastroenteritis and diarrhoea (Jensen, 1994; Lorber, 1997).
Non-invasive Invasive
Figure 1.1: Classification o f  listeriosis in humans. The disease can be classified as ‘non- 
invasive’, which normally results in self-lim iting gastrointestinal symptoms, with no 
significant side-ejfects. Alternatively, ‘invasive’ listeriosis is a  more debilitating disease, 
which normally manifests in susceptible members o f  the population with predispositions to 
infection, such as the immunocompromised and new born infants.
onset
D isse m in a te d  in fec tio n , co m p lic a te d  s e q u a le  a n d  h igh  m orta lity
Immuno- Immuno­
competent compromised
Pregnancy-associated
/  ^
In utero Perinatal
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1.4 Infection
The precise locus o f  bacterial infection has long been debated. Undisputed however, is the 
fact that during an acute infection, multiple tissues are infected. This has also been 
demonstrated in vitro (Cossart and Mengaud, 1989). Further in v/'/ra-mediated cellular assays 
have elucidated a complex cascade o f  host-pathogen interactions that culminate in direct cell- 
to-cell dissemination (Cossart and Lecuit, 1998). Initial exposure to the pathogen generally 
occurs in the gastrointestinal tract following ingestion o f  contaminated food (Schuchat e t al., 
1991a). The infection cascade begins when the pathogen becomes internalised by host 
phagocytic cells (macrophage). L. monocytogenes can also induce its own uptake by cells that 
are not normally phagocytic (non-professional phagocytes). These include epithelial cells and 
hepatocytes. Pron and co-workers (1998) have identified a preferential site o f  early 
multiplication in the phagocytes underlying the Peyer's patches, using a novel rat model. 
Generally, invading cells are cleared rapidly via the lymph system and blood stream to the 
liver. Cells that succeed in evading the Kuppfer cells are internalised by the parenchymal cells 
(hepatocytes) where rapid intracellular replication ensues (Rogers et al., 1996; Gregory et al.,
1997).
1.4.1 Virulence factors involved in adhesion and invasion
1.4.1.1 Internalins
Phagocytic internalisation o f  L. monocytogenes occurs similar to the ‘zipper’ mechanism  
exhibited by Yershina species (Cossart and Lecuit, 1998; Frischknecht and Way, 2001). This 
involves the stimulated development o f  pathogen-accomodating protrusions in the host cell 
membrane, adjacent to the invading bacteria. It is distinct from the ‘trigger’ type pinocytosis 
exhibited during Salmonella and Shigella pathogenisis (Finlay and Ruschkowski, 1991; 
Swanson and Baer, 1995). The principle route o f  infection by L. monocytogenes is via the 
gastrointestinal tract and, more specifically, the gut wall epithelium. The ligands involved in 
the internalisation process have been suitably termed ‘intemalins’. Listeria monocytogenes 
employs two surface bound intemalins, internalin A (InlA) and internalin B (InlB), to 
promote its internalisation by non-phagocytic mammalian cells (Gaillard et al., 1991; Lingnau 
et al., 1995). InlA (also referred to, generically, as ‘internalin’) is essential for entry into 
cultured human epithelial (Caco-2) cells (Dramsi et al., 1993), whereas the 630 amino acid 
InlB protein has been shown to promote bacterial internalisation in several cultured cell types 
including, hepatocytes (Dramsi e t al., 1995; Gregory et al., 1997) and endothelial cells 
(Greiffenberg et al., 1998;Parida et a l ,  1998).
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The primary structure o f  the internalin molecules is conserved within L. monocytogenes and is 
characterised by two repeat regions separated by an inter-repeat (IR) region (Figure 1.2). InlA 
is the most ‘typical’ example o f  the complete internalin modular structure. It is 800 amino 
acids in length (Gaillard et al., 1991), and is the largest member o f  the internalin family. The 
N-terminal positively charged signal sequence is followed by a series o f  15 highly conserved 
leucine-rich repeats (LRRs). These LRR domains are a pervading feature throughout the 
internalin family o f proteins (Kajava, 1998) and normally indicate virulence association. The 
‘B ’ repeat region follows a short IR sequence and consists o f  3 successive repeats, the first 
two consist o f  70 amino acids, the third consists o f  49 amino acids, that lack the periodicity o f  
non-polar (leucine/isoleucine) residues evident in the LRR region.
The anchor structure o f  cell wall-bound InlA has been compared to a wide range o f  Gram- 
positive surface-displayed proteins (Navarre and Schneewind, 1999). The most 
comprehensively studied o f  such proteins are those expressed by Staphylococcus aureus. 
These are characterised by a C-terminal LPXTG motif (where X represents any amino acid) 
that is linked to the pentaglycine cross-bridge via the threonine (T) residue, following 
cleavage the T-G bond with the transpeptidase enzyme sortase (Ton-That et a l ,  1999). InlA 
o f L. monocytogenes produces threonine hydroxamate when treated with the strong 
nuleophile, hydroxylamine, indicating a similar T-G bond cleavage (Dhar et al., 2000). This 
transpeptidase activity covalently links the InlA protein to the /neso-diaminopimelic acid (m- 
Dpm) cross-bridge present in the cell wall o f  L. monocytogenes (Figure 1.4). The gene 
encoding the sortase responsible for InlA anchoring has been identified as srtA (Bieme e t a l ,  
2002; Cabanes et al., 2002).
The In IB protein is only loosely tethered to the cell membrane through a series o f  C-terminal 
GW repeats that associate with lipothechoic acids (Figure 1.4) at the peptidoglycan-cell 
membrane interface (Braun et al., 1997; Jonquieres e t al., 1999; Cabanes et al., 2002). Unlike 
InlA, InlB is generally not very accessible at the cell wall surface (Jonquieres et a l ,  1999) but 
significant amounts can be released into growth media (Cossart, 2001). It has also been shown 
that free InlB in the media can reattach to the cell membrane via the GW repeat region 
without any loss in functionality (Braun et al., 1997).
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Figure 1.2: Primary ‘domain ’ structure o f  the InlA and InlB proteins. The key difference to 
note is that InlC lacks the cell wall anchoring m otif (LPTTG) present in InlA and a ll the other 
classified internalins
The key structural and functional aspects o f  internalin-mediated adhesion to host cells have 
been recently reviewed (Cabanes et al., 2002; Cossart et al., 2003; Schubert and Heinz 2003). 
A central clue to identifying the functional region o f  intemalin is the conserved nature o f  the 
LRR hydrophobic repeats (Figure 1.3). Such sequences are often associated with functional 
domains. The fact that they are highly conserved within the species suggests that they have 
probably been retained as a result o f  functional selective pressure. It has been demonstrated 
that the combined LRR, IR and cap regions are necessary and sufficient to promote entry into 
human epithelial cells (Lecuit e t ah, 1997), while the LRR domain o f  InlB, alone, is sufficient 
to promote entry into parenchymal cells (Braun, 1998; Braun, 1999). The crystal structure o f  
the LRR domain from InlB was successfully resolved by Marino and co-workers (1999), and 
it revealed each tandem repeat to adopt an oval structure, consisting o f  a [3-strand on one side 
and an antiparallel 3io-helix on the opposite side, connected by short loops (Marino et al., 
2000; Schubert et ah, 2001). Similar structural arrangements were first reported in the pectate 
lyase enzyme produced by the plant pathogen Erwinia chrysanthemi (Yoder et al., 1993; 
Heffron et ah, 1998; Herron et al., 2000). It is probable that the LRR domain structure is 
conserved throughout the intemalin family. More recently, the crystal structure o f  the entire 
InlB protein has been elucidated (Schubert et ah, 2001). It demonstrates that InlB is
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composed o f  three clustered domains; an N-terminal cap domain (amino acids 63-79), a 
central LRR domain (amino acids 80-240) and a C-terminal domain (amino acids 241-321 
and 263-343). The cap domain consists o f  three a-helices and one anti-parallel, two-stranded 
P-sheet that resembles a truncated EF-hand motif, similar to those identified in calmodulin 
and related calcium-binding proteins (Babu e ta l.,  1988; Flaherty e ta l.,  1993).
The LRR domain is typified by a (3-strand-loop-antiparallel helix that exhibits an overall 
‘bent’ shape with distinct concave and convex faces. The IR domain represents the most 
conserved region within the internalin family (Schubert et. al., 2001). The domain structure is 
dominated by an imperfect, four-stranded antiparallel (3-sheet, linked to the LRR p-strand that 
contributes structural similarity to single immunoglobulin-like domains. This ‘Ig-like’ 
structure fused to a second domain is unique and distinct from the multiply linked Ig domains 
common in antibodies and cell surface receptor molecules (Harpaz and Chothia, 1994).
E-cadherin was identified as the InlA receptor through a series o f  affinity chromatography 
experiments with extracted surface proteins from cultured epithelial cells (Mengaud, 1996). 
Attempts to demonstrate InlA-mediated epithelial invasion in vivo using mouse or rat models 
proved impossible. The reason for this became evident when it was discovered that a single 
amino acid in the human E-cadherin (hEcad) molecule was responsible for host specificity 
towards the Listeria monocytogenes pathogen (Lecuit el al., 1999). A  single proline residue at 
position 16 was essential to facilitate InlA ‘docking’. However, the mouse model was flawed 
because mouse E-cadherin (mEcad) contains a glutamic acid residue instead o f  proline at 
position 16. This was proven by demonstrating that a Pro^G lu  substitution in hEcad 
prevented InlA binding and, conversely, that a Glu—>Pro substitution conferred InlA 
specificity in mEcad. Using these findings, a hEcad overexpressing transgenic mouse has 
recently been applied to the development o f  a murine model o f  orally acquired listeriosis 
(Lecuit et al., 2001).
The first o f  at least two InlB receptors, gClq-R, was also identified through affinity 
chromatographic experiments (Braun et al., 2000). The crystal structure o f  gC lq-R  (Jiang et 
al., 1999) does not reveal properties typical o f  transmembrane or 
glycosylphosphotidylinositol-anchored proteins and, thus, implies the likely involvement o f  
an ancillary transmembrane protein to mediate membrane-to-cytosol signalling. The second 
confirmed InlB receptor is the hepatocyte growth factor and scatter factor (HGF-SF) receptor 
(Shen et al., 2000). This protein had previously been characterised as a disulphide-linked 
heterodimer consisting o f  a 45 kDa a-, and 145 kDa p-subunit (Birchmeir and Gerardi, 1998;
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Trusolino at al., 1998). The latter contains a transmembrane component and a cytoplasmic 
domain possessing both tyrosine kinase activity and a tyrosine-rich, autophosphorylation site. 
The receptor has also been referred to as the c-met proto-oncogene, c-Met tyrosine kinase and 
simply, MET (Birchmeir and Gerardi, 1998; Trusolino et al., 1998). Evidence to support its 
role as an InlB receptor includes the observed InlB-induced tyrosine phosphorylation o f  the 
adaptor proteins G abl, Cbl and She, linked with concomitant activation o f  p 85-p ll0 , 
mammalian phosphoinositide 3-kinase (PI 3-K) (Ireton et al., 1999). Activation o f  p 8 5 -p ll0  
has been highlighted as an essential mediator o f  bacterial uptake by mammalian cells (Ireton 
et al., 1996; Ireton el al., 1998). In addition, InlB, in common with HGF, activates multiple 
signalling cascades that are not directly involved in the invasion process (Biem e and Cossart,
2002). An overview o f  the receptor-ligand interactions and primary ignalling events is 
provided in Figure 1.4.
Identification o f  the principal InlB receptor molecules may shed light on how the surface- 
bound InlA from the invading bacteria gains access to hEcad that is predominantly located at 
the basolateral suface, and junction regions o f  gut epithelial cells. The ubiquitous distribution 
o f  c-Met on mammalian cell surfaces and more convincingly, its tendency to congregate with 
hEcad (Kamei et a l ,  1999) suggest that free InlB may leach into the epithelial junctions and, 
upon interacting with c-Met, cause ‘scattering’ (Kamei et al., 1999; Mansell et al., 2000) o f  
adjacent cells with concomitant exposure o f  hEcad receptors.
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Figure 1.3: 3-D ribbon structures o f  ln lA ^-m  (PDB code 106T), ln.lHi6.341 (PDB code 1H6U) 
and InlB36.32i (1H6T) view ed using Swiss-PDB viewer. Panel A shows the 3D  structures o f  InlA, 
InlH and InlB in a  view towards the concave surface o f  the leucine-rich repeat (LRR) region, a- 
helices are coloured in red, loops in so lid  grey and (3 strands as yellow  arrows pointing in a  N- 
terminus to C-terminus direction. Panel B shows the structures presen ted  in panel A coloured  
according domain structure. The area coloured in green represents the cap domain, the LRR 
region is coloured in red  and the ‘IgG-like ’ domain coloured in orange. The fin a l (3 strand  
(coloured purple) o f  the LRR region is simultaneously the f ir s t strand o f  the ‘IgG-like ’ domain. 
Panel C  shows the structures coloured in grey with the leucine rich repeats coloured in red. 
Generally LRRs are 20-29 residues long and contain a  conserved 11-residue segment with the 
consensus sequence LXXLXLXXXXL, where X  can be any amino acid and leucine (L) can also be 
substituted with valine (V), isoleucine (I) or phenylalanine (F) (Kobe and Kajava, 2001). In 
Listeria, the internalin fam ily  o f  LRR proteins have varying numbers o f  repeats o f  22 amino acid  
residues. In the diagram only the two repeat residues (i.e. LXXLXLXXXXL) present on the 13- 
strands are coloured in red. InlA has 15 tandemly arranged leucine-rich repeats, InlH  has 8  
repeats and InlB has 7 repeats. Panel D  shows an enlarged view  o f  the InlB structure shown in C  
with the leucine-rich repeat residues coloured in red. The last /3-strand o f  the LRR region  
simultaneously form s the f ir s t strand o f  the IgG-like domain, as shown in panel B. The InlB 
structure presented, can be classified as having 7 or 8  repeats, depending on the classification o f  
the LRR region (i.e. inclusion o f  the last (3-strand).
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Figure 1.4: Schematic overview of L. monocytogenes-mediated host cell interaction. InlB, 
which is loosely tethered to lipoteichoic acid (LTA), is thought to induce tyrosine 
phosphorylation of Gabl, Cbl and She, following binding to gClqR and HGF-SF. These 
mammalian adaptaor molecules are thus primed to associate with the p85 subunit of PI 3- 
kinase and mediate cytoskeletal rearrangements. InlA is covalently linked to cell wall 
peptidoglycan and its N-terminal LRR domain binds to hEcad. Subsequently, the cytoplasmic 
domain of the InlA-activated hEcad interacts directly with (1-catenin, which in turn associates 
with a-catenin to mediate actin rearrangement (Galán et al, 2000). The full complement of 
signalling events in the invasion cascade has yet to be confirmed.
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Such synergies within the internalin family may indeed be more widespread than at first 
appreciated. By studying the effect on internalisation into epithelial-like Caco-2 and the 
human microvascular endothelial (HBMEC) cell lines o f  various ini deletion mutants, 
Bergmann et ah, (2002) have shown that InlA in particular acts in concert with one or several 
other intemalins to function efficiently during invasion. More specifically, it has been 
demonstrated that deletion o f  the inlGHE  cluster results in enhanced expression o f  bicistronic 
inlA and inlB but not inlC. Whereas InlB alone is necessary and sufficient to promote host cell 
invasion in HBMEC (Greiffenberg et ah, 1998), InlA requires the cooperative intervention o f  
InlC and InlGHE or InlB to mediate invasion o f  Caco-2 cells, as had been previously 
suggested (Lingnau, et ah, 1995). Enhanced InlB-mediated invasivness o f  HBMEC has been 
demonstrated for inlGHE-deficient cells and even more so for inlGH- / inlC-deficient cells 
(Bergman et ah, 2002). InlA-induced phagocytosis has conversely been shown to demonstrate 
an absolute requirement for coexpression o f  InlB, or InlC, or both InlC plus inlGHE 
(Bergman et ah, 2002).
These results suggest that InlA-mediated phagocytosis intrinsically relies upon coexpression 
o f  soluble InlC protein and a favourable host cell disposition induced by either InlB or 
InlGHE proteins, which are possibly competing for the same host cell receptors.
1.4.1.2 Listeria adhesion protein (LAP) or pl04
The role o f  a 104 kDa listerial surface protein (p i04) in adhesion o f  Listeria monocytogenes 
to human intestinal cells was demonstrated by Pandripally and co-workers (1999). The 
specific eukaryotic receptor ligand remained unclear until quite recently. Through a sequence 
Western blot ligand overlay assays, the receptor for pi 04, or Listeria adhesion protein (LAP) 
was putatively identified as a 58 kDa protein, ‘heat shock protein 60’ (Hsp60) and this was 
subsequently confirmed by immunoaffinity chromatography (Wampler el ah, 2004).
1.4.1.3 Amidase (Ami)
L. monocytogenes serovar l/2a  EGD produces a 917 amino acid (102 kDa) autolytic amidase 
(Ami) that is targeted to the bacterial cell surface via a dedicated C-terminal GW-repeat 
domain, and it accounts for 66 % o f  the total lytic en2ym e activity (McLaughlan and Foster,
1998). In addition to this confirmed role as a peptidoglycan hydrolase, the GW-repeat region 
has been implicated in adhesion o f  L. monocytogenes to mammalian cells (Milohanic et ah,
2001). It appears that the GW repear region is the key determinant o f  Ami-mediated adhesion. 
The L. monocytogenes serotype 4b-derived Ami (Ami 4b), which, is only 770 amino acids in
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length, contains an identical N-terminal region to that o f  Ami l/2a. However, it contains only 
six GW repeats, in comparison to Ami l/2a’s eight, and this correlates with a reduced ability 
o f Ami 4b to bind Hep-G2 human hepatocytic cells (Milohanic el al., 2004).
1.4.2 Virulence factors involved in intra- and inter-cellular spreading
1.4.2.1 p 60
The p60 protein, encoded by the invasion-associated protein (iap) gene (Kuhn and Goebel, 
1989; Kohler et al., 1990) present in both culture supernatant (Kuhn and Goebel, 1989), and 
localised at the cell surface (Ruhland et al., 1993). Analysis o f  serum from listeriosis patients 
indicates that p60 is a potent B-cell stimulator (Gentschev el al., 1992). The protein comprises 
484 amino acids and is characterised by a central sequence o f  Thr-Asn repeats (Kohler et al., 
1990; Bubert et al., 1992). The C-termnal region possesses a murein hydrolase activity that 
mediates efficient septum formation during cell proliferation (Wuenscher el al., 1993). 
Further evidence for this hydrolase activity stems from the fact that spontaneously occurring 
‘rough’ phenotypes that are made up o f  long filamentous colonies with attenuated virulence in 
fibroblast cells, have been shown to be deficient in p60 expression (Kuhn and Goebel, 1989). 
L. monocytogenes cells that are deficient in p60 also exhibit an uneven distribution o f  ActA  
protein with a concomitant reduction in actin tail formation and, thus, reduced intercellular 
invasiveness (Pilgrim et al., 2003). The full and exact role o f  p60 in listerial virulence is 
unclear. However, it is possible that it essentially fuctions as a dedicated cell wall hydrolase, 
with a significant, yet principally indirect contribution to strain virulence.
1.4.2.2 ActA
Once the bacterium has escaped from the phagosome into the cytoplasm, it adopts an intricate 
system o f  directional propulsion mediated by actin polymerisation (Figure 1.5). The actin 
assembly (actA ) gene product has been highlighted as an essential factor for actin 
accumulation, since actA' genotypes fail to harness actin filaments and thus, grow as localised 
microcolonies in host cells (Domaiin e t al., 1992; Kocks et al., 1992). This 90 kDa protein 
exhibits a C-terminal hydrophobic anchor region indicating membrane bound localisation. In 
fact it adopts an inversely proportional polar distribution (Kocks et al., 1993) at the bacterial 
surface, serving as a focal point for an actin tail formation. Studies conducted with truncated 
ActA derivatives have demonstrated that there are two further distinct functional regions 
(Pistor e t al., 1995; Niebuhr et al., 1997). The first is a central (amino acids 234-395) region 
o f proline rich repeats (PRR), that sequesters actin filaments from the cytoskeleton by
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interfacing with the focal adhesion molecule, vasodilator-stimulated phosphoprotein (VASP) 
(Holt and Koffer, 2001) and mammalian ‘enabled’ (Mena) protein. It has recently been 
demonstrated that binding o f  profilin (Pr), complexed to actin protein, to the PRR domain, 
plays a crucial role in mediating intracellular actin-cbased motility (Grenklo et al., 2003).
The second functionally important domain is a highly positively charged N-terminal region 
that is required for actin filament nucleation. This region activates host cell Arp2/3 complex 
concomitantly stimulating actin polymersation and has been shown to be essential for actin- 
based motility o f  L. monocytogenes (May et al., 1999). In mammalian cells, the Arp2/3 
complex interacts with the C-terminal regions o f  the Wiskott-Aldrich syndrome (WASp/Scar) 
family proteins to mediate rearrangement o f  the cytoskeleton. (Machesky and Insall, 1998; 
Machesky et al., 1999). The N-terminal ActA region functionally mimics WASp/Scar 
activation o f  the Arp2/3 complex (Frischknecht and Way, 2001). The acidic region (amino 
acids 33-46) o f  ActA increases the efficiency o f  Arp2/3-mediated actin nucleation in vitro  and 
enhances the rate and frequency o f  motility in vivo, whereas the 60-101 amino acid actin- 
monomer-binding region is not a prerequisite for in vivo actin-based motility. Conversely, the 
highly basic cofilin-homologous stretch o f  the N-terminal ActA sequence (amino acids 146- 
150) is essential for both Arp2/3 activation and actin-based in vivo motility (Pistor et al., 
2000; Skoble et al., 2000). Although ActA is a major surface-exposed virulence protein, it is 
only presented by either MHC class I or class II molecules when administered in soluble 
form, and CD8 cells so elicited, do not confer in vivo  anti-listerial protection (Daiji et al.,
1998).
In addition to its documented role in cytosolic motility, a possible role for ActA in the 
primary adhesion and invasion processes has been suggested (Alvarez-Dominguez e t al., 
1997; Suárez et al., 2001), following confirmation that expression o f ActA in L. innocua was 
sufficient to promote entry into epithelial cells (Suárez et al., 2001).
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Figure 1.5: M echanics o f  actin-based motility. The ActA protein  contains the fo llow ing  
domains: PRR, proline-rich region; CHR, cofilin homology region; AB, actin-binding  
domain, preceding an acidic N-terminal sequence. Other molecules involved in cytoskeletal 
actin rearrangement include the VASP, vasodilator-stim ulated phosphoprotein and Pr, 
profilin. The AB region serves as the principle site o f  actin nucleation. After nucleation, the 
Arp2/3 complex, having been activated by its interaction with the acidic N-terminal and CHR 
domains, dissociates from  ActA and cross-links actin polym ers during tail formation. The red  
arrows represent actin and indicate the direction o f  the actin ‘ta il’ formation.
1.4.2.3 Listeriolysin O
The production o f  a soluble (3-haemolytic protein by L. monocytogenes was first demonstrated 
in 1941 (Harvey and Farber, 1941). Much effort was invested in the isolation and 
characterisation o f  the native haemolysin (Girard et al., 1963; Jenkins et al., 1964; Siddique et 
a l ,  1974; Daiji et al., 1995a). The haemolysin was identified as listeriolysin O (LLO), a 58- 
60 kDa, sulphydryl-activated member o f  the cholesterol-dependent, pore-forming toxins 
(CDTX), which, also include streptolysin O (SLO) (Geoffroy et al., 1987) and perfringolysin 
O (PFO) (Rossjohn et al., 1997). A  related haemolysin protein has also been identified in L. 
ivanovii (ivanolysin O or ILO) and the non-pathogenic species, L. seeligeri (seeligerilysin O) 
(Geoffroy et al., 1989; Vazquez-Boland et a l ,  1989; Leimeister-Wachter et al., 1992). Unlike 
SLO and PFO, LLO possesses a PEST-like sequence (Decatur and Portnoy, 2000) and a low  
optimal pH for activity (-5 .5 -6 .0 ) (Beauregard et a l ,  1997; Dramsi and Cossart, 2002). The 
latter o f which has been putatively attributed to the presence o f  a specific leucine residue at
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position 461 in the nascent sequence (Glomski et al., 2002). Both o f  these features restrict the 
activity o f  LLO to the cytolytic vacuolar compartments and, thus, underline the principle role 
o f  LLO in escape from primary and secondary vacuoles without compromising the host cell 
membrane integrity.
Recent findings suggest that LLO may play a broader role in the overall virulence o f L. 
monocytogenes. Stimulation o f  the mitogen-activated protein (MAP) kinase cascade, by LLO, 
has been clearly demonstrated (Tang et al., 1994; Tang e t al., 1996; W eiglein et al., 1997). In 
addition, treatment with LLO has been demonstrated to induce apoptosis in dendritic cells 
(Guzman et al., 1996; Carrero et al., 2004), expression o f  cell adhesion molecules on infected 
cells (Krull et al., 1997; Kayal e t al., 1999), nuclear factor kB (NF-kB) induction (Kayal et 
al., 2002), mucin exocytosis in intestinal cells (Coconnier et al., 1998; Lie’ vin-Le Moal et 
al., 2002), cytokine induction in macrophage (Kuhn et a l ,  1994; Kuhn e t al., 1995; Nishibori 
et al., 1996; Kohda e t al., 2002), and degranulation/leukotriene formation in neutrophils 
(Sibelius et al., 1999). Many o f  these responses are Ca2+-dependent (Dussurget et al., 2004) 
and this is not surprising given that free LLO binds to cholesterol-rich membranes, 
oligigomerises and forms arc-shaped Ca2+-permeable pores, leading to a concomitant 
intracellular Ca2H flux (Repp et al., 2002). This intracellular Ca2+-flux has been directly 
implicated in listerial invasion o f  epithelial cells (Dramsi et al., 2003). Furthermore, LLO 
associates with lipid rafts (Coconnier et al., 2000) and the resultant raft clustering has been 
postulated to induce tyrosine phosphorylation in LLO-treated cells (Gekara and Weiss, 2004).
1.4.2.4 Phospholipases
Pathogenic Listeria  spp. produce three different enzymes with phospholipase C (PLC) activity 
that are involved in virulence. Two, PlcA and PlcB, are present in L. monocytogenes and L. 
ivanovii, while the third, SmcL is specific to L. ivanovii (Vazquez-Boland et al., 2001a).
PlcA is a 33 kDa phosphatidylinositol-specific PLC (PI-PLC) enzyme (Leimeister-Wachter et 
al., 1991; Mengaud et al., 1991a; Notermans e t al., 1991; Goldfine and Knob, 1992). Its role 
in mediating escape from the primary host vacuole is disputed (Schwan e t al., 1994), although 
it is suggested that the PlcA may act in concert with PlcB to affect phagosomal escape (Smith 
et al., 1995).
PlcB is a 29 kDa phosphatidlcholine-specific PLC (PC-PLC) enzyme (Geoffroy et al., 1991), 
yet it has a much broader substrate range than its name suugests. It is secreted as a 33 kDa 
proenzyme that becomes activated by a zinc metalloprotease that is encoded by the mpl gene,
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which is proximally located in the PlcA/B-encoding lecithinase operon (Domann et a l ,  1991; 
Mengaud et a l ,  1991b; Poyart et al., 1993; Broer et a l ,  1998; Coffey et al., 2000). It has been 
demonstrated that PC-PLC does indeed play an intimate and essential role in mediating 
escape from the primary vacuole (Marquis et al., 1995; Grundling el a l ,  2003) and, in 
addition, it has been implicated in cell-to-cell dissemination during cerebral infections 
(Schluter et al., 1998).
Both PI-PLC and PC-PLC act synergistically with each other, and with LLO to mediate 
phagosomal escape (Geoffroy et al., 1991; Camilli et al., 1993). In particular, PI-PLC, in the 
presence o f  LLO, induces phosphatidylinositol hydrolysis in macrophage cells (Sibelius et al., 
1996; Goldfine et al., 2000), leading to mobilisation o f  protein kinase C and concomitant 
intacellular Ca2+ elevation that affects listerial internalisation and phagosomal breaching 
(Wadsworth and Goldfine, 2002).
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Figure 1.6: Schematic overview o f  host cell invasion and cellular spreading o f  
L.monocytogenes. (1), host cell ‘docking’ and internalisation by phagocytosis; (2), temporary 
localisation within the phagocytic vacuole (phagosome); (3), enzymatic degradation o f  
vacuolar membrane (mediated by LLO); (4), replication and multiplication within the cytosol;
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(5), act in-based motility. The ‘comet’-like ta ils provide a platform  to propel the bacteria 
through the cytosol. Polymerised actin is represented by the red region o f the tails; (6), 
intercellu lar spreading; (7), temporary localisation w ithin the secondary (double-membrane) 
phagocytic vacuole; (8), enzymatic degradation o f secondary vacuolar membranes (mediated 
by LLO  and PC -PLC '); (9), successful completion o f one round o f ce ll-to-cell dissemination 
and starting point fo r subsequent rounds. (Adapted from  Vazquez-Boland et al., 2001a, 
2001b).
1.4.3 Genom e o rgan isa tion  and  genetic determ inants o f  v iru lence
Comparative analysis of the genomes of L. monocytogenes, strain EGD-e (serovar l/2a) and 
the closely related pathogenic species, L.innocua, strain CLIP 11262 (serovar 6a), revealed 
that L. monocytogenes contained a 2.94 Mbp chromosome with a high G+C ratio (39 %), 
while L.innocua contained a comparably large, 3.01 Mbp chromosome with an equally high 
G+C ratio (37 %) (Glaser et al., 2001; Buchrieser et a l, 2003).
Surprisingly, a perfect conservation of order and relative orientation of orthologous genes was 
observed in both species, showing a high degree of stability in genome organisation, with no 
evidence of significant inversion events or shifting of large genome segments (Buchrieser et 
al., 2003). In addition to the 3.01 Mbp chromosome, L.innocua also harboured an 81.9 kbp 
plasmid, conferring heavy metal resistance (Glaser et al., 2001). However, similar plasmids 
have been previously observed in L. monocytogenes (Poyart-Salermon et al., 1990; Lebrun et 
al., 1994). Current opinion holds that, in addition to a high percentage of transcriptional 
regulator genes, the preponderance of surface and secreted protein-encoding genes in the L. 
monocytogenes genome (which is not reciprocated in the L. innocua genome) directly reflects 
the pathogenicity potential of L. monocytogenes. In particular, its capacity to co-ordinate gene 
expression to maximise environmental persistence and to efficiently colonise many different 
cell types in the host (Dussurget et al., 2004).
1.4.3.1 Central virulence gene cluster
The genes encoding everal of the key virulence factors are housed in a 9 kbp chromosomal 
region, referred to as ‘Listeria  pathogenicity island 1’ (LIP-1) (Vazquez-Boland et al., 2001a, 
2001b; Krefit et al., 2002). The physical organisation of the pathogenicity cassette is depicted 
in Figure 1.7 and it is clearly demonstrated that LIP-1 is absent from the genome of non- 
pathogenic Listeria  spp., with the exception of L. seeligeri (Kreft et al., 2002; Chakraborty et
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al., 2000; Vâzquez-Boland et al., 2001b). Phylogenetic analysis indicates that the most 
parsimonious evolutionary scenario is, that the virulence gene cluster was originally present 
in the common ancestor of L. monocytogenes, L.innocua, L. seeligeri, and L. welshimeri, and 
that the pathogenic capability has been lost in two separate events represented by L. innocua 
and L. welshimeri (Schmid et al., 2005).
L . monocytogenes
L. ivanovii
prs prfA plcA hly in/il actA
L . seeligeri
pIcB ) I orftt orfA idh 
orfX orfZ
prs prfA plcA hly rupi actA picB  J  I or/B orfA Uh 
nrfX orfl.
prs orfC orfD prfA or/E plcA hly orfK mpl actA tplcB picB orfB orfA Idh
L. innocua
prs orfZ orfB orfA Idh 
prs orfL orfB orfA Idh
F igure  1.7: Physical map o f the liste ria l central virulence gene cluster (LIP-1). Genes 
belonging to LIP-1 are indicated in red. These virulence determinants are housed between the 
genes encoding the housekeeping enzymes phosphoribosyl-pyrophosphate synthase (prs) and 
lactate dehydrogenase (Idh). A ll L isteria  spp. harbour two sm all open reading frames, orfB  
and orfA, in the p lcB -ldh intergenic region, and it is thus, likely, that this represents the 
orig ina l site o f LIP-1 insertion. L. monocytogenes contains two sm all ORFs, o rfX  (orange) 
and orfZ  (yellow), which indicate the putative deletion po in t o f LIP-1 in L. innocua. L. 
ivanovii harbours a L. monocytogenes-homologous o rfX  gene and an orfL gene in place o f 
orfZ, and this indicates the possible site o f LIP-1 deletion in L. welshimeri. The L. seeligeri 
genome contains the fu ll complement o f LIP-1 virulence genes and multiple additional ORFs 
(grey). These include tplcB, a truncated variant o f plcb, and orfE, which is situated between 
the prfA and plcA. It is this latter O RF that effectively prevents fa ith fu l regulation o f virulence 
gene transcription and renders L. seeligeri non-pathogenic. The difference in size between the 
actA genes o f L. monocytogenes an L. innocua, which is pronounced at the amino acid  level 
(Kreft et al., 1995; Gouin et al., 1995), suggest a bifurcated divergent evolution o f the genus.
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1.4.3.2 in i virulence gene clusters
The genes that encode the various proteins of the intemalin family are not part of the central 
virulence gene cluster. Instead, as Figure 1.8 shows, they are found as clusters of two or more 
‘islets’, each orientated in the same direction (Buchrieser et al., 2003; Doumith et a l., 2004). 
The largest intemalin island is LIP-2, a chromosomal locus specific to L. ivanovii, which 
contains ten in i genes (Vazquez-Boland et al., 2001a, 2001b).
inlC
(d) rplS mfC
inlF
(e) PEP synthase
LRR domain 
B region
□
GW repeats 
LPXTG anchor
Transcription
direction
Figure 1.8: The intem alin gene cluster that is encoded by the L. monocytogenes chromosome. 
(Adapted from  Vasquez-Boland et al., 2001a, 2001b). These genes are essential fo r  the 
prim ary invasion o f host cells by pathogenic strains o f this species. The internalin-encoding 
genes are arranged into a multi-gene cluster that is specific fo r the genus L iste ria  and 
contains sequences that confer ce ll tropism and pathogenicity upon L. monocytogenes. The 
in lAB  operon was the firs t to be identified, by demonstrating decreased ab ility o f various 
transposon mutants to invade Caco2 cells in vitro (G a illa rd  et al., 1991). Additional 
intem alin genes identified, include inlG, inlC2, in lD  and in lE  (Dramsi et al., 1997; 
Rafflelsbauer et al., 1998), a ll o f which possess a ce ll w a ll anchoring (LPXTG-encoding) C- 
term inal sequence. Even within the serovar l/2a  o f the strain EGD, this cluster demonstrates
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a degree o f heterogeneity with the in lC2D  recombinant gene product (inlH) being 
preferentially expressed in divergent isolates. The in lA  gene arose through recombination o f 
the N-term inal encoding region o f in lC2 and the C-term inal encoding region o f inlD. in lF  cmd 
in lC  are both housed on individual lo c i and in lC  is unique among the internalins in that it 
does not encode a bona-fide ce ll wall- or ce ll membrane- anchoring sequence.
1.4.3.3 Virulence gene regulation: the P rfA  regulon
The majority of the listerial virulence genes, including the entire LIP-1 cassette, are co- 
ordinately regulated by a transcriptional activator protein. This was origninally identified as a 
27 kDa protein that positively regulated the expression of listeriolysin O, and was, thus, called 
the ‘positive regulatory factor of the listeriolysin (hlyA, formerly lisA ) gene, or PrfA 
(Leimeister-Wachter et al., 1990). The PrfA protein is a structural analogue of the cyclic 
AMP receptor protein (Crp/Fnr) family of of transcriptional activators (Mengaud et al., 
1991c; Lampidis et al., 1994).
All PrfA-regulated genes posess a 14 bp palindromic sequence in the -41 region (upstream of 
the transcriptional start site), termed the ‘PrfA box’ (Dickneite et al., 1998), and PrfA- 
mediated transcription requires binding of PrfA protein to this palindromic sequence. There is 
a hierarchy in the ‘quality’ of PrfA boxes, which ranges from sequences exhibiting perfect 
dyad symmetry (e.g. plcA/hly), to those with 1 bp (e.g. mpl/actA/inlC) or 2 bp (e.g. in lA) 
substitutions (Lalic-Miilthaler et al., 2001). Thus, expression of the plcAJhly gene sequences, 
is much more tightly controlled by PrfA, than the inlA gene (Sheehan et al., 1995; Brehm et 
al., 1996; Williams et al., 2000).
PrfA controls virulence gene expression using two distinct mechanisms. The first involves the 
‘de-inhibition’ of translation of prfA  mRNA in response to elevation of temperature to 37 °C. 
This brought about by a sequence of untranslated mRNA that immediately precedes prfA  and 
acts as a thermosensor, masking the ribosomal binding site at temperatures below 37 °C 
(Johansson et al., 2002).
The second involves a PrfA-dependent bicistronic plcA-prfA  transcript that creates a positive 
feedback loop, by which PrfA induces its own synthesis (Ermolaeva et al., 2004). The 
insertional disruption of this autoregulatory circuit leads to a total loss of virulence, even if 
the prfA gene and its promoters remain intact (Mengaud et al., 1991; Camilli et al., 1993; 
Frietag et al., 1993), showing that it is essential for the normal function of the PrfA regulon 
(Ermolaeva et al., 2004).
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It has been demonstrated that simply increasing the temperature to 37 °C alone, is insufficient 
to mediate virulence, because PrfA-dependent genes are expressed weakly in vitro when 
cultured in rich media at this temperature (Ripio el a l,  1996; Ripio e l a l,  1997a). This is in 
contrast to the highly elevated levels of PrfA-dependent proteins, expressed intracellulary, 
following escape from the phagosomal vacuole (Freitag and Jacobs, 1999; Moors el al., 1999; 
Shetron-Rama et al., 2002). Thus, it is presumed that chemical signals, present in the 
intracellular environment, somehow intervene, to upregulate PrfA activity. The requirement 
for an exogenous chemical signalling pathway is further suggested by the observation that, 
adding activated charcoal to nutrient-rich brain heart infusion (BHI) broth cultures, 
significantly increased the expression of PrfA-dependent genes (Ripio et al., 1996; Ripio et 
al., 1997a; Ripio et a l,  1997b; Ermolaeva et al., 2004).
This ‘charcoal effect’ was easily reversed by the addition of cellobiose or other readily 
fermentable sugar (Ripio et al., 1997b; Brehm et al., 1999). However, although cellobiose 
reduces the level of PrfA-dependent gene expression, the level of PrfA protein, itself, is not 
affected (Milenbachs et al., 1997; Renzoni et al., 1999). It would, thus, appear reasonable to 
conclude that efficient expression of PrfA-dependent genes is more infuenced by PrfA 
functionality or activity (Vega et al., 2004), rather than concentration alone. Recent findings 
suggest that the charcoal effect may arise following the sequestration of a diffusible 
autorepressor substance that is specifically released by L. monocytogenes during exponential 
growth, and which, affects directly or indirectly, the activity of PrfA (Ermolaeva et al., 2004). 
Two genetic loci, gcr and csr, both unlinked by general transduction to LIP-1, have been 
shown to be required for cellobiose-mediated repression of the PrfA regulon, thus, suggesting 
the existence of two, semi-independent pathways for cellobiose-mediated repression 
(Milenbachs Lukowiak et a l., 2004).
The quintessential role of PrfA in listerial virulence is underlined by the particular disposition 
of L. seeligeri. Although L. seeligeri possesses the full complement of LIP-1 virulence genes 
(Gouin et al., 1994), they are not expressed correctly. This is due to the presence of a 
divergently transcribed opm reading frame E (o rfE ), inserted between the p lcA  and prfA  gene 
sequences, which prevents the positive autoregulatory loop, necessary for efficient PrfA- 
dependent virulence gene expression (Karunasagar et al., 1997; Vazquez-Boland et al., 
2001b).
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1.5 Epidemiology
Careful assessment of the epidemiological profiles (Table 1.4), indicate that most illness are 
associated with serovars 4b and l/2a (Jacquet el al., 2004). It is clear that serovar 4b is most 
frequently isolated in outbreaks (Farber and Peterkin, 1991). A study of 1363 listeriosis cases 
undertaken by McLaughlin (1990) indicated that serotype 4b was responsible for 64 % of the 
cases, while serovar l/2a was responsible for only 15 %. A more comprehensive profiling of 
24 outbreaks (3338 cases) reported in the literature since 1966, by McLaughlin (1997), 
highlighted that 58 % of the total outbreaks and 40 % of the total cases were attributable to 
serotype 4b. This trend was mirrored by the epidemiology of human listeriosis in Sweden 
between 1976 and 1985, that, showed serotype 4b to responsible for 70 % of cases (Ericsson 
et al., 1996). These observations lend significant weight to the notion that there is a 
significant degree of heterogeneity in the virulence, or pathogenic potential of L iste ria  strains 
(Wiedman et al., 1997), the genetic basis of which has also been investigated (Nelson et al.,
1994).
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Table 1.4: Worldwide reported outbreaks o f listeriosis (1979-2002) with im plicated foods and 
available statistics. Compiled and adapted from  Anon., USD A, 2003; Donnelly, 2001 and
McLaughlin etal., 2004).
i ’ll ses
Date Country Implicated
food
Total
cases
Im muno­
compromised/
predisposed
Pregnancy-
associated
Non
-pregnancy-
associated
Deaths
(%  mortality)
Sero-
var
Original
reference
1978-
79
Australia Raw veg. 12 nd nd nd 0 nd
Le Souefand 
Walters,
1981
1979 USA Salad veg. 23 #a2 nd nd (15%) 4b Ho etal., 
1986
1980
New
Zealand Fish 22 10 22 0 7 (32%) l/2a Lennon et 
a I.. 1984
1981 UK Misc. dairy 
products
11 nd nd nd 5 (45.5%) l/2a Ryser, 1999
1981 Canada Coleslaw 41 0 34 7 (41%) 4b Schlech et 
al.. 1983
1983-
87
Switzerland Soft cheese 122 nd 65 nd 31 (25.4%) 4b Bille, 1990; 
Bula etal., 
1995
1983 USA
Pasteurised 
whole milk 
and 2 % 
milk
49 42 7 42 14 (29%) 4b Fleming et 
a!., 1985
1985 USA Mexican-
style
cheese
142 93 48 49 30 (33%) 4b Linnan et al., 
1988
1986 Austria Unpasl.
milk,
organic
veg.
28 nd 24 nd 5 (17.9) nd Allerberger
and
Guggenbichl 
er. 1989
1986-
87
USA
Ice cream, 
salami, brie 
cheese
36 nd 4 32 16 (44.4%)
4b,
l/2b,
l/2a
Schwartz et 
al., 1989
1986-
87
USA Raw eggs 2 nd nd nd nd 4b Schwartz et 
a l , 1988
1987 USA Butter 11 nd nd nd nd nd Ryser et al., 
1999
1987-
89
UK Pâté 355*b nd 185 129 94 (26.5%) 4b McLaughlin 
etal.. 1991
1989-
90
Denmark Semi-soft
(blue)
cheese
23 nd nd nd nd 4b Jensen et al., 
1994
1989 Finland Salted
mushrooms
1 nd nd nd 0 4b Juntilla and
Brander,
1989
1989 USA Shrimp 2 nd nd nd 0*c 4b Riedo et al., 
1994
1990 Australia Pâté 11 nd 11 nd 6 (54.5%) l/2a Paul etal., 
1994;
Ryser et al., 
1999
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Table 1.4: ..continued
1991 Australia
Smoked
mussels 4 0 0 4 0 l/2a
Mitchel. 1991 ; Misrachi et 
a i,  1991; Paul e tu i ,  1994
1992 New
Zealand
Smoked
mussels
4 2 2 2 1 l/2a Brett et a i ,  1998
1993 France Pork tongue 280 nd 93 nd 63
(22.5%)
4b Jacquet et al., 1995
1993 France Pork rillettes 38 nd 31 7 11 (28.9 
%)
4b Goulet é ta l ,  1998
1993 Italy Rice salad 39 nd nd nd 0 l/2b Salamina et a i ,  1996
1994 USA Chocolate
milk
45 1 1 44 0 l/2b Dalton et al., 1997
1994-95 Sweden Rainbow trout 9 nd 3 6 2
(22.2%)
4b Ericsson et a i ,  1997
1995 France Soft cheese 33 5 11 17 4 4b Goulet et a i, 1995
1996 Canada Crab meat 2 0 0 2 0 l/2a McLaughlin et al., 2004
1997 Italy Sweet com 1566 nd 0 1566 0 4b Aureli éta l., 1997
1997 France
Pon 1’Eveque 
cheese 14 nd nd nd nd 4b Rvser. 1999
1997 Denmark nd 3 nd nd nd 0 4 Heitmann et a l ,  1997
1998-99 Finland Rainbow trout 5 nd 0 5 0 l/2a Meittincn et a!., 1999
1998-99 Finland Butter 25 24 0 25 6 3a Lyytikainen et a l .  2000
1998-
1999
USA Hot dog/deli 
meats
101*dl nd nd nd 21 *d2 (21
%)
4b Anon., 1999
1999 England
Cheese/cheese
salad
sandwich
2 2 0 2 1 4b McLaughlin et a l ,  2004
1999-
2000
France Pork rillettes 10 6 3 7 2 4b de Valk et al., 2001
1999 England
Cheese/cheese
salad
sandwich
2 2 0 2 1 4b McLaughlin et a i,  2004
1999-
2000
France Pork rillettes 10 6 3 7 2 4b de Valk étal., 2001
1999-
2000
France Jellied pork 
tongue
32 11 9 23 10 4b de Valk é ta l ,  2001
1999-
2000
France Pork tongue 
in aspic 26 nd nd nd 7 nd Dorozynski et a l,  2000
2000 New
Zealand
Cold meats 7 nd nd nd 0 Unspecified 
1/2 serovar
S im et a i, 2002
2000 New
Zealand
Cold meats 21 nd nd nd 0 Unspecified 
1/2 serovar
Sim étal., 2002
2000 USA Turkev meat 29*' nd 8 21 7 nd Anon., CDC 2000b
2000-01 USA Mexican-style 
soft cheese
12 1 10 2 5 nd Anon., CDC 2001
2001 USA Sliced turkey 16 nd nd lid 0 l/2a Frye e t a l ,  2002
2002 USA Sliced turkey 63 *f 30 11 7 10*e nd
Current Class Actions. 
2002.
(www.kbmoll.com/class 
Anon., CDC 2002b
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Hospital food  implicated.; *°2, 50 % o f patients were immunosuppressed owing to cancer, 
chemotherapy or steroid treatment. 60 % reported use o f antacids or cimetidine (inhibitors o f 
gastric acid).
*\ Information not available to classify 41 patients.
*c, 1 foeta l demise confirmed.
Spread over 22 states.; ¥>2, Included 15 adult deaths and 6 miscarriages.
Spread over 10 states.
*r, Spread over 8 north-eastern states.
*s, Includ ing  3 m iscarriages o r stillb irth s.
It is clear from examination of frequently implicated foods, that serotype l/2a is more 
frequently isolated from food and food-processing areas than serotype 4b. In fact recent 
studies would indicate that serotype l/2a is becoming the single most frequent cause of 
listerial contamination of food (da Silva el al., 2001; Pak et al., 2002; Wagner and 
Allerberger, 2002). It is also significantly more frequently isolated from infected ruminants 
(Low et al., 1993). Whether this can be taken as evidence that serotype 4b exhibits a 
genuinely more potent tropism towards human hosts, as suggested by Kathariou (2002), is 
debatable. The ability of l/2a serovars to particularly thrive in silage may be responsible for 
its apparent prevalence in ruminants and both dairy and vegetable produce. Moreover, oral 
inoculation of pregnant mice with serovars l/2a and 4b failed to reveal any discernable 
difference in infectivity (Lammerding et al., 1994).
Recent trends indicate that serovar 1/2 strains are becoming increasingly prevalent in human 
isolates (Gemer-Smidt et al., 1995; McLaughlin and Newton, 1995; Loncarevic et al., 1998). 
For instance, the situation in Sweden has changed significantly since 1985. For the period 
1986-1999, 45 % of human isolates belonged to serovar 4b while 44 % belonged to serovar 
l/2a (Unnerstad, 2001). The proportion of serotype 4b strains isolated in human cases has 
decreased markedly, with an estimated 30 % prevalence in 1999-98 falling to 10 % in 2000 
(Unnerstad, 2001), while l/2a prevalence continues to increase.
The prevalence in livestock is conservatively estimated to be between 1 and 10 % and a 
typical report from Germany in 1997 where a 49,324 livestock sample population was tested, 
L. monocytogenes was detected in 4 % of test animals (Anon, 1999 E.C. Vet. Comm.). Low- 
level exposure to L. monocytogenes generally only leads to symptomatic listeriosis in 
susceptible hosts with suppressed immune responses or other predilection to disseminated 
infection. It has been indicated that the prevalence of asymptomatic carriage within the human
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population can range from less than 1 % to as much as 21 % (Kampelmacher and Van Noorle 
Jansen, 1980; Gledel, 1987; Farber and Peterkin, 1991; Hof, 2001; Anon., FSIS/USDA. 
2003b). As with attempts to establish a minimum infective dose, it is undetermined as to how 
faecal carriage relates to length of incubation or manifestation of symptomatic, invasive 
listeriosis (Anon., FSIS/USDA. 2003b). Although described as ‘asymptomatic’, such a high 
circulating prevalence of L. monocytogenes in the human population cannot be disregarded as 
a source of contamination. It is now apparent that L. monocytogenes can rapidly colonise inert 
food-processing surfaces such as stainless steel (Herald and Zottola, 1988; Arizcun et ah, 
1997; Wong, 1998) and become almost endemic, leading to widespread endemic 
contamination of various food types (Jay, 1996; Pak et al., 2002; Silva et al., 2003; Aguado et 
al., 2004). Endemic colonisation with L. monocytogenes has been confirmed in both dairy 
plants (Unnerstad et ah, 1996), and fish-processing plants (Loncarevic et ah, 1996). It is also 
noteworthy that in a recent study conducted by Okutani and co-workers (2004), in Japan, the 
prevalence of L. monocytogenes in foods was found to be comparable to that found in both 
the USA and Europe. However, the mean incidence of listeriosis was substantially lower. This 
re-affirms the notion that the incidence of listeriosis in the population may not be solely 
proportional to the degree of prevalence in food material. It is likely that it is a cumulative 
function of contamination level, food type, serotype virulence/diversity and the health status 
of the population and associated predispositions to infection.
1.6 B io d ive rs ity  o f  c lin ic a lly  im portan t stra in s
It has been suggested that food-related environmental factors (such as presence of 
bacteriocins) may offer an explanation as to why l/2a predominates in food isolates. More, 
specifically, the demonstrated capacity of serotype l/2a to survive prolonged cold storage 
may lead to more efficient isolation of this strain from foods, while the ability of serotype 4b 
strains to proliferate after post-cold storage heat treatment, may lead to more concentrated 
contamination levels and, thus, increased likelihood of infection (Buncic et ah, 2001).
Comparison of the l/2a and 4b genomic sequences has thus far failed to provide a conclusive 
answer to the apparent strain diversity. A l/2a-specific operon that encodes the rhamnose 
biosynthetic pathway, associated with teichoic acid biosynthesis, in addition to operons for 
five glycosyl transferases and an adenine-specific DNA methyl transferase, may confer a 
competitive advantage to l/2a in environmental niches (Nelson et ah, 2004). In addition, a 
gene encoding a bile salt hydrolase (BSH) enzyme has been identified in the L. 
monocytogenes 4b genome, which confers increased bile resistance (Dussurget et ah, 2002).
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More recently, the L. monocytogenes-speciftc ‘au t’ gene, which encodes a GW-anchored 
autolysin (Auto), has been shown to be necessary, but not sufficient for invasion of epithelial 
and fibroblastic cell lines by certain L. monocytogenes strains (Cabanes et al., 2004). 
Curiously, the aut gene is absent from the L. monocytogenes 4b genome (Cabanes et al., 
2004). Correspondingly, at least three L. monocytogenes serovar 4b-specific surface protein- 
encoding genes have been putatively identified in 4b (Doumith et al., 2004), and these may 
confer increased virulence. In addition, the production of truncated InIA protein (Jonquiéres et 
al., 1998) has recently been cited as a major impairment to the cellular invasion mechanism of 
Listeria  monocytogenes (Olier et al., 2003). Furthermore, a close analysis of clinically 
isolated strains has revealed that variant strains, producing truncated InIA proteins tend to be 
of the 1/2 (specifically a and b) serovars (Jacquet et al., 2004).
Following successful internalisation, hexose phosphate transport system (Hpt) is used by L. 
monocytogenes to obtain nutrients from the host cell cytosol, in particular, glucose-1- 
phosphate, which is abundant in the cytosolic compartment (Chico-Calero et al., 2002). The 
significance of Hpt is underlined by the fact that hpt' L. monocytogenes mutants are avirulent 
in the mouse model (Taylor et al., 2002). Moreover, hpt+ L. innocua demonstrate increased 
adherence to Hep-2 cells, although this has not been linked to a concomitant increase in 
overall internalisation efficiency in the same L. innocua mutant (Slaghuis et al., 2004). The 
evidience would suggest that Hpt is a vital virulence determinant for intracellular survival and 
proliferation of L. monocytogenes.
1 .7  Leg is la tio n
The epidemiological profile of listeriosis has highlighted the need for increased clinical 
vigilance as well as improved monitoring, screening and control of the food preparation 
environment.
The USA were the forerunners in terms of addressing clinical surveillance, with the CDC, 
USDA and FDA co-establishing the Foodborne Disease Active Surveillance Network 
(FoodNet) in the mid 1990’s. This incorporated PulseNet, a national network of Public Health 
laboratories that fingerprint foodborne pathogens, such as L. monocytogenes, using pulsed- 
field gel electrophoresis (Donnelly, 2001). The situation in Europe was, until recently, less 
harmonised, with each member state responsible for defining case criteria and collecting 
notifiable case data. Listeriosis is reported to be a mandatory notifiable disease in Finland, 
Italy, Sweden, Denmark and Norway. While, in Spain, reporting is based on the
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microbiological information system operated within hospital laboratories (SIM) (Anon,
2001). Switzerland, in addition to reporting cases to the Federal Office for Public Health 
(FOPH), has established the dedicated Centre National de référence des Listérias (CNRL, 
Institute of Microbiology, CHUV, Lausanne), while the sentinel surveillance network, 
operated in France, is comprehensively reviewed elsewhere (Leclerc et al., 2002). In eight 
countries infections in children under one year old are notified, while, the position in Sweden 
is that mother and child/foetus is regarded as one case and in Germany, a new act notifies co- 
natal infections and cases of meningitis from all sixteen Federal Länder (Anon, 2001). Case 
definitions are less defined in all other member states. Based on EU Decision 2119/98/EC 
(Community Network for the Epidemiological Surveillance and Control of Communicable 
Diseases) the various national reference laboratories have agreed to co-operate in a multi­
lateral surveillance network approach.
In light of the high mortality associated with listeriosis, the USDA/FDA/FSIS have adopted a 
‘zero-tolerance’ approach, that, stipulates L. monocytogenes should not be present in 25g of 
any given food sample (Shank et al., 1996). Italy also enforce a ‘zero-tolerance’ approach, 
while other EU member states such as Germany, Netherlands and France have a tolerable 
level of 100 or 1000 L. monocytogenes I % at the point of consumption (ANON, 1999 Vet 
measures). These discrepancies in acceptable limits have significant economic implications, 
since food that has been processed in a country with a high tolerance level cannot be marketed 
in a country where more stringent cut-off levels are in place.
It has been suggested that complete absence of L. monocytogenes from all food may be 
unnecessary and unattainable (FAO/WHO working group, 1988). The UK PHLS has 
suggested that a cut-off level of 100 L. monocytogenes cells/g food may be more appropriate 
(McLaughlin, 1996). Fifteen trade associations in the USA have recently issued a request to 
the FDA to revise the acceptable levels of L. monocytogenes in certain foods that do not 
support growth of the bacteria, to 100 CFU/g. The FDA has provided the opportunity for 
public comment on the petition, to be submitted by the 9th August 2004 
(http://www.foodlineweb.co.Uk/FoodWeb/~). The epidemiological trends outlined in Section 
1.5, indicate that while such levels may be acceptable in healthy members of the population, 
even levels as low as 100 CFU/g could potentially cause symptoms in pre-disposed 
individuals. Several countries, including Canada (Färber and Hartwig, 1996), Germany, 
(BarteIt et al., 1999) and Denmark (Norrung et a l,  1999) have proposed a differential ranking 
of foods with respect to acceptable levels of L. monocytogenes contamination. These are 
based on each food group’s propensity to support growth of L. monocytogenes, whether or not
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the food is to be heated prior to consumption, the anticipated storage/shelf-life and likely 
consumer profile.
Table 1.5: Prevalence o fL. monocytogenes in food  samples in Europe, (2001).
Food Prevalence (%)
Beef and veal 0.6-15.4
Pork 0-40.6
Other meat 0-22.2
Minced meat 11.9-18.3
Meat products 0-10.2
Poultry meat 2.6-16.7
Poultry meat products 0-7.6
Milk 0-2.2
Milk products 0-4.4
Fish products 0-13.5
Vegetables 0-12.5
Other ready-to-eat 
(RTE) food
0-16.7
Recently, the European Commission has followed the US FDA in adopting a ‘zero tolerance’ 
attitude towards L. monocytogenes in ‘ready-to-eat’ foods in its proposed draft guidelines on 
the application of general principles of food hygiene to the management of L. monocytogenes 
in foods (Anon., 2004), although, current European Community legislation only provides for 
microbiological standards with regard to Listeria  in provisions for soft cheeses, pasteurised 
milk and other selected daily produce under the EU Council Directive 92/46/EEC (Table 1.7). 
Unfortunately, manufacturer-undertaken end-product testing is still not compulsory in the US 
or Europe, rather, this is conducted by the relevant regulatory authority. Manufacturers have 
incorporated the general principles of food hygiene and, in particular, the Hazard Analysis 
Critical Control Point (HACCP)-concept as described in the Food Hygiene Directive 
93/43/EEC. As a consequence, the fall in numbers of reported cases has demonstrated the 
efficacy of both veterinary inspection procedures and corrective measures based on HACCP 
(Goulet et al., 2001; Meyer-Broseta, el al., 2002). However, HACCP is not a ‘final solution’ 
to the problem of Listeria  in food. It is particularly difficult to generalise control points, with 
regard to L. monocytogenes contamination in food, due to the bacterium’s ubiquitous
35

presence, robustness and ability to multiply at refrigeration temperatures. To this effect, in a 
1999 Federal Register notice, the USDA advised manufacturers of ready-to-eat (RTE) meat 
and poultry products of the need to reassess HACCP plans to ensure that they adequately 
address L. monocytogenes. This is in addition to, suggestions from the USDA for the 
incorporation of finished product testing as a verification tool (Donnelly, 2001). Failure to 
detect L. monocytogenes in food prior to product release can result in product recalls. The cost 
incurred with such recalls is frequently, significant, in both financial terms, and in relation to 
consumer confidence and allegiance. In 2002, 27.4 million pounds of turkey produce were 
recalled under the Wampler Foods brand of Pilgrims Pride corp., making it the largest meat 
recall in the history of the United States (www.belluckfox.com/listeria.html). This resulted in 
several fatalities and a subsequent nationwide class-action lawsuit filed by Kenneth B. Moll 
and Associates ('www.kbmoll.com/class) in November 2002. This highlighted the inefficiency 
in relying on manufacturer-implemented HACCP. In fact, several judicial commentators have 
referred to this strategy as “yanking the referees from the football field” and equivalent to a 
“have a cup of coffee and pray” attitude (www.belluckfox.com). In Europe, the Rapid Alert 
System for Food and Feed (RASFF) has been established under Article 8 of Directive 
92/59/EEC, to provide a procedure to inform the member states of when a product represents 
a serious risk for the health and safety of consumers 
(http://europa.eu.int/comm/food/fs/sfp/ras_index). On 21st February 2002, RASFF received a 
new legal base (Regulation (EC) No. 178/2002) to extend the system to include all food and 
feed products finally destined for human consumption. ‘Alert’ notifications relate to products 
which are on the market and which present a risk to the consumer, while, ‘Information’ 
notifications relate to products presenting a risk to the consumer for which it can be assumed 
that they have not yet reached the market or for which the risk is limited. Data for the year 
ending 2002 indicated that L isteria  were responsible for 17 % of microbiological reasons for 
alert notifications and 13 % of information notifications
(http://eurQpa.eu.inl/comm/food/fs/sfp/ras report2002). Thus, it is clearly apparent that both 
the food industry and the consumer would benefit from an efficient means of rapidly 
screening end produce for the presence of L. monocytogenes.
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Tablel.6: Reported cases of listeriosis in Europe, (1996-2001).
Country
Listeriosis cases
1996 1997 1998 1999 2000 2001
Belgium 77 40 60 64 48 57
Denmark 39 33 41 44 39 38
Finland 29 53 46 46 18 28
France - 243 238 275 261 187
Germany 32 27 41 31 33 213’’
Greece - - 1 1 2 3
Ireland - 7 4 - 7 7
Italy 32 64 45 17 13 31
Portugal - - 0 - - -
Spain 21 19 16 32 35 57
Sweden 28 18 32 27 46 67
Holland 22 22 23 12 19 16
Scotland 11 6 13 7 11 15
Northern
Ireland
2 4 6 1 4 5
England/Wales 116 118 91 108 100 136
Norway - - - 19 18 18
New classification o f cases beginning 1st January 2001.
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Table 1.7: Current m icrobiological crite ria  fo r foodstuffs in European Community 
legislation, with reference to L. monocytogenes.
Sam pling
Food ca tegory L im it N c
Cheeses made from raw milk and 
thermized milk
(Directive 92/46/EEC, SI 9/1996)
Absence in 1 g (hard 
cheeses) or in 25 g 
(other)
5 0
Soft cheese (made from heat-treated 
milk)
(Directive 92/46/EEC, SI 9/1996)
Absence in 25g 5 0
Fresh cheese
(Directive 92/46/EEC, SI 9/1996) Absence in 25 g 5 0
Other cheeses than those mentioned 
above
(Directive 92/46/EEC, SI 9/1996)
Absence in lg (hard 
cheeses) or in 25 g 
(other)
5 0
Powdered milk and milk-based products 
(Directive 92/46/EEC, SI 9/1996) Absence in lg 5 0
Frozen milk-based products 
(Directive 92/46/EEC, SI 9/1996) Absence in lg 5 0
Liquid milk-based products 
(Directive 92/46/EEC, SI 9/1996) Absence in lg 5 0
Butter
(Directive 92/46/EEC, SI 9/1996) Absence in 1 g 5 0
N: The number o f units making up the sample.
c: The number o f sample units where the L. monocytogenes ce ll count can be above the 
defined lim it.
1.8 C u rre n t detection m ethods
Originally, the ability of L. monocytogenes to grow at low temperatures was taken advantage 
of for isolation of the bacterium from clinical samples in a process termed ‘cold-enrichment’ 
(Gray et al., 1948; Gray and Killinger, 1966). It was not uncommon for this process to require 
up to eight weeks (Hayes et al., 1991) of continuous, repeated sub-inoculation and incubation 
from the original sample (stored at 4 °C), before L. monocytogenes was successfully isolated
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and identified as blue colonies using oblique trans-illumination or ‘Henry-light’ illumination 
(Henry, 1933). Cold-enrichment is no longer seen as necessary (Grif eta l., 2001).
Contemporary and traditional methods of detection, specifically pertaining to food samples, 
rely exclusively on the use of specific growth media to isolate and enumerate viable bacterial 
cells from food samples, followed by serological and biochemical confirmatory tests (e.g. ISO 
10 560:1999; ISO 11 290:1996), as validated by Scotter et al., (2001a) and Scotter et a l,  
(2001b). It is often necessary to resuscitate contaminating L. monocytogenes cells that may 
have been partially inactivated, by a primary enrichment phase. As the numbers of Listeria  
monocytogenes present in food, especially in daily products, are usually low, attempts to 
directly isolate L isteria  monocytogenes frequently fail (Doyle and Schoeni, 1987). The 
primary enrichment broth is, thus, supplemented with the selective components- one volume 
of LiCl and half volumes of both acriflavine and nalidixic acid (half Fraser broth)- and 
incubated with the relevant food sample at 30 °C for 24 hrs. Secondary enrichment is 
conducted in broth containing a full complement of the selective agents (Fraser broth) at 35 °C 
or 37 °C for 48 hrs. Samples from both the primary and secondary enrichment cultures are 
streaked onto the selective agar media, PALCAM (polymyxin-acriflavine-LiCl-ceftazidime- 
aesculin-mannitol) or Oxford agar. Both these media presumptively identify L isteria  spp. by 
revealing Esculinase ((3-glucosidase) activity. After incubation at 30 °C for 24 hrs the Oxford 
agar plates are examined for the presence of typical small L isteria  spp. colonies. After a 
fiither 24 hrs the L isteria  colonies adopt a distinctly darker shade with a greenish halo and 
concave colony centres. The PALCAM agar is incubated at 30 °C for 48 hrs under 
microaerobic conditions and Listeria  spp. colonies appear grey-green with concave centres 
that are black in colour. It has been reported that PALCAM agar is more selective than 
Oxford agar (Gunasinghe et al., 1994). Suspect colonies are transferred to blood agar plates 
and incubated at 35 °C or 37 °C for 18 hrs. At this stage results are still presumptive and have 
to be further confirmed using a selection of the biochemical tests outlined in Section 1.2.
The diagnostic problems associated with such ‘horizontal’ detection methods have been 
recently reviewed (Beumer and Hazeleger, 2003; Leclercq, 2004). The outstanding limitation 
is the ‘sample-to-result’ time that takes a minimum of six full days. Another major concern is 
the inability to detect L. monocytogenes in the presence of other, non-pathogenic Listeria  
spp., such as L. innocua, that frequently appears as a co-contaminant and exhibits a 
competitive growth advantage over L. monocytogenes in enrichment media (Rijpens and 
Herman, 2004; Cocolin et al., 2002; Cornu et al., 2002; Beumer et al., 1996; Curiale and 
Lewis, 1994; MacDonald and Sutherland, 1994;), possibly due to production, by L. innocua 
of anti-Z. monocytogenes bacteriocin-like inhibitors (Yokoyama et al., 1998). These have
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prompted the investigation of alternative enrichment media with faster and more reliable 
discriminatory selectivity. Two such media are Rapid’L.mono (Bio-Rad) and ‘Agar Listeria 
according to Ottaviani and Agosti’ or ALOA ( Vlaemynck el al., 2000). These discriminate 
on the basis of phosphatidylinositol-specific phospholipase C activity in Listeria  spp.. Both 
media have recently been compared with the recommended PALCAM and Oxford media 
(Leclercq, 2004). Despite improving the degree of successful descrimination of L isteria  spp. 
when used instead of or with the recommended media, neither was effective in reducing the 
selective enrichment period.
1.9 R a p id  m ethods
Most commercially available tests (Table 1.8) for the rapid detection of Listeria  spp. from 
food samples in selective enrichment broths are immunoassay-based (Allerberger, 2002). In 
addition to traditional ELISA-based immunoassays, paddle style dipstick (PSD) and lateral 
flow immunoassay (LFIA) formats, as described by Aldus and co-workers (2003) and Capps 
and co-workers (2004), for detection of verotoxigenic E. co li, have been gaining prominence 
as rapid and easy-to-use commercial platforms. At present, many of the antibodies employed 
in commercial kits are broadly reactive and only allow detection of L isteria  to the genus level.
Similarly, antibodies that favourably react with Listeria  spp. are frequently reported in the 
literature (Bhunia, 1997). However, most are of limited potential for the specific 
immunodetection of L. monocytogenes. Several reportedly react with numerous Listeria  genus 
members (Butman et al., 1988; Mattingly et al., 1988; Siragusa and Johnson, 1990; Torensma 
et al., 1993; Loiseau et al., 1995), while others react with L. monocytogenes in addition to 
non-pathogenic L. innocua (Bhunia et al., 1991; Bubert et al., 1994; Kathariou et al., 1994, 
Solve et al., 2000). Inabilty to differentiate between live and dead cells is also a pervading 
limitation (Siragusa and Johnson, 1990; Butman et al., 1998). Kathariou and co-workers, 
(1994) successfully generated antibodies capable of reliably discriminating live from dead L. 
monocytogenes serotype 4b cells, yet they failed to recognise other L. monocytogenes 
serovars, including the 1/2 (a, b and c) varieties which consistently predominate in food 
isolates (Boerlin and Piffaretti, 1991; Rocourt, 1994; da Silva et al., 2001; Pak et al., 2002; 
Okutani et al., 2004).
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Table 1.8: Table of commercially available antibody-based tests for Listeria.
T est F o rm at S u p p lie r
Assurance Listeria EIA*1 
Used to identify Listeria spp. 
including L. monocytogenes
Enzyme immunoassay
BioControl Systems, Inc.
www.biocontrolsvs.com
VIP for Listeria* '
Used to identify Listeria spp. 
including L. monocytogenes
Visual imniunoprecipitate
BioControl System, Inc 
www.biocontrolsvs.com
Transía Plate
Used to identify L. 
monocytogenes
Sandwich-type enzyme 
immunoassay
Diffchamb
www.diffchamb.com
Dynabeads nnti-Listeria
Used to identify L. 
monocytogenes
IMS
Dynal, Inc.
www.dvnal.no/
EIA Foss Listeria
Combination of ELISA and 
IMS
Foss N. America, Inc. 
www.Fossnorthamerica.com
Listeria Rapid Test*1
Used to identify Listeria spp. 
including L. monocytogenes
EIA Oxoid, Inc.
Listeria-Tek™ * 1 ELISA Organon Teknika Corp.
ListerTest ™*' IMS
Vicam, L.P.
www.vicam.com
MICRO-ID Listeria*1
Used to identify Listeria spp.
Latex agglutination
Remel, Inc. 
www.remelinc.com
Reveal® for Listeria*' 
Used to identify Listeria spp
Sandwich ELISA
Neogen Corporation
www.neoiien.com
VIDAS LMÜ
Used to identify L. 
monocytogenes
Enzyme-linked fluorescent
assay
(Sewell et al., 2003) 
BioMerieux Inc. 
www.biomerieux.com
Singlepath® GLISA Listeria
Used to identify Listeria spp
(LFIA)Gold-labelled 
Immunosorbent assay
Merck, Inc. 
www.merck.com
RapidCliek” for Listeria*1 
Used to identify Listeria spp
LFIA
Strategic Diagnostics
www.sdix.com
Unique® Listeria*1 PSD
TECRA International
www.sdix.com
*' :AOAC Approved (www.aoac.ors).
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Thus, there is still a major requirement for antibodies that are capable of reliably and 
specifically detecting live L. monocytogenes cells for the development of immunoassays 
suitable for routine analysis.
Molecular methods, in particular the polymerase chain reaction (PCR), have gained 
increasing favour for detection of pathogens, such as L. monocytogenes in food samples 
(Wernars et ah, 1991; Fluit et ah, 1993; Makino et ah, 1995; Manzano et al., 1997; Scheu, et 
ah, 1999; Olsen et ah, 2000; Norton, 2002). PCR has provided the basis for many assays 
developed for the detection of L. monocytogenes in recent years with the listeriolysin O (hlyA) 
(Deneer and Boychuk, 1991; Golsteyn Thomas, 1991; Norton and Batt, 1999), the p60 (iap) 
(Bubert et ah, 1997a; Bubert et ah, 1997b; Hein et ah, 2001; Schmid et ah, 2003), the Actin 
A (.ActA) (Longhi et ah, 2003) and the intemalin (in lAB ) (Almeida and Almeida, 2000; 
Ingianni et ah, 2001; Pangallo et ah, 2001; Kaclikova, et ah, 2003; Jung et ah, 2003) genes 
being frequent targets. As with immunoassays, there are several commercial test kits that 
incorporate this strategy for more rapid, sensitive and reliable detection of L. monocytogenes. 
These include the BAX® Screening System (Qualicon, USA) (Norton et ah, 2000; Hoftnan 
and Wiedmann, 2001) and the Probelia® L iste ria  monocytogenes (Sanofi Diagnostic Pasteur) 
microplate method. The latter system employs a peroxidase-labelled probe to detect L. 
monocytogenes-specific amplicons.
Complications with PCR-based approaches are common. The presence of inhibitory 
substances such as organic and phenol compounds, glycogen fats and Ca2+ ions in food 
samples (Rossen et ah, 1992; Wilson, 1997) can effect performance. To combat this, various 
extensive DNA extraction procedures have been described (Lantz et ah, 1994; Makino et ah,
1995), but these are often cumbersome and time consuming and involve hazardous reagents 
such as phenol-chloroform, and present a significant risk of losing target DNA in each 
purification step (Garrec et ah, 2003). With the developments in production of Listeria- 
specific antibodies, immunomagnetic separation (IMS) and immunocapture centrifugation 
(ICC) has been reported to offer a more reliable method of isolating and enriching (Z. 
monocytogenes) cells from food complex food matrices (Uyttendale et ah, 2000; Hudson et 
ah, 2001; Hsih and Tsen, 2001; Kaclikova, et ah, 2001). However, perhaps the single most 
significant limitation associated with direct PCR-based detection, is the inability of the 
process to discriminate dead from live cells. An inherent problem with such methods is, that 
they cannot effectively discriminate viable from dead cells. The only practical way of 
addressing this inherent limitation is by incorporating a lengthy enrichment step to, hopefully, 
‘dilute out’ the dead cell population. This concomitantly negates the perceived improvement 
in sensitivity over the antibody-based approach. Alternatively, targeting mRNA by RT-PCR
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would undoubtedly abrogate false positives arising from dead cells. However, the expression 
of many Listeria- specific genes, such as in i A, is principally synchronised at the transcriptional 
level. Thus, levels of mRNA, even in moderately large populations, may be quite low. It is 
highly likely that reliable detection of InlA-encoding mRNA would necessitate extended 
enrichment at 37 °C to achieve appropriate levels of exponentially growing cells. Thus, 
apparent improvements in sensitivity attributed to PCR-based detection of L. monocytogenes 
must retain the caveat of acknowledgement of the need for an associated enrichment step. The 
necessity of enrichment was clearly demonstrated in a recent comprehensive analysis of 
multiple factors affecting the sensitivity of a PCR-based method for detecting L. 
monocytogenes in food samples, conducted by Aznar and Alarcon (2003).
At present, the traditional horizontal isolation method is still the ‘gold-standard’ (Allerberger,
2002) for detection and identification of L. monocytogenes. With the increasing 
epidemiological significance of L. monocytogenes, in terms of public health concerns and the 
associated implications for food-processing industries, the need for more rapid, user friendly 
and discriminatory tests for L. monocytogenes has never been greater. The major objective of 
this work was to produce a monoclonal antibody suitable for reliable detection of L. 
monocytogenes and also to demonstrate it’s potential for application in ‘real-time’ 
identification of L. monocytogenes from enriched cultures.
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C h a p t e r  2
M a t e r i a l s  a n d  M e t h o d s
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2.1 Equipment
Table 2.1: Equipment model used and suppliers.
Class Model Source
AFM instrument Nano-R™ AFM  instrument 
AFM  Image Analysis 
software
Pacific Nanotechnology, 3350 Scott B lvd., 
Suite 29, Santa Clara, CA 95054,USA.
Biacore™ Biacore™ 1000 
Biacore™ 3000
Biacore A B , Church Farm, Eyeworth, 
Bedfordshire, SGI 2HH, UK.
Blood tube rotator SB 1 Blood tube rotator Stuart Scientific, Holmthorpe Industrial 
Estate, Redhill, Surrey, U K
Centrifuges Heraeus Christ Labofuge 
6000
Biofuge A  M icrocentrifuge
Heraeus Instruments Inc., 111a Corporate 
Boulevard, South P lainfield, New Jersey, 
07080, USA.
Beckman J2-21 centrifuge Beckman-Coulter Inc., 4300N Harbour 
Boulevard, Fullerton, CA 92834-3100, USA.
C02 Tissue culture 
incubators
EG 115 IR Heraeus Instruments Inc., 111a Corporate 
Boulevard, South P lainfield, New Jersey, 
07080, USA.
Thermoforma series I I  
3110 series
Biosciences, 3 Charlemont Tee., Crofton Rd., 
Dun Laoghaire, Dublin, Ireland.
Evaporation unit Pierce Evaporation U nit Pierce, 3747 North M eridian Road, PO box 
117, Rockford, IL  61105, USA.
HPLC apparatus System Beckman Gold 
Software
Beckman-Coulter Inc., 4300N Harbour 
Boulevard, Fullerton, CA 92834-3100, USA.
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Yarian Star 9030 pump, 9012 
U V  detector, Fluorescence 
detector, AI-200 autosampler
J.V.A. Analytica l Ltd., Long M ile  Rd., 
D ublin 12, Ireland.
Phenomenex 3000 SEC 
column
Phenomenex (U K ), Queens Ave., 
Huddersfield Ind. Est., Macclesfield, 
Cheshire SK10 2BN, UK.
Laminar flow units Holten 2448K laminar air 
flow  unit
Holten Lam inar A/S, Gydevang 17, D K  3450 
A llerod, Denmark.
FASTER BH2000 Biosciences, 3 Charlemont Tee., Crofton Rd., 
Dun Laoghaire, Dublin, Ireland.
Microplate reader Titertek Multiscan plate 
reader
M edical Supply Company, Damastown, 
Mulhuddart, Dublin 15, Ireland.
Microscope Nikon Diaphot inverted 
microscope
Nikon Corporation, 2-3 Marunouchi 3- 
chome, Chiyoda-ku, Tokyo, Japan.
Millipore filtration 
apparatus
M illipo re  F iltration Device 
(250 m l reservoir)
M illipo re , 290 Concord Road, B ille rica, M A  
01821, USA.
Orbital incubator Gallenkamp orbital incubator 
(100X400.XX1.C)
Sanyo Gallenkamp PLC., Monarch Way, 
Belton Park, Loughborough, Leicestershire 
L E U  5XG, UK.
pH meter 3015 pH meter Jenway Ltd., Gransmore Green, Felsted 
Dunmow, Essex CM6 3LB, UK.
Protein
electrophoresis
apparatus
A tto  dual m inislab system 
AE-6450
A tto  Corp., 2-3 Hongo 7-Chrome, Bunkyo- 
K ui, Tokyo 113, Japan.
Rocker platform Stuart Platform Shaker STR6 Lennox, P.O. Box 212A, John F. Kennedy 
D rive, Naas Rd., Dublin 12, Ireland.
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UV gel analyser 
UV
Spectrophotometer
Ultrafiltration cell
PCR machine
Waterbath
SEM instrument
UVP ImageStore 7500 gel 
documentation system 
UV-160A
Stirred C ell 8400
Biometra T  gradient Uno II 
Thermocycler
RM6 Lauda waterbath
Hitachi S 300N SEM
SEM Image Analysis 
software
Shimadzu Corp., 1 N ishinokyo- 
Kuwabaracho, Nakagyo-ku, Kyoto 604, 
Japan.
Am icon Inc., Beverly, Massachusetts 01915, 
USA.
Anachem L td ., Anachem House, Charles St., 
Luton, Bedfordshire, UK.
AGB Ltd., D ublin  Industrial Estate, D ublin
11, Ireland.
H itachi Corp. Ltd., 6-6 Marunouchi 1-chôme, 
Chiyoda-ku, Tokyo 100-8280, Japan.
Oxford Instruments, M icroanalysis Group, 
H alifax Road, H igh Wycombe, Bucks HP 12 
3 SE, UK.
Ultra Violet Products Ltd.
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2.2 Consumable items
Table 2.2: Consumables used and suppliers
Class Item
Disposables Eppendorf tubes, PCR tubes and 
pipette tips
Source
Sarstedt Ltd., Sinnatstown, Drinagh, 
W exford, Ireland.
Sterile universals Medical Supply Company, 
Damastown, Mulhuddart, Dublin 15, 
Ireland.
Nunc Maxisorp™ plates (439454)*a Nunc, Kamstrup, D K, Roskilde,
Tissue culture plastic-ware Denmark.
Nitrocellulose membrane Schleicher and Schuell Bioscience 
GmbH, Hahnestrasse3, D-37586, 
Dassel, Germany.
Filters Acrodisc® 0.2 (iM  syringe filters
Nanosep™ u ltra filtra tion  membraues 
Omega™ 1.0, 10.0 and 50 kDa 
polyethersulfone membrane filte rs
PALL Corp., Newquay, Cornwall, 
U K. (c/o VW R International Ltd., 
Rath Business Park, Ashbourne Co. 
Meath, Ireland.)
Durapore® 0.2 and 0.45 jam 
membrane filte rs (HVLP4700)
Sensor Sensor chip CM5 (BR-1000-14)*b
chips Sensor chip C l (BR-1005-40)*h
Sensor chip CM4 (BR-1005-39)*h 
Sensor chip N TA (BR-1004-07fh
(): Catalogue code.
*": Certified grade.
' : Research grade.
M illipore , 290 Concord Road, 
B illerica, M A  01821, USA. (c/o 
AGB Scientific Ltd., Dublin 
Industrial Estate, D ublin 11, 
Ireland.)
Biacore AB, Church Farm, 
Eyeworth, Bedfordshire, SGI 2HH, 
UK.
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2.3 Reagents and chemicals
A ll chemicals were reagent grade and were purchased through Sigma-Aid rich Co. (Poole, 
Dorset, England) except as noted below.
Table 2.3: Reagents and chemicals used:
Class Chemical Supplier
Biochemistry Alkaline phosphatase-labelled secondary 
antibodies:
Caprine anti-mouse IgG and IgM  (222-CK- 
6GM)
Caprine anti-mouse IgG2a (222-AB-6G4Z)
AMS Biotechnonogy (Europe), 
185 A  and B M ilton  Park, 
Abingdon, Oxon, 0X 14 4SR, UK.
BSA-free anti His-tag monoclonal antibody 
(70796-3)
Novagen Inc., 441 Charmany Dr., 
Madison, W I 53719, USA.
Phosphate buffered Saline tablets (BR0014) Oxoid, Basingstoke, Hampshire, 
UK.
Pre-stained molecular weight markers 
BlueRanger® (26681)
BCA protein assay k it (23225)
Pierce, 3747 North M eridian Road, 
PO box 117, Rockford, IL  61105, 
USA.
Amine coupling k it (BR-100-50) Biacore AB, Church Farm, 
Eyeworth, Bedfordshire, SGI 2HH, 
UK.
Osmium tetroxide (75633) Fluka Chemie AG, Industriestrasse 
25, 9471, Buchs, Switzerland.
Genetics PCR Primers MW G-Biotech Ltd., M ilton  Keynes 
MK12 5RD, UK.
Restriction enzymes and compatible buffers New England Biolabs, 32 Tozer 
Rd., Beverley, M A  01915-5599, 
USA.
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Wizard® Plus SV M ini-prep k it (A1330) 
Pfu D N A polymerase (M7741)
Promega Corporation, 2800 Woods 
H ollow  R d„ Madison, W I53711- 
5399, USA.
Perfectprep® gel cleanup k it (0032 007.740) Eppendorf AG, 22331, Hamburg, 
Germany.
N i-N TA  Superflow resin (30430) 
pQE-60 plasmid
Qiagen Ltd., Qiagen House, Fleming 
Way, Crawley, West Sussex RH10 
9AX, UK.
Microbiology Bacteriological media:
Brain heart infusion broth (B H I) (CM225) 
Liste ria  enrichment broth base (LEB) (CM863) 
Yeast extract (L0021)
Tryptone (L0042)
Agar technical (Agar No. 3) (L0013)
Oxoid, Basingstoke, Hampshire, UK.
Tissue culture Briclone Archport Ireland Ltd., D ublin C ity 
University, Glasnevin, D ublin 9, 
Ireland.
Fetal ca lf serum (10270-106)
L-glutam ine (200mM) (lOOx) (25030-024) 
Non-essential amino acids (1 OOx) (11140-035) 
Sodium pyruvate (100 mM) (11360-039)
Gibco BRL, Trident House, Renfrew 
Rd., Paisley PA4 9RF, Scotland, UK.
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Table 2.4: Bacterial cultures used:
Genus Species Strain Source
L iste ria  spp. L. monocytogenes l/2a NCTC 4886 IFR
L. monocytogenes l/2 c NCTC 5348 IFR
L. monocytogenes 4a NCTC 5214 IFR
L. monocytogenes 4b NCTC 4885 IFR
L. innnocua 6a NCTC 11288 IFR
L. innnocua 6b NCTC 11289 IFR
L. ivanovii (PA )*a NCTC 11846 PA Lab, Dublin
L. ivanovii (PHLS) *b PHLS isolate IFR
L. welshimeri NCTC 11857 IFR
L. seeligeri ATCC 35967 IFR
L. monocytogenes (l/2 a ) 
EGDpERL3 50-1prfA-am
IFR*°
Non -L isteria  spp. Escherichia co li N C IM B 9485 DCU
Enterobacter aerogenes N C IM B 10102 DCU
Enterococcus fae c ilis N C IM B 775 DCU
Bacillu s subtilis N C IM B 1650 DCU
Bacillus cereus N C IM B  3329 DCU
Expression hosts Escherichia co li X L  10-Gold® Stratagene
Escherichia co li IN V a F ' Invitrogen
NCTC: National Collection o f  Type Cultures, Central Public Health Laboratory, 61 Colindale Avenue, 
London NW9 5HT, UK.
ATCC: American Type Culture Collection, Manassas, Virginia, USA.
NCIMB: National Collection o f  Food, Industrial and Marine Bacteria Ltd., 23 St. Machar Drive, 
Aberdeen AB24 3RYScotland, UK.
Stratagene: North Torrey Pines Rd., La Jolla, Ca. USA.
Invitrogen: 9704-CH-Groningen, Netherlands.
Provided by the Vincent Young and Rachel Hewitt at the Public Analyst (PA) Laboratory, Sir 
Patrick Duns Hospital, Dublin 2, Ireland.
*b: Serotype unconfirmed. Provided by Gary Wyatt at the Institute fo r  Food Research (IFR), Norwich 
Research Park, Colney, Norwich NR4 7UA, UK. Originally sourced from the UK Public Health 
Laboratory Service (PHLS).
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*c: Provided by Gary Wyatt at the IFR. Originally sourced from Prof. Trinad Chakraborty, Institute for  
Medical Microbiology and Virology, Giessen, Germany (Lingnau e l al„ 1995). This recombinant 
strain produces elevated PrfA protein levels. The origins o f  the pERL3 50-1 construct have been 
outlined elsewhere (Chakraborty et al., 1992; Domann e l al., 1992).
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2.3.1 Standard solutions
Phosphate buffered saline (PBS)
One tablet was dissolved per 100 mis o f d istilled water according to the manufacturer’ s 
instructions. When dissolved, the tablets prepare Dulbecco’s A  PBS which contains 10 mM 
phosphate buffer and 0.15 M  NaCl, pH 1.2-1 A.
Wash buffer (PBS/T)
PBS containing 0.05 % (v/v) Tween-20 {Sigma, P-7949).
D iluen t buffer (PBS/TM )
PBS containing 0.05 % (v/v) Tween-20. This was supplemented w ith  dry skimmed m ilk  
powder (M arvel) was at 1 % (w /v) when used fo r d ilu tion  o f secondary, en2yme-labelled 
antibodies.
Hepes buffered sa line (HBS)
Hepes buffered saline (Biacore running buffer) containing 50 mM NaCl, 10 mM  HEPES 
{Sigma, H-3375), 3.4 mM EDTA and 0.05 % (v/v) Tween-20 was prepared by dissolving 8.77 
g o f NaCl, 2.56 g o f HEPES, 1.27 g o f EDTA. and 500 p.1 o f Tween 20 in 800ml o f d istilled 
water. The pH o f the solution was then adjusted to pH 7.4 by addition o f 2 M  NaOH. The 
fina l volume was then made up to 1000 m l in  a volum etric flask. The solution was filtered 
through 0.2 p n  filte r and degassed prio r to use.
Trichloroacetic acid  (TCA)
A  100 % (w /v) stock solution o f TCA (Sigma T-9159) was prepared by adding 454 m l dH20  
to 1 Kg o f C2HCI3O2 and bringing the resulting solution up to a fina l volume o f 1000 m l w ith  
dH20 . The solution was stored at 4 °C.
(Warning: Due to the highly corrosive nature o f TCA, the so lid  was never weighed out, 
instead the water was always added to the original, fresh ly opened bottle o f TCA.)
2.3.2 Denaturing SDS-PA G E
Denaturing polyacrylam ide g e l electrophoresis (PAGE)
Polyacrylamide gel electrophoresis was carried out using the discontinuous system, in  the 
presence o f sodium dodecyl sulphate (SDS), as described by Laemmli (1970). 12.5 % (w /v)
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reso lv ing  and  5  % (w /v) stacking gels w ere  ro u tine ly  u sed  and  p rep ared  from  th e  fo llow ing  
s tock  so lu tions as ou tlined  in T ab le  2.5,
Stock Solutions
(A ) 30 %  (w /v) acry lam ide {Sigma, A3553) con tain ing  0.8 %  (w /v) N , N '-m ethy lene  bis- 
acry lam ide {Sigma, M-7179).
(B ) 1.5 M  T ris-base, pH  8 .8 , con ta in ing  0.4 %  (w /v) SDS {Sigma, L4509).
(C ) 0.5 M  T ris-base, pH  6 .8 , con ta in ing  0.4 % (w /v) SDS.
(D ) 10 %  (w /v) am m onium  persulphate.
Table 2.5: The quantities o f stock solutions required fo r the preparation o f two standard sized 
resolving and stacking gels used fo r polyacrylam ide gel electrophoresis.
So lu tion Resolving Gel 
(12.5 %)
Stacking Gel
(5%)
A cry lam ide (A ) 8.34 m l 1 . 6 6  ml
D istilled  W ater 6 .6  m l 5 .75m l
R esolving G el 
B uffer (B 1) 5.0 m l --------
S tacking G el 
B uffer (C 1)
2.5 m l
A m m onium  
P ersu lphate  (D )
1 0 0 ^ 1 60 ^ 1
T E M E D 15 nl 15 nl
Sam ples w ere  m ixed 6:1 w ith  6 x  sam ple bu ffer and  bo iled  fo r 5 m inutes before  load ing  onto  
the gel. E lec trophoresis w as conducted  in e lectrophoresis buffer, pH  8.3 a t 12.5 m A  for the 
stack ing  gels and  15 m A  fo r the  reso lv ing  gel, using  an A T T O  vertica l m in i e lectrophoresis 
system , un til the  track ing  dye reached  th e  bo ttom  o f  the gel.
5 4

Staining o f gels with Coomassie b rillia n t blue
G els w ere stained w ith  C oom assie  sta in ing  solu tion  fo r v isualisation  o f  pro te in  bands. G els 
w ere stained fo r 1 hr in 0.2  %  (w /v) C oom assie  b rillian t b lue dye in m ethanol:acetic  
acid :d istilled  w ate r (3:1 :6). G els w ere desta ined  overn igh t in  m ethano l:acetic  ac id :d istilled  
w ater (3:1:6).
Coomassie blue stain solution
C oom assie  B lue R -250 (Sigma, B-7920) 1.250 g
M ethanol 227  m l
dH 20  227 m l
G lacial acetic  acid  46  ml
T he com ponents w ere dissolved, m ixed  thorough ly , filtered  th rough  W hatm an paper
grade num ber 1, and stored a t room  tem peratu re  (R .T .) in a dark  bottle.
Destain solution
M ethano l 300 m l
G lacial acetic  acid  100 m l
dH 20  600 m l
T he above com ponents w ere  m ixed, thorough ly , and stored a t R .T .
5x Electrophoresis buffer
T ris-base  15.15 g
G lycine 72.00 g
SDS 5.00 g
T he com ponents w ere  d issolved in 1L o f  dH 2Q , and stored  a t R.T.
6x  Sample buffer (S1)
1.2 M  T ris-base (pH  6 .8 ) 10.0 ml
2-M E  (2-M ercap toethano l) 66.0 pi
B rom ophenol b lue 0 .06  g
G lycero l (99 .99  % pu rity ) 5.00 m l
SD S 2.40  g
T he com ponents w ere m ixed  in th is  order, b rough t to  20 ml w ith  dH 20  and  stored at -  
20 °C.
5 5

Acrylam ide stock solution (A)
A crylam ide 30 .00  g
M ethylene b isacry laraide 0 .80  g
The com ponents w ere d isso lved  in  100 m l dH 20, an d  sto red  in  the dark  a t 4 °C.
4x Resolving gel buffer (B1)
3.0 M  T ris-base (pH  8 .8 ) 50 .0  m l
1 0 %  (w /v) SD S 4 .0  m l
dH 20 46 .0  m l
The com ponents w ere thorough ly  m ixed  together, and  stored  a t 4 °C.
4x Stacking gel buffer (C1)
1.0 M  T ris-base  (pH  6 .8 ) 50.0 m l
1 0 %  (w /v) SD S 4 .0  m l
dH 20  46 .0  m l
The com ponents w ere tho rough ly  m ixed  together, and  stored  at 4 °C.
Ammonium persulphate solution (D)
A m m onium  p ersu lphate  0 .10  g
dH 20  1.00 m l
The com ponents w ere m ixed  thorough ly  and  stored a t - 2 0  °C.
2.3.3 N on -denatu ring -PA G E
Non-denaturing polyacrylam ide gel electrophoresis (PAGE)
T he procedure w as sim ilar to  th a t fo llow ed  fo r denatu ring  SD S P A G E  w ith  severa l key  
d ifferences. Sam ples an d  reagents w ere  k ep t free from  SD S and  2 -m ercap toethano l, a t all 
tim es. A  4 %  (w /v) stack ing  gel w as rou tine ly  used. R eso lv ing  gels conta in ing  vary ing  
acry lam ide concentrations w ere  em ployed  w ith  each sam ple been  analysed  over at least four 
d ifferen t concentrations (7, 8 , 9 and 10 %  (w /v) acry lam ide). S tock  so lu tions used, and  gel 
form ulations are ou tlined  in  T able 2.6.
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Stock Solutions
(A ) 30 % (w /v) acry lam ide conta in ing  0.8 %  (w /v) m ethy lene  b is-aciy lam ide. 
(B ') 1.5 M  Tris-base, p H  8 .8 .
(C 1) 0.5 M  Tris-base, pH  6 .8 .
(D ) 10 % (w /v) am m onium  persulphate.
Table 2.6: The quantities o f stock solutions required fo r the preparation o f two standard sized 
resolving and stacking gels used fo r polyacrylam ide gel electrophoresis.
So lu tion Stacking
Gel
(4%)
Resolving
Gel
(7%)
Resolving
Gel
(8%1
Resolving
Gel
(9 %)
Resolving
Gel
(10%)
A crylam ide (A ) 1.33 m l 4.67 m l 5.33 m l 6.00  m l 6.66  m l
D istilled  W ater 6.17 ml 10.33 m l 9.66 m l 9.00 m l 8.34 m l
R esolv ing  Gel 
B u ffer (B 2)
----------- 5.00 ml 5.00 m l 5.00 ml 5.00 ml
Stacking Gel 
B uffer (C 2)
2.50 ml
A m m onium  
Persulphate (D )
50 (xl 50 1^ 50 fil 50 1^ 50 1^
TE M E D 10 Hi 10 |4.1 10 jal 10 jj.1 10^1
6x Sample buffer (S2)
1.0 M  T ris-base (p H  6 .8 ) 3.0 m l
B rom ophenol b lue 0.06 g
G lycerol (99.99 % purity) 5 .00 m l
T he com ponents w ere m ixed in th is  order, then  adjusted  to 10 m l w ith  dH 20  and 
stored at - 2 0  °C.
4x Resolving gel buffer (B2)
3.0 M  T ris-base (p H  8 .8 ) 50.0 ml
dH 20 50.0 ml
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T h e  c o m p o n e n ts  w e r e  t h o r o u g h l y  m ix e d  t o g e t h e r ,  a n d  s to r e d  a t  4  ° C .
4x Stacking gel buffer (C2)
1.0 M  T ris-base (pH  6 .8 ) 50 .0  m l
dH 20  50 .0  m l
The com ponents w ere thorough ly  m ixed  together, and  sto red  a t 4 °C.
Sam ples w ere m ixed  6 :1 w ith  6 x  sam ple bu ffer on ice and  loaded im m ediately  onto  the  gel. 
M olecular w eigh t m arkers (T able  2 .7) w ere  added to  dedicated , individual w ells. 
E lectrophoresis w as conducted  in e lectrophoresis buffer, pH  8.3 a t 12.5 m A  fo r the  stack ing  
gels and  15 m A  fo r the  reso lv ing  gel, using  an A T T O  v ertica l m in i e lectrophoresis system , 
until the  track ing  dye reached  a  defined  heigh t above the bo ttom  o f  the gel. T he gel w as then  
stained w ith  C om m assie blue. R elative m obility  (R f) o f  the  standard  and sam ple pro te ins w as 
calcu lated  accord ing  to  the  fo llow ing  relationship:
d is ta n c e  o f  p ro te in  m ig ra t io n
R f =  -----------------------------------------------  (E quation  2.1)
d is ta n c e  o f  t ra c k in g  d y e  m ig ra tio n
100[log (Rf x  100)] values fo r each  p ro tein  w ere p lo tted  against the respective reso lv ing  gel 
concentration (%  (w /v) acrylam ide). T he resu lting  negative slope values w ere p lo tted  against 
the know n m olecular w eights o f  the standards. The unknow n m olecular w eights w ere 
estim ated from  this standard  curve.
Table 2.7: M olecular weight standards used in non-denaturing SDS PAGE.
S t a n d a r d M r  ( k l ) a ) S o u r c e C a ta lo g u e  c o d e
U rease, Jack  B ean 272.0  (trim er) Sigm a U -7752
545.0 (hexam er)
B ovine serum  album in (B SA ) 6 6 .0  (m onom er) Sigm a A -8654
132.0 (trim er)
Chicken egg album in (C EA ) 45.0 Sigm a A -8529
C arbonic anhydrase (CA ) 29.0 Sigm a C-5024
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2.3.4 W estern b lo t analysis
Western blotting
Proteins w ere transferred  from  ac iy lam ide  gels to  n itrocellu lose  u sing  a B ioR ad w e t b lo tter 
fo r 90 m inutes a t 72 V , in e lectrophoresis bu ffer conta in ing  20  % (v /v) m ethano l. The 
m em brane w as b locked  w ith T ris buffered  saline (T B S) conta in ing  5 %  (w /v) m ilk  m arvel 
pow der overn igh t a t 4 °C. P rim ary  an tibody  (hybridom a supernatan t a t 1/5 o r purified  IgG  a t 
1/2000 in T B S /T M  w as then  added  to  the  m em brane and  incubated  fo r 1.5 hours a t room  
tem perature. T he m em brane w as th en  w ashed  th ree  tim es in  T B S /T , fo r 15 m inu tes each  tim e 
and a lkaline phosphatase-labelled  detection  an tibody  (an ti-m ouse) d ilu ted  in  T B S /T M  w as 
incubated fo r 1 h r w ith  the m em brane. T he blo t w as developed  fo llow ing  th ree  10 m inute 
w ashings in T B S /T  and tw o  fu rther w ashes in  TB S using  5 -brom o-4-ch loro-3 '- 
indo ly lphosphate/n itro  blue te trazo lium  ch lo ride (B C IP /N B T ) substrate reagent. C o lou r 
developm ent w as stopped  by add ition  o f  TB S contain ing  0.5 M  E D T A  fo llow ed  by  extensive 
w ash ing  w ith  d istilled  w ater. A lternatively , w hen  horserad ish  perox idase- (H R P )-labeled  
secondary  an tibodies w ere  em ployed, 3 ,3 ',5 ,5 '-te tram ethy lbenzid ine  (T M B ) w as used  as the  
substrate.
Tris-buffered saline (TBS)
10 m M  T ris-H C l, pH  8.0, conta in ing  150 m M  N aC l w as p repared  by  d isso lv ing  1.57 g o f  
T ris-H C l and 8.77 g o f  N aC l in  800 ml o f  d istilled  w ater. T he pH  o f  th e  so lu tion  w as then  
ad justed  to  pH  8.0 by  the add ition  o f  1M  N aO H . T he final vo lum e w as th en  m ade up to  1000 
m l in a  vo lum etric  flask.
Wash buffer (TBS/T)
TB S conta in ing  0.05 %  (v/v) T w een-20.
D iluent buffer (TBS/TM)
TB S contain ing  0.05 % (v/v) T w een-20  and  1 %  (w /v) d ry  skim m ed m ilk  pow der.
Transfer buffer
25 m M  T ris-B ase (pH  approx im ately  8 .3-8 .6 , unadjusted), 192 m M  glycine and  0.1 %  (w /v) 
SDS. A  5x stock w as prepared  b y  d isso lv ing  15.15 g o f  T ris-base, 72 g o f  g lycine and  5 g o f  
SDS in 1000 m l o f  d istilled  w ater. T he stock  solu tion  w as sto red  at R .T . and  a l x  w ork ing  
d ilu tion  prepared  by  adding  1 0 0  m l to  2 0 0  m l m ethanol and 2 0 0  m l d istilled  w ate r and  m ix ing  
thoroughly .
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2.3.5 B ic in ch o n in ic  (BC A ) assay fo r  estim ation o fp ro te in  concentration
B C A  reagen ts w ere  supplied  as com ponents o f  th e  B C A  pro tein  assay  kit. R eag en t ‘A ’ 
contained an op tim ised  fo rm ulation  o f  sodium  carbonate , sod ium  b icarbonate , b ic inchon in ic  
acid and  sodium  ta rtra te  in a  0.1 M  N aO H  solution. R eag en t ‘B ’ consisted  o f  an aqueous 
solution o f  4 %  (w /v) cupric  sulphate. S tandard  so lu tions con ta in ing  B S A  at concen trations o f  
0, 25, 125, 250, 500, 750, 1000, 1500 and  2000  ng/m l w ere  prepared  in  the  sam e b u ffe r as the 
sam ple being  analysed  (th is norm ally  consisted  o f  PB S). 25 p i o f  each standard  w as pipetted  
in trip lica te  into m icrop la te  w ells. T his w as repeated  fo r each  te s t sam ple. T heB C A  w ork ing  
reagen t w as prepared  b y  m ix ing  reagents ‘A ’ and ‘B ’ in th e  ra tio  50:1. A  200 p i a liquo t o f  
w ork ing  reagen t w as added  to  each  w ell and  the  p la te  w as th en  covered  and  incubated  at 37 
°C fo r 30 m inutes. A bsorbance  values w ere  read  a t 590 nm . T he b lank  (0 (ig/m l) absorbance 
value w as subtracted  and  a standard  curve o f  n e t absorbance  at 590 nm  versus concentration  
(pg /m l) w as constructed  and th en  used to  estim ate  the  concen tra tion  o f  each  te s t sam ple. This 
technique w as frequen tly  used  to  estim ate th e  to ta l p ro te in  concen tra tion  in  sam ples p rio r to  
P A G E  analysis, particu larly  w hen  dealing  w ith  crude  o r  im pure sam ples.
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2.3.6 S E M  and A F M  im age analysis so lu tion s
A ll buffers used in fixing, w ash ing  and post-fix ing  sam ples fo r im age analysis w ere  p repared  
using  u ltra-pure w ater (upH 20 ) .  A ll solu tions w ere p repared  in  a  fum e hood.
Cacodylate buffer
A  stock so lu tion  o f  200  m M  sodium  cacody la te  trihyd ra te  (C 2H 6A s 0 2N a.3 H 20 )  (Sigma, 
C0250) w as p repared  w ith  the  pH  adjusted  to  p H  7.4 w ith  200  m M  HC1. A  100 m M  w o rk ing  
solution w as prepared  by  d ilu ting  th e  stock solution 1:1 w ith  upH 20  or fix ing  solution as 
required . ( Warning: This reagent contains arsenic and a ll relevant precautions should be 
taken when handling.).
Glutaraldehyde fix in g  solution
A  25 %  (v/v) aqueous stock  so lu tion  o f  g lu taraldehyde (Sigma G-4004) w as pu rchased  and 
stored in a sealed, sp illage-secure  con ta iner at -20 °C. Im m ed ia te ly  p rio r to  use, the  stock 
solu tion  w as dilu ted  1:10 w ith  cacodylate  buffer. ( Warning: This is a volatile and toxic cross- 
linking agent and should be handled with the appropriate safety precautions).
Osmium tetroxide post fix in g  solution
A  1 % (w /v) aqueous stock  so lu tion  o f  O sm ium  te trox ide  (OSO4)  w as purchased and sto red  in 
a sealed, sp illage-secure  conta iner a t 4 °C. Im m edia te ly  p rio r to  use, the  stock solu tion  w as 
dilu ted  1:1 w ith  cacody late  buffer. ( Warning: This is a volatile and toxic cross-linking agent 
and should be handled with the appropriate safety precautions).
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2.4 Antigen  iso la tion  and preparation
T he L. monocytogenes EG D  pE R L 3 50-1 prfA¥Gu stra in  con ta in s m ultip le cop ies o f  th e  prfA  
gene and  has been  confirm ed to  produce  elevated  levels o f  v iru lence-associa ted  p ro te in s in  L. 
monocytogenes, such as In lA  and, in particular, P rfA -regu lated  v iru lence  proteins, such as 
InlB  (L ingnau el a l, 1995). I t  w as thus, used to  ensure  m ax im um  y ield  o f  pa thogen ic ity - 
associated  proteins during  an tigen  iso lation  experim ents.
2.4.1 Preparation  o f b acte ria l stocks
Iso lated  colonies from  fresh ly  streaked  BH1 agar p lates w ere  p icked  cu ltu red  overn ig h t at 37 
°C and  200 rpm  in B H I bro th . A  1 m l sam ple w as then  sub-cu ltu red  in to  fresh  B H I b ro th  (50 
m is) and  grow n to  late exponen tia l phase a t 37 °C and  200  rpm . S terile glycerol (12.5 m is) 
w as th en  added to  each  50 m l cu ltu re  to  give a fin a l g lycero l concen tration  o f  20 %  (v/v). T he 
cells w ere then  dispensed  in to  2 m l ciyov ia ls  in 1.2 m l vo lum es and  stored  a t - 8 0  °C.
2.4.2 Preparation  o f In lB  extract
O ne 1.2 m l a liquo t o f  L. monocytogenes EG D  pER L3 50-1 prfAEGD, p repared  as above 
(Section  2.4 .1) w as thaw ed  and  inocu lated  into 50 m is o f  B H I con ta in ing  5 (ig/ml 
ery throm ycin  (Sigma, E-5389). T he cu lture  w as incubated  overn igh t fo r  12 hours a t 37  °C and 
200 rpm . T he overn igh t cu ltu re  w as d ilu ted  1/50 w ith  fresh  B H I m edia th a t had  b een  pre- 
filtered  w ith a 10 kD a cu t-o ff  m em brane and then  incubated  at 37 °C a t 120 rpm . W hen an  
O.D.goomn value o f  betw een  0 .8  and  1 . 0  w as reached  the  ce lls  w ere  rem oved by cen trifugation  
a t 4000 rpm  fo r 20 m inu tes at 4  °C. T he supernatan t w as decanted  and  the  ce ll p e lle t w as 
w ashed  three tim es in  0.5 %  (v /v) o f  the o rig inal cu ltu re  vo lum e sterile-filtered  PB S . The 
p e lle t w as re-suspended  in  0.5 % (v /v) the  orig inal cu ltu re  vo lum e o f  1 M  T ris-H C l, pH  7.5 
and  incubated  on ice fo r one  hour, as p rev iously  described  b y  M Uller et al., 1998a. T he cells 
w ere  then  pelle ted  by cen trifugation  a t 10000 rpm  fo r 10 m inu tes a t 4 °C. T he supernatan t 
(In lB -enriched  ex tract) w as d ialysed  ex tensively  again st P B S , concentrated  using  P E G  and  
finally  d ispensed  into ep p en d o rf  tubes and  stored a t -2 0  °C.
2.4.3 Preparation  o f p ro te in -en riched  supernatant
A n exponential phase cu ltu re  o f  L. monocytogenes E G D  pE R L 3 50-1 prfAEQn w as  p repared  as 
above (Section  2 .4 .2). W hen  an O .D .6ooimi value o f  be tw een  0 .8  and 1.0 w as reached , cells 
w ere pelleted  b y  cen trifugation  a t 6000 rpm  fo r 20  m inu tes a t 4 °C. T he resu ltan t supernatan t 
w as decanted  and  filtered  th rough a 0 .2  /im  filte r to  rem ove and residual cells or particu la te  
m atter. T he supernatan t p ro teins w ere  then  precipitated  by  dropw ise addition  trich lo roacetic
6 2

acid  (T C A ) to  a final concentration  o f  10 %  (v /v) and left s tirring  gently  overn igh t a t 4 °C. 
T h e  precip ita ted  p ro teins w ere  pelle ted  b y  cen trifugation  a t 6000 rpm  fo r 30 m inu tes a t 4 °C , 
resuspended  in PBS (a t a  vo lum e equ ivalen t to  0.5 %  o f  the  o rig inal cu ltu re  vo lum e), d ia ly sed  
ex tensively  against PB S  and  concen tra ted  u sing  P E G  before being  d ispensed  in to  ep p en d o rf 
tubes and  stored  a t-2 0 ° C .
2.4.4 Preparation  o f fo rm a lin -in activa ted  L . m onocytogenes ce lls
A n exponential phase culture o f  L. monocytogenes EG D  pE R L 3 50-1 prfAEGD w as p repared  as 
above (Section  2 .4 .2). E xponen tia l phase cells w ere pelle ted  by cen trifugation  a t 8000 rpm  
and  4 °C fo r 15 m inutes. The ce ll p e lle t w as carefu lly  resuspended  in  a 10 %  (v /v) fo rm alin  
so lu tion  (i.e. 3 .7  % (v /v) fo rm aldehyde in sterile-filtered  P B S ) and  incubated  in  a  sterile  
un iversal at 37 °C fo r 1 h r  a t 110 rpm . T he cell suspension  w as  then  cen trifuged  a t 4000  rpm  
and  4 °C fo r 25 m inutes. T he fo rm alin -con ta in ing  supernatan t frac tion  w as care fu lly  decanted 
and  the  rem ain ing  cell p e lle t w as w ashed  three tim es in s terile -filte red  PB S. T h e  final w ashed  
pelle t w as resuspended  in  5 m l sterile  filte red  PBS, d ispensed  in to  ep p en d o rff tubes a t 
appropria te  volum es and  stored  a t - 2 0  °C until required.
2.4.5 E xtractio n  o f L is te ria  su rface p ro te in s
A 1 m l cell suspension  w as asep tica lly  sub-cu ltured  from  an overn igh t B H I broth  cu ltu re  into 
a  fresh  50 m is B H I o r Listeria  en richm ent b ro th  (L E B ), as requ ired . W hen  exponen tia l grow th 
w as achieved, the  cells w ere pelle ted  by  cen trifugation  a t 6000  rpm  fo r 15 m inu tes a t 4 °C. 
T he cell pe lle t w as w ashed  three tim es in  0.5 %  o f  the o rig inal cu lture  vo lum e (i.e. 250 |xl) 
PB S. The w ashed  cells w ere then  resuspended  in  250 |xl o f  a 2 %  (w /v) SD S solu tion  in PB S 
and  incubated fo r 45 m inu tes a t 37 °C and  200  rpm . T he so lubilised  p ro tein  fraction  w as 
iso lated  fo llow ing  cen trifugation  o f  th e  m ix ture  a t 6000 rpm  and 4  °C fo r 15 m inutes. T he 
extracted  proteins in  the  SD S so lu tion  w ere  e ither applied  d irectly  to  an SD S PA G E gel 
analysis o r desalted  and  stored a t -20 °C until required.
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2.5 A n im a l experim ents
2.5.1 L icen c in g  fo r  an im a l usage
A ll procedures involv ing  the use o f  an im als w ere  approved  and  licensed b y  the  D epartm en t o f  
H ealth , and  ev e iy  p recaution  w as tak en  to  ensure the  m in im um  distress to  the an im als.
2.5.2 Im m unisation p ro to co l fo r  m ice fo r  the p roduction  o f m onoclonal 
antibodies to L . monocytogenes
B alb/C  m ice o f  aged 5-8 w eeks w ere  used fo r the  p roduction  o f  m onoclonal an tibod ies to  L. 
monocytogenes w hole  cells o r L. monocytogenes-derived p ro teins, using  the im m unisa tion  
schedule  described  below :
D ay  1: A  1 m g/m l solu tion  o f  antigen ( i f  usin g  L. monocytogenes-derived p ro teins)
or 2 x  109 cells ( i f  u sing  L. monocytogenes w ho le  cells) w as prepared  in  PBS 
and m ixed w ith  an  equal vo lum e o f  F reund 's C om plete  A d juvan t (FC A ) 
0Sigma, F-5581). T h is so lu tion  w as then  vortexed  to  form  an  em ulsion  and 
150-200 |il  o f  the  em ulsion  used to  im m unise m ice by  in traperitoneal (i.p .) 
injection.
D ay 2 1 :  M ice w ere re-im m unised  in traperitoneally , w ith  a  sim ilar dose o f  the
im m unogen (as above) in  F reund 's Incom plete  A d ju v an t (F IC A ) (Sigma, F- 
5506) in the  case o f  L. monocytogenes-derived p ro teins, or, PB S in  the case 
o f  w hole cells.
D ay 28 : M ice w ere b led  from  the  tail vein, and  the  specific  an tibody  titre  determ ined.
P ost-D ay 28 : M ice w ere boosted  in traperitoneally , w ith  a sim ilar m ix  o f  an tigen  and  FIC A
o r PB S as p er day 21.
Post-D ay 28 : T he above im m unisation  and blood  sam pling  sequence w as con tinued  until a
satisfactory  an tibody  titre  w as recorded. O nce the  an tibody  titre  w as 
su ffic ien tly  high, the  m ouse w as im m unised  in travenously  (i.v .) w ith  
respective antigen in P B S , 24 h r p rio r to  conducting  the fusion . In cases w ere 
the im m unogen consisted  o f  com plete  cells, th is final boost w as adm in istered  
v ia  the  i.p route. F inally , the m ouse w as sacrificed  by  cervical d islocation  and 
the  spleen (o r o ther specified  lym ph node) w as rem oved  and  used for 
subsequent som atic cell fusion  procedures.
Note: This represents a generic outline o f the typical immunization regime employed. The 
exact protocol varied fo r each given antigen is outlined in detail in the corresponding 
relevant sections o f chapter three.
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2.5.3 M ono clon a l antibody p roduction  by a sc itic  grow th
A scitic  flu id  (also  called  ascites) is an  in tra-peritoneal flu id  ex tracted  from  m ice  th a t have 
developed  a  peritoneal tum our. F o r an tibody  production , th e  tu m o u r is induced  b y  in jecting  
hybridom a cells into th e  peritoneal cavity  o f  m ice  o f  th e  sam e genetic  background  as the  
hybridom a.
B alb/C  m ice o f  the sam e genetic  background as the  hybridom as w ere  g iven  an  intra- 
peritoneal in jection o f  0.5 m l o f  p ristane (2 ,6 ,10 ,14-te tram ethy lpen tadecane) (S igm a, P -1403). 
T his solu tion  ac ts as an  im m uno-ad juvostim ulan t/irritan t to  the  m ice, w h ich  respond by 
secreting  nu trien ts and  recru iting  m onocytes an d  lym phoid  cells into the peritoneum , thus 
creating  a  rich  env ironm ent fo r hybridom a grow th . A pprox im ate ly  7-10 days later, 2-3 x lO 7 
hybridom a cells w ere  injected in tra-peritoneally . T um o u r grow th  w as ev iden t a fte r 1-2 w eeks 
and the m ice w ere  sacrificed. T he ascitic  flu id  w as then d rained  under sterile  cond itions by  
insertion o f  a needle in to  the  peritoneal cavity .
6 5

2.6 Antibody p u rifica tio n
2.6.1 Am m onium  su lphate p recip ita tion
T he am m onium  su lphate  p recip ita tion  w as carried  ou t acco rd in g  to  the  m ethod  o f  H udson  and 
H ay  (1980). A pprox im ate ly  1 ml o f  ascites flu id  w as d ilu ted  1:2 w ith  PB S and  saturated  
am m onium  su lphate w as then  added  to  b ring  the final concen tra tion  to  45 % (v/v). This 
m ix ture  w as then  stirred  a t room  tem peratu re  fo r 30  m inutes, and the  resu lting  p recip ita te  
cen trifuged  a t 3000 rpm  fo r 20 m inutes a t 4 °C. T he p rec ip ita te  w as then  resuspended  in  a 
vo lum e o f  PB S, equal to  tha t o f  the  orig inal vo lum e o f  ascites. Saturated  am m onium  su lphate 
w as then added to  a  final concentration  to  40 %  (v /v ) and  th e  m ix tu re  cen trifuged  a t 3000 rpm  
fo r 20 m inutes. T he pelleted  p recip ita te  w as th en  resuspended , in a vo lum e o f  P B S  equal to  
tw ice the original vo lum e o f  ascites. T he resuspended  precip ita te  w as th en  d ialysed  overn ight 
against PB S w ith  0 .02  % (w /v) sodium  azide at 4 °C.
2.6.2 Concentration  o f tissue cu ltu re  supernatant
U p to 300 m l o f  spen t supernatan t from  the  re levan t hyb ridom a cell line w as co llec ted  over a 
period  o f  several days. Sodium  azide w as added  to  a  final concen tra tion  o f  0.02 % (w /v) to  
the supernatants and  it w as then  stored  at 4 °C until required . T he supernatan t w as 
concentrated  15-fold to  a  final vo lum e o f  20 m l, using  a  stirred  u ltrafiltra tion  ce ll w ith  a  76 
m m  Omega™  ultrafiltra tion  m em brane, w ith  a  m o lecu lar w eigh t cu t-o ff o f  10 kilodaltons 
(kD a), and the  concentrate  stored  at 4 °C, until required .
2.6.3 P ro te in  A /G  a ffin ity -p u rifica tio n  o f im m unoglobulin
C oncentrated  supernatan t from  cu ltured  hybridom a cells w as stored  a t 4 °C p rio r to  affin ity  
purification . A  1 m l suspension o f  im m obilised  pro te in  A  (im m obilised  on Sepharose 4B, 
stored  in sterile-filtered  PBS contain ing  20 %  (v /v) e thano l) w as equilib rated  in  a  colum n w ith  
20 m l o f  sterile-filtered  PBS. U p to  10 m l o f  concen tra ted  hybridom a supernatan t w as passed  
th rough the colum n and  the  e luan t co llected  and passed  th ro u g h  the  colum n a second tim e. A t 
least 25 m is o f  w ash  buffer w as passed  th rough  th e  co lum n and, subsequently , the  reta ined  
pro tein  w as elu ted  w ith  0.1 M  g lycine-H C l bu ffer (pH  2 .5). F ractions o f  e luate  co llec ted  in 
ep p en d o rf tubes conta in ing  150 jil o f  neu tra liza tion  b u ffe r (2 M  T ris-H C l, pH  8.5). This 
served to  rapidly  neu tra lize  the  h igh ly  acid ic  env ironm ent o f  the elu tion  buffer, thereby , 
p reventing  denatu ra tion  o f  the  elu ted  IgG  fraction . T he absorbance o f  each  fraction  w as 
m easured, a t 280 nm . T hose fractions conta in ing  sign ifican t p ro te in  w ere  pooled , desalted  on 
PD10™  size exclusion  colum ns against PB S  and  stored  at - 2 0  °C until requ ired  fo r fu rther 
use. A ll purification  and desa lting  procedures w ere  conducted  a t 4 °C.
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2.6,4 D esa ltin g  o f a ffin ity -p u rifie d  Ig G  fra c tio n s
A  PD10™  colum n (Amersham Pharm acia Biotech) con ta in in g  an  8,3 m l b ed  vo lu m e o f  
S ephadex  G 25 w as  equ ilib ra ted  w ith  25 m is o f  run n in g  b u ffe r  (PB S). U p  to  2 .5  m l o f  th e  
affin ity -purified  IgG  frac tio n  w as th en  loaded  onto  th e  colum n. W hen  the  sam ple  m en iscus 
reach ed  th e  top  o f  th e  gel, fresh  runn ing  b u ffe r w as added  and  th e  IgG  p ro te in  com ponen ts 
w ere  e lu ted  in approx im ate ly  2.5-3 .5  m l o f  PB S.
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2.7 M am m alian C e ll C u ltu re
A ll m am m alian  cell cu ltures w ere  m anipulated  asep tically  an d  g row n  in a  h um id ified  (5 %  
(v /v) C O 2) atm osphere, a t 37 °C.
2.7.1 Preparation  o f m am m alian c e ll cu ltu re  m edia:
A ll cell lines w ere rou tine ly  g row n  in D M E M  (D ulbecco 's m od ifica tion  o f  E agle 's m edium ) 
(Sigma, D-5671) supplem ented  w ith  10 %  (v/v) foetal c a lf  serum  (FC S), 2 m M  L -glu tam ine, 
and  25 pg/m l gentam ycin  su lphate  (Sigma G-1522).
D M E M  lacking  foetal c a lf  serum  w as prepared  fo r use  during  som atic  cell fusion  procedures. 
A dditionally , H A T  (H ypoxan th ine , A m inop terin  and T hym id ine) m edium  w a s  prepared, 
w hich  consisted  o f  D M E M  supp lem ented  w ith  1 m M  sod ium  pyruvate , non-essen tia l am ino 
acids (N E A A , 1 % , v /v), 100 p M  hypoxanth ine, 400 11M  am inop terin , and 16 p M  thym idine. 
T his particu lar cu lture  m ed ium  a llow ed  fo r the  selective g ro w th  o f  hybridom a cells p o st­
fusion in the  presence o f  Sp2/0 cells, w hich  are unab le  to  p ro lifera te  in  H A T  m edium  because 
th ey  lack the  requisite enzym e system s (Section  3.1.2.). D M E M  supp lem ented  w ith  1 m M  
sodium  pyruvate, non-essen tia l am ino  ac ids (1 %  (v/v)), 100 p M  hypoxan th ine  and 16 p M  
thym id ine w as also  prepared  (referred  to  as H T m edium ). A ll m ed ia  w ere  stored a t 4 °C.
2.7.2 Recovery o f frozen  ce lls
C ells w ere recovered from  liqu id  n itrogen  by  rap id ly  thaw in g  a t 37 °C, and  transferring  to  a 
sterile  universal con tain ing  D M E M . T he cells w ere  then  cen trifuged  a t 2000 rpm  fo r 10 
m inutes, resuspended  in fresh  cu ltu re  m edium , transferred  to  a  tissue  culture flask  and  
incubated a t 37 °C in a  hum id ified  5 % C 0 2 incubator. P rio r to  incubation , a  100 pi sam ple o f  
the resuspended  pelle t w as te s ted  fo r cell v iab ility  using  T iy p an  b lue (S ection  2 .7 .3 .). O n ly  
cells w ith  >90%  v iab ility  on recovery  from  frozen stocks w ere  cu ltured  further.
2.7.3 C e ll counts and v ia b ility  testing
A ll cell counts w ere m ade using  an im proved N eu b au er C oun ting  C ham ber. V iab le  cell 
counts w ere  obtained b y  m ix ing  50 pi o f  cell suspension w ith  10 p i o f  a com m ercial iso tonic 
T rypan  b lue  solution (0.25 % , (w /v)) (Sigma, T-8154). T h e  v iab le  cell coun t w as carried  ou t 
w ith in  5 m inutes o f  the  addition o f  T rypan  blue. A  sam ple o f  th is  m ix tu re  w as th en  used to  
perform  the  cell and v iab ility  count. V iab le  cells excluded  the  dye and  rem ained  w hite, w hile 
dead cells w ere stained blue. C ells w ere  v isualised  un d er phase con trast on an inverted
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m icroscope a t 40x  m agnification . A t a ll tim es cells w ere pelle ted  by  cen trifugation  a t 2000 
rpm  fo r 5 m inutes unless o therw ise  stated.
2.7.4 Grow th o f suspension c e ll lin e s
T he Sp2/0 (A T C C  C R L 1581) m yelom a cell line w as rou tine ly  cu ltu red  in  D M E M . T he cells 
w ere subcultured, using  a  sp lit ra tio  o f  1:4, at approx im ate ly  70 %  confluency . For 
subculturing, the  cells w ere  flushed  o f f  the  surface o f  th e  flask  u sin g  a P as teu r pipette, 
collected  and  cen trifuged  a t 2000  rpm . T he pelle t w as then  resuspended  in 4  m l o f  fresh  
cu lture  m edium . F inally , 1 m l o f  the  resuspended  p e lle t w as transferred  to  T -75 flasks 
conta in ing  14 m l o f  fresh, pre-w arm ed D M E M .
2.7.5 Storage o f c e ll lin e s
C ells w ere  harvested  from  the  surface o f  a confluen t T-75 flask  by  flu sh ing  the  su rface o f  the 
flask  w ith  a  Pasteur pipette, and  pelle ted  by cen trifugation  a t 2000  rpm . P elle ts  w ere 
resuspended  in 3 m l o f  an 8 %  (v /v ) so lu tion  o f  D M SO  (D im ethy l su lphox ide) in  FC S, and 
d ispensed  into 3 cryovials. A  freezing -tray  w as used  to  g radually  coo l the  cells, over a  3.0  hr. 
period , in  the vapour-phase o f  liqu id  n itrogen . T hey  w ere  th en  im m ersed  in  th e  liqu id-phase 
fo r long-term  storage. A lternatively , cells w ere  p laced  in isopropanol baths a t - 8 0  °C  fo r 12 
hours befo re  being  p laced  in liquid  n itrogen  fo r long-term  storage.
2.7.6 M ycoplasm a screen ing
C ell lines w ere screened  for m ycop lasm a contam ination  in  conjunction  w ith  the  N ational Cell 
and T issue  C ulture C entre  (N C T C C ), D ublin  C ity  U niversity .
2.7.6.1 C e ll culture o f N R K  cells
A dheren t N R K  (norm al ra t k idney) cells w ere cultured in  D M E M . W hen  cells h ad  reached 
70 %  confluency, the  m edium  w as poured  off, and the flask  rinsed  th ree tim es w ith  10ml o f  
sterile  PB S. A  3 m l o f  try psin ising  so lu tion  (0.025 % (v /v) and 0 .02 %  E D T A  (v /v)) w as 
added to  the flask, w hich  w as rep laced  back  in the  incubato r un til a ll o f  the  cells had 
detached. N ext, 5 m l o f  fresh  D M E M  w as added to  th is  cell suspension , w hich  w as then 
cen trifuged  at 2000  rpm  and th e  pelle t resuspended  in  the  required  vo lum e o f  fresh  D M E M .
2.7.6.2 Screening fo r Mycoplasma contam ination
N R K  cells w ere  cu ltured  fo r a t least 3 passages p rio r to  m ycop lasm a screen ing  in antib io tic- 
free m edium . H oechst stain  w as used  fo r v isualisation  o f  the  m ycoplasm a. M ouse  m yelom a 
cell lines used fo r som atic cell fusion  procedures, and  various hyb ridom a cell lines w ere
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grow n in an tib io tic-free  m ed ia  fo r 2  w eeks p rio r to  screen ing  fo r m ycoplasm a, to  ensure  any  
in tracellu lar an tib io tic  w as rem oved. C ells w ere  then  seeded  at a  low  density  and  a llo w ed  to 
p ro liferate  fo r 3 days to  70 %  confluence, th e  cond itioned  m edium  w as th en  rem oved  and 
stored fo r subsequen t screening a t - 2 0  °C.
N R K  (N orm al R a t K idney) cells w ere  p repared  to  a final cell density  o f  2 x  103 cells/m l in  a 
m odified  version  o f  D M E M  contain ing  5 % (v /v ) FC S and 1 %  (v /v) L -g lu tam ine , and  1 m l o f  
cell suspension  w as then  added  on to  sterile  coverslips in petri-d ishes. T he cells w ere  then 
incubated  a t 37 °C overnight. The fo llow ing  day, 0.5 m l o f  cond itioned  m edium  w as rem oved  
from  th e  te s t sam ples and  added to  the  N R K  cells  g row ing  on the  coverslips. T he pe tri d ishes 
w ere then  incubated  fo r a  fu rther 3-4 days a t 37 °C.
T he m edium  from  each petri-d ish  w as th en  rem oved and the coverslips w ere  w ashed  tw ice 
w ith sterile  PBS, and once w ith  P B S /C am oy 's  fixative (cold). A  2 m l a liquo t o f  C arnoy 's 
fixative (g lacial acetic  acid: m ethanol, 1:3, (v /v )) w as then  added  to  each  coverslip  and  
a llow ed  to  fix  fo r 10 m inutes. T he sam ples w ere  then  allow ed to  air-dry  overnight.
A  2 m l a liquo t o f  the D N A -in tercalating  dye H o ech st 33258 (w ork ing  stock  50 ng/m l) w as 
then  added  to  each  sam ple. T he sam ples w ere  then  allow ed to  stain  for 10 m inu tes in  low- 
light. A fter 10 m inutes, the  stain  w as very  carefu lly  rem oved and  each coverslip  w ashed  w ith  
3 x  2 m l o f  sterile  d istilled  w ater. T he w ashed  coverslips w ere  th en  m ounted  onto  slides, and 
w ith  the  aid o f  a  drop o f  m ounting  m edium  observed  under th e  m icroscope using  the  lOOx 
objective lens on a fluorescen t m icroscope. U ncon tam inated  ce lls  show  strong  fluorescence 
in the  nucle i only, w hereas m ycop lasm a con tam inated  cells are detec ted  b y  cy toplasm ic 
sta in ing  o f  the  m ycoplasm ic D N A .
2 .7 .7  H ybridom a production  and iso la tion
H ybridom a production  w as perform ed accord ing  to  th e  orig inal m ethod  o f  K o h le r and 
M ilste in , (1975), w ith  am endm ents.
2.7.7.1 Somatic cellfusion
S p 2 /0  cells w ere grow n for at least tw o w eeks, p rio r to  fusion. C ells w ere  no t g row n above 
50 %  confluency, and w ere subcultured  at a  sp lit ratio  o f  1:2 th e  day befo re  fusion . O n the 
day  o f  th e  fusion, the  m edium  w as poured  o f f  the Sp2/0 cells, and  fresh  D M E M  lacking  FCS 
w as added. C ells w ere resuspended  and  counted .
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Lym phocytes, from  an im m unised m ouse w ere  harvested  (from  the sp leen  or re lev an t lym ph 
nodes), resuspended  in  D M E M  lacking FC S, and  counted. T he sp lenocytes and S p 2 /0  cells 
w ere m ixed  to  g ive a cell ra tio  o f  5-10 lym phocy tes p e r Sp2/0 cell. T his cell m ix tu re  w as 
pelle ted  by  cen trifugation  a t 1250 rpm  and w ash ed  4 tim es w ith  5 m is o f  fresh  D M E M  
lacking FCS.
A ll o f  the supernatant, from  the  final w ash, w as rem oved, excep t fo r 50-100 fj.1 (sim ply  
pouring  o f  th e  supernatan t sufficed). T he cells w ere  resuspended  by tapp ing  th e  ou tside  o f  the 
centrifuge tube. T he cell suspension  w as p laced  in  an  ice-w ater bath, and  1.5 m l o f  50 %  
(v/v) P E G  (po lyethy lene  glycol, m o lecu lar w eig h t 1540 D a) th a t had  been p rev iously  chilled  
on ice w as added to  th e  cell suspension over a 1 m inu te  period  w ith  constan t m ix ing . M ixing 
w as con tinued  fo r ano ther 1.5 m inutes. T he cen trifuge tu b e  w as rem oved from  the ice-w ater 
bath, and  clasped  tightly , w hile  20 m is o f  p re-w arm ed  (to  37 °C) D M E M , lack ing  FC S w as 
then  added at a  constan t rate w ith the a id  o f  a  1 m l G ilson  pipette  o v er a  5 m inu te  in terval 
w ith  continual, slow , sw irling  o f  the  cen trifuge  tube. T h e  resu lting  suspension  w as p laced  at 
37 °C in a  w a te r b a th  fo r 15-20 m inutes. T he suspension  w as centrifuged, a t 1000 rpm  fo r 10 
m inutes, and  the cells resuspended  a t a cell d ensity  o f  1.2 x  10 6 cells/m l, in H A T  m edium  
supplem ented  w ith  5 %  (v/v) B riclone. T he suspension  w as p lated , in 96 w ell p lates, a t 0.1 
m l p er w ell, and incubated  fo r 7 days. O n day  7, 75 fil o f  fresh  H A T  m edium  supplem ented  
w ith  5 % (v /v) B ric lone  w as added to  each w ell. W ells w ere  then  fed  as required . M ed ia  w as 
supplem ented w ith  H A T  until a t least day  14 a fte r th e  fusion.
2.7.7.2 Screening fo r  specific m onoclonal antibody production
105 fxl o f  ‘sp en t’ hybridom a supernatan t w as rem oved  from  the  m asterp la te  w ells, and 
rep laced  w ith  105 fj.1 fresh  D M E M  supp lem ented  w ith 5 % (v /v) B riclone. T he 'spent' 
hybridom a m edium  w as then  screened fo r  specific  an tibody  p roduction  by conventional 
ELISA , as described  in Section 2.8.1. P ositive  w ells  from  the  in itia l screen ing  w ere  then 
transferred  to  24-w ell plates, and  subsequently  to  6 -w ell p la tes fo r cloning.
2.7.7.3 C loning o f hybridomas secreting Listeria-specific antibodies
Cells from  w ells, w hich tested  positive in the  E L ISA , w ere  expanded  in H A T  m edium , from  
96-w ell p lates, to  24-w ell p lates, 6 -w ell p la tes and  fina lly  to  T25 flasks. C ells w ere  cloned, 
by  lim iting  d ilu tion , w hen  th ey  had reached  50 % confluency  a t the T25 stage. B riefly , cells 
w ere resuspended , and  d ilu ted  to  a concen tra tion  o f  6 6  cells/m l in H T  supplem ented  w ith  5 %  
(v/v) B riclone. F rom  this stock  ce ll-suspension , d ilu tions o f  1/2, 1/10 and  1/20 w ere  prepared
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in H T  m edia. T hese w ere  then  seeded  a t 150 p l/w e ll in sep ara te  96-w ell p la tes to  g ive  w ell 
densities o f  5, 1 and  0.5 cells/w ell, approxim ately . A fte r  7 days, the  p la tes w ere  exam ined  
m icroscop ica lly  and  w e lls  conta in ing  single co lon ies w ere  no ted . O n days 10-12 screen ing  fo r 
positive  w ells p roceeded , u sing  E L ISA  (as described  in  S ection  2 .8 .1), w ith  n ea t m edium  
from  th e  w ell, as th e  te s t sam ple. O nly  cells th a t dem onstra ted  specific  n d  com petitive  
b ind ing  w ere  expanded  further.
P ositive  w ells  w ere  expanded , as a lready  described , an d  rec lo n ed  once a t 1 cell/w ell, an d  once 
a t 0.5 cell/w ell. T h e  second tim e, cells w ere c loned  in  D M E M  conta in ing  10 %  (v /v ) FC S, 
N E A A  (1 %, (v /v)), and  1 m M  sodium  pyruvate , ra th e r th a n  in  H T  m edium . P o sitive  w ells a t 
th is  stage w ere  considered , to  be m onoclonal.
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2.8 S o lid  phase im m unoassays
2.8.1 E L IS A  ’v fo r  estim ation o f antibody levels in  hybridom a supernatants
From  a  fresh ly  p repared  suspension  o f  L. moncytogenes w ho le  cells in  PB S ( lx lO 9 cells/m l), 
o r Listeria -derived p ro te in s a t an op tim ized  concentration , 100 p i a liquots o f  a so lution, w ere 
added to  all o f  the  w ells o f  a  N u n c  M axisorp™  plate  and incubated  a t 37 °C fo r 1 hour. W ells 
w ere w ashed  w ith  3 x  200  p i o f  PB S, and  200  p i o f  a  5 %  (w /v) so lu tion  o f  dry sk im m ed m ilk  
in PB S w as added to  each w ell, and incubated fo r 1 h r  a t 37  °C. W ells w ere then  w ashed  ou t 
w ith  5 x  200 pi o f  P B S/T . A  100 p i sam ple o f  neat hyb ridom a supernatan t o r purified  
m onoclonal antibody, d ilu ted  in  P B S /T  w as added to  th e  w ells  o f  the  plate. Sam ples w ere 
incubated fo r 1 h r a t 37 °C on a  rock ing  platform . W ells w ere  w ash ed  w ith  4 x  200 pi PB S/T  
and 1 x  200  p i PBS before  100 p i o f  secondary  an tibody  (a lkaline  phosphatase-labeled  goat 
an ti-m ouse antibody), d ilu ted  1/2000 in PB S/T M , w as added  to  each w ell and incubated  fo r 1 
h r  at 37°C. W ells w ere  w ashed  w ith 4 x  200  pi o f  P B S /T  an d  1 x  200 p i o f  PB S  before  adding  
100 p i o f  SigmaFast™  para-n itropheny l phosphate  (pN P P ) substra te  {Sigma, N2770) substrate 
to  all w ells. T he substrate w as left to  develop, in th e  dark  a t 37 °C fo r  30 m inutes. 
A bsorbance read ings w ere  read  a t 405 nm  using  a  T itertek  p la te  reader.
2.8.2 Isotyp ing o f m onoclonal antibodies
E L IS A  plates w ere coated  an d  blocked  as described  in Section  2.8.1. A  100 p i sam ple o f  
cu ltu re  supernatan t from  positive  hybridom as, fo llow ing  c lon ing  b y  lim iting  d ilution, w as 
then  added  to  each w ell o f  th e  coated  p late. A lkaline phosphatase-labeled  goat anti-m ouse 
im m unoglobulin  subtypes w ere  then  added  to  the  w ells  an d  the  E L ISA  developed  as 
described  in Section 2.8.1. T h e  w ells  tha t elicited  a positive  resp o n se  to  a sing le subtype (i.e. 
absorbance a t 405nm  g rea te r th an  the norm al background  +3 S D ’s) w ere  taken  to  ind icate  the 
m onoclonal an tibody  isotype.
2.8.3 D eterm ination o f antibody w orking d ilu tio n
E L ISA  pla tes w ere coated  and  blocked  as described  in S ection  2 .8 .1 . T en  serial d ilu tions o f  
purified  m onoclonal w ere then  prepared  in PB S/T , beg inn ing  d ilu tions at 1/100. A  100 pi 
sam ple o f  m onoclonal an tibody  a t each d ilu tion  w as then  added  to  the  w ells o f  the  plate in 
trip licate, and the  p late  incubated  a t 37 °C fo r 1 hour.
W ells w ere then  w ashed w ith  4 x  200  p i o f  P B S /T  and  1 x  200  pi o f  PB S, before  lOOpl o f  the  
appropriate  secondary an tibody  (i.e. alkaline phosphatase-labeled  goat anti-m ouse IgG 2a
7 3

antibody), prepared  in  P B S /T M , w as added to  each  w ell. T he p la te  w as th en  incubated  a t 37 
°C fo r 1 h r on a rock ing  p latform . W ells  w ere th en  w ashed  4  x  200  (J.I o f  P B S /T  and 1 x  200 
|il o f  PBS before  lOOju.1 o f  substra te  (pN PP) w as added  per w ell T he absorbance  w as 
m easured  after a  30 m inu te  incubation  a t 37 °C, using  a  T ite rtek  p la te  reader a t 405 nm . T he 
optim al d ilu tion  o f  purified  an tibody  w as determ ined  in th is  m anner as the  d ilu tion  c lo sest to 
the m id -po in t o f  the  linear portion  o f  the sigm oidal curve ob tained .
2.8.4 In h ib itio n  E L IS A
N unc M axisorp™  pla tes w ere  coated  and  blocked  as p rev iously  described . Serial d ilu tions o f  
the  appropria te  test cells (o r a lternative  te s t an tigen) w ere  p repared  in P B S /T  and 100 ^1 
aliquots o f  each  w ere th en  p laced in  individual 500 n l m icrocen trifuge  tubes. A  sim ilar 
vo lum e o f  purified  m onoclonal an tibody, d ilu ted  1/2000 in P B S /T  (determ ined  by 
checkerboard  titra tion), w as th en  added  to  each  tube. T he sam ple tub es w ere incubated  a t 37 
°C fo r 1 h r on  a  rocking platform . A t 10 m inu te  intervals, the tubes w ere inverted  to  ensure 
hom ogenous m ixing. Sam ples w ere  then  transferred  to  th e  coated  and blocked  m icrow ells  in 
100 |ul a liquots and  incubated  fo r a fu rther 1 h r a t 37 °C on a ro ck ing  p latform . W ells w ere 
then  w ashed  as before and  1 0 0  (0.1 a liquo ts o f  a 1 / 2 0 0 0  d ilu tion  o f  alkaline phosphatase- 
labeled goat anti-m ouse IgG 2a  secondary  an tibody  in  P B S /T M  w as added to  the  each  w ell 
and  th e  p late  incubated  as before. F o llow ing  w ash ing , pN P P  substrate  w as added  to  the  w ells. 
A fter a  30 m inute incubation  a t 37  °C, the  absorbance values w ere  m easured  a t 405 nm  using  
a  T itertek  p late  reader. A bsorbance  values a t each an tigen  concen tra tion  (A ) w ere  then 
div ided  by  the  absorbance m easured  in the p resence o f  zero  an tigen  (A 0) to  give norm alised  
absorbance readings. A  p lo t o f  the  norm alised  absorbance read ing  versus cell concentration  
(cell/m l) w as used  to  construct the calib ration  curve.
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2.9 M o le cu la r b io logy
2.9.1 Standard  So lu tion s 
Tris-acetic acid-EDTA buffer (TAE)
A  50x stock solu tion o f  TA E b u ffer w as p repared  by  d isso lv ing  242 g T ris-H C l in 700 ml 
upH 20 .  W hen the  salt had d isso lved , 57.1 m l o f  g lacial acetic  acid  and 100 m l o f  0 .5  M  
E D T A . pH  8.0 w ere added and the  final vo lum e b rough t to  1000 m l w ith  upEkO . A garose 
gel e lectrophoresis w as conducted  in IX  T A E  buffer, prepared  in upH 20 .
TES-1 buffer
T ris-H C l (pH  8.0) 10 raM
E D T A  (d isod ium  salt) 1 m M
TES-1 buffer
Tris-H C l (pH  8.0) 10 m M
E D T A  (d isodium  salt) 1 m M
N aC l 50 m M
TES-2 buffer
T ris-H C l (pH  7.4) lO m M
E D T A  (d isodium  salt) 3.5 m M
N aC l 400 m M
K irby m ix
Phenol 
C hloroform  
Isoam ylalcohol 
8 -hydroxy  quinolone
4.0  m l
0.8 g
1 0 0  m l
1 0 0  m l
GES reagent
G uanid ium  th iocyanate  
E D T A  (disodium  salt) 
S a rk o sy lreag en t
5.0 M  
100 m M
0.5 %  (v/v)
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TB buffer g/L
P ipes (lO m M ) 3 .02
M nC l2 (55 m M ) 10.89
C aC l2 (15 m M ) 2.21
KC1 (250 m M ) 18.64
A ll com ponents excep t the M nC l2 w ere  m ixed  until d isso lved  in  up H 20  and  th e  pH  then 
ad justed  to  6.7 w ith  K O H  solution. The M nC l2 w as then ad d ed  and the solution sterile  filtered  
th rough a  0.2 |j.m filte r and stored  at 4 °C.
SOB media
T ryptone 20 .0  g
Y east ex trac t 5.0  g
N aC l 0.5 g
KC1 2.5 m M
M gC l2 20 .0  m M
A ll solutes w ere  d isso lved  fu lly  in 965 m l sterile  upH 20 .  T h is w as fo llow ed  by  the  addition 
o f  10 m l o f  KC1 solution  (250 m M ) an d  th e  p H  adjusted  to  7.0 w ith  5 M  N aO H . T he m edia  
w as the sterilized  by  autoclaving. Ju st befo re  use, 5 m l o f  sterile  2 M  M gC l2 so lu tion  and 20 
m l o f  1 M  M g S 0 4 so lu tion  tha t had been  sterilized  separately  (sterile-filtered) w ere  added  to 
th e  base m edia.
Super optim al catabolites (SOC) media
T iyp tone 20 .0  g
Y east ex trac t 5.0 g
N aC l 0.5 g
KC1 2.5 m M
M gC l2 20 .0  m M
G lucose 20 .0  m M
A ll solutes w ere d isso lved  fu lly  in 950 m l sterile  upH 20 .  This w as fo llow ed  by  the  add ition  o f  
10 m is o f  KC1 solution  (250 m M ) and the  p H  adjusted  to  7.0  w ith  5 M  N aO H . T he m edia  w as 
th en  sterilized b y  autoclaving. Just b efo re  u se , 5 m l o f  sterile  2 M  M gC l2 so lu tion  and  20  m l 
o f  1 M  M g S 0 4 so lu tion  tha t had  been sterilized  separately  (sterile-filtered) w ere  added to  the 
base m edia. F inally , 20  m l o f  1 M  g lucose  (sterile-filtered) w as added.
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Lau ria-Bertan i broth (LBB) g/L
T ryptone 10.0
Y east ex trac t 5.0
N aC l 5.0
The pH  w as ad justed  to  7.0 p rio r to  au toclav ing  w ith  2 M  N aO H .
Lau ria  -B ertan i agar (LBA) g/L
T ryp tone 10.0
Y east ex trac t 5.0
N aC l 5.0
A gar 15.0
T he pH  w as adjusted  to  7 .0  p rio r to  au toclav ing  w ith  2 M  N aO H .
2xty broth g/L
T ryptone 16.0
Y east ex tract 10.0
N aC l 5.0
2xty agar g/L
T ryptone 16.0
Y east ex tract 10.0
N aC l 5.0
A gar 15.0
IPTG  (Isopropylthiogalactoside) 40  m M
T his w as p repared  by  d isso lv ing  238  m gs o f  IP T G  in 10 ml upH jO . T his stock  so lu tion  w as 
sterile-filtered  (0.2 pm  cu t-o ff) and stored in 1 m l a liquo ts at - 2 0  °C.
X -ga l m g/L
40.0
T he stock  so lu tion  w as p repared  in d im ethy lfo rm am ide (D M F ) and stored a t - 2 0  °C in  a light­
p ro o f  glass bottle. T o  incorporate into p rev iously  p repared  agar p lates, 40 p i o f  th e  stock  X - 
gal so lu tion  w as spread  evenly  over the ag a r surface and  left to  dry  fo r app rox im ate ly  15 
m inutes a t room  tem peratu re  w hile  p ro tected  from  light. A g ar p lates w ere trea ted  w ith  X -gal 
accord ing  to  dem and. T hey  w ere  used im m ediately  and n ev er stored fo r ex tended  tim e 
periods.
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dNTP mix
dA T P 10 m M
dC T P 10 m M
dG T P  10 m M
dT T P 10 m M
P/u lOx reaction buffer
Tris-H C l (pH  8 .8 ) 200  m M
KC1 100 m M
(NH4)2S 0 4 100 m M
M g S 0 4 20  m M
N u c le a s e - f re e  B S A  1 m g /m l
T riton®  X - l  0 0  1 %  (v /v )
2.9.2 Iso la tion  o f L . m onocytogenes genom ic D N A
A 15 m l cell suspension  from  a 50 m l overn igh t cu lture o f  L.monocytogenes sero type l /2 a  in 
BHI b ro th  w as asep tically  transferred  into a  sterile  un iversal. The cell suspension w as 
cen trifuged  a t 4000 rpm  fo r 10 m inu tes at 4  °C. T he supernatan t w as d iscarded  and  the 
rem ain ing  pelle t w as w ashed  tw ice w ith  1.5 m l vo lum es o f  T E S  buffer and  once w ith  1.5 m is 
o f  T E  buffer to  rem ove ex traneous con tam inating  salts. T he pellet w as then  resuspended  in 
500 p i o f  lysozym e (50 m g/m l p repared  fresh in  TE  bu ffe r) in  a 1.9 m l ep p en d o rf tube and 
incubated  at 30 °C fo r 1 h r in  a  w ater-bath . A t 10 m inu te  intervals, during  the incubation  
period, the  tu b e  w as inverted  b y  hand to  ensure even m ix ing . A fte r the  1 h r  incubation, 500 pi 
o f  G ES reagen t w as added  to  the suspension  and  the con ten ts w ere then  vo rtexed  fo r 10 
m inutes. 500 pi ice-co ld  o f  7.5 M  sodium  acetate w as  added  to  give a  final concen tra tion  o f
2.5 M  and th e  suspension  w as p laced on  ice fo r 10 m inutes. T he conten ts o f  the ep p en d o rf 
w ere then  sp lit in to  tw o 750 p i a liquots fo r ease  o f  m anageability , and  dispensed  into fresh  
ep p en d o rf tubes. T he rem ainder o f  the  ex traction  pro toco l w as carried  o u t in duplicate, u sing  
both  750 p i crude extracts. 500 p i o f  K irby  reagen t w as m ixed  w ith  the  750 jaIs o f  extract. 
A fter cen trifugation  a t 13000 rpm  fo r 4 m inutes at room  tem peratu re , th e  aqueous phase w as 
rem oved using  a p ipette  and retained. T he so lvent phase and  ce llu lar debris w ere d iscarded. A  
fu rther 500 p i o f  K irby  reagen t w as added  to  th e  retained  frac tion  and, a fte r cen trifugation  at 
13000 rpm  fo r 4 m inutes, the  aqueous phase w as again  re ta ined . A pprox im ate ly  500-700 pi o f  
a  chloroform : isopropyl alcohol (24 :1) m ix ture  w as added to  the re tained  frac tion  and  the 
resu lting  solution w as cen trifuged  at 13000 rpm  fo r 4  m inu tes a t room  tem peratu re  to  partition  
the  aqueous and so lvent phases. O nce again, the  aqueous phase w as retained  and  the D N A
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con ten t w as precip ita ted  by  the  d ropw ise  addition  o f  an  equal vo lum e o f  isopropyl alcohol. 
T he D N A  strands w ere harvested  b y  b riefly  cen trifug ing  th e  sam ple  a t 13000 rpm . T he sm all 
resu ltan t pelle t w as w ashed  w ith  tw ice w ith  200  (il vo lum es o f  70 % (v /v) e thanol and  left to 
a ir  dry  fo r 5-10 m inu tes a t room  tem pera tu re  o r dried  rap id ly  u s in g  a  com m ercial evaporator. 
T he final pe lle t w as resuspended  in  150-200 (j.1 TE  buffer and  sto red  at 4 °C. T he p resence  o f  
genom ic D N A  w as verified  by  sub jec ting  the sam ple to  agarose  gel electrophoresis.
2.9.3 Sequence-specific p rim e r design
Prim ers w ere designed  (T able  2 .8 ) fo r com patib le  ligation  into th e  QlAexpress®  type A T G  
construct pQ E 60 (Q IA G E N ). T he inlA  gene specific  p rim ers w ere  designed in accordance 
w ith  the  sequence determ ined  fo r L. monocytogenes stra in  E G D , seovar l /2 a  (accession 
num ber A J012346). T he sequence cod ing  fo r  the signal pep tides w ere om itted. T he m u lti­
c lon ing  reg ion  o f  the  pQ E 60 v ec to r contains an  N col site  a t th e  N ' end  o f  the  sequence and a 
BamHI site  a t th e  C ' end. T herefore, fo rw ard  prim ers w ere  designed  to  include the Ncol 
bind ing  site sequence and  the reverse  prim ers w ere designed  to  contain  th e  BamHI sequence. 
Forw ard  prim ers w ere designed using  the  sam e bases found  in the  starter sequence o f  the 
required  protein and  reverse  p rim ers w ere  designed  using  th e  com plem entary  b ases from  the 
3' to  5' end o f  th e  sequences. The approx im ate T m  values (i.e. th e  tem pera tu re  at w h ich  50%  
o f  th e  o ligonucleo tide and  its com plem ent are  in duplex) w ere  estim ated  using  the  ‘W allace 
m e th o d ’ accord ing  to  T m  =  2 x  (A  +  T ) +  4 (G  +  C). A  m ore  p rec ise  estim ation o f  T m  values 
w as prov ided  by  th e  data  accom pany ing  the  syn thesized  p rim ers from  th e  m anufactu rer 
(M W G  B iotech), based  on the  fo rm ula T m  =  69.3 +  (0.41 x  G C % )-(650  /  length).
Table 2.8: Prim ers used fo r the specific am plification o f the inlA  gene sequence.
P r im e r  N am e S e q u en ce
In lA R  II 5' G G A T C C -T T T -A C T -A G C -A C G -T G C -T T T -T T T -A G T -A A G -A G C  3'
T A F II-A 5' C C A T G G -G A -A A G -A C G -G T C -T T A -G G A -A A A -A C  3'
t  Ncol t
T A F II-B 5’ C A T G -C C A T G G -G A -A A G -A C G -G T C -T T A -G G A -A A A -A C  3 ’
t  Ncol t
TA B  I 5' C G C -G G A T C C -T G A -T T C -T T T -T G A -A T T -A T A -A G G  3 ’
t  BaniHlt
2.9.4 Agarose g e l e lectrophoresis
D N A  sam ples w ere  analysed  by  horizon ta l e lectrophoresis in agarose gels conta in ing  0.5 
(xg/ml e th id ium  brom ide. A  1 % (w /v) gel w as p repared  by  add ing  0.5 g elec trophoresis grade 
agarose to  50 m l T A E  buffer and bo iling  the m ix tu re  in a  m icrow ave oven. E th id ium  brom ide
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w as added  to  the so lubilised  agarose to  y ie ld  a final concen tra tion  o f  0.5 (xg/ml. W hen  the 
solution  had cooled  suffic ien tly  it w as poured  onto  th e  horizon ta l gel p la tform , the  w ell com b 
w as inserted and the gel le ft to  set a t room  tem perature. O nce set, the  gel w as p laced  in  the 
electrophoresis un it filled  w ith  T A E  b u ffer and  the  com b rem oved. A  tracker dye w as added 
to  sam ples (1 p i dye +  5 p i sam ple) to  increase v isib ility  during  load ing  o f  the  sam ples. The 
sam ples w ere reso lved  b y  apply ing  a d irec t cu rren t o f  appropriate  vo ltage  and  the  resu lts w ere 
v isualized  on  a U V  transillum ina to r and pho tographed  using  a  U V  im age analyzer. A  0.7 %  
(w /v) gel w as used w hen sam ples run  in  agarose w ere required  to  be excised  and  purified.
2.9.5 P reparation  o f h igh  e ffic ien cy  com petent b acte ria l ce lls
H igh effic iency  com peten t cells w ere prepared  as prev iously  described  by  Inoue et a l. (1990). 
C ells from  a  frozen stock  o f  E. co li X L  10® G old  w ere streaked  on  an  LB agar p late contain ing  
te tracycline  (10 pg /m l) and incubated  a t 37 °C overnight. A pprox im ate ly  10-12 large colonies 
w ere  rem oved from  th e  p la te  and inocu lated  in to  250 m l o f  SO B  m edium  in a 2 L  baffled  
flask. T he cu lture  w as grow n at 18 °C w ith  v igo rous shaking  (200-250  rpm ) until an  ODeoo,™ 
o f  0.6 w as reached. T he flask  w as then  rem oved and  p laced  on  ice fo r 10 m inu tes before 
being transferred  to  tw o 250 m l cen trifuge tubes and  cen trifuged  at 4000 rpm  fo r 5 m inu tes at 
4°C in a  B eckm an  J2-21 centrifuge. The tw o  resu lting  pellets w ere  poo led  and resuspended  in 
80 ml o f  ice-co ld  TB buffer, incubated  on an ice-bath  fo r 15 m inu tes and  then  cen trifuged  as 
before. T he cell pe lle t w as gen tly  resuspended  in 20 m l o f  ice-co ld  T B  bu ffer and  D M S O  w as 
then  added  slow ly  and  w ith con tinual gen tle  sw irling  to  a  final concen tra tion  o f  7 % (v/v). 
A fter incubation  in an  ice bath  fo r a  fu rther 10 m inu tes th e  cell suspension  w as d ispensed  in 1 
m l a liquo ts into sterile  cryovials. The com peten t cells w ere  then  flash  frozen  in liquid 
n itrogen  and  stored a t - 8 0  °C.
2.9.6 Polym erase cha in  reaction  (PCR )
Polym erase chain  reaction  (P C R ) w as used  to  am plify  specific  D N A  sequences derived  from  
L. monocytogenes gD N A . A  standard  P C R  reaction  w as set up as follow s:
lx
lO m M  dT N P  m ix  (200 p M  end  concentration) 1 . 0  pi
lOx P C R  buffer 5.0 pi
P rim ers (0.5 nM /pI) (to tal o f  1 p i) 0.5 p i (each)
T em plate  D N A 1 .0  p i
S terile  m o lecu lar grade upH 20 39.5 p i
Taq po lym erase (2.5 units final concentration) 2.5 pi
R e a c t io n  v o lu m e 5 0  p i
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J x
(B ) lO m M  dT N P  m ix  (200 (iM  end concen tra tion) 1.0 jal
lOx Pfu bu ffer (con tain ing  20  m M  M g S 0 4) 5.0 fil
P rim ers (0.5 nM /fil) (to tal o f  1 |il)  0.5 /il (each)
T em plate  D N A  1.5 (0.1
Sterile m olecu lar grade H 20  41 .0  j_l!
H ot start
Pfu  D N A  polym erase (1.5 units fina l concen tra tion) 0.5 pi
Reaction volume 50 jj,1
The optim um  annealing  tem peratu re  fo r p rim er sets w as estim ated  b y  conducting  a  ‘grad ien t 
P C R ’ reaction  over a range o f  tem pera tu res d iffering  by  betw een 1 and  2 °C. T he tem pera tu re  
w hich  gave the  ‘c lean est’ and  m ost specific  band  w as chosen  as the annealing  tem pera tu re  for 
a given p rim er set. O nly  1.5 un its Pfu  D N A  polym erase  p e r 50 ul reac tion  m ix  w as used, ye t 
th is w as deem ed su ffic ien t due to  the  h igh  stringency, fa ith fu l b ind ing  exh ib ited  b y  Pfu 
polym erase  and  its g rea ter hea t resistance. It w as h e ld  on ice un til a fte r th e  addtion  o f  dN TPs 
so as to  avoid  degradation  o f  the  prim ers v ia  th e  in trinsic  3 ’ —> 5 ’ exonuclease  activ ity . Pfu 
D N A  P olym erase exhib its a  low er ex ten tion  rate  (0.5 kb /m inu te) th an  tha t o f  Taq D N A  
Polym erase, so a  5 m inu te  ex tension  tim e  w as em ployed  fo r th e  2.1 kb in lA  gene sequence 
being am plified . P /w -catalysed am plification  w as used  w here  h igh fide lity  P C R  product w as 
essential, as in the  case o f  p rim ary  gene sequence  am plification  from  gD N A . F o r rou tine  P C R  
reactions used  to  check  fo r the presence o f  inserts in  p lasm id  constructs, Taq po lym erase  w as 
adequate.
2.9.7 P C R  p roduct lig a tio n  in to  p C R  2.1 p la sm id  (blunt-ended)
T he ligation reaction  w as set up as fo llow s:
upH 20  (m olecu lar grade) 4  fxl
1 OX ligation  buffer 1 p.1
p C R  2.1 vecto r ( -2 5  n g /  p i) 2  p i
*Fresh P C R  product 2  n l
T 4  D N A  L igase 1 p i
Total volume 1 0  Hi
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T he ligation reaction  w as incubated  a t 14 °C overn igh t and  th en  used im m ed ia te ly  fo r 
transform ation. It w as accep tab le  to  store  the  ligated  construc t at - 2 0  °C fo r  an  ex tended  
period o f  several m onths.
*Only fresh PCR product was used so as to reduce the risk  o f the single stranded 3 ' poly-A 
overhangs degrading.
2.9.8 Transform ation o f p C R 2 .1 -in lA  p lasm id  in to  b acte ria l ce lls  
T he v ial contain ing  the  fresh ligation reaction  w as cen trifuged  briefly  and p laced on  ice. An 
aliquo t o f  com peten t cells (E . co li X L10-Gold® ) w as rem oved  from  sto rage a t -80°C  and 
allow ed to  thaw  at room  tem perature. A  200  p i a liquo t o f  the cell suspension  w as transferred  
to  a sterile, p re-ch illed  15 m l po lypropy lene  tube  and p laced  im m edia te ly  on ice. A  2 jj.1 
vo lum e o f  the  fresh  ligation  reaction  w as then  p ipetted  d irectly  into th e  tube  and  the  tube 
sw irled  briefly  and gently  gently  before  being  incubated  o n  ice fo r 30 m inutes. T he rem ain ing  
ligation m ixture w as sto red  a t - 2 0  °C. E ach V ia l w as hea t shocked  fo r exactly  30 seconds in  a 
42 °C w a te r bath  (w ithou t ag ita tion) and transferred  back  to  ice. 250 pi o f  SO C  m edium  (LB 
broth  w as also  accep tab le) a t room  tem peratu re  w as added  to  the  tube. T he tube  w as then 
shaken horizontally  a t 37 °C fo r 1 h r  a t 225 rpm  in an  o rb ita l incubator. A fte r 1 hour, 50-100 
p i from  each transfo rm ation  tu b e  w as spread on separate, labelled  LB agar p lates coated  w ith 
X -G al and conta in ing  10 |o,g/ml te tracycline, 50 fig/m l o f  kanam ycin  and  100 pg/m l 
am picillin . The p lates w ere then  inverted  and  incubated  a t 37 °C for 18-24 hours befo re  being 
p laced  at 4 °C fo r 2-3 hours to  a llow  fo r fu ll co lou r developm ent.
2.9.8.1 Restriction Analysis o f *white colonies’ (pCR2.1-inlA transformants) from  X -ga l 
agar plates
A restriction  d igest w as carried  ou t a t 37 °C fo r  1 hour, on  p lasm ids derived  from  individual, 
iso lated  w hite  co lon ies as follow s:
REact® 3 bu ffer (lO x) 
P lasm id  D N A  
upH 20  (m o lecu lar g rade) 
EcoRI
1 . 0  p i
3.0  p i
5.0 p i
1 . 0  |il 
1 0 . 0  p iTotal volume
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E ach  d igest w as run  in  a  1.0 %  (w /v) agarose gel and  exam ined  fo r the  p resence o f  a  band 
correspond ing  to  the  desired  in lA  insert.
2.9.8.2 Restriction digestion o f pCR2.1-in lA constructs
P lasm ids confirm ed to  con ta in  the in lA  in sert w ere  d igested  as fo llow s:
REact® 3 buffer (lO x) 3.0 \il
P lasm id  D N A 2 0 . 0  n l
upH 20  (m olecu lar grade) 3 .0  nl
B a m H I 3.0 (il
Ncol 3.0 |ol
Total volume 50.0 (il
E ach  d igest w as run  on  a  0.7  %  (w /v) agarose gel and  the  restric ted  in i A insert cu t from  the 
gel using  a clean sharp  scalpel and p laced  in  sterile  1.5 m l cen trifuge tub es fo r fu rther 
purification , i f  necessary .
2.9.9 R estriction  d igestion o f in lA  P C R  p roduct (d irectiona l)
F resh  T^w-amplified inlA  P C R  p roduct w as pu rified  from  50 (il o f  fresh  P C R  reac tio n  m ixture. 
T his w as ach ieved  by  iso lation  and  purifica tion  o f  the P C R  p roduc t from  a 0 .7  %  (w /v) 
agarose gel (Section 2 .9 .12), o r e thanol p rec ip ita tion  (S ection  2 .9 .13). T he p rincip le  ob jective 
w as to  separate th e  P C R  p roduct from  P C R  reaction  com ponen ts th a t m igh t adverse ly  affect 
restric tion  enzym e activ ity  and, thus, e thanol prec ip ita tion  w as favoured  because it w as 
qu icker and less harsh , thereby  reducing  the  poten tia l fo r  degradation  o f  the P C R  am plicon  
and  concom itan tly  y ie ld ing  a  g rea ter p roduct recovery .
P urified  in lA  am plicon 2 0 . 0  (U
REact® 3 bu ffe r 3.0 nl
Ncol 3.0 (il
BamHI 3.0 (il
H 2O (m olecu lar grade) 1 .0  (il
Total volume 50.0 ( J
T h e  r e s t r i c t e d  in lA  a m p l i c o n  w a s  r e c o v e r e d  b y  e th a n o l  p r e c ip i t a t i o n  ( S e c t io n  2 . 9 . 1 2 ) .
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2.9.10 P C R  p roduct lig a tio n  in to  pQ E60 p la sm id  (d irectiona l) 
T he ligation reaction w as set up  as follow s:
upH 20  (m olecu lar grade)
10X ligation  bu ffer
pQ E 60 v ec to r (BamHUNcol d igested) 
in lA  insert (BamYWNcol d igested) 
T4 D N A  L igase
Total volume
1.5 jul
1 . 0  jul
1.5 pi
5.0 p i
1 . 0  pi 
1 0 . 0  pi
T he ligation reaction w as incubated  a t 15.5 °C overn igh t and then used im m edia te ly  fo r 
transform ation . It w as accep tab le  to  store the  ligated con stru c t a t - 2 0  °C fo r an  ex tended  
period  o f  several m onths.
2.9.11 Transform ation o f p Q E 60 -in lA  p lasm id  in to  b acte ria l ce lls
A n a liquo t o f  com peten t cells (E. co li X L10-G old® )*a w as rem oved  from  storage a t -80°C  and 
allow ed to  th aw  a t room  tem perature. 2 0 0  p i o f  the  cell suspension  w as transferred  to  a 
sterile, pre-ch illed  15 m l po lypropy lene  tube  and placed im m ediately  on ice. 2  p i o f  the  fresh, 
BamH MNco\-d\gestcd  in lA  insert w as added  to  the  200 p i com peten t ce ll suspension . The 
rem ainder o f  the  procedure w as as p rev iously  described  (S ection  2 .9 .7). H ow ever, L B  agar 
se lection  plates w ere n o t trea ted  w ith  X -gal and  25 pg /m l ch lo ram phen ico l w as used  in p lace 
o f  50 pg/m l o f  kanam ycin , in addition  to  10 pg/m l te tracycline  and  100 pg/m l am picillin .
*a XLIO-Gold genotype: TETR A(mcrA) 183 A(mcrCdSMR-mrr) 173 endAl supE44 thi-1 recAl 
gyrA96 relA l lac Hte [F’ proAB /ac/'ZAM15 TnlO (TetR) Amy CamK* ].
Chloramphenicol resistant (CamR)  at < 40 fig/ml, Chloramphenicol sensitive (Cams)  at > 100 fig/ml. 
The genes indicated in italics signify mutant alleles carried by the bacterium. The genes The F ’ 
episome genes indicate the wild-type alleles.
2.9.12 P C R  product p u rifica tio n  (G e l clean-up)
D N A  w as purified  from  the  agarose gel using an  E p p en d o rf Perfectprep®  G el C leanup PC R
kits ou tlined  below :
T he D N A  band o f  in terest w as located  in a  0.7  %  (w /v) agarose gel and  excised  using  a clean, 
sterile  scalpel blade. T he agarose slice w as transferred  to  a sterile  1.5 ml ep p en d o rf tu b e  and 
w eighed . U p to  400 m g agarose cou ld  be p rocessed  in a  sing le  1.5 m l ep p en d o rf tube. T hree
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volumes o f biding buffer (containing guanidium thiocyanate) were added for every one 
hundred volumes of gel (1 mg gel was taken as equivalent to 1 ^1 o f volume). The tube was 
incubated at 50 °C until the agarose melted (5-10 minutes). When the gel had completely 
dissolved, one volume o f isopropanol (equal to the original gel volume) was added and mixed 
by inverting several times. The suspension was then placed in a spin column housed in a 2 ml 
collection tube. Up to 800 (j.1 o f sample could be added to the spin column. The spin 
column/collection tube assembly was centrifuged at 7500 rpm for 1 minute and the resultant 
flow-through discarded. Next, 750 jj,L wash buffer (1 part concentrated wash buffer : 4 parts 
100 % ethanol) was added to the spin column and the assembly centrifuged at 7500 rpm for 1 
minute. The flow-through was again discarded and the empty spin column rehoused in the 
same collection tube before being centrifuged at 7500 rpm for a further 1 minute to remove 
residual wash buffer. The spin column was placed in a fresh, sterile 1.5 ml eppendorf tube and 
30 jul o f molecular grade water or TE buffer was added carefully. The column was 
centrifuged at 10,000 rpm for 1 minute and the purified DNA was eluted into a final volume 
o f 30 fxl. Purified DNA was stored in the tube at 4 °C for up to 24 hr or at -20  °C for long­
term storage (several months).
2.9.13 PCR product pu rifica tion  (ethanol precip itation)
DNA was purified directly from the PCR reaction mixture by precipitation as follows. 
Typically, 40 fil o f PCR reaction mixture was diluted to a final volume of 400 fxl with 
molecular grade upw. An equal volume o f Kirby mix (400 |J.l) was added and the solution 
mixed by inverting. The contents were then centrifuged for 5 minutes at 13,000 rpm and 4 °C. 
The aqueous (upper) layer was removed to a fresh, sterile 1.5 ml eppendorf tube carefully 
avoiding disruption of and cany-over from the interlayer and organic phase. An equal volume 
of molecular grade chloroform was added to the aqueous retentate. The contents were mixed 
and centrifuged as before. The aqueous layer was again removed to a fresh eppendorf tube 
and 1/10 the volume of 3 M sodium acetate (to a final concentration o f 0.3 M) was added. 
Next, 2.5 volumes of 100 % (v/v) ethanol were added, the contents mixed by inverting and 
incubated at -20  °C for at least 1 hr. The precipitated DNA was harvested by centrifuging for 
20 minutes at 13000rpm and 4 °C. The supernatant was decanted and 200 jil cold 70 % (v/v) 
ethanol added to the remaining pellet (without mixing) to wash out any residual salts. The 
contents were then centrifuged at 13000 rpm for 10 minutes at 4 °C and the supernatant was 
again carefully decanted and any residual liquid removed by brief and gentle vacumn 
evaportion. The pellet was then resuspended in TE buffer or molecular grade upw and stored 
on ice for immediate use or at -20  °C for long-term storage.
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2.9.14 P lasm id pu rifica tion
A Promega Wizard® Plus SV Minipreps DNA Purification System was used to purify plasmid
DNA as follows:
A 5-10 ml overnight bacterial culture was centrifuged for 5 minutes at 4000 rpm, the 
supernatant decanted and tubes blotted dry on a paper towel. A  250 fil aliquot o f cell 
resuspension solution (50 mM Tris-HCl, pH 7.5, 10 mM EDTA and 10 fig/ml RNase A) was 
added and the cell pellet completely resuspended by repeat pipetting. The mixture was 
transferred to sterile 1.5 ml microcentrifuge tube(s), 250 (il o f cell lysis solution (0.2 M 
NaOH and 1%  (w/v) SDS) added and mixed by inverting the tube 4 times. 10 (4.1 of alkaline 
protease solution was then added and the suspension mixed by inverting the tube 4 times. This 
helped to inactivates endonucleases and other undesirable proteins released during the lysis of 
the bacterial cells that could adversely affect the quality o f  the isolated DNA). After 5 minutes 
incubation at room temperature 350 (J.1 o f Wizard® Plus SV neutralisation solution (pH 4.2 
buffer containing 4.09 M guanidine hydrochloride, 0.759 M potassium acetate and 2 .12  M 
glacial acetic acid) was added and immediately mixed by inverting the tube 4 times. The 
bacterial lysate was then centrifuged at 14000 rpm for 10 minutes at room temperature. The 
cleared lysate was transferred (~ 850 jal) to the prepared spin column using a sterile pipette. 
The cleared fraction was centrifuged at 14000 rpm for 1 minute at room temperature after 
which the spin column was removed from the collection tube and the flow through discarded. 
750 fxl o f column wash solution (162.8 mM potassium acetate, 22.6 mM Tris-HCl, pH 7.5 and 
0.109 mM EDTA), previously diluted with ethanol to 95% (v/v) final concentration, was then 
added to the reinserted spin column. Wash solution was flushed through the spin column by 
centrifuging at 14000 rpm for 1 minute at room temperature. The flow-through was again 
discarded from the collection tube and the wash procedure repeated using 250 |il o f column 
wash solution. In order to remove any residual wash solution the decanted spin column was 
centrifuged at 14000 rpm for a further 2 minutes at room temperature. Subsequently the spin 
column was transferred to a fresh, sterile 1.5 ml eppendorf, taking care not to transfer any 
residual column wash solution with the spin column. The plasmid DNA was finally eluted by 
addition of 65-100 (jl o f sterile ultra pure water to the spin column and centrifuging the 
supernatant at 14000 rpm for 1 minute at room temperature. After eluting the plasmid DNA, 
the spin column was discarded and DNA stored in the tube at 4 °C for up to 24 h or -20  °C 
for long-term storage (several months).
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2.9.15 Protein expression and time course analysis
Approximately 5 mis o f LB broth containing 100 |ig/ml ampicillin, 10 jig/ml tetracycline 25 
jig/ml chloramphenicol and 1 % (v/v) glucose was inoculated with 100 f,il o f stock 
transformant and grown overnight at 37 °C. A 5 ml volume o f this culture was then used to 
inoculate 50 mis LB broth containing 100 ng/ml ampicillin, 10 pg/ml tetracycline and 25 
(ig/ml chloramphenicol and 1 % (v/v) glucose was incubated at 37 °C until an OD6oonm of 0.6 
was reached. At this point a 1 ml sample was taken and placed at -20  °C until needed. The 
culture was induced with IPTG to a final concentration o f 1 mM and a 1 ml sample taken 
every hour. Each 1 ml sample was centrifuged at 14000 rpm for 5 minutes, at 4 °C, and the 
supernatant discarded. The pellet was resuspended in 200 (il o f appropriate buffer, PBS for 
native extract and lysis buffer (8 M urea, 10 mM Tris-HCl, 100 mM Nat^PC^, pH 8.0) for 
denatured extract. The samples were then sonicated for 45 seconds at an amplitude of 40, 
using a microtip Vibra C ell™  sonicator, and the cell debris removed by centrifugation at 
14,000 rpm for 5 minutes. The supernatant was mixed with SDS-PAGE sample buffer and 
SDS-PAGE analysis carried out as described in Section 2.3.2.
2.9.16 P urifica tion  o f  recombinant His-tagged pro te in  by im m obilised metal 
a ffin ity  chromatography (IM AC )
A  1 ml aliquot o f Ni+-NTA agarose resin (QLAgen) was added to a 20 ml universal tube and 
equilibrated with 20 ml o f running buffer (PBS/T with 1% (v/v) Tween-20, 500 mM NaCl 
and 10 mM P-mercaptoethanol). The solution was centrifuged at 4000 rpm for 10 minutes and 
the supernatant (running buffer) removed. 2-3 ml o f sonicated cytoplasmic extracts containing 
His-tagged recombinant protein were added to the pellet (Ni+-NTA resin) and mixed for 1-2 
hours at room temperature on a rocking platform. The mixture was then centrifuged at 4000 
rpm for 10 minutes and the supernatant (unbound material) removed. The pellet (resin with 
bound protein) was washed 3 times with 20 ml o f running buffer as before. The proteins were 
eluted with 2-3 ml o f sodium acetate buffer, pH 4.5, and neutralised with 2 M Tris buffer, pH 
8.8. Purified proteins were stored at -20  °C. This represents a generic protocol for IMAC 
purification. Optimisation for purification o f the protein o f specific interest is discussed in 
detail in chapter 4 (Section 4.4.6).
2.9.17 Identification o f recombinant protein by Western blotting
Purified proteins were analysed by SDS-PAGE and Western blotting, as described in Sections
2.3.2 and 2.3.4. Purified recombinant protein bands were detected with a commercial mouse 
anti-His tag monoclonal antibody or with a specifically generated anti-inlA murine 
monoclonal antibody.
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2.10 B iacore studies
Analyses were carried out on a Biacore 3000™ instrument using the CM5 sensor chip. The 
running buffer for all Biacore experiments was HBS buffer, pH 7.4, containing 10 mM HEPES, 
150 mM NaCl, 3.4 mM EDTA, and 0.05% (v/v) Tween 20. Running buffer was freshly 
prepared, filtered (pore size o f 0.22 (.im) and degassed using a vacum filtration apparatus 
(Millipore sintered glass filtration unit) before use. All data points were collected at a frequency 
o f !  Hz.
2.10.1 Pre-concentration studies* a
Proteins were diluted in sterile-filtered 10 mM sodium acetate buffers that had been adjusted 
with 10% (v/v) acetic acid to pH values 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0. 10 jil of protein at each 
respective pH was sequentially passed over an un-activated carboxymethylated dextran sensor 
chip surface at a flow rate o f 10 ^l/inin. The pH that afforded the greatest degree o f pre­
concentration, reflected by the highest response unit (RU) value, was chosen as the carrier 
buffer for immobilisation. TES buffer was used when optimising pre-concentration o f nucleic 
acid probes.
2.10.2 Im m obilisation o f  monoclonal antibody * a
The carboxymethylated dextran matrix on the sensor chip was activated by mixing equal 
volumes of 100 mM NHS (N-hydroxysuccinimide) and 400 mM EDC (N-ethyl-N-(dimethyl- 
aminopropyl) carbodiimide hydrochloride), and injecting the mixture over the sensor chip 
surface for 10 minutes at a flowrate o f 5 ^1/minute. The purified monoclonal antibody was 
diluted in 10 mM sodium acetate, pH 4.0, at a concentration of 100 (.ig/inl. This solution was 
then injected over the activated chip surface for 24 minutes at 5 ^1/minute. Unreacted NHS 
groups were capped and loose, non-covalently attached proteins were removed by injection o f 1 
M ethanolamine hydrochloride, pH 8.5, for 1 1  min. Loosely bound material was further 
removed using a 30 second pulse o f 5 mM NaOH and 5 mM HC1, respectively.
*a: These methods represent generic template protocols, and where specific modifications or 
amendments have been made, they are clearly cited and justified within the releyant results 
and discussion sections in chapter 4.
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2.10.3 Preparation o f  IgG2a contro l surface
A standard, purified murine IgG2a antibody (Sigma, M9144) was immobilised on the flowcell 
immediately downstream o f the test flowcell at a similar level to the immobilised test surface 
(anti-InlA or anti-His-tag).
2.10.4 L. monocytogenes-specific, direct -ce ll-b ind ing assay
All bacterial cells tested were prepared from cultures that had been grown in LEB broth at 37 
°C and 200 rpm. Cells were harvested, washed twice in PBS buffer and adjusted to the desired 
cell concentration in PBS (estimated from a standard curve o f OD55onm versus cell 
concentration). Cells were passed over the sensor surface at 1 u 1/m in and surface regeneration 
was mediated by a 45 second pulse o f 5 mM NaOH.
2.10.5 B ind ing  analysis using the N T  A  chip
The NTA chip surface was activated by passing 20 nl o f a 500 nM solution o f NiCk across 
the surface at a flow rate o f 20 (xl/min. The His-tagged ligand (recombinant InLA protein) was 
then passed across the activated surface at 20 [j 1/m in, until the desired immobilisation level 
was achieved. The complementary analyte (anti-InlA monoclonal antibody) was the injected 
and the binding interaction monitored and noted. The surface was regenerated by injecting 20 
|il of a 400 jiM solution o f EDTA.
2.10.6 Measurement o f  steady-state a ffin ity
Approximately 10500 RUs of anti-His antibody was immobilised onto a CM5 chip surface. To 
ensure an optimally active anti-His surface it was important that the antibody was pure and free 
from BSA  or other stabilising proteins as amine coupling is non-specific and could lead to more 
favourable attachment o f the undesired protein component. IMAC-purified recombinant InlA 
(rlnlA) protein in HBS buffer was passed over the anti-His surface at 5 |il/min for 2 minutes 
generating an approximate response of 470 RUs. The His-tag capture approach ensured that the 
rlnlA protein was in an accessible orientation for mAb2B3 binding. 200 (il o f serial doubling 
dilutions o f mAb2B3, ranging from 3.3 x  10 6 to 1.29 x 10 '8 M, were individually passed over 
the rlnlA surface. To conserve antibody, samples o f mAb2B3 were passed over the rlnLA 
surface at a reduced flow rate o f 2 (i I/m in. After the 40 min exposure equilibrium was 
approached and the equilibrium response (Req) was noted. Regeneration was achieved by 
stripping the rlnlA from the anti-His surface with two 30 second pulses of freshly prepared 5 
mM NaOH. All sensorgrams were reference subtracted from a murine IgG-immobilised 
reference surface. To remove systematic anomalies a blank run consisting of HBS that 
contained no mAb2B3 was subtracted from each of the test sensorgrams. Results were plotted
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as Req versus mAb2B3 concentration and the data analysed using the BLAevaluation™ steady 
state affinity model for bivalent analytes.
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2.11 H P LC  analyses
All buffers used throughout high performance liquid chromatography analyses were degassed 
and sterile filtered with a 0.2 |im cut-off membrane filter prior to being used. The column 
employed for size exclusion chromatography (SEC) was a Phenomenex 3000 SEC, packed 
column.
Table 2.9: Molecular weight standards used in size exclusion chromatography.
Standard Mr (kDa) Source Catalogue code
Blue dextran 2000.0 Sigma D-4772
p-amylase (P-A) 200.0 Sigma A-8781
Alcohol dehydrogenase (AD) 150.0 Sigma A-8656
Bovine serum albumin (BSA) 66.0 Sigma A-8531
Carbonic anhydrase (CA) 29.0 Sigma C-7025
Cytochrome C (CC) 12.4 Sigma C-7150
IgG2a 150.0 Sigma M9144
2.11.1 Analysis o f  a ffin ity -pu rified  antibody frac tions
The column equilibration and mobile phase buffer used was PBS. 50 pi o f affinity-purified 
monoclonal antibody in PBS buffer was injected onto the SEC column at a flow rate o f 0.5 
^l/min and the protein content o f the eluted fractions monitored spectrophotometrically at 280 
nm. The resulting chromatogram (A280mn versus retention time) was compared to that for a 50 
|il sample o f commercial IgG2a standard, prepared in PBS buffer.
2.11.2 Standard curve fo r  estimation o f  m olecular weight (M r)
The column equilibration and mobile phase buffer used was PBS. The void volume (v0) o f the 
SEC column was estimated by calculating the column retention time for a 50 (4,1 sample of 
blue dextran at a concentration o f 1 mg/ml and a flow rate o f 1 fil/min, again using UV 
detection at 280 nm. A  standard curve was constructed using the standards (P-A), (AD), 
(BSA), (CA) and (CC). The retention times o f each standard (ve), when applied individually 
to the column, were normalised with respect to the void volume (ve/v0) and plotted against the 
logio value o f the corresponding molecular weight, to generate a linear calibration curve.
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A 50 |il sample o f IMAC-purified recombinant His-tagged protein in PBS buffer was injected 
onto the SEC column at a flow rate o f 1 ^1/min. The normalised retention time was used to 
estimate the Mr o f the major components o f the IMAC-purified sample from the standard 
curve as described in Section 2 .11.2 .
2.11.3 A nalysis o f  IM A  C -purified  recom binant p ro te in
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2.12 S E M  and A F M  image analysis
2.12.1 Sample preparation
2.12.1.1 Fixing
Bacterial cells that bound to specific antibody immobilized on the dextran matrix o f a CM5 
chip were fixed in situ according to the following. Briefly, the CM5 chip was undocked from 
the Biacore instrument having been exposed to a completed cycle o f bacterial sample 
analysis. The chip was then immediately placed in a glass petri dish (sample surface facing 
upwards) containing 25 mis 2.5 % (v/v) glutaraldehyde in cacodylate buffer and left overnight 
at 4 °C.
2.12.1.2 Post-fixing
The chip was removed from the glutaraldehyde solution and washed (x2) in 40 mis fresh 
cacodylate buffer. The chip was then incubated in freshly prepared 1 % (w/v) osmium 
tetroxide in cacodylate buffer for 90 minutes at room temperature.
2.12.1.3 Drying
The chip was washed briefly in fresh cacodylate buffer before being exposed to a graded 
series o f ethanol in ultra-pure water (25, 50, 75, 90 and 100 % (v/v)) for 10 minute periods at 
room temperature. After the final incubation in 100 % (v/v) ethanol, the dehydrated chip was 
removed from the PVC mounting and placed in a sealed dessicator for 8-10 hours, or 
overnight. Samples fixed in this fashion were suitable for both SEM and AFM imaging.
2.12.2 Sample analysis
2.12.2.1 SEM analysis
The sample chip was mounted on the SEM stage and the sample chamber was then evacuated. 
The filament was saturated and then the electron gun was aligned, as appropriate. The voltage 
and working distance were set at 7.0 kV and 27.9 mm, respectively and images were collected 
via an incorporated secondary electron detector module.
2.12.2.2 A F M  analysis
The sample chip was examined by ‘contact mode’ surface probing using a Nano-R™ AFM  
instrument. This experiment was kindly facilitated by the National Centre for Plasma Science 
and Technology (NCPST) in DCU.
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C h a p t e r  3  
P r o d u c t i o n  a n d  C h a r a c t e r i s a t i o n  o f  
M o n o c l o n a l  A n t i b o d i e s  t o  L .  
m o n o c y t o g e n e s
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3.1 In troduction
3.1.1 The immune system
The term immunity is derived from the latin ‘ immunitas’ , (meaning freedom from) and in it’ s 
original usage referred to exemption from military service and payment o f taxes (Weir, 1988). 
The current definition o f immunity relates to the complex cascade o f genetic and biochemical 
events that, in healthy mammals at least, reduces the individuals susceptibility to infection 
and attack by foreign bodies.
Innate immunity is best described as a ‘general’ or ‘non-specific’ defence mechanism. It 
represents the body’s first line o f defence against infection and includes anatomic barriers 
(skin and mucous membranes) and physiological barriers. The latter include the presence o f 
the hydrolytic enzyme, lysozyme in tear secretions and the acidic environment o f the 
stomach. In instances were the external innate immune barrier becomes breached, the internal 
innate immune system becomes activated. The predominant elements include the cells derived 
from the mononuclear phagocyte system, such as, macrophage that engulf and destroy foreign 
bodies. Neutrophils and especially natural killer (NK) cells are directed against host cells that 
have been infected with virus material and/or become malignant. The body’ s inflammatory 
response is a means o f expediting the concentration of such cells around the areas o f infected 
tissue.
Adaptive or acquired immunity is distinct from innate immunity by virtue o f its extreme 
specificity and is sub-divided into humoral and cell-mediated immune responses (Figure 3.1). 
The foreign body that elicits an adaptive response is termed the ‘ immunogen’ , the specific 
molecules present on the immunogen that allow the adaptive immune system to distinguish 
between different immunogens are referred to as ‘antigens’ . The smallest defined region o f a 
given antigen recognised by an antibody is termed the ‘epitope’ . Thus, an individual’ s 
adaptive status is a reflection o f the diversity o f antigens to which they have been exposed, 
and the frequency o f such exposures. Since the efficiency of the adaptive response improves 
with each subsequent exposure to a given antigen, it is also a reflection o f the frequency o f 
exposure. The cells o f the lymphatic system, termed lymphocytes mediate adaptive immunity. 
These include the antibody-producing B-cells (Bursa-equivalent-derived small lymphocyte) 
and T-cells (Thymus-derived small lymphocytes), the latter o f which include helper (TH), 
cytotoxic (Tc) and suppressor (Ts) varieties. The approximate percentage o f each type within 
the major lymphoid organs is outlined for a typical murine model in Table 3 .1.
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Table 3.1: Lymphocyte sub-populations o f major murine lymphoid organs. (Adapted from  
Hudson and Hay, 1980).
Organ % T-Cells % B-Cells
Thymus 97 1
Lymph node 77 18
Spleen 35 38
Blood 70 24
Thoracic duct lymph 80 19
3.1.1.1 The humoral immune response
Far from being mutually exclusive events, the B and T-cell activation cascades are 
inextricably linked. A  key co-ordinator o f the adaptive immune response is the major 
histocompatibility complex (MHC) set o f molecules. These glycoproteins, act as cell 
membrane appendages that display, or present antigen molecules for processing by the 
adaptive components. The two principal variants include; MHC I (present on most nucleated 
cells), and MHC II (only expressed by antigen-presenting cells). To elicit an immune 
response, a given immunogen must generally be o f molecular weight greater than 5-6 kDa 
and exhibit a degree o f complexity within its structure. Small molecules, such as certain drug 
and pesticide compounds, are often incapable o f eliciting an immune response on their own 
by virtue of their size and are called ‘haptens’ . From a research point o f view, such molecules 
can be altered, by conjugating to larger molecular weight carrier molecules (e.g. BSA, KLH 
or THG), which are easily appreciated by the immune system. Larger molecules, such as 
bacteria contain a multitude o f surface antigens, which each in turn may contain many 
epitopes, rendering them easily identifiable as ‘ foreign’ , to the immune system. In fact, 
inactivated Mycobaterium and Bordetella spp. have been used as the principal constituent of 
adjuvant preparations (e.g. Freund’ s adjuvant). When immunogens are delivered suspended 
within such adjuvants, the inactivated bacterial content stimulates heightened macrophage 
activity localised around the area o f immunisation.
Following phagocytosis and partial digestion o f the foreign entity, the antigenic material is 
displayed on the surface o f the macrophage or antigen-presenting cell (APC) via MHC II 
molecules. Th cells then bind to the MHC II molecules using T-cell receptor molecules that 
are present on the surface o f T-cells. Like an antibody, each T-cell receptor is a heterodimer 
composed o f a- and p- chain domains that incorporate both variable and constant domains.
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This initial binding event sets in place a sequence of events that revolve around the release o f 
stimulatory molecules called cytokines. At this stage Interleukin-1 (IL-1) induces rapid 
proliferation and differentiation o f T-cells, while release o f IL-2 induces B-cell proliferation. 
Circulating B-cells can also take up, process and present antigens to TH cells. Only one B-cell 
is reactive towards any given epitope, and this specificity is dictated by the nature o f the 
antibody displayed on the surface o f each B-cell. The B-cell/TH cell interaction stimulates IL- 
4 receptor production on the B-cell surface and secretion o f IL-4 itself by the activated TH 
cell. Concomitant secretion o f IL-5 by the B-cell itself culminates in differentiation o f the B- 
cell into ‘plasma’ and ‘memory’ B-cell variants. Plasma B-cells are short-lived variants o f the 
parent B-cell, which are characterised by heightened rough endoplasm reticulum activity, 
conducive to rapid production and secretion o f soluble antibody. Conversely, the memory B- 
cells are pervasive, circulating variants that display surface-bound antibody and are ready to 
respond rapidly during instances o f re-exposure to antigen.
3.1.1.2 Antibody structure
At any given time the population of soluble antibodies in an individuals serum is wide and 
varied and is generally referred to as ‘polyclonal’ . It is this circulating pool o f antibodies that 
directs humoral clearance of invading entities, such as bacterial cells.
Antibodies are a class o f predominantly soluble, globular proteins with specific features that 
place them in the ‘ immunoglobulin’ (Ig) family o f folded protein structures. Immunoglobulin 
y (IgG) is the predominant antibody component within polyclonal serum and it serves as a 
good generic representation o f the key monomeric Ig structural features. These include two 
identical copies o f a heavy (H) chain (approximately 50 kDa) and two identical copies o f a 
light (L) chain (approximately 25 kDa), with each light chain being attached to a 
corresponding heavy chain by a disulphide bond. Both H chains are also covalently linked by 
disulphide bonds located proximal to the ‘hinge’ axis. The L chain is divided into two 
domains ( lx  variable (Vl) and 1 x  constant (CL)) and the H chain into four domains (lx  
variable (VH) and 3 x  constant (Vl)). Each domain consists o f homologous units o f 
approximately 1 10  amino acids arranged in antiparallel fi-strands and stabilised by intra­
strand hydrogen bonding and core hydrophobic localisation. Sequence analysis o f the amino 
acid content o f the VL and V H regions indicates that sequence variation is predominantly 
focused around three ‘hypervariable’ regions that contain residues and structures 
complementary to their respective antigens. They are referred to as ‘complementarity 
determining regions’ or CDR’ s. The remaining, more conserved region o f the variable 
domains, are referred to as ‘ framework’ regions.
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Figure 3.1: Outline o f the immune response to following exposure to an invading bacterium. 
The bacterial cell is identified as foreign' by circulating macrophage, which then 
phagocytises the cell. The bacterial cell is then hydrolytically and oxidatively digested in the 
endosome compartment o f the macrophage. Bacterial debris is translocated to the 
macrophage surface where it is displayed on M H C II molecules and these are recognised by 
complementary IgG-bearing B-lymphocytes or CD4+-restricted helper T cells. This begins the 
cascade o f cytokine release, which direct CD8+-restricted cytotoxic T-cell activation and B- 
cell differentiation. CD8 ' -restricted cytotoxic T-cells can also directly degrade host cells that 
display antigens on their MHC I  appendages signalling alterations within the cell due to viral 
infection or tumour growth. In addition, secreted bacterial proteins in the extra-cellular 
environment can directly stimulate circulating B-cells differentiation.
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In the natural course o f the humoral immune response, the primary objective in the 
development o f an immunoassay targeting a given antigen, is to isolate an antibody with the 
requisite degree o f specificity and affinity for reproducible analysis. Both of these attributes 
are controlled by the CDRs. At a structural level, each CDR folds into a ‘canonical’ loop 
formation (Chothia and Lesk, 1987). Each VL and VH domain contain three CDR loops 
(CDR1, CDR2 and CDR3) that juxtapose at the amino terminal o f the associated domains. All 
CDRs can potentially make contact with the antigen, although, very seldom all at the same 
time for anti-hapten or anti-peptide antibodies (Muyldermans, et ah, 2001). The CDR3 region 
(of both V L and Vh domains) exhibits the greatest sequence diversity and coincidently, exerts 
the greatest influence on the antigen specificity. In addition, the size o f the V H CDR3 loop, in 
conjunction with the flexible association of the V L and V H domains at various angles and 
distances, generates a structural diversity o f binding sites (Muyldermans, et ah, 2001). These 
can include cavities, grooves and planar sites that correspond to the size and type (hapten, 
peptide and protein, respectively) o f the antigen (Webster et al., 1994).
The structural analysis o f the anti-HTV-l IgGl antibody, designated ‘b l2 ’ , (Protein Data Bank 
reference code: lh7h.pdb) and recently characterised by Saphire and co-workers, (2002), 
serves as a useful case study for highlighting the key structural facets relevant to antibody 
specificity, affinity and efficacy. Figures 3.2 to 3.5 demonstrate that antibody ‘b l2 ’ represents 
the first intact human IgG with a full length hinge region for which all domains are ordered 
and visible in the electron density map and in essence offers a ‘ snapshot’ within the wide 
spectrum o f conformers that can be attained by the immunoglobulin molecule (Saphire et al., 
2002). In itself, this serves to dispel the common misconception that antibodies are rigid and 
symmetrical ‘Y ’ shaped molecules. Moreover, the extreme asymmetry evident in the crystal 
structure suggests extraordinary interdomain flexibility (rotational, linear and planar) about 
the hinge regions that, until recently, was often overlooked in terms of assessing and 
characterising immunoglobulin structure-related function. The ‘b l2 ’ antibody is a 
recombinant human antibody isolated from a phage display library, which had been 
developed from a long-term asymptomatic, HIV-1 infected individual (Burton et al., 1994). 
Antibodies produced by recombinant means are generally capable o f a much greater diversity 
in terms of antigen specificity and affinity. Whereas, during the humoral process o f affinity 
maturation, an ‘affinity ceiling’ (Foote and Eisen, 1995) normally manifests at K D values 
approaching 10 '10 M (Ohlin and Zouali, 2003), recombinant antibodies have been routinely 
isolated with affinities in excess o f 10 '14 M. The IgGl b l2  antibody has been postulated to 
neutralise approximately 75% o f primary HIV-1 isolates (Burton et ah, 1994) and has been 
highlighted as significant in the development o f a EHV vaccine (Saphire et al., 2001). The 
noteworthy feature o f this particular antibody is its extremely prominent and extended CDR
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H3 loop, which incorporates a 10-residue insertion (Figure 3.4). This is postulated to enable 
the loop to protrude into and thus, recognise the highly recessed CD4 binding site o f the HTV- 
1 protein gpl20 (Kwong el ah, 1998; Saphire et a l, 2001). IgGl b l2  thus emphasises the role 
o f the CDR 3 loop in ‘ fine-tuning’ the specificity o f the hypervariable element o f the Fv 
domains with respect to corresponding antigen, especially when the given antigen is o f 
‘hapten-like’ dimensions and/or embedded within non-antigenic recesses.
Although IgGl is a useful example o f generic immunoglobulin structure, it represents only 
one, among a suite o f antibody molecules. They are divided into five classes (IgG, IgM, IgA, 
IgE and IgD) and each class is referred to as the ‘ isotype’ . The light chain component o f all 
antibodies is either o f kappa ( k )  or lambda (k) designation. Whereas, IgG, IgE and IgD consist 
o f one monomeric H2L2 unit, IgA can be mono- di- or tri-meric and IgM exhibits a 
pentameric structure. Multivalent IgM is the first antibody secreted in response to primary 
exposure to antigen but normally accounts for only approximately 10  % o f the polyclonal 
population in human serum. IgG is the predominant component and would normally represent 
in excess o f 70 % o f the polyclonal pool. In addition to valency, the classes can be 
distinguished based upon the number of Ch domains. IgG, IgA and IgD molecules contain 
three Ch domains, while both IgM and IgE contain four Ch domains, the fourth compensating 
for the dedicated hinge domains present in the aforementioned IgG, IgA and IgD. The IgG 
class itself is further sub-divided into sub-classes that vary in their flexibility around the hinge 
region and their ability to trigger dedicated effector functions. The murine IgG subclasses 
consist o f IgG l, IgG2a, IgG2b and IgG3, whereas, the human IgG subclasses comprise IgG l, 
IgG2, IgG3 and IgG4. The structures o f the subclasses vary in their pattern o f disulphide 
bonding (King, 1998). Human IgG l, IgG2a, IgG2b and IgG3 contain two, four, fifteen and 
two disulphide bonds, respectively, while murine IgG4 contains four disulphide bonds and the 
remaining subclasses contain three disulphide bonds each. Additionally, the position of the 
disulphide bond between the heavy and light chains varies from between the CL and CH1 
region to between the CL and VH/CH1 interdomain region (King, 1998). The humoral immune 
response in humans is dominated by IgG 1 -mediated events. Attached to residue 297 o f the 
Ch2 domain o f all IgG subclasses is an N-terminal linked oligosacchaaride residue that 
controls the quartenary structure about the Fc region (Elgert, 1996). This is o f paramount 
importance in directing the effector function o f IgG. As a result, when producing human 
antibodies for therapeutic purposes by recombinant means, the type of expression system 
employed must be carefully assessed in terms of its ability to properly glycosylate the 
recombinant molecule in a compatible fashion (Parekh, el a l, 1989; Raju, 2000; Raju, 2003).
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Figure 3.2: Structure o f an IgG molecule. The generic immunoglobulin components are 
demonstrated in the ribbon structure which is based on the published sequence data fo r  the 
IgG l antibody ‘b l2  ’ (PDB reference code: lh7h.pdb). The molecule comprises two identical 
heavy chains that each consist o f three constant heavy chain (Ch)  and one constant light (C j 
domains. These are joined to two identical light chains, each or which consists o f one 
constant light (Ci) and one variable light (Vj) region, by disulphide bonds and multiple non- 
covalent interactions. The structure can be broken down into four distinct segments as 
follows. The crystallisable fragment (Fc), that incorporates a carbohydrate element and 
dictates the isotype specificity and thus, effector function o f the antibody. This is separated by 
a hinge region from the antigen-binding fragment (Fab). The antigen-binding specificity is 
determined by the variable fragment (Fv), more specifically, the hypervaiable or 
complemtarity determining region (CDR). Each VH and Vi. domain possesses three 
complementary CDR regions and these are indicated as prominent red, green and cyan loop 
structures, situated at the extreme N-terminus o f the molecule. The bottom right-hand corner 
shows a side profile o f the IgG molecule with its carbohydrate component visible in the Fc 
region.
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Figure 3.3: Structure o f the immunogolubulin constant domain. A ribbon structure o f the 
constant heavy domain o f an IgG l antibody (PDB reference code: lh7h.pdb) is depicted with 
the ¡3 strands coloured yellow. The ¡3 strand arrows point from the N  terminus to the C 
terminus and are numbered in green. A ll constant domains are built up from seven /3 strands 
arranged so that four strands form one ¡3 sheet and remaining three strands form a second 
sheet. The sheets are closely packed against each other and joined together by a disulphide 
bridge from (3 strand 6 in the three-strand sheet to ¡3 strand 2 in the four-strand sheet. Most o f 
the invariant residues o f the constant domain, including the disulphide bridge, are found in 
the sheets o f the framework region. These invariant residues have two important functions. 
One is to form and stablise the framework, or molecular scaffolding, by packing the (3 sheets 
through hydrophobic interactions to give a hydrophobic core between sheets. Their second 
function involves interactions between constant domains o f different chains to form  a 
complete immunoglobulin molecule.
102

Figure 3.4: Structure o f the immunogolubulin variable domain. The model demonstrates a 
ribbon structure o f the variable heavy domain o f an IgG l antibody (PDB reference code: 
lh7h.pdb). The overall structure o f the variable domain is very similar to that o f the constant 
domain but there are nine (3 strands instead o f seven. The two additional [3 strands are 
inserted into the loop region that connects f3 strand 3 and 4 (labelleled 3a and 3b). 
Functionally, this part o f the polypeptide chain is important since it contains the 
hypervariable region CDR2. The two extra ¡3 strands provide the framework that positions 
CDR2 close to the other two hypervariable regions in the domain structure. The CDR1 and 3 
loops are found between (3 strands 2 and 3, and 6 and 7, respectively. (3 strands are coloured 
in yellow, and the canonical CDR loop structures are higlighted individually. The (3 strand 
arrows point from  the N  terminus to the C terminus and are numbered in green.
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Figure 3.5: Overview o f the CDR-binding ‘cleft’ using the published ‘b l2 ’ crystal structure 
(Saphire et al., 2001; 2002; PDB reference code: lh7h.pdb). The VH and VL scaffold domains 
are colured yellow and purple respectively. (A), Top-view o f complete Fv domain with the 
CDR loops 1, 2 and 3 highlighted in red, green and cyan, respectively. (B), Top-view o f CDR- 
binding cleft, with the Fv scaffold removed. (C), Side-view o f CDR-binding cleft. This clearly 
demonstrates the prominent protrusion o f the CDR H3 loop.
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3.1.1.3 L. monocytogenes and the immune response
L. monocytogenes is an intracellular pathogen and as such, it circumvents the hosts 
extracellular humoral immune system. The principal immune response to listerial infection 
involves close interaction between the innate cellular and dedicated T-cell response (Unanue, 
1997a). Invading L. monocytogenes cells are efficiently engulfed by macrophage cells 
through phagocytosis. In addition, L. monocytogenes can induce its own uptake by normally 
non-phagocytic cells (Schuchat et a l,  1991). L. monocytogenes cells that infect via the 
intestinal route, following oral exposure, are transported to the mesenteric lymph nodes, 
spleen and liver, while, reticulo-endothelial-infecting L. monocytogenes cells are sequestered 
by the liver-resident macrophage or Kupffer cells (Ebe et al., 1999). Immediately following  
phagocytosis, the L. monocytogenes cells reside in phagosomes, where the majority, are 
efficiently killed by the combined oxidative effects o f  reactive oxygen intermediates (ROIs) 
and reactive nitrogen intermediates (RNIs) (Unanue, 1997b; Ohya et al., 1998a; Ohya et al., 
1998b; Ouadrhiri et al., 1999). The listericidal activity o f  the macrophage is amplified by 
increased secretion o f  cytokines such as interferon gamma (INF-y) and tumour necrosis factor 
alpha (TNF-a), that in turn, upregulate inducible nitric oxide synthase (iNOS) and intensify 
the oxidative process within the phagosome. Listeria-derived, degradation products are 
subsequently displayed on the macrophage MHC-II surface molecules and CD4+THi cells are 
recruited and these control the perpetuation o f  the antigen-induced T-cell response. The 
efficacy o f  this, principally, innate response is not 100 % and it has been suggested that only a 
small percentage o f  L. monocytogenes cells need to survive the oxidative environment o f  the 
phagosome and reach the cytosol, to elicit infection (De Chastellier and Berche, 1994). In 
fact, L. monocytogenes cells can take advantage o f  their ability to survive within macrophage 
and the rapid recruitment o f  macrophage to infected endothelial cells, by using them to 
facilitate a “Trojan horse”-type (Drevets, 1999; Vazquez-Boland, 2001) delivery to 
endothelial epithelia (Drevets et al., 1995; Greiffenberg et al., 2000) and transfer across the 
blood brain barrier, leading to disseminated CNS infection. This also ensures the pathogen 
remains isolated from the humoral branch o f  the immune system.
It has been suggested that intracellular pathogens such as L. monocytogenes may be able to 
counteract the oxidative effect o f  ROI and RNI by producing the enzymes catalase and 
superoxide dismutase, or SOD (Haas and Goebel, 1992; Miller and Britigan, 1997). However, 
deletion o f the genes encoding either the catalase (Leblond-Francillard et al., 1989), or SOD 
(Brehm et al., 1992) enzymes was not found to substantially reduce the proliferation capacity 
o f  L. monocytogenes in host cells.
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Much more significant, and particular to L. monocytogenes, is its ability to escape from the 
phagosome into the cytosol o f  the host macrophage. This is principally mediated by secretion 
o f  listeriolysin O (LLO) (Portnoy et al., 1988; Cossart et al., 1989), in addition to 
phospholipase C (PI-PLC) and phosphatidylcholine-preferring phospholipase C (PC-PLC) 
(Cossart and Lecuit, 1998; Cossart et al., 2003). LLO is a potent pore-forming cytolysin, that, 
exhibits optimal activity in the low pH environment o f  the phagosome (Dramsi and Cossart, 
2002; Glomski et al., 2002). It also possesses a PEST-like sequence (Decatur and Portnoy,
2000) that, targets LLO for phosphorylation in the mammalian cytosol and subsequent 
degradation. These features restrict the cytolytic activitiy o f  LLO to the host phagosome and 
prevent damage to the host cell. Having successfully escaped the hostile environment o f  the 
phagosome, L. monocytogenes proceeds to proliferate and differentiate within the cytosolic 
compartment. At this stage, the MHC-I-restricted CD8+ T cell-mediated immune response 
(the classical, MHC-Ia and non-classical MHC-Ib responses) is initiated (Brunt et al., 1990; 
Lara-Tejero and Pamer, 2004) resulting in activation o f  Tc cells and destruction o f the 
infected cell. Although both macrophages and dendritic cells (DCs) are able to take up, 
process and present antigens in vitro, there is mounting evidence indicating that macrophages 
do not have the ability to prime naïve T cells to become Tc cells and that this function is 
carried out exclusively by DCs (Jung et al., 2002; Lara-Tejero and Pamer, 2004). It was also 
commonly theorised that once primed to proliferate by the appropriate stimulus, CD8 ' T cells 
proceeded to proliferate and differentiate, independent o f  the priming antigen (W ong and 
Pamer, 2001). It has been shown, however, that effective antigen presentation leading to 
activation o f  naïve or memory CD8+ T cells is limited to the first three days o f  infection, 
despite persistence o f  the bacterial cell and associated antigens for up to a week, following 
primaiy exposure (Wong and Pamer, 2003). The major conclusions drawn from these 
observations and related work (Badovinac et al., 2002; Badovinac et al., 2003) were, that the 
larger the T cell memory pool, the stronger the Tc response, leading to elimination o f  
effective antigen presentation and thereby, limiting the recruitment o f  naïve T cells (Lara- 
Tejero and Pamer, 2004).
The non-classical MHC-Ib response, as demonstrated by the H2-M3-restricted CD8+ T cell 
response to L. monocytogenes infection in mice (Lenz and Bevan, 1997), is distinct from the 
classical response in several respects. In infected mice, the H2-M3 molecule can present 
peptides with N-formylated amino termini that, are typical o f  prokaryote N- 
fonnylmethionine-initiated proteins, produced in the cytoplasm. H2-M3-restricted cells 
exhibit an activated phenotype in naïve animals and demonstrate a more rapid primary 
response. However, following a secondary challenge they demonstrate more limited 
expansion (Kerksiek et al., 1999; Lara-Tejero and Pamer, 2004). Despite their inability to
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proliferate, it is thought that a population o f  H2-M3-restricted mem oiy cells is generated and 
that they are indistinguishable from MHC-Ia-restricted CD8+ T cells, with respect to surface 
markers and longevity (Kerksiek et a l,  2003). It has also been shown that H2-M3-restricted 
CD8+ T cells can be selected in the thymus on bone marrow-derived cells (Urdahl et al., 
2002) and it has been postulated that differences in thymic selection might account for the 
distinct behaviour H2-M3-restricted T cells during memory responses to L. monocytogenes 
infection (Lara-Tejero and Pamer, 2004).
The major CD8+ T cell response in L. monocytogenes-infected cells is directed against LLO 
(Berche et al., 1987; Bouwer et al., 1992; Hitbold et al., 1996). LLO has been demonstrated 
to be processed efficiently into peptides that are presented by MHC I molecules (Darji et al., 
1995; Villanueva et al., 1995). A  specific nine residue peptide subunit from LLO has been 
shown to be especially immunodominant and capable o f  conferring L. monocytogenes 
resistance when administered to naive mice (Pamer et al., 1991; Harty and Bevan, 1992). In 
addition to LLO, the L. monocytogenes p60 protein, a murein hydrolase enzyme that is 
needed for efficient cell division during cytoplasmic proliferation, is the next most potent 
elicitor o f  T cell reponse to L. monocytogenes infection (Harty and Pamer, 1995; Geignat et 
al., 1999; Geignat el al., 2001). Protective L. monocytogenes-specifie T cell epitopes from 
LLO and p60 have been recombinantly expressed on the surface (Verma et al., 1995; Spreng 
et al., 2003) o f  Salmonella spp. and successfully used as live vaccines to confer T cell- 
mediated protection against murine listeriosis.
It is noteworthy that both these immunodominant proteins are secreted proteins. Indeed, it has 
been reported that somatic or cell-surface-localised antigens, are not able to generate a 
protective CD8+ T cell response to L. monocytogenes (Shen et al., 1998). This paradigm was 
elaborated upon in a series o f  experiments performed by Zenewicz and co-workers (2002). 
The authors investigated the degree o f  protection afforded against recombinant variants o f  L. 
monocytogenes expressing a heterologous epitope derived from lymphocytic choriomeningitis 
virus (LCMV) in somatic or secreted form, in mice that had been immunised with either the 
somatic or secreting variants or the LCMV virus alone. The recall response o f  LCMV- 
immune mice was similar in mice challenged with either the somatic or secreting variants, 
yet, significant CD8+ T cell-mediated protection was only afforded against the variant 
expressing the secreted LCMV antigen, not the somatic form. These results indicated that the 
lack o f  protection against L. monocytogenes, expressing the somatic antigen, was not 
attributable to a lack o f  T cell memory response. Rather, since presentation o f  the somatic 
antigen was most likely limited to cross-presentation, and the fact that cells actively infected
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with L. monocytogenes might not present the somatic form o f  the antigen, they therefore fail 
to be eliminated by the complementary CD8+ T response (Lara-Tejero and Pamer, 2004).
L. monocytogenes has evolved a variety o f  mechanisms to combat the host T-cell responses. 
For instance, LLO has been implicated as a cause o f  down-regulation o f  the gene encoding 
MHC II antigen I-Ab and MHC I antigen, H-2K, in infected host cells (Schuller et al., 1998). 
Furthermore, although there is no evidence to suggest that L. monocytogenes bacterial cells 
invade T cells (Merrick et a l 1997), a potent, L. monocytogenes-specific counter-T cell 
response has recently been proposed by Zenewicz and co-workers, (2004). The FasL protein 
is a member o f  the tumour necrosis family and it is predominatly expressed by activated T- 
cells, B cells, neutrophils and macrophage (Suda et al., 1995; Hahne et al., 1996; Liles et al., 
1996; Kiener et al., 1997). When FasL binds to its receptor molecule (Fas), which is 
constitutively expressed on many cell types (Watanabe-Fukunaga et al., 1992), it leads to 
apoptosis o f  the Fas-expressing cell (Suda and Nagata, 1994). Expression o f  FasL is normally 
only apparent in T-cells following activation and manifests in a biphasic process. Immediately 
following activation, pre-stored intracellular FasL is released to the surface by degranulation 
(Bossi and Griffiths, 1999) and this is followed by transcriptional activation o f  FasL 
synthesis, which is induced by NF-kB (Kasibhatla et al., 1999). It was shown that both LLO 
alone, as well as PC-PLC acting in synergy with LLO, were capable and sufficient to induce 
early FasL expression on T cell surfaces (Zenewicz et al., 2004). This is probably a result o f  
LLOs ability to increase calcium permeability in mammalian membranes (Repp et al., 2002) 
and alter intracellular calcium homeostasis and calcium flux, a condition which has 
previously been confirmed to induce degranulation in T cells (Glass et al., 1996). Thus, it is 
proposed that upregulation o f  FasL on T cells by L. monocytogenes may allow the pathogen 
to exploit Fas-FasL-mediated apoptosis and associated cytokine production to modulate the 
host immune response and influence the course o f  infection (Zenewicz et al., 2004).
3.1.1.4 Antibody diversity
The complete collection o f antibody specificities available within an individual is known as 
the ‘antibody repertoire’ and is estimated to consist o f  up to 10n uniquely distinct antibodies 
in the human (Janeway and Travers, 1997). The study o f  human monoclonal antibodies to 
different infectious agents shows that the antibody response is generated to a relatively small 
number o f  target surface proteins and carbohydrates expressing an array o f  epitopes (Ohlin 
and Zouali, 2003). Given the huge variety o f  potentially infectious foreign bodies an 
individual is exposed to throughout a lifetime it is not plausible to entertain the notion that a 
naive pool o f  B-cells, producing a limited number o f  antibodies, with a degree o f  variation 
dependent on and proportional to the levels o f  germ-line genetic material dedicated to
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antibody production, is sufficient to meet such a challenge. In 1983, Tonegwa demonstrated 
that the embryonic germline DNA encoding immunoglobulin expression actually consisted o f  
a consecutive but non-sequential alignment o f  variable (V), joining (J) and constant (C) 
exons, separated by substantial, non-coding intron sequences. Heavy chains contain an 
additional diversity, (D) exon, between the J and C regions. The manner in which these 
principal V, J, D and C sequences assembled to form a composite coding sequence is the 
primary determinant o f progeny antibody specificity. ‘Combinatorial diversity’ is the name 
given to the permutations that are generated by the recombination o f  gene segments selected 
from these sets (Collins et al., 2003). Figure 3.6 gives an outline o f  the combinatorial events 
involved. It is as a direct consequence o f  the limited number o f  germline V exons that a 
relatively low number o f  different V H/V L combinations can be generated based on this 
diversity alone, in total, amounting to 6 x  106 different sequences (Ohlin and Zouali, 2003).
The process o f  ‘junctional diversity,’ which, manifest at V D, DJ and VJ regions, accentuates 
the diversity o f  the composite sequences and thus, the repertoire potential. Junctional diversity 
arises as a result o f  palindromic (P) nucleotide additions (Feeney et al., 1994) during RAG1 
and RAG2 mediated (Oettinger el al., 1990; M cBlane et al., 1995 and Sawchuk et al., 1997) 
hairpin loop opening in the early stages o f  recombination. Random enzymatic N-terminal 
nucleotide addition by terminal deoxynucleotidyl transferase can occur at the light chain VJ, 
and especially the heavy chain VD and DJ junctions resulting in further generation o f  
diversity (Benedict et al., 2000), notably in the CDR 3 regions o f  both chains, which are the 
quintessential determinants o f  immunuglobulin specificity. In addition to nucleotide 
additions, exonuclease-catalysed removal o f  multiple nucleotides within the coding regions 
can significantly alter immunoglobulin specificity. However, this may not be an entirely 
random activity as it has been reported that the amount o f  nucleotide excision varies 
depending on the coding sequence (Feeney et al., 1994), with ‘pliable’ AT rich regions 
potentially more prone to such events (Gauss and Lieber, 1996).
When considering infection with pathogens, especially intracellular pathogens such as L. 
monocytogenes, the ‘neutralising’ activity o f  immunoglobulins can be o f  paramount 
importance. This has recently been purported to account for antibody-mediated resistance to 
L. monocytogenes as a result o f  studies indicating neutralisation o f  the pathogen following in 
vivo administering o f  anti-listeriolysin O monoclonal antibody (Edelson and Unanue, 2001). 
Although not a typical example o f  the humoral immune response (in fact such neutralising 
activity has been attributed to a separate branch o f  intrinsic antibody-mediated immunity 
(Wentworth et al., 2000; Wentworth Jr. el al., 2002)) the efficiency o f  neutralisation is 
dependent on the antibody’s intrinsic affinity and avidity towards the respective infectious
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material. Whereas, combinatorial and junctional diversity could account for a suitably varied 
repertoire o f  B-cells capable o f  recognising one, or several epitopes on an invading bacteria, 
the likelihood that the affinity o f  the antibody would be sufficient to effect neutralisation, is 
less certain.
The process o f  somatic point (hyper)mutation adds a further element o f  diversity to the 
repertoire. A random mutation rate o f  approximately 1 03 mutatons/base pair (Jacob et al., 
1993) with affinity-improving mutations preferentially retained (McHeyzer-Williams et al.,
2001), results in selection o f ‘affinity-matured’ immunoglobulin. Although the mutations 
themselves are random, they are localised to certain regions o f  the composite 5' V regions o f  
both the heavy and light chains, referred to as ‘hot spots’ (Domer et al., 1998; Rada and 
Milstein, 2001; Rogozin et al., 2001 and Diaz and Casali, 2002). The process o f  affinity 
maturation occurs in the disseminated nodes o f  the lymphatic system. Co-localised within the 
nodes is a cytidine deaminase homologue termed ‘activation-induced-deaminase’ or AID 
(Lieber, 2000). Knockout mice, deficient in AID have been shown to be incapable o f  
producing IgG, IgE and IgA (Muramatsu et al., 2000). Furthermore, deficiency in this enzyme 
has been associated with ablation o f somatic hypermutation, as occurs in sufferers o f  type 2 
hyper-IgM syndrome (Muramatsu et al.,2000; Revy et al., 2000), as well as indicating a 
concomitant association with class switching. Recent studies (Rogozin et al., 2001; Pavlov et 
al., 2002) indicate that the error prone DNA polymerase, DNA polymerase r| may be 
responsible for the preponderance o f  somatic mutations within the V region ‘hot spots’. This 
polymerase exhibits an error rate one thousand times greater than the commonly associated 
replicative polymerases (Matsuda et al., 2000).
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Figure 3.6: Generic overview o f somatic recombination in humans. Light chain V-region 
genes are constructed from two germline DNA segments, a variable (V) and jo ining (J) that 
are joined to form a complete light-chain V-region gene. The C region is encoded on a 
separated gene locus and is joined to the variable region gene segment by splicing o f the 
light-chain RNA to remove the J  to C introns. X-light chains comprise 29 VL segments and 4 
pairs o f functional Jl and CA segments. K-light chains comprise 40 VL segments and 5 JL 
segments that are arranged in a cluster, preceding a single CK segment. Heavy chain V 
regions are constructed from three gene segments as shown on the right hand side o f the 
diagram. First, the diversity (D) and JL gene segments join, then the VL gene segment joins to 
the combined D J sequence, forming a complete VH gene. The heavy chain C-region genes are 
each encoded by several exons (the exon encoding the hinge region is shaded olive/brown). 
The C-region exons are spliced to the V-domain sequence during processing o f the heavy 
chain RNA transcript. The heavy chain gene locus comprises 51 functional VH gene segments 
and approximately 27 Dh segments, preceeding 6 Jh segments. Light chain and heavy chain 
genes are translated into large polypeptide chains that associated to form the antibody 
molecule. The diagram present here was adapted from Janeway et al., (1999).
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3.1.2 M onoclona l antibody production
In 1900 the phrase “ magic bullets” was used to emphasise the specific function of antibody 
molecules within the body’ s immune system (Ehrlich, 1900; Little et al, 2000). It was 75 
years later before scientists gained the ability to successfully produce these highly specific 
molecules. This was facilitated by the publication of the Nobel Prize-winning method o f 
somatic cell fusion between a myeloma (plasmacytoma) and an immune lymphoblast 
expressing a specific gene (Kohler and Milstein, 1975). Each individual resultant hybridoma 
(hybrid-myeloma) combines the immortality o f the myeloma with the antibody production 
virtues o f the lymphocyte, thus serving as a stable (cloned) source o f mono-specific antibody.
The ability to routinely produce and maintain homogeneous populations of monoclonal 
antibodies with defined specificities and affinities has enhanced the biochemists 
armamentarium and significantly increased the potential for immunoassay and biosensor 
development and commercialisation. Monoclonal antibodies are finding ever-diversifying 
applications in areas such as environmental and food analysis, immunodiagnostics and 
clinical therapeutics (Fitzpatrick et al., 2000).
3.1.2.1 Production o f  monoclonal antibodies follow ing in vivo immunisation
The decision to produce a given monoclonal antibody should always begin with careful 
examination of the intended application o f the resultant antibodies and assessment o f the 
availability and purity o f the antigen in question. Mice (BALB/c strain) are then immunised 
with the antigen of interest and boosted periodically over a period of weeks or months. 
Specific serum antibody levels or titres are measured (Kemeny et al., 1992) from tail bleed 
samples. When the serum titre is deemed sufficient (usually > 1/50,000) the animal is 
sacrificed and the lymphocytes are removed from the spleen (or alternatively, the lymph 
nodes) and used for the cell fusion procedure. The myeloma cells used as the fusion partner 
were originally derived from BALB/c lineage mice and were selected on the basis o f their 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency. It is possible to select 
for cells deficient in HGPRT with the agent 6-azoguanine, which becomes toxic to cells 
expressing HGPRT. Two o f the most commonly used myeloma cell lines include Sp2/0- 
A gl4  (Shulman et al, 1978) and X63/Ag8.653 (Brown and Ling, 1988). Neither o f these cell 
lines posses the inherent genetic capacity to produce immunoglobulin. Although, the original 
fusing agent, was UV-inactivated Sendai virus, this has now been supplanted by the chemical 
fusion agent, polyethylene glycol (PEG) (Zola and Brooks, 1995). This polywax causes 
membrane fusion between adjacent cells. Subsequent cell division facilitates chromosome
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mixing between the fused parent cells. Fusion progeny consists o f a heterogenous population 
o f unfused myelomas and lymphocytes, fused myeloma/myeloma, lymphocyte/lymphocyte 
and the desired myeloma/lymphocyte hybrids. Selective propagation o f these desired 
hybridomas is based on the HAT (Hypoxanthine, Aminopterin and Thymidine) system, 
originally proposed by Littlefield (1964). Myeloma cells demonstrate excellent proliferation 
in favourable in vitro cell culture conditions. However, they lack the HGPRT enzyme and 
thus, when the de novo synthesis o f purines and pyrimidines is blocked by the addition of 
HAT to the growth media, the compensatory salvage pathway cannot be induced and the cells 
cease to be able to synthesise DNA (Figure 3.7). Lymphocytes, although HGPRT+ do not 
grow well in culture and naturally die off. Thus, in the presence o f HAT only 
myeloma/lymphocyte hybrids will thrive.
H y p o x a n th in e
\
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Figure 3.7: Aminopterin (HAT) is used to block de novo synthesis o f purines. Hypoxanthine 
(HAT), a major source o f purine precursors, w ill only be effectively incorporated into mature 
purines i f  HGPRT is present. Since aminopterin also prevents synthesis o f thymidine (HAT), 
an exogenous source o f thymidine must also be present.
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s y n th e s is
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Figure 3.8: Overview o f monoclonal antibody production by somatic cell fusion. B- 
lymphocytes are isolated from the excised spleen o f a mouse that has been immunised with a 
defined antigen. These HGPRT cells are somatically fused with a compatible, murine 
myeloma cell line using polyethylene glycol (PEG). The latter cells are HGPRT-deficient 
(HGPRT), and thus, only proliferate in vitro, in the presence o f HAT supplement, i f  
successfully fused with a B-lymphocyte cell.
114

3.1.2.2 Screening o f hybridomaprogeny
The fusion progeny consist of wells containing multiple heterogenous populations of 
hybridomas. Each hybridoma within a given well population can contribute anywhere 
between 0 and 100 % o f the secreted antibody content. It is imperative that wells containing 
hybridomas secreting antibodies exhibiting the desired traits for the intended application are 
confidently identified as early as possible. ELISA  screening assays facilitate multiple 
screening o f wells and are the method of choice in many cases. A  direct ELISA format can be 
easily optimised and is particularly suitable for initial screening o f a very large number of 
wells. This consists o f coating the antigen o f interest onto an ELISA plate, adding test 
supernatant (diluted in PBS-T to limit non-specific binding) followed by an anti-species 
detection antibody. The physical nature o f the antigen also requires consideration. I f  for 
instance the antigen used is a pure and defined peptide sequence, each antigen thus presents a 
single epitope and the relationship between the corresponding specific antibody and peptide is 
a purely arithmetic one. Such peptides or other defined small molecules (e.g. elicit drugs or 
pesticides) can be simply adsorbed or linked via adaptor molecules to the surface o f the 
ELISA  plate (Danilova, 1994). In cases where more complex antigens are employed such as a 
bacterial cell, the scenario becomes more complicated. Surface adsorption of cells may 
actually distort the physical conformation o f the cell and render epitope-bearing regions 
inaccessible to or ‘masked’ from the corresponding antibody. Covalently attaching the cells to 
the surface may exacerbate the problem by introducing undesirable chemical modification of 
the surface epitopes.
The adoption of a sandwich ELISA approach can help overcome some o f these problems. 
This involves anchoring the cells to a polyclonal antibody that has been raised using the same 
antigen, in a non-murine (i.e. rabbit or goat) host. If, however, the cell only expresses a small 
number o f the monoclonal-reactive epitopes, these may become ‘swamped’ by the polyclonal 
anchor layer. Once the number o f hybridoma populations has been streamlined it is possible 
to employ a more informative screening assay. A  competitive, or inhibition assay is favoured 
because the monoclonal antibodies and complex antigen are allowed to interact in the solution 
phase, where epitope accessibility is not compromised. This also more closely resembles the 
conditions of the intended final application. Further information regarding the identity o f the 
specific antigenic protein can be gleaned by conducting a western blot analysis o f the resolved 
protein components o f the complex antigen with the selected monoclonal antibodies.
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3.1.2.3 Cloning o f hybridoma cells
Once a hybridoma population secreting the desired antibody has been identified, it is essential 
that the individual hybridoma be isolated form the heterogenous mixture (Figure 3.9). The 
simplest method to implement, particularly where 96 well plates are being employed is that 
of, cloning by ‘ lim iting dilution’ . This entails seeding the mixed population o f hybridomas 
over a range o f dilutions calculated to maximise the chances o f only one cell being distributed 
in a given well.
(Lim iting D ilution)
Figure. 3.9: Schematic overview of the stages involved in the identification and isolation of 
stable clones secreting desired antibody. Samples from positive hybridoma populations are 
frozen as soon as possible to serve as a ‘back-up’ stock. The original heterogenous 
population of ‘first-round’ hybridomas is sub-cultured by limiting dilution to generate sub­
populations. After several rounds of such cloning, the hybridoma populations within each 
well can be considered homogenous or monoclonal.
A  mathematical approach indicates that were less than 63 % o f the wells seeded with 
concentrations o f < 1 cell/well demonstrate cell growth, Poisson-distribution dictates that they 
most likely contain a single clone (Lefkovitz, 1979; Eshhar, 1985). The tendency o f cells to 
clump, however, means that this mathematical explanation is not the most appropriate. To
116

ensure ‘monolconality’ it  is best to repeat the cloning procedure again for several rounds, 
after which the hybridoma can be statistically considered ‘monoclonal’ (Lietske and Unsicker, 
1985). One o f the main problems w ith seeding the cells at such low concentrations is the need 
to add feeder layers to increase the seeding efficiency. The use o f conditioned growth media 
such as Briclone™ can obviate the need for such layers. Cloning in semi-solid agar is the 
principle alternative to lim iting dilution. The medium allows the cells to easily divide and 
grow to produce a viable, defined colony, without permitting cells to break away and cause 
disperse colony development (McCullough and Spier, 1990). Isolated colonies can then be 
picked o ff with a pipette tip and transferred to fresh liquid media. A  more direct approach to 
cloning is one that involves the use o f a Pelteir controlled pipette (Wewetzer and Seilheimer, 
1995) to select a single colony and transfer it to the new well o f a microtitre plate. This 
method increases confidence that only single hybridoma cells have been seeded and reduces 
the cloning period significantly in comparison to the traditional methods.
The strategies outlined above, allied w ith  the methodologies detailed in sections 2.4-2.8 were 
exploited in an attempt to isolate stable hybridoma clones producing antibodies specific for 
various L. monocytogenes-specific pathogenicity markers. This approach was three-pronged 
insofar as three different antigen preparations were used in three distinct immunsiation and 
screening/selection regimes. The first immunogen tested was a p60-enriched protein extract, 
crudely fractionated from the culture supernatant o f exponential-phase L. monocytogenes 
cells. The second consisted o f a crudely extracted, yet highly enriched wild-type InlB 
preparation, selectively isolated from the L. monocytogenes cell surface by a simple buffer 
extracion. The final and ultimately, most successful strategy employed formalin-inactivated 
whole L. monocytogenes cells as the primary immunogen.
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3.2 Results and discussion
3.2.1 Production o f a panel o f monoclonal antibodies to L . moncytogenes- 
derived supernatant proteins:
3.2.1.1 Precipitation ofL. monocytogenes supernatant proteins
Supernatant from a 1 L  culture o f exponentially growing L. monocytogenes EGDpERL3 50-1 
prfAEGD in B H I media that had been pre-filtered through a 10 kDa cut-off membrane filter, 
was collected. To remove any cell debris the supernatant was then filtered through a 0.2 (¿m 
syringe filter. The clarified supernatant was then concentrated twenty fold by ultrafiltration 
using a 10 kDa cut-off membrane filter. The major protein content in the concentrated 
supernatant was precipitated with 10 % (v/v) TCA, resuspended in PBS and dialysed 
extensively against PBS (Section 2.4.3). A  sample o f the precipitated protein fraction was 
resolved on a 12.5 % (w/v) SDS PAGE gel (Figure 3.10). Major bands were evident at the 30, 
60 and the 66 kDa regions.
The 30 and 66 kDa proteins were most like ly attributable to Intemalin-related protein or ‘Irp ’ 
(Lingnau et al., 1996), and InlB, respectively. Both are under control o f  the PrfA regulator 
protein and thus, expected to be over-produced by this particular recombinant L. 
monocytogenes strain. The 60 kDa band was postulated to comprise principally o f p60, which, 
although not subject to PrfA-induced over-expression, is a major extracellular protein 
transcribed from the iap gene. It  is regulated at the post-transcriptional level (Kohler et al., 
1991) and although classically considered as a cell wall-localised protein, as much as 75 % o f 
total expressed p60 has been reported to be present in the culture medium (Ruhland et al., 
1993). Listeriolysin O (Cossart et al., 1989; Darji et al., 1995), a 60 kDa, secreted protein, 
was also expected to contribute to the 60 kDa protein region on the gel. In wild-type L. 
monocytogenes, LLO is known to be produced at quite low concentrations, approximately 20 
to 200 hemolytic units (HU)/m l in conventional broth culture (Geoffroy et al., 1987). 
However, the LLO-encoding gene (hly) is transcriptionally regulated by PrfA and, therefore, 
was expected to be up-regulated in the recombinant strain employed here.
3.2.1.2 Titration of LLO-specific antibody against L. monocytogenes supernatant 
proteins
Classically, antibody titre has been described as the lowest dilution o f the sample that can be 
detected at a predetermined cut-off (C iclitira et al., 1986). Unlike using a reference curve, 
where values are recorded over a range o f antibody/antigen dilution ratios, the titre is an end-
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point measurement w ith a constant antibody/antigen ratio. This assumes that the coating 
antigen component o f the assay is sufficiently in excess so that differences in affin ity 
(particularly w ith polyclonal antisera) are minimised and the result is as close to the actual 
concentration as possible (Kerneny, 1991). It  is important to emphasise that the titre end-point 
is not the least amount o f antibody present, but the smallest quantity that can be reliably 
detected. Some researchers suggest taking 0.2 units above the background (Kemeny, 1992). 
However, this measurement would be subject to variable interpretation depending on 
parameters such as time and temperature o f incubation and, therefore, cannot be used as 
generic criteria for comparative titration. For the purposes o f this research, the titre was 
defined as the greatest antibody dilution that gave an absorbance value greater than or equal 
to 1.5 x  the background response at the similar dilution o f  the control serum (in  the case o f 
polyclonal antisera) or diluent buffer (in the case o f affinity-purified antibody).
LLO-specific polyclonal antiserum was kindly donated by Trinad Chakraborty and Ayub 
Darji (Institute for Medical M icrobiology and Virology, Giessen, Germany). This was affin ity 
purified as described in Section 2.6.3. When this affinity-purified polyclonal anti-LLO 
antibody was tested against various dilutions o f the supernatant fraction, a titre o f 1/25,600 
was achieved (Figure 3.11). This indicated that there was indeed a significant amount o f LLO 
present in the concentrated supernatant fraction.
3.2.1.3 Estimation of total protein concentration in TCA-precipitated supernatant
Total protein content in the TCA-precipitated fraction was estimated by conducting a BCA 
assay, as described in Section 2.3.5. BSA was employed as the protein standard since it is a 
globular protein o f  comparable molecular weight (66 kDa) to that o f the principle protein o f 
interest in the crude precipitate (60 kDa). A  neat sample, in addition to a sample diluted 1 in 2 
in PBS, were assayed and the resultant absorbance values were read from the standard curve 
(Figure 3.12), yielding an estimated total protein concentration o f 853 ng/ml.
3.2.1.4 Immunisation with L. monocytogenes supernatant proteins
Three mice were immunised in the peritoneal cavity w ith TCA-precipitated protein from 
concentrated L. monocytogenes culture supernatant mixed 1:1 with Freund's complete 
adjuvant (FCA) at day 20, pre-fusion. Subsequent boosts were prepared in PBS at days 18, 
14, 10, 6, 2 and 1, pre-fusion.
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3.2.1.5 Hybridoma production using lymphocytes primed with L. monocytogenes
supernatant proteins
The spleens were removed from each o f three immunised mice and the lymphocytes from 
within were harvested and pooled. Following the fusion procedure, hybridoma supernatants 
were screened approximately 9 days post fusion for specific antibody, as described in 
Sections 2.8.1 and 2.1.12. ‘Positive’ wells were scored on the basis o f a positive result being 
greater than the control normal background reading plus 3 standard deviations (SDs), and 
scaled up to 48 well plates. A  total o f 30 wells were selected for scaling up to 24-well, 6-well 
and finally to tissue culture flasks. A t this stage samples from each o f the 30 preliminaiy 
positives were cloned out at 10 cells/well on 96 well plates. Samples were subjected to 
Western blot analysis. The majority demonstrated affin ity towards an -60  kDa protein band 
although some samples showed binding to multiple protein bands (Figure 3.13). An inhibition 
ELISA format (Section 2.7.7.2) was used in this second round o f screening. The wells were 
coated with 100 jil o f approximately 10^g/ml total protein in PBS. Hybridoma supernatants 
were diluted 1/25 with PBS/T and 50 (il added to each well. The wells were then 
supplemented with 50 nl o f supernatant protein at specified dilutions. The supernatant 
proteins were diluted to 200 ng/ml in PBS/T prior to preparing the serial dilutions. Thus, the 
1/10 dilution corresponded to approximately 10 ng/ml.
Samples from 19 o f the selected 30 clones demonstrated competitive binding to the free 
supernatant proteins and a typical profile is demonstrated in Figure 3.14. Following several 
rounds o f cloning, hybridoma clone ‘G94F8’ was selected on the basis that it  demonstrated 
stable secretion o f antibody, competitive solution-phase binding to antigen and specific 
binding to a 60 kDa band, when used to probe the supernatant protein preparation in Western 
blot analysis (Figure 3.15).
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Figure 3.10: SDS PAGE analysis of TCA-precipitated concentrated culture supernatant 
derived from L. monocytogenes EGDpERL3 50-1 prfAEGi> A 12.5 % (w/v) acrylamide 
resolving gel was used and 20 fil of neat sample was loaded onto the gel. Major protein 
bands were evident at the 30, 60 and 66 kDa region. ‘M3’ represents SigmaMarker ™ (low 
range) molecular weight marker.
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Figure 3.11: Estimation of listeriolysin O (LLO) content in TCA-precipitated L. 
monocytogenes supernatant. Protein G-purified polyclonal anti-LLO antibody was diluted in 
PBS/T and titrated against TCA-precipitated L. monocytogenes supernatant in a 
checkerboard fashion. Coating dilutions of TCA-precipitated supernatant proteins ranged 
from 1/100 to 1/500 in PBS. The negative control comprised of uncoated wells that had been 
blocked with 5 % (w/v) dried skimmed milk The titre of the polyclonal antibody was 
estimated to be 1/25600, thus, indicating significant LLO content in the precipitate.
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Figure 3.12: Standard curve for estimation of iota! protein concentration in TCA-precipitated 
fractions of L. monocytogenes supernatant. The assay was performed according to Section 
2.3.4. The mean absorbance reading for the neat sample tested was 0.953, which, when 
extrapolated from the curve, corresponded to 0.812 mg/ml. The mean absorbance reading for 
the 1/2 diluted sample was 0.543, which, when extrapolated from the curve, corresponded to 
0.894 mg/ml. The final estimate was taken as the mean of the two test determinants, 853 
Hg/ml.
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Representative immunoblots from a selection of six 
different hybridoma supernatants after primary cloning.
Figure 3.13: Western blot analysis of hybridoma supernatants after the first round of cloning 
by limiting dilution. The lane designated ‘M3’, contained SigmaMarker™ (wide range) 
molecular weight marker. A sample of TCA-precipitated protein from concentrated L. 
moncytogenes culture supernatant was resolved on a 12.5 % (w/v) SDS gel and the separated 
supernatant proteins were transferred to a nitrocellulose membrane. The membrane was then 
cut into strips to facilitate multiple sample screening. Most of the hybridoma supernatants 
tested reacted with a band in the ~60 kDa region. However, some demonstrated multiple- 
reactivity (e.g. immunoblots 3 and 5).
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Figure 3.14: Typical results of solution phase inhibition ELISA for hybridoma supernatants 
from a selection of clones produced using lymphocytes primed with L. monocytogenes 
EGDpERL3 50-1 pi-fA^y-derived supernatant proteins.
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Figure 3.15: Western blot analysis of monoclonal antibody derived from hybridoma clone 
G94F8. The lane designated 'M2\ contained Blue Ranger0 (prestained) molecular weight 
marker. A 20 pi sample of TCA-precipitated protein from concentrated L. monocytogenes 
culture supernatant was resolved in 12.5 % (w/v) SDS-PAGE gel and the separated protein 
bands were transferred to a nitrocellulose membrane. The hybridoma supernatant was used 
at a 1/1000 dilution in PBS/TM containing 1 % (w/v) dried skimmed milk. The purified 
antibody reacted with a single protein band at an approximate molecular weight of 60 kDa.
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3.2.1.6 Affïnity-purification o f  monoclonal antibody G94F8 (mAbG94F8)
Spent hybridoma supernatant was collected from hybridoma clone G94F8 cells that had been 
grown to exhaustion. The supernatant was concentrated ten fold by ultrafiltration, using a 10 
kDa cut-off membrane filter. A 10 ml volume o f concentrated supernatant was purified using 
a freshly prepared 1 ml Protein G column (Section 2.6.3). The elution profile for the 
purification process is demonstrated in Figure 3.16. Fractions 1-6 were pooled, desalted and 
resuspended in PBS buffer. The approximate concentration o f purified IgG was estimated 
from the A280nm value, assuming a molar extinction co-efficient o f 1.4.
Fraction Number
Figure 3.16: Typical elution profile for monoclonal G94F8 following purification on a 1 ml 
Protein G column. A total of 10 mis of concentrated hybridoma supernatant was applied to 
the column, which was then washed with 20 mis of wash buffer. Elution was performed using 
0.1 M Glycine-HCl (pH 2.5) and 850 pi fractions were collected in microcentrifuge tubes 
containing 150 pi of 1 M  Tris-HCl (pH 8.0) as a neutralisation buffer. Fractions 1-6 were 
found to contain the majority of the eluted antibody.
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3.2.2 Characterisation o f  mAbG94F8
3.2.2.1 Determination of mAbG94F8 isotype
The isotype o f the affinity-purified mAbG94F8 was determined using ELISA, as described in 
Section 2.8.2. The results o f the isotyping ELISA (Figure 3.17), clearly indicated that 
mAbG94F8 was an IgGl type antibody, comprising kappa light chain domains.
Isotype reactivity
Figure 3.17: Isotype profile of affinity-purified monoclonal antibody (Clone G94F8). ELISA 
plates were coated with TCA-precipitated L. monocytogenes supernatant proteins at 
approximately 10 pig/ml. Monoclonal antibody G94F8 was used at a 1/500 dilution in PBS/T. 
The absorbance values indicated that the monoclonal antibody was composed of IgGl heavy 
chains and kappa light chains.
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3.2.2.2 Demonstration of solution-phase inhibition ELISA  with L. monocytogenes- 
derived supernatant proteins
ELISA plates were coated with approximately 10 |ig/ml o f L. monocytogenes EGDpERL3 50- 
1 prfAEGD-derived supernatant proteins in PBS. Supernatant proteins were also freshly 
prepared from a 50 ml culture o f exponentially growing L. monocytogenes serotype l/2a  cells, 
as described in Section 2.8.4. In this instance the supernatant was not concentrated prior to 
precipitation with TCA. Serial dilutions o f this freshly precipitated supernatant fraction were 
prepared in PBS/T and 50 fil o f  each dilution was added to the wells o f the coated ELISA 
plate along with 50 fil o f  a 1/2000 dilution o f affinity-purified mAbG94F8 in PBS/T. 
Inhibition o f mAbG94F8 binding to the coated plate by the free L. monocytogenes l/2a- 
derived supernatant proteins was clearly demonstrated (Figure 3.18).
3.2.2.3 Confirmation of p60-specificity of mAbG94F8
It is almost impossible to distinguish between p60 and listeriolysin O (LLO) bands using 
standard SDS-PAGE resolution, as their comparable, approximate molecular weights o f 58-60 
kDa renders both electrophoretic mobilities identical. It was tempting to designate the reactive 
protein, LLO, especially since the L. monocytogenes strain from which the proteins were 
derived was the recombinant EGD pERL 3-50prfA variant, which harbours additional copies of 
the prfA gene. The anti-LLO polyclonal titration had confirmed there to be an appreciable 
LLO content in the supernatant protein fraction. Whereas expression o f LLO from the hlyA 
gene is under direct transcriptional control o f the PrfA protein, p60 expression from the 
invasion-associated protein (jap) gene, is independent o f PrfA levels. The amount of LLO 
expressed in wild-type L. monocytogenes cells is quite low, especially when grown in rich 
media such as BHI, as already stated. Thus, the ability o f mAbG94F8 to demonstrate 
solution-phase inhibition by wild-type supernatant proteins (Figure 3.18), further suggested 
that the protein being recognised was indeed, p60.
p60 has been shown to elicit the strongest B- and T- cell responses following exposure to 
Listeria spp. (Gentshev et al, 1992; Geignat et al., 1999; Kolb-Máurer et al., 2001) and 
although all the results thus far indicated that mAbG94F8 was specific for p60, a source o f 
pure p60 protein was required in order to confirm the specificity. This was provided as a 
recombinantly-expressed L. monocytogenes p60 protein (rp60), by Paul Leonard (DCU, 
Ireland). The recombinant version comprised the complete mature L. monocytogenes p60 
amino acid sequence fused to a C-terminal hexahistidine tag and was heterologously 
expressed in E. coJi. The protein was provided in PBS buffer, following purification by 
immobilised metal affinity chromatography (IMAC) via the hexahistidine tag.
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A neat sample (20 jj.1) was resolved on a 12.5 % (w/v) acrylamide gel using SDS PAGE, to 
confirm that it exhibited the correct molecular weight (60 kDa) and also to assess the degree 
o f purity. Figure 3.19(A) demonstrates that the major band corresponded to the expected 
molecular weight o f  p60 (i.e. 60 kDa) and only a small amount o f lower molecular weight 
impurities were evident. These were attributed to inefficiencies in the IMAC purification 
process.
A 1/20 dilution o f the rp60 protein was also prepared in PBS buffer. Following SDS PAGE, 
this diluted sample was transferred to a nitrocellulose membrane and subjected to Western 
blot analysis using the affinity-purified mAbG94F8 antibody. After substrate addition, a 
specific band was evident at 60 kDa, thus, strongly corroborating the postulated p60- 
specificity o f  mAbG94F8 (Figure 3.19-right). It was not possible however, to perform a 
comparative experiment confirming non-specificity for LLO due the unavailability o f a 
suitably pure source o f LLO. This problem was addressed later, in chapter 5 (Section 
5.2.3.1.2).
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Figure 3.18: Inhibition ELISA using affinity-purified mAbG94F8 antibody. The competing 
antigen was TCA-precipitated L. monocytogenes serotype J/2a-derived supernatant proteins. 
The supernatant proteins were diluted to 200 pg/ml in PBS/T prior to preparing the serial 
dilutions. Thus, the 1/10 dilution corresponded to approximately 10 pg/ml.
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Figure 3.19: Immunoreactivity of mAbG94F8 towards recombinant p60 protein (rP60). The 
gel on the left, (A), represents 20 /// of neat, IMAC purified rp60 in PBS resolved on a 12.5 % 
(w/v) SDS PAGE gel. ‘Ml ’ and ‘M2’ refer to SigmaWide ™(wide range) and BlueRanger® 
(prestained) molecular weight markers, respectively. There is one principal band apparent at 
approximately 60 kDa. There are also several lower molecular weight contaminating bands. 
It was not confirmed whether these were degradation products of the rp60 protein, or distinct 
impurities. The membrane on the right, (B), corresponds to a 1/50 dilution of the rp60 protein 
following Western blotting with mAbG94F8 used as the immunoprobing antibody at a 1/1000 
dilution in PBS/TM containing 1 % (w/v) dried skimmed milk.
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3.2.2.4 Cross-reactivity analysis o f mAbG94F8
Although the inhibition ELISA (Section 32.2.2), and rp60 investigations (Section 3.2.23) 
strongly suggested that mAbG94F8 recognised a L. monocytogenes p60 epitope, p60 
homologous proteins have been reported to be present throughout the Listeria genus (Bubert 
et al., 1992a; Bubert et al., 1992b). It was, thus, necessary to investigate the degree of cross­
reactivity and whether in fact, mAbG94F8 was specific for L. monocytogenes-derived p60 
protein.
Supernatant protein fractions were prepared from 50 ml cultures o f exponentially growing 
Listeria spp. and representative non -Listeria spp. The supernatant protein preparations from 
each test strain were then subjected to Western blot analysis using affinity-purified 
mAbG94F8 at a 1/2000 dilution in PBS/T (Figure3.20). Specific binding was apparent at the 
expected 60 kDa position for all o f  the L. monocytogenes strains tested (Z. monocytogenes 
l/2a, l/2c, 4a and 4b). However, mAbG94F8 also appeared to recognise 60 kDa bands in both 
L. innocua strains tested (Z. innocua PA and PHLS) and the Z. ivanovii PA strain. In addition, 
tnAbG94F8 reacted with a band slightly greater than 60 kDa in Z. ivanovii PHLS. The fact 
that p60 has been shown to demonstrate heterogenous molecular weights among Listeria spp. 
(Bubert, et al., 1992a) could explain why the reactive band appeared slightly greater than 60 
kDa.
No apparent cross-reactivity was observed for any o f the other strains examined. The status o f 
Z. ivanovii as a pathogen o f considerable veterinary concern meant that cross-reactivity with 
this species could, perhaps, be tolerated and even incorporated into the development o f a test 
for pathogenic Listeria spp. (i.e. L. monocytogenes and Z. ivanovii). Listeria genus-specific 
immunoassays that target the p60 protein have been previously described (Bubert el al., 1994; 
Wieckowska-Szakiel, et al., 2002) and commercial assays using this strategy have also been 
developed (Axelsson and Sorin, 1998). However, as the stated objective was to isolate a 
monoclonal antibody for detecting Z. monocytogenes o f food origin, from enriched cultures, 
cross-reactivity with Z. innocua was seen as a major limitation o f mAbG94F8. Cross­
reactivity with Z. innocua was particularly undesirable, given that this species is often found 
as a co-contaminant in food and demonstrates a competitive advantage over Z. 
monocytogenes in enrichment broths, thereby indicating a potential propensity for false- 
positive results if this anti-p60 monoclonal antibody were used for detection purposes.
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Figure 3.20: Western blot analysis of mAbG94F8 cross-reactivity. The top membrane (A) 
represents supernatant proteins derived from: (1), L. monocytogenes l/2a; (2), L. 
monocytogenes l/2c; (3), L. monocytogenes 4a; (4), L. monocytogenes 4b; (5), L. innocua 
PA; (6), L. innocua PHLS; (7), L. ivanovii PA and (8), L. ivanovii PHLS. The bottom 
membrane (B) represents supernatant proteins derived from: (9), L. welshimeri; (10), L. 
seeligeri; (11), E. coli; (12), B. subtilis; (13), B. cereus; (14), S. faecilis; (15), E. aerogenes 
and (16), BHI broth precipitate (negative control). Since neither L. innocua nor L. ivanovii 
produce LLO, the binding of mAbG94F8 evidenced here was further confirmation that p60 
was the protein being recognised by mAbG94F8. The lanes designated ‘M2’, contained 
BlueRanger9 (prestained) molecular weight marker.
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3.2.3 Productionof a panel o f  monoclonal antibodies to InlB
3.2.3.1 Preparation o f L. monocytogenes-derived InlB-enriched extract
InlB was extracted from the surface o f PBS-washed L. monocytogenes EGDpERL3 50-1 
prfAEGD cells by incubating the cells with 1 M Tris-HCl on ice for 1 hour (Section 2.4.2). This 
method has been shown to provide superior quantitative extraction o f InlB, which possesses a 
very high isoelectric point o f 10.1 (Muller et al., 1998a). It is hypothesised that the high ionic 
strength o f the Tris-HCl extractant interferes with the amino-carboxylate salt bridges 
anchoring InlB to the cell surface and this mediates the release o f InlB. The extract was 
dialysed extensively against PBS.
A 20 ^1 sample o f  the dialysed extract was analysed by SDS PAGE (Figure 3.21) to confirm 
the efficacy o f the extraction process and to assess the approximate degree o f purity. The 
major protein band was evident at 6 6  kDa, which, corresponded to the molecular weight of 
InlB.
3.2.3.2 Estimation o f total protein concentration in the Tris-HCl extract
Total protein content in the InlB-enriched, Tris-HCl extract was estimated by conducting a 
BCA assay, as described in Sections 2.3.5 and 3.2.1.3. BSA was again employed as the 
protein standard since it is a globular protein o f identical molecular weight (6 6  kDa) to that of 
the principle protein o f interest in the extract, InlB. A neat sample, in addition to a sample 
diluted 1 in 2 in PBS, were assayed and the resultant absorbance values were read from the 
standard curve o f net absorbance at 590 nm versus protein (BSA) concentration (mg/ml), as in 
Section 3.2.1.3. The estimated total protein concentration was calculated to be 720 ng/ml.
3.2.3.3 Immunisation with L. monocytogenes-derived InlB-enriched extract
Balb/C mice were immunised via the peritoneal cavity with InlB-enriched, Tris-HCl extract 
o f L. monocytogenes EGDpERLS 50-1 prfAEGD cells, mixed 1:1 with Freund's Complete 
adjuvant (FCA). Subsequent boosts were prepared in Freund’s Incomplete adjuvant (FICA) 
and administered by i.p. injection over a period o f 6-8  months. When the specific serum titre 
was deemed sufficiently high (Figure 3.22), the mice were primed for fusion. This consisted 
o f administering booster i.p injections prepared in PBS on days 5 and 3 before fusion. The 
final boost was administered in pre-warmed (37 °C) PBS on day 1 before fusion, 
intravenously, via the tail vein.
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3.2.3.4 Hybridoma production using lymphocytes primed with L. monocytogenes-derived 
InlB-enriched extract
On the day o f the fusion (day 0), the spleen was removed from one primed mouse and the 
lymphocytes from within were harvested. Following the fusion procedure, hybridoma 
supernatants were screened approximately 9 days post fusion for specific antibody as 
described in Sections 2 .1.12  and 2.8.1. In excess o f  85 % o f the wells tested demonstrated 
‘positive’ reactivity towards the plates coated with InlB. 'Positive' wells were initially scored 
on the basis o f a positive result being greater than the control normal background reading + 3 
standard deviations. Due to such a high percentage o f ‘positives’ a higher nominal cut-off 
value o f 0.5 absorbance units at 405 nm was employed. In addition, wells that exhibited a low 
number o f defined colonies were preferentially selected above those which contained a visibly 
higher proportion o f multiple, defined colonies. The selected well populations were scaled up 
to 24 well plates. An inhibition ELISA format (Section 2.8.1) was used in this second and all 
subsequent rounds o f screening and a typical profile for a selection o f isolated clones is 
demonstrated in Figure 3.23. Following several rounds o f cloning, hybridoma clone ‘G54D4’ 
was selected on the basis that it demonstrated stable secretion o f antibody and competitive 
solution-phase binding to the InlB-enriched, Tris-HCl extract.
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Figure 3.21: SDS-PAGE analysis of the InlB-enriched, Tris-HCl-extracted L.
monocytogenes EGDpERL3 50-1 prfA[,:GD surface proteins, resolved on a 12.5% (w/v) 
acrylamide gel. Lane ‘M3, contained SigmaWide ™ (low range) molecular weight marker. 
The 66 kDa band was very prominent and asssumed to principally comprise oflnlB. Only a 
small number of significantly less pronounced contaminating bands were evident. Overall, the 
analysis demonstrates the efficiency of the crude extraction procedure.
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Figure 3.22: Specific serum antibody titre from mouse that had been immunised with InlB-
enriched Tris-HCl extract. ‘A ’ and ‘B ’ represent a serum sample taken from the immunised 
mouse and a control serum taken from a naïve, non-immunised mouse, respectively. Both 
were screened against InlB-enriched Tris-HCl extract at a coating concentration of 10 fig/ml. 
The same serum samples were also screened against heat-killed L. monocytogenes l/2a cells 
at 1 x l ( f  cells/well (C and D). The specific titre obtained was 1/102,400 when screened 
against InlB-enriched Tris-HCl extract and 1/51,200, when screened against heat-killed L. 
monocytogenes l/2a cells. This was deemed sufficiently high to proceed with the fusion 
process.
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Figure 3.23: Typical results of solution phase inhibition ELISA for hybridoma supernatants 
from a selection of clones produced using lymphocytes primed with L. monocytogenes- 
derived InlB-enriched Tris-HCl extract. The wells were coated with 100 pi of approximately 
10 f4g/ml total protein in PBS. Hybridoma supernatants were diluted 1/100 with PBS/T and 
50 fil added to each well. The wells were then supplemented with 50 pi of Tris-HCl extract at 
specified dilutions. The supernatant proteins were diluted to 200 fig/ml in PBS/T prior to 
preparing the serial dilutions.
139

3.2.4 Characterisation o f  anti-InlB monoclonal antbody (mAbG54D4')
3.2.4.1 Determination of mAbG54D4 antibody isotype
The isotype of the anti-InlB antibody secreted in hybridoma G54D4 supernatant was 
determined by ELISA, as described in Section 2.8.2. The results o f the isotyping ELISA 
(Figure 3.24), clearly indicated that mAbG54D4 was an IgGl type antibody, comprising 
kappa light chain domains. Although the hybridoma had been fully cloned out by limiting 
dilution, the background values across the isotype range tested were slightly higher than 
expected, particularly for isotypes IgG2a and IgG2b. This was attributed to the fact that the 
monoclonal had not been purified prior to testing and thus the hybridoma supernatant 
contained heterogenous proteins such as BSA at appreciable concentrations.
2.5
lgG1 lgG2a lgG2b lgG3 IgM Lambda Kappa !gG+A+M lgG1
I s o t y p e  r e a c t i v i t y
Figure 3.24: Isotype profile of anti-InlB monoclonal antibody in hybridoma supernatant from 
clone G54D4. ELISA plates were coated with InlB-enriched, Tris-HCl extract at a coating 
concentration of approximately 10 fig/ml. G54D4 hybridoma supernatant was employed at a 
1/10 dilution in PBS/T. The absorbance values indicated that the monoclonal antibody was 
composed of IgGl heavy chains and kappa light chains.
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3.2.4.2 Immunoreativity of mAbG54D4 towards Tris-H Cl extract
A 20 nl sample o f L. monocytogenes EGDpERL3 50-1 prfAEGD -derived, InlB-enriched, Tris- 
HCl extract was resolved on a 12.5 % (v/v) acrylamide gel (Sections 2.3.2 and 3.2.3.1) and 
transferred to a nitrocellulose membrane (Section 2.3.4). The membrane was blocked with 5 
% (w/v) milk in PBS/T and then probed with a 1/10 dilution o f fresh mAbG54D4 hybridoma 
supernatant in PBS/TM containing 1 % (w/v) milk (Figure 3.25). The mAbG54D4 
supernatant was shown to react with a single ~ 6 6  kDa band, that was assumed to represent the 
InlB fraction in the Tris-HCl extract.
Tris-HCl 
e x tra c t
X  M2
m A bG 54D 4 82 7 kDa
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Figure 3.25: Western blot analysis of InlB-enriched, Tris-HCl-extracted L. monocytogenes
EGDpERL3 50-1 prfAgGD surface proteins with mAbG54D4. A specific band was obtained at 
~66 kDa, corresponding to the molecular weight InlB. The lane on the right, designated ‘M2 ’ 
contained Blue Ranger0 (prestained) molecular weight markers.
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3.2.4.3 Solution-phase immunoreactivity of mAbG54D4- inhibition ELISA
In order to ensure that the solution-phase binding capacity o f mAbG54D4 had not been 
compromised during the cloning-out process, an inhibition ELISA was performed (Section 
2.8.4). The ELISA plate was coated with approximately 10 pg/ml o f  L. monocytogenes 
EGDpERL3 50-1 prfAEGD-derived, InlB-enriched, Tris-HCl extract. A  dilution series o f Tris- 
HC1 extract was prepared in PBS/T, from an initial stock solution at a concentration of 
approximately 200 pg/ml total protein and 50 fil from each o f the dilutions were added to the 
ELISA wells. Next , 50 pi o f fresh mAbG54D4 hybridoma supernatant (diluted 1/250 in 
PBS/T) was added to each o f  the wells. Thus, the 1/100 dilution o f extract corresponded to 
approximately 1 ng/ml, the 1/1000 dilution corresponded to approximately 0.1 n-g/ml, etc. In 
addition, to assess solution phase binding to cell bound InlB, a similar inhibition series was 
set up using live L. monocytogenes cells and mAbG54D4 hybridoma supernatant at the same 
dilution. In order for the test to simulate a real detection scenario, wild type L. monocytogenes 
serotype l/2a (expressing normal, wild type levels o f InlB) was used instead o f the 
recombinant L. monocytogenes EGDpERL3 50-1 pr£AEGD strain. Live L. monocytogenes l/2a 
cells were prepared in PBS/T at a starting stock concentration o f approximately 5 x 10n 
cells/ml and thus, the 1/100 dilution corresponded to approximately 2.5 x  1010 cells/ml, the 
1/1000 dilution corresponded to approximately 2.5 x 109 cells/ml, etc
The findings (Figure 3.26) indicated that mAbG54D4 demonstrated solution-phase binding to 
InlB-enriched, Tris-HCl extract, with inhibition apparent at levels in excess o f 270 ng/ml of 
extract. No apparent inhibition was achieved with L. monocytogenes cells. However, as a 
caveat, these observations must be qualified by acknowledging that the inhibition assay had 
not been optimised in terms o f antigen coating concentration or antibody working dilution 
prior to the analysis. It is expected that the assay sensitivity for the InlB-enriched Tris-HCl 
extract could be improved following judicious parameter optimisation. Nonetheless, it would 
appear, from the inability o f  very high concentrations o f  L. monocytogenes cells to elicit 
inhibition, that a comparable improvement in sensitivity, with respect to detection o f cells, 
could not be achieved.
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Figure 3.26: Inhibition ELISA using mAbG54D4 hybridoma supernatant at a 1/1000 dilution 
in PBS/T (effective dilution, 1/2000) against free InlB-enriched, Tris-HCl extract (A) and L. 
monocytogenes cells (B). The range of inhibition with respect to the Tris-HCl extract was 
between 2.5 fig/ml and 270 ng/ml. In fact, the lower limit may have been substantially less 
than 270 ng/ml, however, since the assay did not reach a curve saturation point it was not 
possible to extrapolate an exact cut-off. Unfortunately, the presence of cells did not appear to 
induce any significant level of competitive inhibition of mAbG54D4 to the immobilised Tris- 
HCl extract across the range of concentrations tested.
3.2.4.4 Determination of cell-binding potential mAbGS4D4
The apparent inability o f mAbG54D4 to bind L. monocytogenes-bound InlB protein, as 
indicated by the results in Section 3.2.4.3, was seen as a major limitation to the application of 
mAbG54D4 in an assay for the detection o f L. monocytogenes cells. Given, that the serum 
sample from the immunised mouse used in the fusion, had demonstrated a significant titre 
against both the InlB-enriched, Tris-HCl extract (1/102400) as well as L. monocytogenes 
EGDpERL3 50-1 prfAEGD cells (1/51200), this problem had not been anticipated. However, 
given the polyclonal nature o f the serum and the heterogenous protein impurities evident in
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the crude Tris-HCl extract (Figure 3.21) it was entirely possible that the cell binding antibody 
component o f in the serum, was specific for one o f these unidentified proteins and that this 
was the reason for the discrepancy between the polyclonal mouse serum and the selected, 
anti-InlB monoclonal antibody, in terms o f their cell binding capacity. This may be seen to 
reflect an inherent flaw and short-sightedness in the screening and selection process. It is 
acknowledged that screening against whole cells may have revealed a more appropriate 
antibody, capable o f reliably binding the L. monocytogenes via the cell-bound form o f InlB. 
However, in regard to this issue, it is pertinent to note that the aim o f this particular strategy 
was to exploit the specific expression o f  InlB by L. monocytogenes spp. as a cell surface- 
localised protein, by efficiently targeting this particular protein to produce a correspondingly, 
L. monocytogenes-specific monoclonal antibody.
The cells used in the serum titration were L. monocytogenes EGDpERL3 50-1 prfAEGo that 
had been heat-killed by inactivation at 80 °C for 25 minutes, whereas, the cells used in the 
inhibition assay (Section 3.2.4.3) were live, wild-type L. monocytogenes l/2a cells. In order to 
assess the effect o f heat killing process and over-expression o f InlB by L. monocytogenes 
cells, on the capacity o f mAbG54D4 to bind cells, a simple, direct ELISA was performed 
(Section 2.8.1). Individual sets o f microplate wells were coated with samples o f  heat-killed 
and live, wild-type and recombinant, L. monocytogenes cells. The test wells were then 
incubated with 100 jj.1 o f mAbG54D4 hybridoma supernatant diluted 1/2 in PBS/T. Although 
the overall absorbance response values were low, there did appear to be a slightly higher 
propensity for binding to the recombinant strain (Figure 3.27). This was hardly surprising 
given that it was capable o f expressing significantly higher levels o f InlB protein. More 
significant, was the fact that mAbG54D4 also exhibited an apparent predilection for cells that 
had been heat-killed. This suggested that the cell wall morphology may have been preventing 
the antibody binding to InlB and that the heat-killing process altered the morphology 
sufficiently to render the epitope-bearing region recognised by mAbG54D4 more accessible.
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Figure 3.27: Direct cell ELISA for determination of mAbG54D4 cell binding capacity (n=3). 
Wells were coated with approximately 1 x 1011 cells/ml. ‘HK’ denotes heat-killed cells and ‘L. 
monocytogenes EGD’ refers to L. monocytogenes EGDpERL3 50-1 prfAEc,D. The G54D4 
hybridoma supernatant was used at a 1/2 dilution in PBS/T and an additional set of wells 
were coated with InlB-enriched, Tris-HCl extract (approximately 20 fig/ml) to act as a 
positive control. Despite the high cell coating concentration and minimally diluted 
supernatant, only very weak binding to cells was evident. The strongest response was for the 
L. monocytogenes l/2a and EGD strains. In both strains there was a slight increase in 
apparent response between the native and heat-killed cells.
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The crystal structure o f  the major domain components o f the InlB protein has been published 
(Marino et al., 1999). The mature protein consists o f  four distinct domains (as outlined in 
Figure 3.28). A recombinant version of the complete InlB protein (1), as well as, several 
truncated variants, were kindly provided by Paul Leonard and Liz Tully (DCU, Ireland). The 
truncated versions comprised o f the mature InlB protein minus (2), the GW repeat anchor 
region; (3) the GW repeat anchor region and the B repeat region and (4) the GW repeat 
anchor region, the B repeat region and the lgG-like domain.
B a c t e r i a l - s u r f a c e
a n c h o r i n g  d o m a i n  I n t e r n a l i n  d o m a i n
^________ A _________^ _____________________ -'A-------------
G W G W G W B I R L R R  r e g i o n Cap
Figure 3.28: Outline o f the tertiary domain structure o f mature InlB protein from available 
crystallographic data (PDB reference code: 1M9S, adapted from Marino et al., 1999; Cossart 
et al., 2003), viewed using the Swiss-PDB viewer program. There are four distinct domains; a 
cap region, leucine rich repeats (LRRs), an IgG-like domain, also known as an inter-repeat 
(IR) region, and a B-repeat region. The amino terminal part encompassing the LRR is the 
most exposed region of cell-bound InlB. The protein is anchored to the cell surface via it 
carboxy-terminal GW repeat domains.
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The com plete recom binant InlB protein was provided in PBS buffer and had been purified by 
IM AC. The recom binant variants were provided as crude cell lysates in urea-based denaturing 
buffer ‘B ’. Samples o f  each recom binant protein were resolved on a 12.5 % acrylam ide gel 
(Figure 3.29a) and then transferred to  a nitrocellulose m em brane and probed w ith 
m AbG54D4 hybridom a supernatant (Figure 3.29b). The results indicated that the antibody 
was specific for the N -term inal, LR R  domain. This domain is the m ost exposed dom ain o f  L. 
monocytogenes surface-bound InlB and thus, suggested that m A bG54D4 should be capable 
o f  binding to  cells. M oreover, since the antibody w as capable o f  binding to  the recom binant 
LR R  domain, following crude cell lysis in a urea-based denaturing buffer and denaturing SDS 
PAGE, it appeared that the epitope being recognised w as not conform ation-dependent.
On the basis o f  these results it seemed surprising that mAbG54D4 was not capable o f  binding 
live cells. Some success has also been reported when polyclonal anti-InlB antibodies were 
em ployed in a sandwich im m unoassay for the detection o f  L. monocytogenes cells (Gary 
W yatt, personal com m unication). However, problem s have been encountered by others 
(Trinad Chakraborty, personal com m unication) and it has been proposed that the m anner in 
w hich InlB is associated w ith the cell surface can render it inaccessible to antibodies 
(Jonqières e t al., 1999).
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F igu re  3 .29: Immunoreactivity ofmAbG54D4 towards complete and truncated versions o f  
recombinant InlB proteins. Samples o f each o f the proteins (20 fil) were resolved on a 12.5 % 
(w/v) SDS PAGE gel (A). ‘M l ’ and 'M2 ’ refer to SigmaWide ™ (wide range) and 
BlueRanger® (prestained) molecular weight markers, respectively. The complete InlB protein 
had been provided in purified form and thus, generated a single band (1). The truncated 
versions comprised o f the mature InlB protein minus; the GW repeat anchor region (2), the 
GW repeat anchor region and the B repeat region (3), and the combined GW repeat anchor 
region, B repeat region and IgG-like domain (4). These were provided in crude cell lysates 
and thus, contained multiple heterogenous, E. coli-derivedproteins. The bands corresponding 
to the InlB proteins are indicated with the green arrows. The resolved samples were then 
subjected to Western blot analysis using G54D4 hybridoma supernatant at a 1/1000 dilution 
in PBS/TM containing 1 % (w/v) dried skimmed milk (B). The binding profile suggested that 
the epitope being recognised by mAbG54D4 was contained within the N-terminal LRR 
domain ofInlB, which was the smallest fragment tested (lane 4).
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3.2.5 Production o f  monoclonal antibodies to whole-cell L. monocytogenes
3.2 .5 .1  P reparation  o f  fo rm a lin -in a c tiva ted L . m on ocytogen es cells
Previous unpublished results had indicated that polyclonal antibodies raised against L. 
monocytogenes, that had been heat-inactivated, were not suitable for detection o f  the live 
bacteria. This was thought to be due to the fact that m any o f  the surface proteins had become 
excessively denatured during the inactivation process. H eat inactivation was not considered 
an option since favourable detection o f  heat-killed cells over healthy cells was contrary to the 
envisaged diagnostic application and w ould likely render false positive results an inherent 
problem with any resulting assay. It was thus decided inactivate the cells using a formalin 
solution in PBS (Section 2.4.4) before im munising m ice in order to  present a m ore stable 
surface protein topography.
3 .2 .5 .2  Im m u n isa tion  w ith fo m a lin -in a c tiv a te d L . m on ocytogen es ce lls
Three m ice w ere immunised v ia  the peritoneal cavity w ith approxim ately 1 x  107 formalin- 
inactivated L. moncytogenes serotype l/2 a  cells prepared 1:1 with PBS and Freund's 
Com plete adjuvant (FCA). Subsequent boosts were prepared in PBS and adm inistered by i.p. 
injection over a period o f  6 - 8  months. W hen the specific serum titre (Figure 3.30) was 
deemed sufficiently high, the m ice were prim ed for fusion. This consisted o f  adm inistering 
booster i.p injections prepared in PBS on days 5 and 3 before fusion. The final boost was 
adm inistered in PBS on day 1 before fusion, via the i.p route. It was not possible to  adm inister 
the final booster intravenously because the com plex cellular suspension could quite 
conceivably have led to toxic shock or even pulm onary embolism.
On the day o f  the fusion (day 0), the spleen was rem oved from one prim ed m ouse and the
lymphocytes from  within were harvested. Following the fusion procedure, hybridom a
supernatants w ere screened approxim ately 9 days post fusion for specific antibody as
described in Sections 2.8.1 and 2.7.7.2. The initial 600 hybridom a containing w ells were
screened using a comparative, negative screening direct ELISA format, where one set o f  wells
was coated w ith L. monocytogenes serotype l/2 a  cells in PBS (1 x  10 8 ce lls /w e ll)  and a
separate set o f  wells was coated w ith a com bination o f  L.welshimeri, L. seeligeri and L. 
8 •innocua cells ( 3 x 1 0  cu m u la tiv e  ce lls /w e ll) , prepared under the same conditions. From 
this prelim inary screening, 39 clones were identified that dem onstrated favourable binding to 
L. monocytogenes. Following scale-up, the hybridom a populations were re-screened. A  
proportion o f  the 39 clones tested exhibited substantial cross-reactivity (Figure 3.31). 
However, a significant percentage also continued to  dem onstrate an enhanced response to L. 
monocytogenes cells.
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F igure 3 .30: Specific serum antibody litre from  a mouse that had been immunised with 
form alin-inactivated L. monocytogenes l/2 a  whole ceils. The sam e cells were used as the 
coating antigen in the ELISA at a  concentration o f  approxim ately 1 x I ( f  cells/ml. 'A ’ 
corresponds to the serum from  the immunised mouse, while ‘B ’ refers to a  control serum  
taken from  a  naive, un-immunised mouse. The specific litre was estim ated to be 1/100,000.
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In particular, clone no. 39 was found to  sim ultaneously generate the greatest response against 
L. monocytogenes l/2 a  cells and the lowest response to the heterogenous population o f  non- 
pathogenic strains. It w as also demonstrated to bind L. monocytogenes cells in a  solution 
phase inhibition ELISA. This clone was further isolated and stabilised by limiting dilution and 
was designated ‘m A b2B 3’.
□  L WSi
■  L. monocytogenes
Clone number
F igu re  3 .31: Screening of supernatants from preliminary selected hybridoma populations. 
The light bars in the chart foreground represent the supernatant activity towards the 
heterogeneous population of non-pathogenic L. welshimeri, L. seeligeri and L. innocua ( ‘L. 
wsi), while the shaded bars in the chart background represent the supernatant activity 
towards L. monocytogenes serotype l/2a cells.
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3 .2 .6  C h a r a c te r is a tio n  o f  m A b 2 B 3  m o n o c lo n a l  a n tib o d y
3 .2 .6 .1  D eterm in a tion  o f  m A b2B 3 iso type
The isotype o f  the antibody secreted by hybridom a clone ‘2B 3’ w as carried out using ELISA, 
as described in Section 2.8.2. The results o f  the isotyping ELISA (Figure 3.32), clearly 
indicated that mAb2B3 w as an IgG2a type antibody, com prising kappa light chain domains.
2.5- '
Isotype reactivity
Figure 3.32: Isotype profile o f monoclonal antibody mAb2B3. ELISA plates were coated with 
live, PBS-washed L. monocytogenes serotype l/2a cells at 1 x lOr cells/well. mAb2B3 
hybridoma supernatant was employed at a 1/10 dilution in PBS/TM containing 1 % (w/v) 
dried skimmed milk. The absorbance values indicated that the monoclonal antibody was 
composed of!gG2a heavy chains and kappa light chains.
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3 .2 .6 .2  A ffin ity-pu rifica ton  o f  m A b2B 3
Spent hybridom a supernatant w as collected from hybridom a clone 2B3 cells that had been 
grown to exhaustion. The supernatant was concentrated ten fold by ultrafiltration, using a  10 
kDa cu t-off membrane filter. A  10 m l volum e o f  concentrated supernatant was purified using 
a freshly prepared 1 ml Protein A  colum n (Section 2.6.3). Protein A  was chosen because is 
known to bind m urine IgG2a strongly but not BSA /bovine lgG  and thus, prevents co­
purification o f  such proteins from the culture supernatant. The approxim ate concentration o f 
purified IgG  was estim ated from  the A 2 80nm value, assum ing a m olar extinction co-efficient o f 
1.4 and was calculated to  be 620 ng/ml. The protein-containing eluant fractions were pooled, 
desalted and resuspended in PBS buffer.
3 .2 .6 .3  D eterm in a tion  o f  in tegrity  a n d  degree  o fp u r if ic a to n  o f  m A b2B 3
The purity and integrity o f  the protein A-affinity purified mAb2B3 m onoclonal antibody was 
confirmed by SEC HPLC (Section 2.11.1) and combined SDS PAGE and W estern blot 
analysis. For the SEC HPLC analysis (Figure 3.33), the purified antibody exhibited a single 
peak with an identical retention tim e to that o f  the standard IgG2a antibody (15 minutes). This 
corresponded to  approxim ately 155 kD a by reference to a  standard curve o f  globular proteins 
o f  known m olecular weight.
The purity and integrity o f  the purified m onoclonal antibody w as further confirmed by 
subjecting neat samples o f  both the purified mAb2B3 antibody and the concentrated 
unpurified mAb2B3 hybridom a supernatant, to  SDS PA G E analysis on a 12.5 % (w/v) 
acrylam ide resolving gel. The resulting electrophoretic profiles were com pared w ith that o f  
the standard IgG 2a (Figure 3.34, top). The concentrated supernatant yielded m ultiple bands 
reflecting a heterogeneous protein population contained within. In  addition, there was a 
dom inant protein band at 66 kDa and this was attributed to  the foetal-bovine BSA content in 
the growth m edia composition (Section 2.7.1). It was also possible to  discern strong bands at 
approxim ately 50 kDa and 25 kDa, which corresponded to the IgG heavy and light chain 
fragments, respectively. The affinity-purified mAb2B3 antibody yielded ju s t heavy and light 
chain bands, which corresponded exactly with the protein bands yielded by the IgG2a 
standard. The im munoreactivity (w ith regard to goat-anti m ouse-IgG 2a antibody) o f  the three 
antibody test samples was confirm ed by subsequent W estern blot analysis (Figure 3.35, 
bottom).
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Figure 3.33: SEC HPLC profiles of a commercial standard (1 mg/ml in PBS) murine IgG2a 
antibody (pink), and a neat sample of protein A-purified mAb2D3 in PBS (blue), performed as 
described in Section 2.11.1. A Phenomenex 3000 SEC column was used with PBS mobile 
phase at a flow rate of 0.5 ml/min and monitored by UV absorbance at 280 nm. The retention 
times for both the standard and test antibody correlate at a value of 15 minutes. The single 
peak evident at this retention time is indicative of sample purity.
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Figure 3.34: Determination of antibody purity. Gel (A) represents SDS PAGE analysis of (I), 
concentrated mAb2B3 hybridoma supernatant; (2), protein A-affmity purified mAb2B3 and 
(3), a commercial IgG2a standard in PBS. ‘M l' and ‘M2' refer to SigmaWide ™ (wide range) 
and BlueRanger® (prestained) molecular weight markers, respectively. The heavy and light 
chain protein bands are dearly visible at 50 kDa and 25 kDa, respectively. The bottom image 
(B) represents the corresponding Western blot following immuno-probing with an AP- 
labelled, goat anti-mouse-IgG2a antibody.
155

3 .2 .6 .4  O bservations on  th e  n ature o f  th e  specific  m A b2B 3-cell b in d in g  in teraction
In order to glean further inform ation regarding the exact nature o f  m Ab2B3’s ability to bind 
L. monocytogenes cells, a panel o f  pathogenic Listeria spp. were comparatively assessed 
following a selection o f  treatments. These treatments included growth in BHI, as opposed to 
LEB broth, the effect o f  solubilising the listerial cell wall proteins and the effect o f  heat 
inactivation. The test form at employed throughout, for the determination o f  the extent o f 
mAb2B3 binding to  treated cells, was a direct ELISA (2.8.1 and 2.8.3), such as had been used 
for screening hybridom a supernatants. The absorbance values recorded (A) w ere norm alised 
against the background response (A 0) according to A/A 0 and the results were plotted in Figure 
3.35.
It w as apparent that the activity o f  mAb2B3 was m ost potent against L. monocytogenes 
serotype l/2 a  cells and strongest when cells were prepared in LEB rather than BHI medium 
(Figure 3.35, 1). No activity towards L. ivanovii was detected in either media. The strong 
response to L. monocytogenes serotype l/2a  was undoubtedly due to  the fact that this was also 
the serotype used for im m unisation and hybridom a screening. However, the cells used for 
im munisation and screening had also been cultivated in BHI broth. The higher response to 
LEB-cultured serotype l/2 a  cells suggested some degree o f  up-regulation o f  the epitope- 
bearing protein. The response to the L. monocytogenes l/2c, 4a and 4b strains was, weaker, 
yet still significant. Interestingly, the serotype 4a strain w as the only species that 
dem onstrated a weaker response w hen cultured in LEB m edium  than BHI. M ore significantly, 
the response against the serotype 4b strain tested was substantially enhanced by growth in 
LEB medium. This is im portant given the frequent association o f  L. monocytogenes 4b strains 
w ith invasive listeriosis in humans. It has previously been reported that, although, there is a 
high degree o f  hom ogeneity between all strains o f  the sam e L. monocytogenes serovar, there 
are large differences between serovars o f  the 1/2 fam ily and serotype 4b (Tabouret et al., 
1992). W hen the cell wall proteinaceous content was partially solubilised by treatm ent with 
detergent (Figure 3.35, 2) the activity was generally reduced, thus, reaffirming the cell-wall 
localisation o f  the reactive protein. Subjecting the cells to  a  tem perature o f  80 °C reduced the 
reactivity (Figure 3.35, 4 and 5). This was viewed as a significant advantage fo r the 
developm ent o f  a L. monocytogenes-specific im munoassay since it could potentially abrogate 
false positive results arising from non-viable, heat-inactivated L. monocytogenes cells.
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F ig u re  3.35: R eactivity profiles o f  purified  mAb2B3 against representative pathogenic 
Listeria spp., grown in either BHI (panel A) or LEB (panel B), broth media. The data  
represents the mean o f  triplicate measurements. The top profile (1) represent ELISA wells 
coated  with 1 x  l ( f  fresh ly p repared  cells, w ashed and resuspended in PBS. Profile (2) 
represents the sam e cell sam ples after having been subjected to SDS-mediated surface protein  
extraction, w ashed and resuspended in PBS, while profiles (3) and (4) refer to the freshly  
prepared  samples after being held a t 80 °C fo r  15 and 20  minutes, respectfully.
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3 .2 .6 .5  C ross-reactiv ity  o f  apa th ogen ic  L is te r ia  spp. w ith m A b2B 3
Although both the immunisation and screening that led to  the selection o f  mAb2B3 had been 
conducted using cells that had been cultivated in BHI medium, it was clear from the results 
outlined in Section 3.2.6.4, that mAb2B3 exhibited a greater binding capacity to L. 
monocytogenes l/2 a  and 4b cells that had been cultured in LEB medium. This was interpreted 
to  suggest an up-regulation o f  the reactive protein and/or a change in the surface topography 
o f  the cells. It was im portant to  determ ine w hether a sim ilar effect was exhibited by non-Z.. 
monocytogenes strains. A  selection o f  test bacteria were grown under identical conditions to 
those o f  the representative L. monocytogenes strains under investigation, in LEB broth. The 
subsequent binding o f  mAb2B3 to the various cell types was com pared using a direct ELISA 
and the results are outlined in Figure 3.36. It was clearly evident that significant binding was 
only apparent in wells coated w ith the representative pathogenic L. monocytogenes strains. No 
significant cross-reactivity w as observed in any o f  the non-Z,. monocytogenes strains tested.
3 .2 .6 .6  E lu c ida tion  o f  th e  m A b2B 3-reactive  lis te ria l p ro te in
In order to putatively determine the key identifying parameters o f  the protein being 
recognised by mAb2B3 and to  re-affirm  degree o f  cross-reactivity determ ined in Section 
3.2.6.5, a  series o f  im m unoblotting experim ents were performed. Surface proteins were 
extracted from  L. monocytogenes cells (Section 2.4.5) that had been grown in BHI and LEB 
media, in addition to  a selection o f  apathogenic Listeria  spp. that had been grown in LEB 
medium. The heterogenous surface protein profiles were visualised by SDS PAGE analysis 
(Figure 3.37a). These w ere then subjected to  W estern blot analysis, w ith the mAb2B3 
antibody, and it was revealed that the antibody reacted only w ith extracts derived from L. 
monocytogenes spp. and specifically w ith an 80 kDa-localised protein (Figure 3.37b). When 
this estim ated m olecular w eight was considered along w ith the dem onstrated cell surface 
localisation o f  the protein and its apparent exclusivity to L. monocytogenes spp., the 
m Ab2B3-reactive protein was tentatively theoriseded to be InlA. However, this was subject to 
further confirmation (Chapter 4). A lthough InlA is exclusive to L. monocytogenes, a 
significant num ber o f  internal in hom ologues have been identified within the L. ivanovii 
species (Engelbrecht, et ail., 1998a; Engelbrecht, et al., 1998b) com prising the characteristic 
LRR dom ain (Kajava, 1988). In prokaryotes, this particular domain structure is usually 
restricted to  virulence-associated appendages. Cell wall-anchored proteins are w idespread in 
gram-positive bacteria (Navarre and Schneewind, 1999) and m any share the common LPXTG 
m o tif and the sim ilarly hydrophobic C-term inal dom ain present in InlA. However, since this 
region is buried w ithin the cell w all and thus inaccessible, it was highly im probable that this 
region housed the reactive epitope for mAb2B3 and, correspondingly, w as unlikely to mediate 
cross-reactivity.
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F ig u re  3.36: Cross-reactivity profiles o f  purified  mAb2B3 against representative pathogenic 
and apathogenic Listeria spp., grown in LEB broth media. The data represents the mean o f  
triplicate measurements. The concentration o f  each cell sample was adjusted in PBS to give a 
fin a l coating concentration o f  1  x  l ( f  cells/well.
It w as no t possible to  infer a significant up-regulation or variance in the expression levels o f 
the 80 kDa protein between the different L. monocytogenes serotypes tested, or between 
identical serotypes cultured in LEB as opposed to  BHI, from the surface-extract profiles and 
corresponding immuno-blots with m Ab2B3. It is m ore likely that the overall cellular 
m orphology and surface topography is influenced by the type o f  growth medium used, with 
m ore accessible reactive epitope sites dom inating in LEB-cultured cells. Furthermore, despite 
an obvious decrease in binding capacity o f  mAb2B3 to heat-inactivated cells (Section 3.2.6.4) 
this could not be entirely attributed to  protein denaturation, since reactivity was observed 
following denaturing SDS-PAGE (Figure 3.39b). This adds further w eight to  the postulation 
that successful binding o f  mAb2B3 antibody to  L. monocytogenes is dependent not only on 
expression o f  the specific 80 kD a protein, but also on the overall surface topography and 
accessibility o f  the epitope site.

M2 1 2 3 4 5 6 M2 M2 7 8 9 10 11 12 13 14 15 16 M2
84 kDa -► 84 kDa-^
47.9 kDa-^ 47.9 kDa-^
F igu re  3.37: Determination o f  the specific immunoreactivity o f  mAb2B3. SDS-extracted 
protein  fractions (~100-150 fig/ml) from  various Listeria genus members grown under 
identical conditions in either BHI (A) or LEB (B) broth media, were resolved by SDS-PAGE  
(top) and then immunoprobed with mAb2B3 (bottom). ‘M l ’ and ‘M 2 ’ refer to SigmaWide ™ 
(wide range) and Blue Ranger0  (prestained) molecular weight markers, respectively. Gel A  
represents; (1), L. monocytogenes l/2a ; (2), L. monocytogenes l/2c; (3), L. monocytogenes 
4a; (4), L. monocytogenes 4b; (5), L. ivanovii PA and (6), L. monocytogenes EGDpERL3 50-1 
prfAEGD■ Gel B  represents; (7), L. monocytogenes l/2a ; (8), L. monocytogenes l/2c; (9), L. 
monocytogenes 4a; (10), L. monocytogenes 4b; (11), L. ivanovii PA; (12), L. innocua; (13), L. 
innocua; (14), L. welshimeri; (15), L. seeligeri and (16), L. monocytogenes EGDpERL3 50-1 
prfAEGD. The mAb2B3 antibody reacted with an -8 0  kDa protein  exclusively present in the L. 
monocytogenes-derived sam ples tested. No non-specific binding to extracts derived from  the 
other genus members tested  was observed.
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3.2.7 Optimisation o f  ELISA fo r  detection o f L. monocytogenes cells using
mAb2B3
Having established that mAb2B3 was specific for an 80 kDa protein present on the surface o f 
L. monocytogenes cells, it was decided to dem onstrate the potential usefulness o f  this 
m onoclonal antibody in an im munoassay for the direct detection o f  live L. monocytogenes 
cells.
3.2 .7 .1  C h eckerboard  E L IS A  f o r  determ in ation  o f  op tim a l load in g  ra tios o f  ce ll coating
a n d  op tim a l an tibody d ilu tion  f o r  m A b2B 3 m on oclon a l an tibody
It is likely, that, all reagents being equal and optimal, coating o f  antigen can play a very 
influential role in determ ining assay performance. The sim plest approach to coating microtitre 
plates with antigen is to do so directly, by passive adsorption (Canterero el al., 1980). The 
effectiveness o f  such an approach is dependent on how w ell the integrity o f  the adsorbed 
antigen is preserved (Pesce et al., 1977; Butler et al., 1992) and how firmly the antigen is 
bound (Rubin et al., 1977; Salonen and Vaheri, 1979). Ideally, the antigen should retain its 
native conform ation and accessibility o f  the reactive epitope should not be compromised. In 
general, at high concentrations o f  coating antigen there is a  tendency o f  protein m olecules to 
bind to each other due to saturation o f  available binding surface. These intra-molecular 
interactions are often w eaker than those between the protein and the plastic surface and can, 
thus, result in dissociation o f  supposedly ‘bound’ protein during the assay (Kemeny, 1992). 
The acceptable range o f  protein concentrations at which there is no interference with binding 
to the plastic is called the ‘zone o f  independent binding’ (Canterero et al., 1980; Kemeny, 
1992). W hen coating w ith w hole cells these considerations rem ain pertinent (Sedgwick and 
Czerkinsky, 1992). Often, cells, particularly m am m alian cells are ‘fixed’ with a cross-linking 
reagent such as form aldehyde or glutaraldehyde. However, due to the non-discrim inatory 
cross-linking activity m ediated by these potent fixatives, epitope structure and/or accessibility 
could quite conceivably be im paired by this procedure.
In polyclonal antisera, raised against whole cells, this potential complication would most 
likely not arise. The heterogenous com position o f  such antisera would ensure that a 
significant proportion o f  the im munoglobulin content was capable o f recognising its 
com plem entary com ponent epitope on the surface o f  the fixed cells. The key advantage with 
using m onoclonal antibodies, and in particular, the reason for the high discrim inatoiy power 
o f  mAb2B3 with regard to L. monocytogenes, lies in the fact that it recognises a single
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epitope. Thus, any deleterious effect on the cell surface, epitope-bearing protein, brought 
about by fixing, could totally abrogate the capacity o f  the m onoclonal antibody to bind cells.
It m ay be argued that because mAb2B3 was produced from m ice immunised with formalin- 
inactivated L. monocytogenes cells, it w ould be expected to  be capable o f  recognising or even 
preferentially bind to sim ilarly treated cells. However, the principal objective was to  isolate a 
m onoclonal antibody specific for live L. monocytogenes cells and this was reflected in the 
screening process and selection o f m Ab2B3, w hich had been performed using live L. 
monocytogenes l / 2 a cells.
In an inhibition ELISA format, the degree o f  sensitivity in terms o f  detection limits 
(proportional to the slope o f  the curve), is a cum ulative function o f  the antibody affinity and 
the antigen valency and results are interpreted at equilibrium between both free and 
immobilised antigen. Consequently, using too high a coating concentration o f  antigen will 
shift the binding equilibrium  in favour o f  binding to  the ELISA plate and cause reduced 
sensitivity to free antigen in solution. Similarly, utilising too high an antibody concentration, 
will require high concentrations o f free antigen in solution to  inhibit antibody binding to the 
ELISA plate, and will therefore result in decreased assay sensitivity.
In order to determ ine the optimal working dilution o f  the purified antibody and optimal cell 
coating concentration, a  checkerboard ELISA was perform ed as described in Section 2.8.3. 
For the purposes o f  assay standardisation and reproducibility it is desirable to have a pure and 
readily available source o f  coating antigen. In the absence o f  such and being restricted to 
coating with whole cells, as w as the case described herein, it may be argued that the 
recom binant L. monocytogenes EGDpERL3 50-1 prfA EGD strain would be the best choice for 
coating, due to  its inherent, constitutive high level expression o f  prfA-regulated virulence 
proteins. However, the principal objective was to  dem onstrate the absolute, generic 
application o f  mAb2B3 for detection o f  live L. monocytogenes cells. Thus, w ild type L. 
monocytogenes serotype l/2 a  was em ployed as the coating and solution-phase antigen. The 
checkerboard results were plotted (Figure 3.38) and these indicated that the optimal coating 
concentration o f  L. monocytogenes cells was approxim ately 1 x  109 cells/ml. The optimal 
mAb2B3 antibody dilution, w hich gave the greatest change in absorbance per change in 
antibody dilution, w as determ ined to  be 1 / 1 0 ,0 0 0 .
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Figure 3.38: Checkerboard ELISA fo r  determination o f  optim al L. monocytogenes cell 
coating concentration and mAb2B3 antibody working dilution fo r  the developm ent o f  an 
inhibition immunoassay fo r  detection o f  live L. monocytogenes cells. The absorbance values 
w ere rea d  a t 405 nm after 15 minutes exposure to substrate a t 37  °C.
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3 .2 .7 .2  In h ib ition  E L ISA  evaluation
Protein A-affinity-purified mAb2B3 m onoclonal antibody was em ployed in an inhibition 
ELISA form at for the detection o f  free L. monocytogenes cells in solution as described in 
Section 2.8.4.
Typically, im munoassay response curves are inherently non-linear and adopt a sigmoidal bell 
shape on semi-log plots (Findlay et al., 2000). Such assays are most effectively modelled 
using a four-param eter equation, o f  the form:
R =  R HI — R„, — RLO
I +
r Cone
Z "
~\
A2
(Equation 3.1)
Where Rhi ~ Response at infinite concentration
R lo R esponse at zero concentration
( 'one = A nalyte concentration (M or cells/ml)
Aj Fitting constant
and a 2 Fitting constant
The four-param eter (4-param eter) equation above was fitted to the data sets for each 
im m unoassay run, using BIAevaluation 3.1 software™ . When used as a calibration curve, the 
4-pararaeter fitting facilitated the estim ation o f  sample test concentrations from the resultant 
plot. It w as thus possible to  estim ate the degree o f  precision o f analytical measurem ent at 
different standard concentration points relative to the fitted 4-param eter plot. This was 
reported as the %  relative error (%  RE) between the standard ‘input’ concentration and the 
estim ated ‘output’ concentration generated from the curve.
A lternatives to the 4-param eter equation include the log-logit and linear models. Although the 
log-logit function fits m any im munoassays quite effectively it is not suitable when a 
significant degree o f  asym m etry is present such as can often occur when using polyclonal 
antibodies at very low working dilutions or when labelled antigen exhibits heterogeneity with 
respect to  unlabelled antigen (Raggatt, 1992). Both the log-logit and, in particular, the linear 
m odelling o f  the straight-line portion o f  the sigmoidal curve, frequently render the asymptote 
regions o f  the data plot unreliable and unusable. The 4-param eter equation however, 
confidently fits the asym ptote region thereby greatly extending the working range o f  the 
im munoassay calibration curve at both ends o f  the concentration range employed.
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The intermediate precision and repeatability was calculated by conducting the assay over 
three consecutive days. Each day, two assay runs were performed and sample cell 
concentrations were measured in triplicate. This was sufficient to satisfy the validation criteria 
outlined by Findlay et al., (2000). The absorbance values (A) for each data point were then 
divided by the measured absorbance in the presence of zero cells (Ao) to yield normalised 
response values (A/A0). A calibration curve of the mean normalised absorbance values was 
plotted against the standard cell concentrations (cells/ml) on a logarithmic x-axis (Figure 
3.40). The normalised mean values for the standard cell concentrations were entered as 
‘input’ values into the fitted equation and the resulting mean, back-calculated ‘output’ values 
were then used to calculate the coefficient of variation for the inter-assay performance (Table 
3.2). The differences between the actual or ‘input’ concentrations and the ‘output’ cell 
concentrations extrapolated from the curve were used to calculate the % recovery and the 
associated % relative error (% RE).
I2 L u  ( r f - r x)  (Equation 3.2)
^  =  1
It was possible to estimate the ‘goodness-of-fit’ of the 4-parameter equation by measuring the 
chi2 (jf) value. This is a standard statistical parameter that facilitates a numerical 
interpretation of the ‘goodness-of-fit’ and was calculated according to the following equation:
Where rf  = The fitted value at a given mean data point
rx = The experimental value at the same point
n = Total number of data points
and p  = The number of fitted parameters
The %2 value obtained for the fit in Figure 3.39 was very low (2.56 x 10‘4) and thus, reflected 
an acceptable fitting. However, using the %2 value alone, as a measure goodness-of-fit is can 
be unreliable, since the presence of even a few points that deviate wildly from the fitted curve 
can markedly affect the absolute value. A more meaningful and robust estimate of the 
goodness-of-fit was obtained by plotting the ‘residual’ values. When plotted against the 
nominal cell concentration values, the residual plots reflect the difference between the 
experimental and fitted data. These can also be expressed as relative residual values, which 
reflect the absolute residuals as a fraction of the experimental value.
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Figure 3.39: Inter-assay calibration curve for estimation of L. monocytogenes cell 
concentration in PBS. Data is the result of three replicate measurements from six independent 
assay rims and the curve was fitted using a four-parameter equation. A residual plot for the 
calibration curve is included to provide a visual illustration of the ‘goodness of f it’ of the 4- 
parameter model.

Table 3.2: Inter-assay reproducibility determinants fo r  detection ofL. monocytogenes cells in
PBS.
Mean (actual) cell 
concentration
Back calculated cell 
concentration
CV (%) Recovery (%)
1.23 x 10' Low 2.25 -
1.85 x 107 1.55 xlO7 2.50 83.63
2.77 x 10y 3.10 x 107 3.00 111.77
4.16x10' 4.45 x 107 2.71 106.87
6.24 x 10' 6.01 x 10^ 6.76 96.23
9.36 x 10' 9.62 x 10r 11.33 102.78
1.41 x 10s 1.39 x 10s 7.75 98.72
2.11 x 10s 1.40 x10s 10.22 91.69
3.16 x 10s 2.81 x 10* 7.84 88.78
4.74 x 10s High 8.86 -
(-): denotes that data could not be extrapolated from the standard curve.
The lower limit of quantitation (LLOQ) was estimated to be 1.85 x 107 cells/ml, with inter­
assay reproducibility within the set 20 % acceptance limit recommended by Findlay et al., 
(2000). Although similar, inhibition type assays have been reported in the literature for 
detection of bacterial cells (Eriksson et al., 1995, Leomard et al., 2004), this format may not 
be the most appropriate for direct cell detection. The bulky dimensions of the bacterial cells 
may interfere with free antibody binding to the immobilised cells. This would be expected to 
compress the working range of assay and may explain why the dynamic range of this 
particular assay appeared slightly constricted. The sensitivity and working range could 
perhaps be improved by adopting an alternative format. A possible candidate may be a 
sandwich immunoassay that incorporates a sequential capture and signal generating labelled- 
antibody binding event. A polyclonal genus-specific antibody could potentially fill the role of 
either the signal-generating antibody component, as has previously been demonstrated by 
Gavalchin and co-workers (1991). Alternatively, the polyclonal genus-specific antibody could 
be used as the capture-antibody component, with subsequent binding of species-specific, 
fluorescently-labelled monoclonal antibody, such as described by Sewell and co-workers 
(2003). The incorporation of such broadly reactive antibodies could conceivably impinge on 
the specificity of the assay.
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Overall, considering that the initial cell contamination level is going to be substantially 
augmented by an incorporated enrichment incubation step, and the fact that unlike other L. 
monocytogenes virulence proteins, InlA expression is not down-regulated by growth in 
nutrient-rich media at 37 °C (Bohne et al., 1996; Bubert et al, 1999), a slight improvement in 
sensitivity is not essential and definitely not warranted at the expense of assay specificity. 
Alternatively, it has also been shown that a monoclonal antibody can be used as both the 
capture and signal generating components of a sandwich immunoassay for detection of L. 
monocytogenes and L. innocua (Solve et al, 2000). This is a facet of sandwich immunoassays 
that is restricted to the detection of large, multi-epitope bearing analytes, such as cells. The 
high copy number and wide distribution of accessible InlA on the surface of L. 
monocytogenes make this protein a particularly suitable target for future development of such 
an assay. Moreover, expression of most listerial virulence-associated (and consequently, 
pathogenicity marker) genes closely correlates with that of prfA, and appreciable amounts of 
the nascent proteins are only achieved when growth conditions mimic those of the 
intracellular environment, such as was experimentally achieved by addition activated charcoal 
to growth media (Ripio et al, 1996; Ermolaeva et al., 2004). InlA expression, on the other 
hand, is not subject to this ‘charcoal-effect’ and, thus, sample enrichment can proceed in rich 
media and at 37 °C, resulting in more rapid attainment of detectable levels of L. 
monocytogenes cells without fear of compromising the key antigen expression level.
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3.3 Summary and conclusions
The principal objective of this chapter was to isolate a monoclonal antibody that was specific 
for the pathogenic Listeria  species, L. monocytogenes. Three strategies for isolation of a 
suitable monoclonal antibody were explored.
A panel of monoclonal antibodies was initially produced against a concentrated preparation of 
L. monocytogenes culture supernatant proteins. The L. monocytogenes strain used was the 
recombinant strain (L. monocytogenes EGDpERL3 50-1 prfAgGD), which had been provided, 
supplemented with multiple copies of the prfA, virulence regulator gene. It was reasoned that 
this would lead to increased virulence protein expression and thus, improve the chances of B- 
cells being stimulated against a virulence-, and therefore, pathogen-associated protein when 
mice were immunised. An IgGl-K antibody was isolated (mAbG94F8) that reacted 
specifically with a 60 kDa protein present in the supernatant of L. monocytogenes 
EGDpERL3 50-1 priAEGD- The supernatant fraction was shown to contain a significant level 
of the LLO protein, attributed to the heightened PrfA expression and since this protein was 
known to have an approximate molecular weight of 60 kDa, an initial assumption was made 
that was the protein recognised by mAbG94F8. However, when the antibody was tested 
against supernatant proteins from panel of representative bacterial species that included non- 
pathogenic Listeria  spp. and non-Listeria  spp., the antibody was found to cross-react with a 
60 kDa protein produced by L. innocua and L. ivanovii. Although L ivanovii was known to 
produce a homologous cytolisin similar to listeriolysin, termed ivanolysin, L. innocua does 
not produce an equivalent protein. This indicated that the protein being recognised was not 
LLO and more likely to be p60, which is an immunodominant, prfA-independent and 
constitutively expressed protein. This was confirmed by demonstrating immunoreactivity 
towards a purified recombinant L. monocytogenes p60 protein. Although p60 homologous 
proteins are shared throughout the Listeria  genus, nonetheless, the antibody was 
discriminatory up to point, insofar as it appeared to recognise all the pathogenic Listeria  spp. 
tested, in addition to only one non-pathogenic Listeria  spp. (L. innocua). Since Listeria- 
positive food samples usually contain low numbers (-10 %) of L. monocytogenes and high 
numbers (—90 %) of, typically, L. innocua spp. (Bhunia, 1997), a situation that is exacerbated 
by L. innocua’s  competitive advantage over L. monocytogenes in enrichment media (Cornu el 
al., 2002; Beumer et a l ,  1996; Curiale and Lewis, 1994; MacDonald and Sutherland, 1994; 
Yokoyama et al., 1998), this antibody may be of diagnostic use in an indicative-type test 
where indication of potential listerial (i.e Listeria  genus) contamination is the main criteria. 
However, it was deemed unsuitable for the stated objective of reliable and specific detection 
of L. monocytogenes.
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A second m onoclonal antibody w as produced, against the protein InlB. U nlike p60 there are 
no reported InlB-hom ologous proteins expressed by non-pathogenic Listeria spp. and it was 
felt that the strategy o f  targeting InlB w ould overcom e the undesirable species cross-reactivity 
apparent w ith the anti-p60 antibody. A lso, whereas p60 is predom inantly secreted into the 
culture supernatant, InlB is localised to  the L. monocytogenes cell envelope and thus, it was 
postulated that antibodies to this protein w ould facilitate direct cell detection. As transcription 
o f  the InlB-encoding gene was highly dependent on prfA regulation, the PrfA-over-expressing 
recom binant L. monocytogenes strain was again used as the antigen source, which was 
reliably extracted from the cell surface using 1 M Tris-HCl. A n IgGl-K  antibody 
(m AbG54D 4) w as isolated that was capable o f  recognising L. monocytogenes-extracted InlB 
in solution. However, it failed to significantly react with intact, viable L. monocytogenes cells. 
Subsequent analysis o f  the activity o f  the anti-tnlB m onoclonal antibody towards selected, 
domain-truncated recom binant InlB proteins confirmed that the antibody was specific for the 
LRR domain, w hich is known to be sim ultaneously the region o f  greatest heterogeneity and 
specificity to  L. monocytogenes and m ore importantly, the m ost surface exposed region o f  the 
protein. Thus, the inability o f  the antibody to  react w ith cell bound InlB was interpreted to 
indicate a potentially unfavourable L. monocytogenes cell surface m orphology that rendered 
the epitope inaccessible and concom itantly rendered the protein an unreliable target for 
specific detection o f  L. monocytogenes cells.
The final strategy that was investigated for isolation o f  a L. monocytogenes-specific 
m onoclonal antibody was based on a ‘shotgun’ im munisation approach. This entailed 
im m unising m ice with form alin-inactivated L. monocytogenes l/2 a  cells. Although this was 
anticipated to  stimulate a hum oral response to a m ultitude o f  proteins, reflecting the diverse 
and heterogenous L. monocytogenes cell surface protein topology, it was also felt that as the 
intact cell im munogen w ould m ost appropriately simulate the envisaged diagnostic target 
morphology o f  the antibody being sought. This placed greater significance on the antibody 
screening process, w hich had to be m ore rigorous and discriminatoiy. A negative screening 
approach was employed, whereby hybridom a clones were selected from the prelim inary 
population pool and all subsequent rounds o f  cloning, on the basis o f  demonstrated significant 
binding to  L. monocytogenes cells and failure to  bind a heterogenous selection o f  non- 
pathogenic Listeria spp. Using this method, an IgG2a-K isotype (m Ab2B3) antibody was 
identified that demonstrated favourable binding to L. monocytogenes. The selected antibody 
was affinity-purified and subsequently, extensively characterised in term s o f  its ability to 
specifically bind L. monocytogenes cells. It was concluded that the antibody reacted most 
potently w ith L. monocytogenes serotype l/2 a  cells and was strongest following cultivation o f 
cells in basic LEB, rather than BHI broth. In  addition, it was dem onstrated that the antibody
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binding capacity was significantly reduced in L. monocytogenes cells that had been subjected 
to heat inactivation. This was regarded as highly desirable characteristic since it could 
potentially safeguard against false-positive detection o f  dead cells in the envisaged 
application o f  this antibody in a food-industiy setting.
The propensity for cross-reactivity was initially assessed in a simple, direct ELISA format. 
The antibody failed to  react with any o f  the non-I. monocytogenes species investigated. These 
observations were mirrored by the results o f  W estern blot analyses o f  detergent-extracted 
surface proteins from the panel o f  test species. N o reactivity was observed in any o f  the 
extracts derived from non-Z. monocytogenes strains. A  single dominant mAb2B3- 
immunoreactive band was in the extracts derived from the five L. monocytogenes strains 
tested. The m olecular w eight o f  the reactive protein was estim ated to  be ~80 kDa and in view 
o f  this, in addition to  its cell surface location and apparent exclusivity to  L. monocytogenes, it 
was putatively identified as InlA.
As a  final com ponent o f  this chapter, the potential use o f  mAb2B3 in an inhibition 
im munoassay for routine detection/enum eration o f  Z. monocytogenes cells from enriched 
cultures was demonstrated by perform ing an inter-assay-repeatability study over several 
consecutive days. The LLO Q w as estim ated to  be approxim ately 1.85 x  107 cells/ml. It is 
acknowledged, though, that this type o f  assay may not be the m ost appropriate for detection 
o f  cells and several avenues o f  im provem ent in term s o f  sensitivity are proposed. M oreover, 
an improved sensitivity in term s o f  reliable quantitation is perhaps not a prerequisite, 
especially given the current state o f  affairs w ith regard to  acceptable limits o f  this Listeria  in 
food. W hat is desired is an effectively ‘presence or absence’ test capable o f  specifically 
identifying L. monocytogenes in enriched cultures.
Overall, when the perform ance o f this antibody w as com pared with published anti -Listeria 
antibodies and available im munoassay-based detection systems for L. monocytogenes, it was 
concluded that mAb2B3 dem onstrates significant advantages and potential for further 
developm ent with regard to  the specific detection o f  L. monocytogenes.
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C l o n i n g ,  H e t e r o l o g o u s  E x p r e s s i o n  a n d  
P u r i f i c a t i o n  o f  R e c o m b i n a n t  I n l A  P r o t e i n
C h a p t e r  4
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4.1 Introduction
The m onoclonal antibody ‘m A b2B3’, selected in C hapter 3, had been shown to specifically 
bind to  a surface-localised protein in L. monocytogenes. In addition, the antigen was 
confirmed to  be approxim ately 80 kD a in size (Section 3.2.6.6). On this evidence, the antigen 
was tentatively postulated to  be InlA. However, in order to  substantiate this presumption, it 
was necessary to clearly dem onstrate specific binding o f  mAb2B3 to highly purified InlA 
protein.
The InlA protein is typical o f  m any Gram -positive bacterial cell wall proteins insofar as it is 
tethered to the peptidoglycan scaffolding via a dedicated covalent link. W hile it is possible to 
differentially fractionate secreted intem alin proteins and isolate those that are localised to the 
cell surface by loose, non-covalent interactions (e.g. InlB), no m ethod exists for purification 
o f  native InlA  from L. monocytogenes cells. It was possible to  design prim er sequences to 
m ediate PCR-based am plification o f  the inlA gene sequence encoding the m ature protein, 
using the recently com pleted L. monocytogenes genotype (Glaser et ah, 2001). This gene can 
then be introduced, using a suitable expression vector, into an unrelated Gram -negative host 
cell (e.g. E. coli) that facilitates heterologous translation from the inlA gene into a soluble, 
recom binant form o f  the protein. A  key attribute o f  this recom binant approach is the relative 
ease by w hich various fusion tags can be selectively incorporated into the recom binant protein 
for the purposes o f  downstream purification or detection o f  expression constructs. 
Furtherm ore, heterologous expression com pletely obviates the need to culture large volumes 
o f  pathogenic cells in order to crudely extract even a  small am ount o f  the desired protein.
The principal objective o f  this chapter was to selectively clone the inlA gene o f  interest into a 
suitable expression vector and optim ise its expression and purification from a compatible 
expression host. Once purified, it was anticipated that the recom binant InlA protein (rlnlA) 
w ould be used to  confirm  the putatively designated specificity o f  mAb2B3 for InlA.
4.1.1 Expression vectors
The majority o f  expression vectors are based on either, or a combination o f  two promoter 
systems (Sutton and R ichardson, 1998). The com ponent criteria o f  a ‘good’ prom oter include 
high potency and a  capacity to  reach expression levels in excess o f  10-30% o f  the total 
cellular protein content. This potency should be easily repressible so as to  minim ise basal
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transcription, particularly in the case o f  toxic proteins and also be amenable to controllable 
induction (Hannig and M akrides, 1998). The T7 prom oter system  employs a prom oter that is 
recognised by the RN A polym erase from  bacteriophage T7 (P T7). This prom oter is not 
recognised by E. coli RNA polym erase and, thus, facilitates cloning and propagation o f 
sequences encoding toxic proteins by abrogating basal transcription. Induction can only be 
achieved by supplying the T7 RNA polym erase gene on a second com patible plasmid, a 
phage or on the chromosome o f  a specialised E. coli host strain (Sutton and Richardson, 
1998).
The lac operon prom oter system is the m ost w idely used bacterial expression system. 
Classically, the lac operon in E.coli encodes proteins that facilitate the uptake and metabolism 
p-galactosides. Negative regulation is brought about by binding o f  the lac repressor protein to 
the lac operator (positioned between the prom oter and the coding regions), a specific 
sequence o f  DNA to which the lac repressor binds, greatly decreasing the frequency o f 
successful transcription elongation events by the RN A  polym erase (Novy and M orris, 2001). 
IPTG (an allolactose analogue) is a  gratuitous inducer o f  the lac  operon (Singleton, 1995), 
insofar as it com petes strongly w ith the lac  operator for binding to  the lac repressor, yet is 
itse lf not m etabolised in the process and can, thus, be used to induce expression.
Positive regulation is stim ulated by the presence o f  3', 5'-cyclic adenosine monophosphate 
(cAM P) and the cyclic AM P receptor protein, called CRP or CAP. The CAP/cAM P complex 
binds ju st upstream  o f  the lac prom oter and directly stimulates transcription by RNA 
polymerase. However, cAM P levels are strongly influenced by the carbon source present in 
the m edium. In the presence o f  glucose, (an easily m etabolised m onosaccaride), cAM P levels 
are low, so transcription from the lac  prom oter is low, a phenom enon known as the ‘glucose 
effect’ or ‘catabolite repression’ (Novy and Morris, 2001). Thus, com plete induction o f  the 
lac operon system only occurs in the presence o f  both inducer and elevated cAM P levels. The 
lac repressor protein can be encoded upstream  from the prom oter region, or, as is the case o f 
the pQE60 vector, the lac repressor protein can be encoded on a separate plasmid.
QIAgen™  pQE® vectors contain an optim ised prom oter-operator elem ent consisting o f  the 
coliphage T5 prom oter (recognised by E. coli RNA polym erase) and tw o lac operator 
sequences that increase lac repressor binding and ensure efficient repression o f  the powerful 
T5 prom oter. Each vector also contains a  synthetic ribosomal binding site for high translation 
rates, a  hexahistidine, or, 6 xHis tag (5' or 3' to the multiple cloning site) for convenient 
detection and purification, strong transcriptional term inators to  prevent read-through 
transcription and ensure stability o f  the expression product, a P-lactamase gene (bla)
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conferring resistance to ampicillin and a Col El origin of replication (QIAgen Ltd., 2000). 
Regulation of expression from the pQE60 vector (Figure 4.1) can be controlled by the 
addition of glucose (catabolite repression) and by co-expressing the plasmid in cells 
containing the pREP4 plasmid, a low copy number plasmid that expresses the lac repressor 
protein encoded by the lacf gene (QIAgen Ltd., 2000). E. coli strains that harbour the lacP 
mutation, such as XL1 Blue, TGI and XL10-Gold®-Gold, produce enough lac repressor to 
efficiently block transcription, and are ideal for storing and propagating pQE plasmids 
(QIAgen Ltd, 2000).
pQE60 in particular, facilitates expression of functional proteins with a C-terminal 6xHis tag. 
The number of His-tagged recombinant protein constructs listed in the Protein Data Bank 
(www.rcsb.org/pdb) is continually growing. It is acknowledged that proteins with a His-tag 
may vary slightly with regard to their mosaicity and diffraction pattern when compared to the 
native protein (Hakanson et al., 2000). In principle, it cannot be excluded that the affinity tag 
may interfere with the protein activity (Wu and Filutowicz, 1999), although the relatively 
small size and charge of the polyhistidine tag normally ensure that protein activity is rarely 
affected (Terpe, 2003).
4.1.2 Expression hosts
In E. coli, successful transcription requires the presence of a promoter region, recognised by 
RNA polymerase, situated immediately upstream of the gene of interest. Comparison of many 
promoters has led to the formulation of a consensus sequence that consists of the -35 region 
(5'-TTGACA-) and the -10 region, or ‘Pribnow’ box (5'-TATAAT-), the transcription start 
point being assigned the +1 position (Old and Primrose, 1989). Effective translation depends 
on the mRNA transcript possessing a dedicated ribosome-binding site. Shine and Dalgamo, 
(1975) were the first to postulate that in addition to a translational start codon (AUG or 
GUG), a recognisable ribosome binding site required a sequence of bases complementary to 
the 3' end of 16s ribosomal RNA. The accepted consensus sequence is 5'-TAAGGAG-3' 
(Karlin and Mrazek, 2000), with the central 5’-AGGA-3’ representing the most highly 
conserved region (Kibler and Hampson, 2002). Traditionally it has been shown that ligated 
DNA molecules transform at a significantly lower efficiency than supercoiled molecules, and 
large plasmids less efficiently than small plasmids. E. coli XL 10-Gold are preferred for 
accomodating large expression contstructs, by virtue of the fact that they possess the Hte 
phenotype, that increases transformation efficiency (Jerpseth et al, 1997). This was 
particularly pertinent, given the large size of the inlA gene to be cloned.
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4.1.3 Cloning strategies
TA cloning using the pCR2.1® vector (Figure 4.2) does not allow  directional cloning o f  PCR 
products, a fact that can result in the desired genes being present in the wrong orientation or in 
the w rong reading frame. The pCR2.1 vector is supplied as a linearlised plasmid with 3' -T 
overhangs flanking the multiple cloning site (M CS), that conveniently and universally 
accom odate PCR products that have com plem entary 3' -A overhangs. This latter feature is a 
pervading characteristic o f  PCR products that have been am plified using TAQ polymerase. 
This process is com m only referred to  as ‘blunt-end’, or, ‘non-directional’ cloning. The lacZa 
gene sequence encodes the first 146 am ino acids o f  (3-galactosidase. I f  self-ligation or 
reannealing o f  the pCR2.1 plasm id occurs, transcription can proceed through lacZa and the 
lacZ a protein is expressed. Com plem entation in trans w ith the Q  fragm ent leads to active f3- 
galactosidase in host bacterial cells bearing such plasmids. These are easily identified by their 
ability to cleave X-gal and thus, produce blue-colured colonies on X-gal supplemented agar 
media.
The housing o f  the M CS w ithin the lacZa  gene sequence means that transformants harbouring 
pCR2.1 w ith a ligated insert have a redundant lacZa  gene and are easily identified as white 
colonies. This is referred to as ‘blue-w hite’ screening.
The ‘non-directionality’ o f  the ligation process is not a problem  since the principal function o f 
TA cloning is to provide a universal and rapid, one-step cloning strategy for the direct 
insertion o f  unm odified PC R  product into the pCR2.1 vector. This vector thus acts as a 
‘u tility ’ vector providing a stable and reproducible source o f  the sequence o f  interest in a 
fram ew ork-construct that facilitates gene m odification and manipulation. M ost restriction 
enzym es require additional DNA flanking the restriction site in order to sufficiently digest 
DNA. Cloning o f  the inlA gene sequences into a TA cloning vector also provides the 
additional DNA needed for the efficient digestion o f the PCR  products. Technically, the pCR
2.1 vector can m ediate protein gene expression in host bacterial cells that do not possess the 
lacP  genotype, by virtue o f  the lac promoter. However, in order to ensure that the gene o f 
interest is in the correct reading fram e and ligated in the correct 5' —* 3' orientation it is 
necessary to  directionally clone the in!A gene into the purposely selected or designed 
expression vector (e.g. pQE60). This concomitantly ensures that the corresponding protein o f 
interest is subject to  controllable (or inducible) expression and fused to  a suitable tag for 
expression signalling and purification purposes.
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Figure 4.1: Vector map of the Qiagen 3.4 kbp pQE60 plasmid and its principal components. 
PT5 refers to the phage T5 promoter, which is followed by a dual lac operator (lac O) 
sequence to increase the probability of lac repressor binding and concomitant repression of 
the strong PT5 promoter. The ATG universal start codon is coupled within the Ncol 
restriction sequence, which is followed by a BamH I restriction site within the multiple 
cloning site (MCS). A hexahistidine sequnce (6xHis) is located at the 3' end of the coding 
sequence, which translates to a C-terminal tag. Translational stop codons are located 
immediately downstream of the 6xHis sequence in all reading frames to facilitate convenient 
preparation of expression constructs. The Col El origin of replication and ampicillin- 
resistance gene (Ampr), permit propagation and selection of E.coli cells, respectively, which 
have been transformed with a pQE60-basedplasmid construct.
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lacZa ATG Bam H I
ÀCAG GAA ACA GCT ATG AC C ATG ATT ACG CCA AGC TTG G TA CCG AGC TCG GAT CCA CTA 
GTC CTT TGT CGA TAC TG G TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
EcoR I
I
GTA ACG GCC GCC AG T GTG CTG G A A  TTC GGC TT 
CAT TGC CGG CGG TC A CAC GAC C TT AAG CCG
Eco Rl
J.GCC G A A  TTC TGC 
TT CGG C TT  AAG  ACG
AGA TAT CCA TC A CAC TGG CGG CCG CTC GAG CAT GCA TC T AG A GGG CCC AA T TCG CCC 
TCT ATA GGT AG T GTG ACC GCC GGC GAG CTC G TA CGT AG A TCT CCC GGG TTA AGC GGG
TAT AG T GAG TCG TAT TA C AAT TC A CTG GCC GTC GTT TTA C AA CGT GAC TGG  GAA AAC 
ATA  TCA CTC AGC A TA  AT  G TTA AG T GAC CGG CAG CAA AAT G TT GCA CTG ACC CTT TTG
Figure 4.2: Vector map o f the Invitrogen pCR2.1 plasmid. Key features include the lacZa 
gene (position 1-545) that also incorporates the MCS site (234-355) and facilitates ‘blue- 
white’ screening. EcoRI sites are located at +283 and +299 bps providing convenient 
restriction sites fo r  ‘insert’ excision and analysis. The ampicillin-resistance (Ampr)  and 
kanamycin-resistance (Kan1)  open reading frames (ORF) confer resistance to ampicillin and 
kanamycin and, in conjunction with the pUC origin o f replication, facilitate propagation and 
selective plasmid retention in E. coli cells.
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4 .1 .4  H ig h fid e lity  P C R
‘Pfu’ DNA polymerase is a thermostable enzyme of approximately 92 kDa isolated from 
Pyrococcus furiosus (Fiala and Stetter, 1986). It catalyses the DNA-dependent polymerisation 
of nucleotides into duplex DNA in the 5'—» 3' direction. More significantly, it exhibits 3' —> 5’ 
exonuclease (or ‘proofreading’) activity. This means that base mismatches that can occur 
(albeit infrequently) during polymerisation, are rectified by the proofreading element 
(Lundberg el al., 1991). Pfu DNA Polymerase, unlike Taq DNA Polymerase, lacks terminal 
transferase activity and generates blunt-ended PCR products, lacking terminal - ‘A’ 
overhangs. Sequences amplified in this fashion are not amenable to TA cloning. The 
replication fidelities of Pfu and a number of commercial DNA polymerases have been 
compared using a PCR-based forward mutation assay (Cline et a l,  1996). The error rates o f a 
TaqtPfu DNA polymerase mixture and a Klenow frdgmenX/Taq!Pfu DNA polymerase mixture 
were found to be less than the error rate of Taq DNA polymerase, but approximately 3-4-fold 
higher than the error rate of Pfu DNA polymerase. Confidence in the PCR fidelity is 
especially relevant when the gene sequence being cloned is large (> 2  kbp), such as is the case 
with in i A.
The above technologies were cumulatively exploited for the efficient cloning, heterologous 
expression and purification of a recombinant version of the L. monocytogenes InlA protein.
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4 .2 R e su lts  a n d  d iscussion
4.2.1 Extraction of genomic DNA
Initial attempts to extract genomic DNA (gDNA) from L. monocytogenes using Proteinase K 
and lysozyme treatment were unsuccessful. This was probably due to the high peptidoglycan 
content and robust nature of the cell wall, which is typical of Gram-positive bacteria. 
Genomic DNA was successfully extracted from a fresh culture of L. monocytogenes l/2a 
cells, using guanidium thiocyanate, in a modification of the method recommended by Pitcher 
and co-workers, (1989) and as outlined in Section 2.9.2. The quality of the extracted gDNA 
was checked by running a sample on a 1 % agarose gel (Figure 4,3).
5000 bp 
3000 bp 
2 0 0 0  bp
Fig 4.3: Electrophoretic profile o f extracted L. monocytogenes genomic DNA (gDNA). The 
lane on the extreme right (2) represents a neat, undiluted sample o f freshly isolated gDNA. 
The concentration o f nucleic acids was very high, so high in fact that a large portion actually 
remained in the reservoir. A sample diluted 1/20 was run in the central lane (1) and resulted 
in a high molecular weight band, typical o f gDNA. The lane on the left, labelled ‘M ’ consisted 
o f a graduated molecular weight marker (1 kbp ladder) fo r  band size approximation.
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4 .2 .2  C lo n in g  o f  fu ll-le n g th  in lA  g en e  in to  pC R 2 .1  (T A  c lon ing )
The primer sequences TAFII-A and InlARII (Section 2.9.3) were designed to amplify the 
complete inlA protein gene minus the signal and precursor peptide sequence, beginning from 
the L. monocytogenes 1 /2a inlA native translational start codon, ‘ATG’. The primers were also 
synthesised with terminal ends designed to incorporate dedicated Ncol and BamHl restriction 
sequences at the respective 5' and 3' termini of the amplified inlA gene. A 500 |^ 1 TAQ-YCR 
master reaction mixture was set up according to the component ratios outlined in Section 
2.9.6. The mixture was split into individual 50 pi reaction volumes in PCR tubes that were 
then subjected to temperature gradient PCR over the range 59 °C - 69.0 °C. The results are 
depicted in Figure 4.4. The optimum temperature was taken as 65 °C. Although all the 
temperatures tested gave suitably defined, single bands at the desired molecular weight (-2.4 
kb), the temperature at the higher end of the scale was selected to maximise primer fidelity 
and reduce the propensity for non-specific annealing.
3000 bp 
2 0 0 0  bp
Figure 4.4: Temperature gradient analysis fo r  optimisation o f TAFII/InlARlI-primed TAQ- 
PCR amplification o f the inlA gene. The lanes 1-8 represent PCR products obtainedfollowing 
annealing at 59.0, 59.9, 61.5, 63.2, 64.8, 66.5, 68.0 and 69.0 °C. The outer lanes, designated 
‘M ’, contain molecular weight markers.
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A 2 [il sample of freshly amplified TAQ PCR reaction mixture was !blunt-end’ ligated into 
linearlised pCR2.1 vector at 14 °C, overnight, as described in Section 2.9.7. The freshly 
ligated pCR2.1- inlA construct was then transformed (Section 2.9.7) into One Shot® E. coli 
INVaF' cells that were supplied in ultra-competent status as part of the TA cloning kit 
supplied by Invitrogen Ltd. Plates containing transformed cells were screened following 
overnight incubation at 37 °C and subsequent cooling at 4 °C for 2 hours. A total of 10 
isolated white colonies and one blue, control colony were picked and sub-cultured into fresh 
LB broth for overnight propagation at 37 °C. When the overnight cultures were examined, 
growth was only evident in the control sample. This suggested that expression of the 
recombinant InlA (rlnlA) product was toxic to the host E. coli INVaF' cells. In order to 
overcome this problem, the transformation process was repeated using E. coli XL 10-Gold® 
cells. Unlike E. coli INVaF' cells, the E. coli XL10-Gold® cell genotype included the lad1 
gene, encoding the lac repressor protein. This meant that expression of the rlnlA protein from 
the pCR2.1- inlA construct could only proceed following induction with IPTG. Basal leakage 
of the rlnlA protein was further inhibited by adding 1 % (w/v) glucose to the broth media, 
thereby abrogating rlnlA-induced cellular toxicity. Hence, following blue-white screening, all 
selected colonies where successfully cultured in LB broth. Plasmid preparations were 
subsequently conducted on all the cultured transformants (Section 2.9.14) and each sample 
was then analysed by agarose gel electrophoresis (Figure 4.5). The results indicated that nine 
out of the ten selected clones contained an insert. The presence of the inlA sequence was 
further confirmed by subjecting each of the samples to PCR using the ¿«¿4-specific primers 
(Figure 4.6).
Two representative samples that were deemed positive, based on the PCR analysis, were 
subjected to restriction analysis in order to confirm the presence of the desired 2.2 kb inlA 
gene insert. Plasmid samples from clones 7 and 8 (XG7 and XG8) were digested with EcoRA 
enzyme (Section 2.9.8.1). In additon, a plasmid sample from clone 4 (XG4) was also digested 
with EcoBl to serve as a control. Figure 4.7 demonstrates that the presence of the inlA insert 
was confirmed in both XG6  and XG8 .
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Figure 4.5: Plasmid preparations from E. coli XL 10-Gold cells following transformation with 
pCR2.1- inlA construct. The lanes were loaded with 5 /jI of each 'plasmid prep'. Lanes (Cl 
and C2) contained the control plasmid isolated from two individual ‘blue ’ colonies. A ll of the 
plasmid samples, except for sample 4 (lane 4), derived from the selected ‘white’ colonies, 
yielded a single plasmid band of universally greater molecular weight than that of the 
control. These were predicted to contain the inlA gene insert. A possible reason for the 
unexpectedly high molecular weight of control sample plasmid (Cl) was, that two linearlised 
pCR2.1 plasmids had ligated together, producing an 'double-blue' genotype. If it was the 
case that sample 4 contained only re-annealedpCR2.1 plasmid, it would also be expected that 
the control sample C2 should appear as a band at the same molecular weight. The fact that 
the C2 plasmid appeared at a slightly higher molecular weight suggested that it contained a 
higher concentration of plasmid, arising from a higher cell yield. This is not surprising given 
that the total absence of the inlA gene insert would render the clone at a competitive 
advantage, in terms of growth rate, over those cells bearing the inlA gene insert (even if 
expression is minimised by the presence of lacf and glucose). The outer lanes, designated 
‘M ’, contain molecular weight markers.

Figure 4.6: PCR analysis of plasmid preparations from E. coli XL10-Gold cells following 
transformation with pCR2.1-inlA construct. The results corresponded with the plasmid 
molecular weight analysis (Figure 4.5). Sample 4 was the only sample that failed to yield an 
inlA band following PCR amplification. The outer lanes, designated ‘M ’, contain molecular 
weight markers. The appearance of a small amount of inlA PCR product in lane 4 was due to 
accidental sample run-over from lane 3 during loading.

Figure 4.7: EcoRI restriction analysis of plasmids purified from selected pCR2.1-inlA 
transformants. The lane labelled ‘M ’ represents the molecular weight marker. Lanes 1-3 
correspond to clones ‘XG4’, ‘XG7’ and ‘XG8’, respectively. The XG7 and XG8-derived 
plasmids yielded a linear Used pCR2.1 fragment at 3.9 kbp and an inlA insert band at ~2.2 
kbp. The additional high molecular weight band in XG7 was due to incomplete plasmid 
digestion. The control plasmid, deived from XG4 yielded only a 3.9 kbp band corresponding 
to linearlised pCR2.1.

4 .2 .3  C lo n in g  o f  fu ll-le n g th  in lA  g en e  in to  p Q E 6 0
It is pertinent to re-emphasise that the pCR2.1 plasmid was being employed as a ‘utility 
vector’ to allow rapid, high fidelity reproduction of the insert gene, not as an expression 
construct. The ‘blunt-end’ (non-directional) ligation associated with TA cloning did not 
favour one particular orientation of the insert over another. Thus, normally at this stage the 
positive PCR and EcoRl restriction analyses would be deemed sufficient information to 
proceed, pending confirmatory sequence analysis. The plasmid from XG8 was digested with 
Ncol and BamHl enzyme (Section 2.9.8.2) in preparation for directional ligation of the inlA 
gene into complimentary, restricted pQE60 expression plasmid (Figure 4.8). The pQE60 
plasmid used was one that had been previously ligated with the L. monocytogenes p60 protein 
encoding gene or invasion associated protein (iap) gene, (kindly donated by Paul Leonard, 
DCU).
Following ZtamlTLWcoI-restriction, the ‘donor’ pQE60 plasmid yielded an upper 3.4 kbp band 
(corresponding to linearlised pQE60) and a lower band (corresponding to the excised iap gene 
insert). The BamHVNcol-restncted XG8 -derived pCR2A-inlA plasmid yielded only two 
bands also. However, upon consultation with the relevant restrictrion map for plasmid pCR2.1 
(Figure 4.9) it was concluded that the upper band actually consisted of two fragments. One of 
which was the desired 2.2 kbp inlA gene, yet it was ‘contaminated’ with a second, 2.275 kbp 
fragment that arose due to restriction of the plasmid at the Ncol site located at position +1877. 
This was an unfortunate coincidence that made excision of the inlA band and subsequent 
purification impossible. The lower band (~1.6 kbp) was due to restriction of the plasmid at the 
BamHl (+252) and Ncol (+1877) sites.
One possible way to overcome this problem was investigated. Plasmids from both XG7 and 
XG8 were preliminarily restricted with BamHl enzyme alone. It was clear from the results 
(Figure 4.10) that the XG8-derived plasmid contained the insert oriented with its 5' BamHl 
site proximal to that of the pCR2.1 BamHl (+252) site. Thus, BamHl restriction yielded a 
single, effectively linearlised band corresponding to the combined molecular weights of both 
pCR2.1 and inlA (~ 6.1 kbp). Conversely, it was apparent that the XG7-derived plasmid 
harboured the inlA insert in the opposite orientation. BamHl restriction therefore, yielded two 
bands. In addition to providing a useful means of determining the insert orientation these 
results also suggested that it might be possible to isolate the band of interest (inlA) by 
conducting a stepwise digestion. However, this would also necessitate two separate digest 
incubations and two sequential purifications of the inlA band from the gel. BamHl and Ncol
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digested termini had proved to be quite susceptible to degradation and thus, prolonged 
holding at elevated temperature associated with a double sequential digest and purification 
was not favoured. It would also be impossible to distinguish whether the secondary Ncol 
restriction had been successful, since the small amount of DNA removed would not be visible 
on the gel and its removal would have no discernable effect on the migration distance of the 
primary, ÆamHI-digested fragment. Conversely, by digesting the XG8-derived plasmid 
simultaneously, with a BamHl/Ncol cocktail, the presence of two bands was taken to indicate 
successful and complete restriction of the insert gene. The fact that this was contaminated 
with an equal amount of the residual pCR2.1 was not unduly worrying. This was because any 
re-annealing between the inlA and residual pCR2.1 sequence was expected to result in a 
product that would be constrained by having two identical terminal restriction sites (i.e. 
BamWl at both ends or Ncol at both ends). These would therefore, fail to ligate into 
5a/«HIA¥col-digested pQE60.
4000 bp 
3000 bp
2000 bp
Figure 4.8: Lane (1) contained 5 ptl o f undigested ‘donor’ pQE60 plasmid containing the iap 
gene insert; lane (2), 5 f i l  o f  undigested XG8-derived pCR2.1-inlA plasmid; lanes (3) and (4), 
20 f i l  each o f BamHI/Ncol-restricted ‘donor’ pQE60 and lanes (5) and (6), 20 p i each o f 
BamHI/Ncol-restricted XG8-derived pCR2.1-InlA plasmid. The ~2.2 kbp band in lanes 5 and 
6 (indicated by blue arrows) appears twice as intense as the lower band because it contains 
twice the amount o f DNA due to co-migration o f the inlA insert gene and the residual pCR2.1 
fragment. The outer lanes, designated ‘M \ represent molecular weight markers.
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Figure 4.9: Restriction map for plasmid pCR2.1 with the inlA gene insert in both possible 
orientations, (A). The predicted products resulting from restriction with either EcoRI, (B), 
BamHI, (C), or a BamHI/NcoI cocktail, (D), are given along with their approximate 
molecular sizes.
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3000 bp
2 0 0 0  bp
-6 .1  kbp
Figure 4.10: BamHI analysis ofinlA insert orientation in selectedpCR2.1 plasmids. The lane 
labelled ‘M ’ represents the molecular weight marker. Lanes 1-3 correspond to BamHI- 
restricted plasmids, derived from clones ‘XG4’, ‘XG7’ and ‘XG8’, respectively. The BamHl- 
restricted XG4 plasmid served as a control. I t  did not harbour the inlA gene insert and thus, 
generated a band at approximately 3.9 kbp. XG7-derived plasmid yielded two distinct bands, 
indicating a distal separation o f the BamHI sites. The XG8-derived plasmid generated only 
one apparent, high molecular weight band (~6.1 kbp), indicating proximal separation o f the 
BamHI sites.
The BamHIINcoI-excised inlA insert was ligated into compatibly restricted pQE60 expression 
plasmid (Section 2.9.10) and transformed into E. coli XL10-Gold®-Gold cells (Section 
2.9.11). Following overnight incubation at 37 °C, a total of twenty isolated colonies were 
randomly selected and individually sub-cultured into fresh 5 ml volumes of LB broth. The 
selected clones were grown overnight at 37 °C and 200 rpm, reaching stationary growth 
phase. Plasmid isolation was performed on the resulting cell pellet and a sample of each 
plasmid prep’ was then analysed by EcoRl restriction. Unlike the pCR 2.1 vector that has 
£coRI restriction sites conveniently bracketing the MCS region, pQE60 only harbours one 
EcoK\ restriction site, immediately preceeding the 5' insert region (Figure 4.1). However, the 
fact that the inlA gene insert also possesses a single £coRl site located just upstream from its 
C-terminal encoding region, means that both the presence and orientation of the inlA gene in 
pQE60 can be confirmed by a one-step EcoRI restriction. Six out of the twenty samples
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tested, demonstrated a 2.2 kbp inlA insert band (Figure 4.11). The parent clones were 
designated XGQ3, XGQ4, XGQ7, XGQ10, XGQ12 and XGQ19. The presence of the inlA 
sequence was further confirmed by inlA gene-specific PCR (Figure 4.12). Considering the 
fact that the inlA gene was exactly 50 % contaminated with a residual pCR 2.1 fragment of 
similar size, the results indicated a successful cloning efficiency of 60 %, using the TA 
strategy.
I—2.2 kbp
12 13 14 15 16 17 18 19 20
I I I I I  L
4000 bp -l
3000 bp •»
2000 bp S -2.2 kbp
Figure 4.11: EcoRI-mediated restriction analysis ofplasmids purified from twenty randomly 
selected pQE60-inlA transformed E. coli XL10-Gold® clones. Clones 3, 4, 7, 10, 12 and 19 
harboured a 2.2 kbp insert and were putatively deemed positive fo r  the inlA gene. The 
peripheral lanes, labelled ‘M ’, represent the molecular weight marker.
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Figure 4.12: inlA gene-specific PCR o f plasmids previously confirmed to harbour 2.2 kbp 
insert. The lanes 1-6 represent PCR products obtained following ini A gene-specific 
amplification o f plasmids that had previously confirmed to contain a 2.2 kbp insert (Figure 
4.9). The outer lanes, designated ‘M ’, contain molecular weight markers. A ll six plasmids 
generated an inlA gene-specific band at 2.2 kbp, thus confirming the plasmid insert to be the 
inlA gene.
4.2.3.1 Time course experiments to determine the full-length rlnlA expression levels 
The six selected E. coli XL10-Gold transformant cells harbouring the pQE60-InlA plasmid 
construct were induced with 1 raM IPTG and samples taken every hour. Due to the potential 
toxicity associated with the InlA recombinant protein, particularly at higher growth 
temperatures (37 °C), expressing cultures were evaluated at 30 °C. Time point cell samples 
were resuspended in lysis buffer (2x PBS) and sonicated. The resulting cytoplasmic extracts 
were analysed by SDS-PAGE as shown in Figure 4.13. No apparent expression of any up- 
regulated band in the 80 kDa region was discemable. When the corresponding Western blots 
were probed with an anti-His-tag monoclonal antibody (Section 2.9.17) no obvious band 
development was apparent. However, although not readily visible, when the blot was held up 
to a light source it was possible to barely discern a very faint band in the 80 kDa region of the 
latter stage lysates from clones XGQ3, XGQ4 and XGQ12. Each of these three clones were

then re-analysed. The clones were induced overnight (-10 hrs) and then lysed as before. In 
addition, a duplicate set of samples was lysed in a urea-based denaturing buffer. It was hoped 
that this buffer would combat aggregation or vesicle/membrane localisation of the rlnlA. 
However, when the lysates were subjected to SDS PAGE analysis, there was still no visible 
up-regulation of a band corresponding to the expected rlnlA molecular weight (Figure 4.14, 
top). The corresponding Western blot did, however, develop a slightly reactive band at ~80 
kDa when probed with the anti-His-tag monoclonal antibody (Figure 4.14, bottom).
Despite repeated attempts, it proved impossible to improve the expression levels or even 
achieve reproducible expression levels with the three selected clones. In order to confirm that 
the inlA gene sequence had been faithfully cloned in terms of nucleotide content and was ‘in- 
frame’, XGQ8 was taken as a representative clone and its plasmid DNA was sequenced. The 
XGQ8 -derived plasmid DNA, when translated, demonstrated 100 % homology with the 
native InlA protein (Figure 4.15). This confirmed that the problem was most probably post- 
translational and prompted a fundamental re-assessment of the InlA protein with respect to its 
amino acid content and associated physicochemical properties. It has been reported that 
recombinantly produced proteins with appreciable hydrophobic regions can have a toxic 
effect on host cells (as was also seen with this protein when expressed at even a basal level in 
permissive InvaF' cells), due to association of the protein with, or incorporation into vital 
membrane structures (Qiagen, 2002). The fully translated InlA amino acid content was 
evaluated in terms of its hydrohobicity, using the hydropathic index and associated method 
outlined by Kyte and Doolittle, (1982). The region between amino acid 776 and the C- 
terminus was calculated to exhibit the most pronounced hydropathic characteristics (Figure 
4.16). This corresponded exactly with the LPTTG-anchored cell wall domain and its 
preceding, cell membrane localised sequence. It was thus highly likely that this anchoring 
region, typical of Gram-positive cell wall proteins, was preventing efficient expression of the 
recombinant InlA protein in the Gram-negative E.coli expression host.
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Figure 4.13: Time course analysis o f selected transformants containing the pQE60-inlA 
expression construct. Lysates were prepared in non-denaturing buffer (2x PBS) from 1 ml 
samples taken at time T—0 and six, hourly intervals, plus a T=10hr (overnight) sample, 
following induction at 30 °C with mM IPTG. Time-point samples are indicated with red 
numerals. ‘M l ’ indicates lanes containing SigmaWide ™molecular weight marker. There was 
no discernable up-regulated expression o f rlnlA protein in the anticipated 80 kDa region.
XGQ3
1 2 3 4 5 6 10 l'*1
97kDa 
84 kDa 
66 kDa ^ __
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Figure 4.14: Comparison o f  expression levels following overnight induction when lysates are 
prepared in denaturing (urea-based) or non-denaturing (2x PBS) buffer. Lanes 1, 4 and 7 
contain lysates in 2x PBS buffer prepared from pre-induction cultures o f XGQ3, XGQ4 and 
XGQ12, respectively. Lanes 2, 5 and 8 contain samples from the same set o f cultures 
following overnight induction at 30 °C with 1 mM IPTG, prepared in denaturing buffer. 
Lanes 3, 6 and 9 contain a simlar sample from the overnight, induced cultures, but, prepared
kDa
kDa
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in 2x PBS. Although the SDS PAGE gel (A) did not reveal any remarkable expression in the 
80 kDa region, the corresponding Western blot (B) did develop a weak band (indicated by 
blue arrows) in this region when probed with anti-His-tag monoclonal antibody. This was 
only noticeable in samples that had been prepared in no-denaturing buffer. ‘M l ’ and ‘M2 ’ 
refer to SigmaWide ™ wide range and Pierce BlueRanger ™ (prestained) molecular weight 
markers, respectively.
4.23.2 Sequencing of the clonedfull-length inlA gene sequence
T he resu lts  o f  the  W estern  b lo t depicted in F igure  4 .14, w ere  inconclusive. T he X G 4 clone 
sam ple had  dem onstra ted  the strongest apparen t band  and thus a  sam ple o f  plasm id D N A  
from  th is  c lone w as sent to  M W G -B io tech  (U K ) L td, fo r  sequencing. S equencing  results, 
received  as linear nucleo tide sequences, w ere  subsequently  translated  into am ino acid 
sequences and  aligned  w ith  the know n am ino acid  sequence o f  each  pro te in  using the 
C lustalW  m ultip le  a lignm en t program . A ligned  sequences w ere im ported  into G enedoc, and 
exam ined  (F igure 4 .15). T he cloned inlA gene sequence dem onstrated  100 %  hom ology w ith 
the  correspond ing , com plete  m ature  In lA  p ro te in -encod ing  sequence, p rov ided  by G enedoc 
(reference AJO12346).
T he sequence hom ology  suggested  tha t th e  inlA gene w as being fa ith fu lly  transla ted  and that 
the  d ifficu lties apparen t in the  apparen t expression  and detection  o f  the  recom binant InlA  
pro te in  w ere  rela ted  to  in trinsic com plications w hen  expressed  in the  hetero logous host 
species, E. coli. M ore specifically , it w as fe lt th a t inheren t reg ions o f  localised 
hydrophob icity , com m only  associa ted  cell w all proteins, m igh t be prohib iting  efficient 
so luble  expression  o f  the recom binan t protein. T he sequence data w as subjected  to  a 
hydropathy  pro file  analysis and  a  p rom inen t C -term inal hydrophobic  reg ion  w as revealed 
(F igure 4 . 16). I t w as concluded  th a t th is  represen ted  the  m ost p robable  cause o f  the  w eakly  
detectab le  exp ression  levels.
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Figure 4.15: Alignment o f the cloned inlA gene sequence with the inlA gene sequence 
(accession number AJ012346), derived from Genebank. The nucleotide sequences were 
translated into their respective constituent amino acid sequences 
(//ca.expasy.org/tools/dna.html) and aligned using the online ClustalW program 
(www.ebi.ac.uk/clustalw). The aligned sequences were imported into Genedoc and 
manipulated using Genedoc software (www.psc.edu/biomed/genedoc). Sequences highlighted 
in black demonstrated 100 % homology. I t  was apparent from  these results that the cloned 
protein was 100 % homologous with the native amino acid sequence from amino acids 58- 
800. The only areas o f non-homology were the six histidine residues that had been purposely 
added to the C-terminal o f  the cloned protein and the additional glycine (G) residue at 
position two o f the cloned protein. This was incorporated during the cloning stage to ensure 
that the gene sequence was ‘in-frame ’ when ligated into the pQE60 plasmid.
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Figure 4.16: Hydropathy p lo t o f the complete, 800 amino acid sequence o f native InlA. The 
sequence corresponded to the accession number AJ012346. The plot was approximated by 
calculating the average hydropathy, over Sections (or ‘windows') o f nine amino acids in 
length, traversing the entire sequence using an unbiased, ‘even linear weight variation 
model ’. The average ‘score ’ fo r  each window was plotted against the amino acid position 
using online software (http://ca.expasy.org/cgi-bin/protscale). More hydropathic regions 
were reflected by higher score values. The initial region, comprising the firs t 56 amino acids 
was highly hydropathic. However, this represented the signal peptide region that had not 
been included in the cloned sequence. I t  is clear from the data that the region between amino 
acid 776 and the C-terminus is the most hydropathic region o f the cloned sequence.
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4 .2 .4  C lo n in g  o f  ‘tru n c a te d ’ in lA  g en e  in to  p Q E 6 0
The problems encountered during the attempts to clone the full-length InlA protein (Sections
4.2.2 and 4.2.3), indicated that it may be necessary to remove the problematic hydrophobic 
anchor region. The anchor region is not exposed on the L. monocytogenes cell surface. Thus, 
it was not considered possible that the epitope recognised by mAb2B3 was contained in this 
region. In addition, because the anchor sequence of native InlA is buried in the cell wall of L. 
monocytogenes, it is unlikely to contribute to folding of the extracellular InlA domain. The 
anchor region was therefore, ‘expendable’ in terms of the overall experimental objective, 
which was to confirm the InlA-specificity of mAb2B3.
The primer sequences TAFII-B and TABI (Section 2.9.3) were designed to amplify the major 
extracellular, surface expressed domain of the InlA protein gene. This consisted of the 
complete protein sequence minus the 105 bp hydrophobic C-terminal anchor region. Both 
primers contained ‘clamping’ sequences flanking the restriction site to be incorporated. These 
clamps provided sufficient overhang DNA for efficient digestion of the flanked {Ncol and 
BamHl) restriction sites thus obviating the need for preliminary blunt end TA cloning.
Cloning of the truncated inlA gene sequence was attempted using both Pfu- and Taq- DNA 
polymerase in separate experiments. It was felt that, since the sequence being cloned was ~2.1 
kb in length, use of a high annealing temperature, coupled with the proof reading capacity of 
Pfu should ensure a higher fidelity product.
The respective PCR reaction mixtures were set up as described in Section 2.9.6. The reaction 
program consisted of the following parameters:
Stage Temperature (°C) Time (s)
1 Primary dénaturation 95 300
2 Dénaturation ' 95 60
3 Annealing
4 Extension
>- x 30 cycles
6 6
72
30
300
5 Final extension > 72 600
6  Holding 4 (Indefinate)
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While the TAQ enzyme was added to the reaction mixture prior to stage 1, the Pfu enzyme 
was held on ice and only added to its respective mixture after the primary denaturation stage. 
This was to ensure that none the component primers were degraded by promiscuous 
exonuclease activity. Reaction mixtures that demonstrated a high yield of the specifically 
desired 2.1 kbp inlA amplicon were subjected to purification by ethanol precipitation (Section
2.9.13). The purified PCR products were then digested with BamW\ and Nco\ restriction 
enzymes. Only the P/w-catalysed PCR resulted in successful amplification of the inlA gene 
when performed at the elevated annealing temperature (Figure 4.17). It was thus necessary to 
optimise the annealing temperature for the TAQ and corresponding TAFII/TABI primer set by 
performing a temperature gradient PCR (Figure 4.18). The optimal annealing temperature, 
when using Taq enzyme was 61 °C. Next, the inlA gene was amplified using both Pfu and 
Taq enzyme at their respective optimised annealing temperatures and the inlA amplicons were 
purified by ethanol precipitation. These were subsequently digested using an TVcol/BamHI 
cocktail, and recovered by ethanol precipitation (Figure 4.19) in preparation for ligation into 
compatibly-restricted expression vector.
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Figure 4.17: Comparison o f high temperature annealing on the performance ofPfu and Taq 
DNA polymerase in conjunction with primers TAFII and TABI. The outer peripheral lanes 
consisted o f graduated molecular weight markers. Lane 1, inlA 2.1 kbp sequence successfully 
amplified using Pfu enzyme. Lane 3, indicates unsuccessful amplification using Taq enzyme. 
Lanes 2 and 4 represent negative controls (i.e. no gDNA present) fo r  the respective Pfu- and 
Taq-based reaction mixtures. The outer lanes, designated ‘M ’, contain molecular weight 
markers.

Figure 4.18: Gradient PCR profile fo r  amplification o fin lA  gene sequence using Taq DNA 
polymerase. The lanes 1-6 represent PCR products obtained following annealing at 59.0, 
59.9, 61.5, 63.2, 64.8, 66.5, 68.0 and 69.0 °C. Each lane contained 5 f i l  o f respective fresh 
PCR reaction product. In agreement with the results outlined in Figure 4.17, no amplification 
was apparent at the 66 °C annealing temperature. A fa in t product was evident at the 64 °C 
annealing temperature. However, significant yield o f the desired 2.1 kbp product was only 
achieved at or below 62 °C. The optimal annealing temperature was concluded to be 61.0 °C. 
The peripheral lanes, designated ‘M ’, contain molecular weight markers.

Figure 4.19: Digested Pfu- and Taq-generated inlA sequences, following purification by 
ethanol precipitation. Gel A represents 20 f i l  o f the NcoI/BamHl-digested Pfu-amplified inlA 
sequence. Gel B represents 20 p,l o f the NcoI/BamHl-digested Taq-amplifled inlA insert 
sequence. The inner peripheral lanes, labelled ‘M ’, contained graduated DNA molecular size 
markers.
A duplicate ligation mixture was set up using NcoVBamW I-digested Pfu and Taq amplicons, 
respectively. The composition of the ligation mixture was as follows:
Component Volume (fil)
Insert (digested amplicon) 5
pQE60 vector (Nco\/BamW\ digested) 1.5
10X ligation buffer 1
H2O (molecular grade) 1.5
T4 DNA ligase 1
The separate ligation mixtures were incubated in a heating block overnight (16-18 hrs) at 15.5 
°C and then held on ice prior to transformation into competent E. coli XL 10-Gold cells. 
Freshly transformed cells were spread onto LB agar plates and incubated overnight at 37 °C. 
Non-transformed XL 10-Gold cells were spread onto a similar plate, as a control. On
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inspection after overnight incubation, colonies were only evident on the plates that had been 
inoculated with transformed cells. Ten colonies derived from P^w-amplified inserts and eight 
from Ja^-amplified inserts were selected and innoculated into 10 ml volumes of LB broth in 
sterilie universals. The tubes were incubated overnight at 30 °C and 220 rpm. The low 
temperature (30 °C rather than 37 °C) was employed to reduce the growth rate and safeguard 
against basal transcription and deleterious ‘leakage’ of the potentially toxic InlA protein. All 
of the colonies demonstrated significant growth (as determined by an increase in the ODeoonm 
value) after overnight incubation. In order to ensure that the colonies contained the desired 
pQE60-/«L4 construct, a ‘plasmid prep’ was conducted on a portion of each culture (Section
2.9.14). The presence of the inlA sequence insert was verified by subjecting a sample of each 
purified plasmid to TAQ-mediated PCR with the inlA primer set TAFII and TABI. The correct 
size and orientation of the inlA insert was further confirmed by digesting a sample of 
individual purified plasmid with EcoRi and running it on an agarose gel. The results are 
outlined in Figures 4.20 and 4.21. In order to clarify the information that can be ascertained 
from the digest analysis, a schematic restriction map of the pQE60-/w/yl construct with the 
inlA insert in both the desired and incorrect orientation is provided (Figure 4.22).
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4000 bp -p 
3000 bp >
2 0 0 0  bp >
B
4000 bp 
3000 bp
2 0 0 0  bp
4*
1
Figure 4.20: Analysis o f plasmids bearing Pfu-amplified inlA inserts. The lane numbers 
correspond to the Pfu clone number, from which plasmids were isolated. Gel (A) depicts 
electrophoretic profile o f EcoRI-digested plasmids. The lanes on the left and right extremes, 
designated ‘M ’, contain a graduated DNA molecular weight marker. A ll o f the samples 
exhibited a 3.4 kb band which represented linearlisedpQE60 plasmid. Moreover, a ll except 
sample 4 exhibited a 2.1 kb band, characteristic o f the correctly orientated inlA sequence 
insert. The fact that only a single band o f similar molecular weight to the linearised plasmid 
band was evident in sample 4 suggested that this plasmid was more than likely a result o f re- 
circularisation during the during the ligation stage. Gel (B) illustrates the inlA sequence- 
specific PCR products fo r  plasmid samples 1 to 10. Samples 1, 2 and 4 were run in duplicate 
(denoted '* )  because cross over contamination during the loading process was suspected. 
The results agreed with those in the digest profile insofar as the 2.1 kb inlA sequence 
appeared to be present in a ll but sample 4.
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A M
4000 bp 
3000 bp>>
2 0 0 0  b p > -
B
4000 bp 
3000 bp
2 0 0 0  bp
Figure 4.21: Analysis o f selected plasmids bearing Taq-amplified inlA inserts. The lane 
numbers correspond to the Taq clone number, from which plasmids were isolated. The 
peripheral lanes, designated ‘M ’, contain a graduated DNA molecular weight marker. Gel 
(A) demonstrates the electrophoretic profile o f EcoRI-digested plasmids. Gel (B) represents 
inlA sequence-specific PCR products fo r  plasmid samples 1 to 7. Both sets o f results 
demonstrated a clear agreement and suggested the presence o f the desired inlA sequence in 
a ll seven plasmids tested. They also indicated that the insert was correctly orientated.
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Correct orientation Incorrect orientation
N co  I N co  I
E co  RI
-2.1 kbp 
(2068 bp)
EcoR I
B
EcoR I ^coR I
! - ■I l
<100 bp
N co  I -2.1 kbp 
(2126 bp)
BàmH I N co  I
-2.1 kbp BàmH I
Figure 4.22: Possible restriction profile o f the pQE60-inlA construct with the insert in both 
the desired, or, correct orientation fo r  efficient transcription and the incorrect orientation. 
‘A ’ represents the 5.5 kbp constructs. A single EcoRI restriction site was located 59 bp 
upstream from the 3' terminal o f the inlA sequence being cloned. The fact that the pQE60 
plasmid itself had also, jus t one EcoRI restriction site, 25 bp upstream o f the Ncol restriction 
site made it possible to deduce the orientation o f the insert sequence by means o f a simple 
EcoRI digest. B ’ demonstrates that when the insert is in the correct 5' —*■ 3' orientation the 
pQE60 EcoRI and inlA EcoRI sites are furthest apart resulting in restriction products o f ~2.1 
kbp and 3.4 kbp. When the incorrect orientation prevails, the EcoRI sites are proximal to 
each other and yield a tiny 100 bp fragment. ‘C ’ depicts the excised insert using an 
NcoI/BamHI restriction digest. This digest is independent o f the orientation o f the insert in 
the plasmid as both excised sequences are o f similar molecular weights and would each be 
expected to appear as ~2.1 kbp bands, in addition to a linearised plasmid band o f 3.4 kbp on 
an agarose gel.
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4.2.4.1 Determination o f rlnlA protein expression
Once the clones that contained the correctly orientated pQE60-inlA construct had been 
identified it was necessary to determine whether they were capable of expressing the 
recombinant protein in an active form. Nine selected P/w-derived clones and eight selected 
ZL40-derived clones were induced with 1 mM IPTG overnight (10 hrs) at 30 °C. 1 ml samples 
were then taken from each induced culture and sonicated in 2x PBS buffer. Samples were 
then subjected to SDS PAGE analysis and Western blotting using an anti-His-tag monoclonal 
antibody. All of the Pfu clones, except Pfui demonstrated a clearly up-regulated band at -80 
kDa (Figure 4.23a). Similarly, all except Pfu% contained an ~80 kDa protein recognised by 
anti-His-tag monoclonal antibody (Figure 4.23b). The only Taq clone that failed to generate a 
visible ~80 kDa protein in SDS PAGE, was Taq2 (Figure 4.24a). This was also the only Taq 
clone that failed to be recognised by the anti-His-tag monoclonal antibody (Figure 4.24b). On 
the basis of these results, four positive clones were randomly selected for further evaluation. 
These were ‘TaqY, ‘ Taq5\ ‘Pfu2’ and ‘Pfu9\ When probed with mAb2B3 monoclonal 
antibody, TaqS, Pful and Pfu9 lysates demonstrated strong and specific reactivity (Figure 
4,25). However, Taq\ lysate was not recognised by mAb2B3. This was despite the fact that 
Taq 1 had been earlier confirmed to produce an ~80 kDa protein bearing a His-tag (Figure 
4.24). Such a conflicting result highlights the weakness in relying solely on fusion-tag 
‘flagging’ for determining expression of recombinant proteins. The clone Pfu9 was selected 
for further analysis.
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121.5 kDa
86.95 kDa
2 1 6  kDa
49.8 kDa ►
32.9 kDa
26.4 kD a-^
97 kDa 
84 kDa 
66 kDa
18.2 kDa
216 kD a-^
121.5 kDa "► 
86.95 kDa>>
UjjS Mi/Sf SpfcS InIA band
49.8 kDa-^
32.9 kDa-^
26.4 kDa->-
18.2 kDa ->
Figure 4.23: SDS PAGE (A) and Western blot (B) analysis o f cell lysates from Pfu clones. 
Lysates from all clones, except Pfu8  (indicated by small arrow), demonstrated clearly up- 
regulated expression o f an -80 kDa protein that was specifically recognised with anti-His-tag 
monoclonal antibody. The loading volume was 20 fil throughout. ‘M l ’ and 'M2 ’ refer to 
SigmaWide ™ wide range and Pierce BlueRanger ™ (prestained) molecular weight markers, 
respectfully.
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97 kDa 
84 kDa 
66 kDa
B M2 1 2 3 4  5 6 7 8
216 kDa— ►
121.5 kDa— ►
86.95 kDa— ►
49.8 kDa— ►
A—  InIA band
32.9 kDa-
26.4 kDa—
18.2 kDa— ►
Figure 4.24: SDS PAGE, (A), and Western blot, (B), analysis o f cell lysates from Taq clones. 
Lysates front all clones, except Taq2 (indicated by green arrow), demonstrated clearly up- 
regulated expression o f an ~80 kDa protein that was specifically recognised with anti-His-tag 
monoclonal antibody. The loading volume was 20 fxl throughout. The Taql sample was 
accidentally loaded twice onto the SDS PAGE gel, hence, the extra lane 1. ‘M l ’ and ‘M2 ’ 
refer to SigmaWide ™ wide range and Pierce BlueRanger ™ (prestained) molecular weight 
markers, respectfully.
2 1 0

r5  hr
■ V "
3  hr
Taq 5 Tag 1 Pfu 9 Pfu 2
“  W  H
Taq 5 Taq 1 Pfu 9 Pfu 2 
 ^  ^  ^ ^ M 2
8 6 .9 5  kD a
<4 -  49.8 kDa
Figure 4.2S: Immunoreactivity o f recombinant InlA towards mAb2B3 monoclonal antibody. 
The set o f results on the left hand side represent lysates from cultures induced for 5 hours 
with 1 mM IPTG and those on the right had been induced for just 3 hours. There was no 
apparent difference in the results for 5 and 3 hour induction periods. Lysate samples from 
clones Taq5, Pfu9 and Pfu2 exhibited strong activity when probed with monoclonal antibody 
2B3.Taql lysate exhibited no significant activity. All lysates were prepared in 2x PBS and 20 
jul loading volumes were used throughout. ‘M l ’ and ‘M 2’ refer to SigmaWide ™wide range 
and Pierce BlueRanger ™ (prestained) molecular weight markers, respectfully.
4.2.4.2 Sequencing o f the cloned truncated inlA gene sequence
In order to fully validate the apparent faithful expression of rinlA protein by Pfu9 it was 
necessary to confirm the fidelity of the pQE60-bome inlA gene sequence. Plasmid DNA 
derived from PfiS  was sent to MWG-Biotech (UK) Ltd, for sequencing. The sequence data
2 1 1

was aligned (Figure 4.26), as previously described (Section 4.2.3.2). The cloned truncated 
inlA gene sequence demonstrated 100 % homology with the corresponding, respective 
sequences provided by Genedoc (reference AJ012346 ).
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Figure 4.26: Alignment o f the cloned inlA gene sequence encoding truncated rlnlA, with the 
inlA gene sequence (accession number AJ0I2346), derived from Genebank. The nucleotide 
sequences were translated into their respective constituent amino acid sequences and aligned 
using the online ClustalWprogram (www.ebi.ac.uk/clustalw). The aligned sequences were 
imported into Genedoc and manipulated using Genedoc software. Sequences highlighted in 
black demonstrated 100 % homology. It was apparent from these results that the cloned 
protein was 100 % homologous with the native amino acid sequence from amino acid 58-776. 
The only areas o f non-homology were the six histidine residues that had been purposely 
added to the C-terminal o f the cloned protein and the additional glycine (G) residue at 
position ‘2 ’ o f the cloned protein. This was incorporated during the cloning stage to ensure 
that the gene sequence was ‘in-frame ’ when ligated into the pQE60 plasmid.
4.2.4.3 Time course experiments to optimise rlnlA expression in Pfu9 
Pfu9 rlnlA expression levels were analysed at 25 and 30 °C. Time point cell samples were 
resuspended in 2x PBS buffer and sonicated. The resulting cytoplasmic extracts were 
analysed by SDS-PAGE as shown in Figure 4.25. Lysates from the cultures induced at 30 °C 
exhibited significantly enhanced rlnlA expression at significantly high levels within the 6 
hour analysis window. Optimum expression levels were achieved between 4 and 6 hours of 
IPTG-induced expression at 30 °C.
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4.2.4.4 Determination o f  the optimum IPTG concentration fo r  induction
Experiments to determine the optimum IPTG concentration for induction of recombinant InlA 
expression were carried as previously described in Section 4.2.3.1. Essentially the same set of 
time course experiments were conducted, however, the EPTG concentration was varied over 
the range 0, 0.05, 0.1, 0.5 and 1 mM IPTG. Figure 4.27 shows the corresponding SDS-PAGE 
time course gels obtained over this induction range. No significant levels of expressed rlnlA 
protein bands were observed in the absence of IPTG induction, indicating that E. coli strains, 
such as XL 10 Gold, harbouring the laqP gene, produce sufficient quantities of the lac 
repressor protein to prevent undesired levels of basal expression rlnlA. There was no 
pronounced difference in the level of expression between 0.05 and 1 mM IPTG induction. 
Slight variations in the sonication of each sample can result in the observation of unevenly 
expressed bands on the same gel. Due to the type of sonicator used, exact replication of 
sonication conditions (e.g. exact position and dept of the probe) were difficult to reproduce.
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Figure 4.27: Effect o f IPTG concentration and induction temperature on the expression of 
rlnlA protein over time. The left-hand column represents Pfu9 clone induction at 25 °C and 
the right-hand column represents Pfu9 clone induction at 30 °C. Gels A-E represent inlA gene 
products induced with 0 mM, 0.05 mM, 0.1 mM, 0.5mM and 1.0 mM IPTG, respectively. The 
red number headings refer to the duration o f induction before sampling, (i.e. 0, 1, 2, 3, 4, 5 
and 6 hours, respectively). ‘M l ’ and ‘M 2’ refer to SigmaWide™ (wide range) and 
BlueRanger® (prestained) molecular weight markers, respectively. The expected, rlnlA band, 
is indicated by a green arrow. At 25 °C no significant levels o f InlA protein expression were 
evident. This indicated that rlnlA expression at this induction temperature was slow. It may 
well have been that allowing the induction period to run for longer than just 6 hours would 
have generated a more quantifiable level o f rlnlA. At 30 °C a significant increase in rlnlA 
expression was evident, even at the lowest IPTG concentration, when compared to the 0 mM 
IPTG samples. Moreover, there seemed to be no discernable difference between the level o f 
expression between the 0.05 and 1 mM IPTG samples. Thus, 1.0 mM IPTG was used for all 
further inductions o f clone Pfu9 at an induction/expression temperature o f 30 °C.
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4.2.5 Purification o f the inlA gene product by IMAC
Having selected clone Pfu9 on the basis of its stable production and activity of recombinant 
InlA, it was necessary to optimise the purification process and maximise the yield of pure and 
active product.
Immobilised metal chelate affinity chromatography (IMAC) is a technique by which proteins 
or other molecules can be separated based on their ability to form coordination complexes 
with immobilised metal ions (Porath et al., 1975; Hermanson et al., 1992). The majority of 
chelating groups used in IMAC are multidentate chelating compounds formed by the protein, 
metal ion and chelating group (Ueda et al., 2003). Generally, Histidine residues are 
infrequent, amounting to approximately only 2 % of the amino acid content of globular 
proteins. In addition, only half of these residues are normally exposed on the protein surface 
(Ueda et al., 2003). However, certain proteins from E. coli, namely superoxide dismutase (8 
histidines, 195 amino acids), chloramphenicol acetyltransferase (12 histidines, 219 amino 
acids) and heat-shock protein (14 histidines, 624 amino acids), have been identified, which 
might bind to IMAC columns depending on the conditions used (Muller et al., 1998b). 
Histidine is also the amino acid that exhibits the strongest interaction with immobilised metal 
ion matrices, as electron donor groups on the histidine imidazole ring readily form 
coordination bonds with the immobilised transition metal (Terpe, 2003). Hochuli and co­
workers, (1987) reported the first practical application of histidine-targeted purification. This 
resulted in the development of a nitrilotriacetic acid matrix (NTA resin) currently supplied by 
Qiagen Ltd. (as Ni-NTA coupled to Sepharose® CL-6B) and used widely for routine IMAC 
processes. The hexahistidine tag facilitates binding to Ni-NTA matrices. It is poorly 
immunogenic, and at pH 8.0 the tag is small, uncharged and, thus, does not generally affect 
secretion, compartmentalisation or folding of the fusion protein within the expression host 
(Qiagen, 2000). Purification using polyhistidine tags has been carried out successfully using 
a number of expression systems including bacteria (Wizemann and von Braun, 1999; Rank et 
al., 2001; Brennan et al., 2002), yeast (Kaslow and Shiloch, 1994), mammalian cells 
(Janknecht et al., 1991; Janknecht and Nordheim, 1992), and baculovirus-infected insect cells 
(Kuusinen et al., 1995; Schmidt et al., 1998). Figure 4.28 shows that NTA is a tetradentate 
chelating adsorbent that occupies four, of the six ligand binding sites, within the coordination 
sphere of the nickel ion, leaving two valency sites free to interact with the His-tag.
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Figure 4.28: Momomeric subunit o f Nickel-charged NT A resin. The high affinity coordination 
complex formed by interaction o f the resin-bound Ni2" molecule with histidine residues is 
highlighted by the red coordinate bonds.
4.2.5.1 Optimisation o f IMACpurification process
Retention of activity was of paramount importance in the case of the recombinant InlA 
protein and, as such, it was decided to attempt to optimise purification under native 
conditions. This entailed using a PBS-based, rather than a urea-based lysis buffer. It may be 
argued that the expression level results outlined in the previous section indicate a universally 
low level of recombinant InlA expression. This in turn may be construed as evidence that the 
recombinant protein was being housed in inclusion bodies and that yields might have been 
improved under harsher, ‘denaturing’ lysis conditions. However, previous experience with 
similar proteins, using the same expression system did not support this generalisation. 
Essentially, in this case a lower yield was seen as an affordable payoff for a higher quality end 
product. Given the low expression levels evident it was also decided to use a batch 
purification method (Section 2.9.16) in order to maximise sample:column interaction time and 
maintain strong 6xHis-tag/Ni-NTA retention.
A major consideration when purifying under native conditions, particularly in batch 
purification processes, was the potential for high background contaminants. The first 
consideration was thus, the overall Ni-NTA resin:lysate ratio. Figure 4.27 demonstrates that, 
by reducing the resin volume and diluting the lysate (thereby increasing its volume) it was 
found that purity was improved only slightly. However, the InlA sample loss, evident in the
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flow-through, was also slightly reduced, indicating a small improvement in the process 
efficiency. Nonetheless, the amount of non-specific, contaminating bands was still at an 
unacceptably high level.
Attention next switched to the buffer composition used in the binding and washing stages of 
the purification process. This was principally PBS buffer at pH 6.6 containing 15 mM P- 
mercaptoethanol. The latter was added to prevent co-purification of unrelated host proteins 
that may have become coupled to the recombinant protein of interest via disulphide bonding 
during cell lysis. In order to combat charge-related non-specific ionic interactions occurring, 
the effect of increasing the salt concentration was examined (Figure 4.30). Increasing the 
concentration of NaCl in the buffers from 0.15 (standard PBS), to 0.5 and even 1.0 M NaCl 
did not reduce the binding capacity for the 6xHis-tagged recombinant protein. This was not 
surprising, as Hochuli and co-workers, (1988) had previously demonstrated that the 6xHis- 
tag/Ni-NTA interaction was stable in salt concentrations as high as 6 M guanidine 
hydrochloride. Unfortunately, the highest concentration of NaCl employed in this experiment 
only slightly reduced the proportion of contaminating bands as ascertained in the SDS PAGE 
gel analysis.
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Figure 4.29: The effect ofNi-NTA resin volume and resin: lysate ratio on the yield and purity 
o f IMAC-isolated recombinant InlA protein. Each lane was loaded with a 20 i l l  sample 
volume. The binding/running/washing buffer used throughout was PBS supplemented with 15 
mM p-mercaptoethanol. Lane ‘A ’ represents the eluted fraction obtained from a 1/10 lysate 
(i.e. a 20 ml culture pellet resuspended in 2 mis lysis/binding/running buffer). The volume o f 
Ni-NTA resin used was 1 ml (1:2, resin.lysate ratio). Lane ‘B ’ represents a 1/20 lysate (i.e. a 
20 ml culture pellet resuspended in 4 mis lysis/binding/running buffer). ‘B1 ’ demonstrates the 
result using a 1:4, resin:lysate ratio and ‘B2 ' shows the purified components obtained using a 
1:8 resin:lysate ratio. There was little apparent difference between the results fo r  B1 and B2. 
Lane ‘M l ’ contained SigmaWide ™wide range molecular weight marker. Overall, the results 
indicated that greater resin. lysate ratios resulted in slightly purer yields o f recombinant His- 
tagged protein (probably due to competitive inhibition o f non-specific binding). Moreover, 
when using the higher ratio, the flow  through fraction contained significantly less 
recombinant protein, thereby reducing sample loss.
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By far the most effective means of reducing the non-specific component was to supplement 
the binding and washing buffer with 20 mM imidazole and also to incorporate this during the 
pre-equilibration of the resin. In Figure 4.31 the results demonstrate that the presence of 10 
mM imidazole gave rise to a significant reduction in the amount of co-purified contaminants. 
Increasing the concentration further, to 20 mM, removed almost all of the contaminants. This 
was due to the imidazole ring structure (which is a major component of the histidine 
molecule), ‘mopping up’ excess available nickel binding sites on the Ni-NTA column matrix 
and thus, inhibiting non-specific binding. On the basis of the results obtained, the optimum 
buffer composition for binding and washing was found to be PBS containing 15 mM (3- 
mercaptoethanol, 1 M NaCl and 20 mM imidazole. In addition, as demonstrated in Figure 
4.31, adding 1 % (v/v) of ionic detergent (Tween 20) did not have a deleterious effect on the 
6xHis-tagged InlA/Ni-NTA column interaction and wasrthus, also added to the running 
buffers as a precautionary additive, to prevent non-specific hydrophobic interactions.
The ‘mopping up’ effect of low imidazole concentrations referred to above could have been 
extrapolated to competitively elute the specifically bound 6xHis-tagged protein by simply 
increasing the concentration. Suggested concentrations for elution are reported to be between 
20 and 250 mM (Janknecht et al., 1991; Hefti et a l, 2001; Qiagen, 2002). However, reported 
disadvantages of using imidazole have indicated that it can have negative influences on NMR 
experiments, competition studies and crystallographic studies (Terpe, 2003). Significant 
residual imidazole can also result in protein aggregation (Hefti et al, 2001). With this in 
mind, alternative elution methods were considered.
The highly efficient metal chelating compounds EDTA and EGTA could potentially have 
been employed to elute the recombinant protein as a metal-6xHis-tag-protein complex. This 
however, would have necessitated further processing to remove the ‘stripped’ Nickel ions 
from the eluant. Furthermore, this ‘stripping’ of Nickel from the NTA resin would have 
drastically reduced the lifetime of the column and required it to be recharged with Nickel 
(NiCy after every run. A useful feature of the histidine residues in the 6xHis-tag is that they 
have a pKa of approximately 6.0 and thus become protonated if the pH is reduced to pH 4.5- 
4.3. In such conditions, the positively charged His-tag is no longer able to bind the Ni-NTA 
resin and is eluted. Sodium acetate buffer was chosen and the elution efficiency analysed over 
a broad range of buffer pH values from 5.76 to 4.5. The results indicated that for complete 
elution of bound His-tagged InlA, sodium acetate buffer at a pH of 4.5 was necessary (Figure 
4.31). This pH was close to the isoelectric point (pi) of the native InlA protein (4.93) and the 
predicted pi of the recombinant version (4.92), calculated using online software 
(www.ca.expasv.org/tools/pi tool.html). Hence, eluted fractions were immediately
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neutralised with 1/10 the eluant volume of 1 M Tris-HCl (pH 8.5), to prevent denaturation of 
the recombinant InlA protein.
The full suite of optimised IMAC purification conditions were applied to the preparative, 
large-scale batch purification of rlnlA protein for use in further studies involving the antibody 
‘mAb2B3\ Samples from each stage of the purification process were analysed by SDS 
PAGE to ensure no significant sample loss was occurring (Figure 4.32). Once purified and 
dialysed, the purified rlnlA was probed separately with both anti-His-tag monoclonal 
antibody and the mAb2B3 monoclonal antibody (Figure 4.33). The results confirmed that the 
purification process had not adversely affected the rlnlA protein and what was equally 
significant was that the ability of mAb2B3 to recognise its complementary, InlA-bome 
epitope and the anti-His-tag antibody to bind the C-terminal His-tag sequence had not been 
compromised.
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Figure 4.30: The effect o f salt and imidazole concentration on the purity o f IMAC-isolated 
recombinant InlA protein. Each lane was loaded with a 20 fil sample volume. The 
binding/running/washing buffer used throughout was PBS supplemented with 15 mM /?- 
mercaptoethanol. All samples originated from the same lysate (1/20 original culture volume) 
and were purified using a 1:4 (Ni-NTA:lysate ratio). In lanes 1 and 4 the buffer salt 
concentration had been increased to 0.5 and 1 M  NaCl, respectively. In lanes 2 and 3 the 
buffer contained 1 M  NaCl supplemented with 20 and 10 mM imidazole, respectively. The 
results indicated that increasing the salt concentration from 0.5 to 1 M  NaCl only very 
slightly reduced the amount o f non-specific components in the eluant. However, when 10 mM 
imidazole was present a significant reduction in the overall concentration o f non-specific 
components became evident. Supplementing the buffer with 20 mM imidazole reduced the 
non-specific content even further. It was decided not to increase the imidazole concentration 
further as this could have competitively inhibited binding o f the recombinant InlA protein to 
the Ni-NTA resin. Lane ‘M l ’ contained SigmaWide ™wide range molecular weight marker.
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Figure 4.31: The effect o f detergent concentration and elution pH  on the purity o f IMAC- 
isolated recombinant InlA protein. Lane ‘M l ’ contained SigmaWide ™wide range molecular 
weight marker. The binding/running/washing buffer used throughout was PBS containing 15 
mM ft-mercaptoethanol and 1 MNaCl. Each lane was loaded with a 20 pi sample volume. 
All samples originated from the same lysate (1/20 original culture volume) and were purified 
using a 1:4 (Ni-NTA:lysate) ratio. In lanes A and B the buffers used contained 0.5 and 1.0 % 
(v/v) Tween 20, respectively. There appeared to be no significant difference between the 
degree o f apparent purity between samples A and B. The set o f samples grouped under ‘C ’ 
represent a sequential gradient elution using 100 mM sodium acetate buffer at pH  5.76 to 4.5. 
The running buffer in this case, was similar to that used for sample ‘B ’ (i.e. containing 1 % 
v/v Tween20). These results indicated that for complete elution o f the recombinant InlA 
protein, a pH  o f 4.5 was required.
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Figure 4.32: Purification o f the recombinant InlA protein by immobilised metal affinity 
chromatography (IMAC). The Pfu9 clone was subcultured from an overnight culture at 1/20 
into fresh LBB (containing ampicillin, tetracycline and 1 % (v/v) glucose), grown to an
O.DfflOnm o f 0.6 and induced with 1.0 mMlPTG for 5 hours at 30°C. After 5 hours the cells 
were centrifuged for 20 minutes at 4000 rpm and the pellets resuspended in binding buffer 
(PBS containing 0.5 MNaCl, 20 mM imidazole, 15 mM fi-mercaptoethanol) to a volume o f 
1/20 the original culture volume and sonicated. Cell lysates were incubated with Ni-NTA 
resin (1/4 the lysate volume, pre-equilibrated with binding buffer) for 1 hour 30 minutes at 
room temperature with constant mixing. The mixture was then centrifuged at 4000 rpm at 6  
°C for 5 minutes and the supernatant decanted into a fresh tube (flow through). The Ni-NTA 
pellet with bound His-tagged protein was washed 3 times with PBS/T containing 0.5 M  salt 
and 10 mM /3-mercaptoethanol. Bound His-tagged proteins were eluted by incubation with 5 
mis 100 mM sodium acetate buffer (pH 4.5) and neutralised with a 1/10 volume 1M Tris-HCl, 
pH  8.5. The resultant eluate was dialysed extensively against PBS and concentrated using a 
Centricon ™ ultra-filtration tube with a 10 kDa cut-off. Purified proteins were stored at -20° C 
until required. Samples from each stage o f the purification process (labelled on gel) were 
analysed by SDS PAGE to estimate the degree o f purity and efficiency o f the overall process.
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'M l ' and ‘M2' refer to Sigma Wide ™ wide range and Pierce BlueRanger™ (prestained) 
molecular weight markers, respectfully.
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Figure 4.33: Immunoreactivity o f purified recombinant InlA. Lanes designated 'M2', 
contained BlueRanger ™ molecular weight marker. Panel ‘A ' represents the purified rlnlA 
protein following immuno-probing with mAb2B3 monoclonal IgG2a antibody and secondary, 
AP-Iabelled caprine anti-IgG2a antibody. Panel 'B ’ demonstrates the same band following 
imnnmoprobing with murine HRP-labelled anti-His-tag monoclonal antibody.
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4.3 Summary and conclusions
The previous chapter outlined the production of three panels of monoclonal antibodies to 
intact L. monocytogenes cells and L. monocytogenes-derived proteins. It also concluded that 
the most promising monoclonal antibody, in terms of specificity towards L. monocytogenes 
cells, was that which had been designated ‘mAb2B3\ Analysis of the specific reactivity of 
this antibody towards a single, cell surface-derived protein (-80 kDa), led to the postulation 
that the antigen being recognised was possibly Intemalin A (InlA). In order to confirm this, it 
was essential to derive a pure source of InlA protein and demonstrate specific reactivity of 
mAb2B3 towards it. In the absence of any published protocol for extraction of native InlA 
from L. monocytogenes cells, it was necessary to produce a recombinant version of the 
protein.
Genomic DNA was extracted from L. monocytogenes serotype l/2a cells, using guanidium 
thiocyanate, and this was then used as the source material for PCR-based amplification of the 
inlA gene sequence. Initially the gene sequence encoding the full-length protein (minus the N- 
terminal signal sequence) was cloned into a pCR2.1 vector using a TA cloning kit and 
transformed into E. coii XLIO-Gold® cells. Transformants containing the desired pCR2.\-inlA 
construct were selected using blue-white screening on LB agar plates containing X-gal 
reagent and were confirmed to contain the inlA insert by a combination of site-specific 
restriction and inlA gene-specific PCR. A pCR2A-inlA plasmid construct was purified from a 
selected clone and digested with BamRl and Ncol enzymes, before being directionally 
cloned into a pQE60 expression plasmid and transformed into competent E. coli XL 10-Gold® 
cells. Successful transformants were again identified by inlA gene-specific PCR and EcoR\- 
restriction. The latter was made possible by virtue of a single Eco\\l site being present on the 
native pQE60 plasmid several bps before the 5' Ncol insert ligation site and a second EcoR\ 
site being introduced into the construct several bps before the 3' BamHl insert ligation site 
when the insert was in the desired orientation. This construct positioned a 6xHis sequence at 
the C-terminal end of the rlnlA protein.
Sequence analysis of the selected E. coli-borne pQE60-inlA plasmid construct indicated a 100 
% homology with the known published sequence. However, when the selected clone was 
tested for specific InlA expression by SDS PAGE analysis of lysed cell cytoplasmic extract 
and subsequent immunoprobing with an anti-His-tag monoclonal antibody, results were 
somewhat inconclusive. Only very faint bands were evident upon immunoprobing samples 
that had been lysed under both native and denaturing conditions. A reassessment of the
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strategy employed led to the conclusion that the most probable cause of this apparent lack of 
expression lay within the structure of the recombinant protein being expressed. More 
specifically, the presence of the hydrophobic cell wall anchoring domain was likely rendering 
the expression inefficient. Recombinant proteins with appreciable localised hydrophobic 
regions can have a toxic effect on host cells, most likely due to the association of the protein 
with or incorporation into vital membrane systems (Qiagen, 2002). The effect can be acute or 
chronic, whereby the toxic protein primarily reduces the growth rate of the host cells. The 
highly efficient transcription rates afforded by the optimised promoter regions on the 
expression plasmid exacerbate the negative effect on growth rates. This is even further 
compounded by metabolic demands imposed by translation of the recombinant protein. Even 
if only mildly toxic, as indicated by an initial poor level of expression for a given host cell 
culture this would, however, undoubtedly place a selective pressure on the host cells in favour 
cells bearing mutated, non-expressing plasmids. This would also explain why it was not 
possible to propagate /'«^-transformed cells that did not harbour the lacP genotype and were, 
thus, inherently subject to ‘leaky’ basal expression.
Therefore, the inlA gene sequence was cloned a second time. However, in addition to the 
sequence encoding the N-terminal signal peptide, the sequence encoding the 34 amino acid 
long C-terminal hydrophobic region was also excluded. At all times the overriding objective 
remained clear; that the recombinant product should retain activity towards the monoclonal 
antibody ‘mAb2B3’ (if this was in fact an InlA-specific antibody). The antibody had been 
raised against intact L. monocytogenes cells and thus, the removal of the signal sequence was 
not expected to affect the recognition process, since this would not have been present on the 
cell-bound version presented during immunisation and primary B-cell development. 
Likewise, the C-terminal region, being located principally in the sub cell wall, transmembrane 
region would not have been exposed on the intact cell. The truncated version was, therefore, 
expected to contain all the amino acid sequences necessary for correct functional folding and 
consequently for recognition by an InlA-specific antibody. The truncated inlA gene was 
‘directionally’ cloned, into pQE60, thus, bypassing the TA cloning step and the associated 
complications earlier encountered with this method. This was made possible by employing 
primers that contained suitable ‘clamp’ sequences flanking the BamHl and Ncol restriction 
termini. In addition, high fidelity Pfu polymerase was used in the inlA PCR amplification, 
thereby, obviating the need to perform confirmatoiy sequence analysis during the preliminary 
cloning stages.
Expression of the rlnlA protein was investigated by SDS PAGE analysis of sonicated cell 
lysates in 2x PBS buffer, following optimised IPTG induction. Specific expression of an 80
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kDa protein band was demonstrated only in cells containing the complete pQE60-mL4 
construct. No 80 kDa band was detectable in cells harbouring pQE60 alone. The 80 kDa 
protein also reacted specifically with an anti-His-tag monoclonal antibody in Western blot 
analysis, thus, confirming that the His-tag fusion had been faithfully translated, was 
accessible and had not been adversely affected during cell lysis.
Finally, purification of the His-tagged rlnlA protein was optimised using Ni-NTA resin and 
the purified rlnlA was shown to specifically react with the monoclonal antibody emAb2B3’. 
The latter was thus, confirmed to be an anti-lnlA antibody.
To the best of my knowledge, this represents the first reported heterologous expression, in E. 
coli, of the complete extracellular domain of InlA with a 6xHis fusion tag suitable for rapid 
and efficient purification.
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5.1 Introduction
The use of biosensors for detection of pathogenic bacteria (Ivnitski et al., 1999) and in 
particular, for the detection of foodbome pathogens (Haines and Patel, 1995; Rand et al., 
2002; Leonard et al., 2003; Deisingh and Thompson, 2004a; Leonard et al., 2004 and 
Leonard et al., 2005) is gathering increasing prominence in the vast food-pathogen detection 
market (Alocilja and Radke, 2003). This is undoubtedly a direct result of the increasing 
industry-driven demand for rapid ‘sample-to-result’ analyses that can be automated and 
integrated ‘on-line’.
5.1.1 Definition o f  biosensors
A biosensor is best described as ‘a compact analytical device incorporating a biological or 
biologically-derived sensing element that is either integrated within, or intimately associated 
with a physico-chemical transducer’ (Turner et al., 1997). The main transduction technologies 
employed in biosensor formats measure analyte-induced changes in optical, electrochemical 
or piezoelectric properties and are comparatively reviewed by Diamond, (1998) and Quinn 
and O’Kennedy, (1999).
The relative merits of each of the biosensor formats/categories, with specific reference to their 
capacity to mediate detection of bacterial entities, have been comprehensively reviewed 
elsewhere (Ivnitski et al., 1999; Patel, 2002; Deisingh, 2003; Leonard et al., 2003; Deisingh 
and Thompson, 2004b). Optical transducers are particularly attractive for application to direct 
(label-free) detection of bacteria (Ivnitski et al., 1999). The research described in this chapter 
is restricted to the use of an optical biosensor that exploits the surface plasmon resonance 
(SPR) phenomenon, which, according to current market and research trends (Homola et al., 
1999a; Baird and Myszka, 2001; Rich and Myszka, 2001) is predicted to become one of the 
most widely used immunosensor platforms over the next 10 years.
5.1.2 History o f  surface plasmon resonance sensing
Optical SPR was first demonstrated in 1968 by Otto. The technique found its first practical 
application as a tool for characterising solid phase media, such as thin films (Raether, 1977; 
Pockrand et al., 1978) and monitoring processes at electrochemical interfaces (Gordon II and
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Ernst, 1980). It was first employed in a sensing format for gas detection (Nylander et al., 
1982) and subsequently, was adapted for ‘immuno-biosensing’ of a specific antibody-antigen 
interaction (Liedberg et al., 1983). These developments employed the ‘Kretschman 
configuration’ (Kretschman and Raether, 1968; Kretschman, 1971), which is more 
appropriate than the ‘Otto configuration’ for solution-phase sensing, typically required in 
clinical, food and environmental diagnostics. This technology was refined and optimised for 
biosensing applications and led to the commercialisation of the Biacore™ SPR biosensor in 
1990 (Lofas et al., 1991; Liedberg et al., 1995) for generic biospecific/biomolecular 
interaction analysis (BLA) (Malmqvist, 1999).
5.1.3 Theory o f  surface plasmon resonance biosensing
An appreciation of the physico- and electro-chemical basis of SPR sensing (Salamon et al., 
1999; Liedberg and Johansen, 1998) requires a basic understanding of total internal reflection, 
evanescent wave and surface plasmon theory.
Total internal reflection (TIR) occurs at the interface between two non-absorbing materials 
when light impinges on the interface at or above an angle, specified as the critical angle (0C). 
Although no refraction occurs and the intensity of the reflected light is equal to the incident 
light intensity, a weak electrical field intensity component (evanescent wave) leaches 
perpendicularly into the lower refractive index medium and penetrates to a depth of 
approximately one wavelength, its amplitude decaying exponentially with increasing distance 
from the interface. If the interface is coated with a non-magnetic, noble-metal film that is 
much thinner (d=50 nm) than the wavelength of the incoming visible light (X= 400-800nm, 
760 nm in Biacore™), a p-polarised charge density oscillation manifests at the metal/ambient 
dielectric interface. This is referred to as a surface plasmon wave. Gold thin films are 
preferred due to their demonstrated chemical resistance and tendency to produce strong 
plasmons and consequently, sharp reflectance minima (De Bruijn et al., 1992).
Under conditions of TIR and when the energy and momentum of the incident light exactly 
matches that of the surface plasmon wave (i.e. when the vector component of the p-polarised 
incident light parallel to the interface, ‘Kx’, is equal to the surface plasmon wave vector, 
‘Ksp’), a resonance condition is achieved. Resonance results in an increase in energy 
‘coupling’ from the incident light, culminating in an enhanced evanescent wave field that is 
concomitantly reported as a decrease in the intensity of the reflected light. This can be ‘tuned’
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by varying the wavelength or angle of the incident light. The main disadvantage of the latter 
method is the requirement for complex, bulky and slow optical angle scanning components. 
However, this is overcome by employing a wedge-shaped incident beam (Matsubara et al., 
1988a; Matsubara et al., 1988b) that comprises a continuum of pre-defined incident angles 
and a photodiode detector array that can accurately extrapolate the angle at which the 
reflected light intensity is minimal ( 0 s p r ) .  Thus, when the prism, incident wavelength, metal 
properties and temperature are kept constant, 0spr varies only in response to changes in the 
refractive index of the ambient medium (n2), which is directly influenced by bio-specific 
binding events at the metal surface that occur within the approximate 300nm range of the 
enhanced evanescent field. The refractive index change can be directly related to the progress 
of the binding event (Stenberg et al., 1991) by:
AC = A/j](8C/8ni) (Equation 5.1)
Where 8C/8«i = 5-7g/cm3
A/j i = refractive index of sample,
and AC = protein concentration.
The change in position of 0 Sp r  is quantified in response units (RUs) and is monitored in ‘real­
time’ as a function of time in a sensorgram.
There are a variety of Biacore™ sensor chips available (http://www.biacore.com) for general 
or specific applications. The majority incorporate a carboxymethylated (CM) dextran surface. 
This functions as an extended 3D-coupling matrix or ‘hydrogel’ (Lofas and Johnsson, 1990) 
and increases both the binding capacity and dynamic range of the biosensor. The most 
commonly used sensor chip is the ‘CM5’ chip, which possesses a hydrogel -100 nm thick. 
For such a surface, a 1000 RU change corresponds to a 0.1° shift in 0spr and a change in 
surface concentration of ~1 ng/mm2 (Stenberg et al., 1991). Assuming a 100 nm thick 
hydrogel, this corresponds to an effective surface concentration of 10 mg/ml. Generally the 
measured change in surface refractive index is independent of the protein/peptide type, 
although it can vary for more complex molecules, such as glycoproteins, lipids and nucleic 
acids (Stenberg et al., 1991; Hashimoto, 2000; Hahnefeld et al., 2004). The hydrogel also 
serves to create a hydrophilic environment with a low propensity for non-specific binding. 
The extensive carboxylation provides convenient sites for covalent attachment of amine 
containing molecules.
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SPR biosensors have a number of advantages over traditional immunoassays and these were 
highlighted by Canziani et al., (2004), as follows:
1. SPR technology can be used to measure complex formation without labelling of the 
reactants.
2. Complex formation can be monitored in real-time, providing detailed information 
about the kinetics and equilibrium dissociation constants.
3. Samples from crude preparations may be analysed.
In addition, the Biacore™ system is fully automatic, incorporates a reliable microfluidic 
system that facilitates accurate and precise sample delivery and flow-rate manipulation. 
Significantly, it also permits multi-channel analysis and thus, reference-subtraction (Ober and 
Ward, 1999), which is useful for comparative analyses and is a quintessential prerequisite for 
kinetic and affinity estimations. A significant advantage of SPR over optical detection 
techniques is that the incident light energy does not actually penetrate the bulk sample and 
thus, measurements can be made equally on coloured or turbid solutions and on clear clear 
samples (Markey, 2000). Typically Biacore™ and SPR/evanescent wave-based technologies 
have been routinely used for analysis of small molecules. With specific reference to 
foodstuffs, these include hormone (Gillis et al., 2002), antibiotics (Haasnoot et al., 2003) 
residues and small molecules that are indicative of microbial contamination such as microbial 
toxins (Homola etal., 1999b; Daly etal., 2000; Rasooly, 2001).
An overview of the Biacore™ system principles is provided in Figure 5.1. For a 
comprehensive treatment of the general principles and applications of Biacore™, the reader is 
directed to the dedicated text of Nagata and Handa, (2000). The technology and 
instrumentation underpinning SPR-based biosensors itself is well established. The most 
crucial determinant of assay performance undoubtedly surrounds the biospecificity 
component, more specifically, the choice of ligand and the immobilisation strategy. This is 
limited by the availability of suitably specific and stable receptor ligands. The role of ligand 
can be filled by molecules such as, antibodies, natural biological receptors or nucleic acids 
(McCormack et al., 1998; Rogers, 1998). Most commonly, antibodies are used as current 
technologies allow for the production, selection and engineering of antibodies with the 
desired degree of specificity, affinity and physicochemical robustness for optimal 
performance as the biospecific component of biosensors (Alfthan, 1998; Fitzpatrick et al., 
2000; Benhar et al., 2001; Hock et al., 2002).
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Figure 5.1: Evanescent wave theory cmd surface plasmon resonance at a metal-dielectric 
interface. S; and e2 refer to the dielectric constants o f the prism and ambient media, 
respectively. These constants determine the complex indices o f refraction o f each media (N; 
where N  = n-ik; i = V-/; k = the extinction coefficient and n = refractive index), according to 
s = N2. Total internal reflection occurs at 6>dc = arcsin (Ve/V £]), where Ve/ >V £2 and thus, 
ni > n2 and an evanescent wave (Ej) extends across the metal film, decaying exponentially 
into the ambient medium. When the p-polarised incident light vector (Ky), parallel to the 
incident plane, matches exactly the surface plasmon wave propagation vector (KSP), energy 
from the incident light is coupled into the surface plasmon wave and leads to an enhancement
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o f the net evanescent field (E^) and reduction in the intensity o f the reflected light. That is, 
surface plasmon resonance occurs when Kx = KSPi where; Kx = (’m/c).Etu2 sinQspR and KSP = 
(co/c).)N (bq)(s2)/(£o+S2)}. (o = frequency o f the incident light and surface plasmon wave 
(2itc/X), p,q = dielectric constant o f the metal and c = speed o f light in a vacumn. Thus, the 
resonance condition can be timed by keeping the p-polarised incident wavelength (X) constant 
and varying the incident angle (9), until Kx  = KSP, or vice versa. Furthermore, assuming e0 
»  62, it follows that sinO spR go e2 00 «2 and thus, when £;, So and X are held constant, A Ospr  i s  a 
function o f mass changes caused by molecular binding events at the surface. (Adapted and 
amended from Liedberg and Johansen, 1998; Salomon et al., 1999).
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Figure 5.2: Schematic overview o f BIA process using Biacore ™ instrumentation. A light 
emitting diode (LED) emits light at 760 nm, which is then p-polarised and focused as a 
wedge-shaped beam (of multiple, defined angles) onto the sampling area. Under ambient
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conditions, with continual buffer flow over the sensor chip surface, a reflectance dip (the SPR 
minima) or ‘shadow is detected by a PDA detector, for 0SPIU. When analyte, (e.g. antigen) 
that is complementary to the immobilised ligand (e.g. antibody), is passed over the sensor 
chip surface it binds to the ligand and causes an increase in the mass concentration at the 
surface o f the sensor chip and thus, an increase in the ambient refractive index close to the 
surface. This is detected as a shift in the angular position o f the ‘shadow ’ (6Sp r 2) .  A 6Sp r  is 
measured in response units (RU) and it is monitored in real-time, with an adjustable data 
collection frequency o f 1-10 Hz, on a sensorgram.
The Biacore™ instrument is an extremely useful tool for rapidly evaluating antibody-antigen 
interactions, and throughout this chapter, it was employed as such, with respect to the 
monoclonal antibodies isolated in Chapter 3. The ELISA-based detection of L. 
monocytogenes cells (Section 3.2.7) was essentially, an indirect measurement, where solution- 
phase binding of mAb2B3 to cells was reported as an inversely proportional signal response. 
Moreover, the ELISA assay, by its very nature, incorporated multiple incubation stages, in 
addition to intermittent washing steps.
The key objective of this chapter was to assess the potential of using the SPR-based approach 
to monitor direct, real-time binding of L. monocytogenes cells to immobilised L. 
monocytogenes-specific antibody (mAb2B3).
238

5.2 Results and discussion
5.2.1 Direct detection o f  L. monocytogenes cells using surface plasm on resonance
The monoclonal antibody (mAb2B3) was chosen based on its demonstrated capacity to bind 
whole L. monocytogenes cells (Section 3.2.6.4) specifically via the InlA protein (Sections
4.2.4 and 4.2.5). In order to facilitate cell binding at the sensor chip surface, it was necessary 
to stably attach the antibody to the surface. Thus, a sequence of exploratoiy experiments was 
conducted, to find the optimal immobilisation strategy and sensor chip substrate-matrix 
compatability.
5.2.1.1 Pre-concentration o f mAb2B3 monoclonal antibody onto the CM5 sensor chip 
surface
Pre-concentration was assessed empirically, on a single flow cell of a freshly primed CM5 
sensor chip surface (Section 2.10.1). The first consideration when designing the assay was to 
achieve efficient immobilisation of the monoclonal antibody. Efficient pre-concentration 
serves to concentrate the antibody to very high levels within the immediate vicinity of the 
dextran hydrogel and thus improve coupling yield to the activated carboxyl branches. Optimal 
pre-concentration is mediated by maximising the electrostatic interaction between the 
negatively-charged carboxymethylated dextran and the antibody. The antibody was prepared 
in a low ionic strength buffer, 10 mM sodium acetate (to minimise charge screening) at a 
range of pH values below the anticipated pi of immunoglobulin proteins (to confer a positive 
charge on the antibody molecule). Amine coupling, mediated by EDC/NHS surface-activation 
(Johnsson et al., 1991; O’Shannessey et al., 1992; Barie and Rapp, 2001) was employed 
throughout these studies and since activated carboxyl groups react best with uncharged amino 
groups, the highest buffer pH generating appreciable pre-concentration was chosen as the 
carrier buffer for immobilisation. In the case of mAb2B3, this was determined to be pH 4.0 
(Figure 5.3a).
5.2.1.2 Pre-concentration o f  IgG2a control antibody onto the CMS sensor chip surface
In order to facilitate reference-subtraction of bulk refractive index, systematic deviations, 
temperature drift and matrix effects, it was decided to conduct sample analysis in parallel, by 
simultaneous sample exposure to L. monocytogenes-specific (mAb2B3)- and a control 
(IgG2a)-immobilised surface (Sections 2.10.3). Blank dextran or dextran that had been 
subject to EDC/NHS activation and capping in the absence of a coupling ligand have been
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frequently employed in this capacity. However, as mAb2B3 is an IgG2a monoclonal 
antibody, it was felt that an unrelated murine IgG2a antibody would serve as the most suitable 
control, since it would be expected to most closely replicate the ligand topography exhibited 
by the mAb2B3 test surface. Thus, a commercial, affinity-purified murine IgG2a standard 
was sourced (Sigma, M-9144) and it was subjected to the same pre-concentration evaluation 
as mAb2B3 (Section 2.10.1). For this particular antibody, optimal pre-concentration was 
achieved at pH 4.4 (Figure 5.3b).
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Figure 5.3: Antibody pre-concentration analyses. (A): pre-concentration of mAb2B3 onto the 
CMS sensor chip surface. Maximum pre-concentration was observed at pH 4.0. (B): pre­
concentration of IgG2a standard onto the CM5 sensor chip surface. Maximum pre­
concentration iras observed at pH 4.4. Thus 10 mM sodium acetate buffer at pH 4.0 and 4.4 
were chosen as the immobilisation buffers for mAb2B3 and the standard IgG2a antibodies, 
respectively.
2 4 1

5.2 .1 .3  Im m obilisa tion  o f  m A b2B 3 on to  CM S sen so r  ch ip
Protein A affinity-purified mAb2B3 was diluted to 100 (ig/ml in 10 mM sodium acetate 
buffer at pH 4.0 and passed over a freshly EDC/NHS-activated CM5 surface in flowcell 
position 4 (Section 2.10.2). This was followed with a ‘capping’ step, mediated by exposure to 
1 M ethanolamine for 11 minutes and a brief acid/base purge to remove loosely bound 
material. A final immobilised level o f-30000 RUs was achieved (Figure 5.4).
For the purposes of reference subtraction, the flowcell surface immediately downstream of the 
mAb2B3 active surface (flowcell surface 3) was immobilised with an equivalent level of the 
IgG2a control antibody (Section 2.10.3). The degree of non-specific binding to the control 
surface was challenged by simultaneously passing L. monocytogenes cells at 1.07 x 109 
cells/ml in HBS buffer over the mAb2B3 and control IgG2a surfaces. While a response in 
excess of 1200 RUs was achieved on the mAb2B3 surface, negligible binding was apparent 
on the control surface (Figure 5.5). This can be attributed to the high degree of 
immunospecificity of mAb2B3 with respect to L. monocytogenes cells and also to the NaCl 
and detergent content (150 mM and 0.05 % (v/v), respectively) in the sample and running 
buffer.
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Figure 5.4: Immobilisation of mAb2B3, anti-InlA monoclonal antibody onto the CMS sensor 
chip surface. (A) EDC/NHS activation, (B) binding of mAb2B3, (C) capping of unreacted 
groups, (D and E) regeneration pulse of 5 mM NaOH and 5 mM HCl, respectively. A final 
level of28931.8 RUs covalently attached mAb2B3 was achieved.
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5 .2 .1 .4  A ssessm en t o f  specific  cell-b in d in g  p o te n tia l o f  m A b2B 3-C M 5 sen so r su rface:
It was clear that the amine coupling method resulted in a large amount of mAb2B3 efficiently 
coupled to the CM5 surface (Section 5.2.1.3). However, since this coupling procedure results 
in randomly cross-linked ligand, it was necessary to establish whether the intrinsic, L. 
monocytogenes cell-binding capacity of mAb2B3 had deteriorated significantly, following 
immobilisation. Fresh, LEB-cultured L. monocytogenes cells were washed, resuspended in 
PBS buffer at approximately 1.07 x 109 cells/ml and simultaneously passed over both the 
mAb2B3-CM5 and IgG2a-CM5 surfaces at a flow rate of 1 pl/min. While the response at the 
control surface remained essentially at the baseline level throughout, a clear kinetic 
association was observed for the mAb2B3 surface (Figure 5.5). The interaction was allowed 
to proceed for 15 minutes, to approach equilibrium. It was clear that the immobilised 
mAb2B3 retained sufficient activity to mediate binding of L. monocytogenes cells at the 
sensor surface. Binding of rlnlA to the mAb2B3-cm5 surface was also clearly demonstrated 
(Figure 5.6).
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F igure 5.5: Real-time comparison of the mAb2B3-CM5 and control IgG2a surface binding- 
respouses to L. monocytogenes. Approximately 1.07 x lGr cells/ml L. monocytogenes cells in 
PBS were simultaneously passed over both surfaces at a flow rate of 1/il/min. The 
sensorgram clearly shows that there was substantial binding of L. monocytogenes cells to the
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mAb2B3 surface (red) at the concentration employed. Conversely, there was no apparent 
binding to the reference surface (blue). As the L. monocytogenes cel! concentration used here 
was equivalent to the highest cell concentration used in all subsequent experiments, it was 
assumed that the chosen control surface was sufficient and underlined the cell-specijicity of 
the mAb2B3 monoclonal antibody.
Time (s)
Figure 5.6: Real-time comparison of the mAb2B3-CM5 (red) and controI-IgG2a (green) 
surface binding-responses to rlnlA protein. Neat, freshly purified rlnlA (Section 4.2.5) was 
simultaneously passed over both surfaces at a flow rate of 10 pl/min. The appreciable 
reference-subtracted response (red) re-affirmed that the immobilised mAb2B3 antibody was 
specifically binding to lnlA protein.
2 4 4

5.2 .1 .5  S E M  a n d  A F M  im age  analysis o f  m A b 2B 3-cap tu red  L. m on ocytogen es ce lls  on  
m A b2B 3-im m obilised  sen so r ch ip  su rface
In  o rder to  visualise the bound L . monocytogenes cells on  the  senso r ch ip  surface SE M  and 
A F M  im age analysis (S ection  2 . 12)  w as perform ed (F igure  5 .7).
A ■  I ■ : u s a
B
40.19 jjm
F igure 5 .7 : S E M  (A) and A F M  (B) a na lysis o f surface topography o f the sensor chip surface 
w ith mAb2B3-captured L . monocytogenes cells. The injected ce ll concentration corresponded 
to ~ 4 .74 x  108 cells/m l.
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5 .2 .1 .6  Im m obilisa tion  o f  m A b2B 3 on to  C l  sen so r chip
It has been suggested that the use of planar surfaces can eliminate certain problems relating to 
diffusion of ligates through a dextran matrix (Schuck, 1996), particularly if measuring whole 
cell binding (Leatherbarrow and Edwards, 1999). The main reasoning behind this theory is 
that the distance between the effective evanescent sensing region and bound cells is reduced, 
since there is no hydrogel barrier, thus, favouring an improved response-to-cell concentration 
ratio. This strategy was investigated for the mAb2B3-Z. monocytogenes capture interaction, 
by coupling mAb2B3 to a Cl sensor chip surface. This possesses a planar, carboxylated 
surface that supports the same immobilisation chemistry as CM dextran surfaces, but lacks a 
dextran matrix. The mAb2B3 antibody was coupled to the Cl surface using ostensibly the 
same conditions as for the CM5 surface (Section 5.2.1.3). However, the coupling 
concentration was increased to 200 ng/ml of antibody and an extended activation time was 
incorporated to maximise ligand immobilisation potential and compensate for the expected 
reduction in net immobilisation due to absence of hydrogel matrix. Even with these 
precautionary amendments to the immobilisation procedure, the mAb2B3 level achieved was 
only 1709 RU (Figure 5.8).
5 .2 .1 .7  A ssessm en t o f  sp ec ific  ce ll-b in d in g  p o te n tia l o f  m A b 2 B 3 -C l sen so r  su rface  
Fresh, LEB-cultured L. monocytogenes cells were washed, resuspended in HBS buffer at 
approximately 1.07 x 109 cells/ml and simultaneously passed over both the mAb2B3-Cl and 
control-Cl surfaces at a flow rate of 1 fil/min. In this case the control consisted of a blank Cl 
surface that had been activated and capped in the absence of ligand. It was clear from the 
resulting binding profile that, even after 10 minutes exposure to the L. monocytogenes sample, 
that there was no significant binding to either the mAb2B3-Cl or control-Cl surfaces and 
consequently, no net binding response (Figure 5.9).
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Figure 5.8: Immobilisation of mAb2B3, anti-InlA monoclonal antibody onto the Cl sensor 
chip surface. (A) EDC/NHS activation, (B) binding of mAb2B3, (C) capping of unreacted 
groups and (D), regeneration pulse of 5 mM HC1. A final level of 1709.08 RUs covalently 
attached mAb2B3 was achieved.
Figure 5.9: Real-time comparison of the mAb2B3-Cl (red) and control-Cl (blue) surface 
binding-responses to L. monocytogenes. Approximately 1.07 x 109 cells/ml L. monocytogenes 
cells in HBS were simultaneously passed over both surfaces at a flow rate of ljil/min. The 
negligible reference-subtracted response (green) indicated a clear failure of the planar 
biointerfacial assembly to capture L. monocytogenes cells under the operating conditions 
employed.
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5.2.1.8 C ritica l explanation  o f  fa c to rs  con tribu tin g  to  L. m on ocytogen es c e ll cap tu re
It was initially, somewhat surprising to discover that the planar surface failed to perform 
better, or even on a par with the dextranated surface.
The feasibility and reliability of direct, covalent attachment of antibodies to 
carboxymethylated dextran surfaces has been widely validated (Buckle et al., 1993; Johnsson 
el al., 1995; Brynda et al., 1999; Howell et a t, 1999). The benefit of using such hydrogel 
surfaces, with regard to the majority of molecular analytes, is the enhanced ligand 
immobilisation capacity and consequently, improved response-to-analyte concentration ratio.
Although models explaining the principal aspects of multivalent binding to immobilised 
ligands (Muller et al., 1998c) are currently well established, similarly convincing models of 
whole cell binding to fixed ligands are not widely available and no general consensus 
prevails. The difficulty in explaining such binding is undoubtedly due to the extreme ‘bulk’ 
and non-ideal viscoelastic properties, exhibited by cellular structures. The frequently reported 
disproportionately low signals for whole cells (with an approximate dry cell weight of 10'13- 
1 O'12 g), obtained relative to those from proteins (Perkins and Squirrel, 2000), is most likely 
due to the a major portion of the cell being outside the range of the evanescent field. This 
shortcoming is compounded by the fact that the refractive index of a typical bacterial cell 
ranges from 1.37 to 1.42 for the cytoplasmic and cell wall components, respectively, in 
comparison to that of protein solutions, which normally exhibit refractive indices approaching 
1.51 (Watts and Lowe, 1994).
One of the most intuitive and rigorous insights into SPR-based whole cell-ligand interactions, 
was provided by Quinn et al., (2000). The analysis was conducted on a CM5 chip similar to 
that used in the experiments described herein. It cannot be entirely extrapolated to describe 
the immobilised mAb2B3-Z. monocytogenes cell interaction however, since, mammalian 
whole red blood cells were employed, the particular viscoelastic characteristics of which, 
caused them to adopt a flat-concave morphology. This caused them to essentially ‘collapse’ 
toward the high-amplitude region of the evanescent sensing region and meant that the capture 
antibody could be optimally orientated on a covalently pre-immobilised protein A hydrogel, 
without fear of subsequently captured cells being held predominantly outside the sensing 
region. Nonetheless, the model is consistent with accepted opinion, particularly in relation to 
mass-transfer limited (MTL) components (Schuck, 1996; Schuck and Minton, 1996), 
particulate fluid dynamics (Stamatakis and Tien, 1993; Hwang et a t, 1996), including the 
effect of wall shear stress (Zydney and Coulton, 1984), and many of the key thermodynamic 
interpretations and hypotheses were expected to relate directly to the immobilised mAb2B3-X.
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monocytogenes binding interaction, under investigation. A lthough M TL contributions have to 
be eliminated for accurate kinetic interpretation (generally by increasing the flow  rate) they 
can be tolerated for concentration m easurem ents and generate quantifiable response at, or 
approaching the equilibrium level (Req), when the interaction time is sufficiently lengthened. 
Hence, the fifteen m inute interaction tim e em ployed in the im mobilised mAb2B3-Z. 
monocytogenes binding cycle and reduced flow rate o f  1 (xl/min. Surprisingly, K oubovâ and 
co-workers (2000) have reported that increasing the flow  rate actually improved bacterial cell 
binding, speculatively attributing the result to the narrow ing o f  the boundaiy solvent layer 
(Kurrat et al., 1994) at the sensor surface. However, this w ould appear to contradict the basic 
thermodynamic model, in particular, the shear induced force determ inant w hich increases 
linearly with respect to the fluid velocity and the square o f  the cell diam eter (Quinn, 1999) 
and is anom alous w ith all other available citations on biointerfacial cell-ligand interactions. In 
fact, it could quite conceivably, be a  m atrix artefact effect, especially since no reference 
subtraction step was included.
Fs =  1.276k  ( P f ) . ( dp ) . (  f ) . (U f )  (Equation 5.2, Quinn,
1999)
Where;
and
Fs Shear-induced force.
Pf = Fluid (buffer) density.
dp Particle (cell) diameter.
f  = Friction factor.
uf Fluid velocity.
The cell surface location o f  the InlA  protein, recognised by m Ab2B3, has earlier been defined 
(Sections 3.2.6.4, 4.2.4 and 4.2.5) and it is felt that the distribution and accessibility o f  this 
antigen on the L. monocytogenes cell surface is o f  param ount im portance in m ediating whole 
cell binding at the sensor biointerface. Clear advantages o f  targeting somatic (O) antigens and 
the influence o f  the associated topographical microenvironment, with specific reference to 
biosensor-based cell detection, have also been cited by O lsen et al. (2003). This importance 
derives from the fact that a minim um , threshold avidity is required to  enable cell binding and 
retention at the biointerface. This minimum threshold is in turn, dictated by the accum ulative 
resistive forces that com prise shear, ionic, gravitational and lateral-elevation forces.
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The controlled orientation of antibodies on sensor surfaces using protein A/G and Fc-specific 
antibodies has previously been reviewed (Lu et al., 1996) and experimentally investigated 
(Quinn et al., 1999) and has found recent generic application in a hybridoma screening format 
(Canziani et a l, 2004). Given the dimensions of the bacterial cell in relation to the surface- 
localised evanescent field, it was felt that such an orientation, constructed upon the -100 nm 
hydrogel, would potentially render the cell attachment to the distal Fab domain of the 
immobilised antibody, beyond the effective evanescent sensing range. This postulation is 
supported by the findings of Lathrop and co-workers, (2003), who investigated a similar 
sensing platform using an anti -Listeria antibody in conjunction with a resonant mirror 
biosensor. The Biacore-based detection of E. coli 0157:H7 reported by Fratamico and co- 
workers, (1998) yielded a similar observation, with a directly immobilised antibody surface 
exhibiting vastly superior performance than the protein A-anchored antibody surface. A 
further concern when using such a configuration was the associated requirement to constantly 
replenish the detector antibody between analyses leading to high consumption of valuable 
purified monoclonal antibody.
It might be suggested that oriented immobilisation of antibody on the planar Cl chip surface 
would ensure that subsequently bound cells were not rendered prohibitively distant from 
sensing region. However, while such a homogenous monolayer arrangement would 
undoubtedly be capable of high avidity binding to multiple sites on a planar, macromolecular 
structure, it is less certain that the non-planar nature of a typical bacterial cell would achieve 
the avidity threshold required for binding. In contrast, specific dynamic events within the 
hydrogel that contravene its restrictive classification as a classical ‘brush-border’ may aid cell 
binding. These include a significant degree of elasticity within the polymeric dextran (Rief et 
al, 1997; Piehler et a l, 1999) that allows polymer-tethered antibodies to extend beyond the 
average, ambient equilibrium configuration (dependent on running buffer) and bind to 
complementary, surface-exposed antigen. Bonds formed by these ‘rare extended 
conformations’ are further aided by the increased intrinsic translational and rotational 
mobility exhibited by the tethered ligand when compared to the polymer itself (Jeppesen et 
al., 2001). Thus, notwithstanding the random nature of the amine-coupling method employed 
and the associated risk to binding site integrity (Vaughan et al., 2001; Vaughan et al., 2003), a 
significant population of rare extended conformations bearing active antigen-binding domains 
can mediate attainment of the avidity treshold required for cell binding (Figure 5.10).
In summary, the successful binding of L. monocytogenes cells to the immobilised mAb2B3 
antibody was attributed to the intrinsic antibody affinity and specificity towards somatically-
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expressed InlA protein, selection of suitable thermodynamic operating conditions (i.e. low 
flow rate and extended contact time), and favourable contributions from the dextran hydrogel.
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Figure 5.10: Schematic representation of whole cell binding to planar (A) and hydrogel- 
immobilised (B) ligand (antibody). Surface displayed ligand-complementary antigens are 
indicated as green (if accessible) and blue (if unaccessible). The binding of the 
macromolecular (cell) structure to the homogenously oriented, planar ligand is inherently 
less stable. This is due to the fact that the maximum number of accessible antigens is 
constrained by the non-planar complementarity of the cell morphology and thus, the 
threshold avidity is not achieved. Conversely•, although the polymer-tethered ligand is 
randomly oriented within the hydrogel matrix, which itself adopts an apparent composite 
‘brush-border’, dictated by the buffer ambience (grey), a significant number of ‘rare extended 
conformations ’ are accommodated. These extend beyond the composite hydrogel matrix and 
thus, can probe a wider cell surface area and form multiple bonds with compatible surface 
antigen. The antigen binding is further perpetuated by the increased rotational and 
translational freedom exhibited by the polymer-tethered ligand over the rigidly immobilised 
planar arrangement. These key facets allow the minimum threshold avidity determinant to be 
more reliably achieved by the hydrogel-immobilised sensor chip surface.
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5.2 .1 .9  D eve lopm en t o f  a  m o d e l S P R -based , ce ll-b in d in g  a ssay  f o r  d irec t detec tion  o f  L. 
m on ocytogen es
L. monocytogenes serotype l/2a cells, that had been actively growing at 37 °C in LEB broth, 
were harvested and washed twice in cold, sterile-filtered phosphate buffered saline (PBS) 
buffer before being adjusted to the desired cell concentration in fresh HBS buffer. The aims of 
the primary analysis were two-fold. Firstly, to establish whether real-time monitoring of the 
mAb2B3-i. monocytogenes cells was possible using the configuration employed and 
secondly, to estimate an approximate lower limit of quantitation (LLOQ). A flow rate of 1 
(il/min was employed for all sample analyses in order to maximise the mAb2B3-Z. 
monocytogenes interaction exposure and a nominal interaction time of 15 min was chosen, so 
as to allow the cell-antibody binding interaction to approach equilibrium.
Following a series of exploratory experiments, the concentrations of L. monocytogenes cells 
selected for testing ranged from 1.07 x 109 to 1.23 x 107 cells/ml (Figure 5.11). The upper cut­
off concentration was defined to reduce the risk of the instruments intricate microfluidic valve 
assembly becoming clogged with cellular material. As a further precaution, each sample was 
mixed manually by pipette aspiration immediately prior to injection and a portion of each 
sample examined using an optical microscope to ensure there was no clumping of cells.
It was clear that the relationship between Req and cell concentration did not exhibit a direct, 
linear proportionality, this was particularly evident at the higher cell concentrations were Req 
values seemed disproportionately exaggerated. This is remarked upon in more detail in 
Section 5.2.1.13. Despite postulations to the contrary by Watts and Lowe (1994), it may be 
that the presence of previously bound L. monocytogenes cells at the surface actually result in 
cooperative binding of free cells, by reducing the frequency of free cell collisions with bound 
cells and thereby optimising spatial interaction with localised unoccupied ligand regions 
Stamatakis and Tien, 1993; Quinn et al., 2000). Such a distribution would be further stabilised 
by the pervading intra-cellular zeta-potential.
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Figure 5.11: Overlayed binding profile for increasing concentrations of L. monocytogenes 
serotype l/2a cells. The cells were passed over the mAb2B3-CM5 chip surface at a flow rate 
of 1 pl/min for 15 minutes.
5 .2 .1 .10  A ssessm en t o f  s ign a l am plifica tion  u sin g  a san dw ich -assay  approach  
In an effort to elicit signal enhancement following direct binding of bacteria to the 
immobilised capture antibody several authors have suggested merit in adopting a sandwich 
approach whereby a secondaiy, genus-specific polyclonal antibody is applied (Fratamico et 
al., 1998; Bokken et a t, 2003). Typically, polyclonal antibody concentrations of at least 50 
(xg/ml were required to achieve significant enhancement. With such a large consumption of 
polyclonal reagent the cost factor and batch-to-batch heterogeneity may hinder the routine 
testing potential. The effect of sandwich-enhancement using two anti -Listeria polyclonal 
antibodies was investigated. However, as Figure 5.12 clearly shows, no enhancement was 
achieved. This was not an entirely surprising result given the similar findings of Lathrop and 
co-workers, (2003).
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Figure 5.12: Sandwich approach to signal enhancement using polyclonal antibodies. 
Approximately 270 RUs of fresh L. monocytogenes l/2a cells were captured on the mAb2B3 
at a flow rate of 1 fil/min. A 50 pi aliquot of each of the anti-L.monocytogenes (Anti-Lml and 
Anti-Lm2) polyclonal antibodies were sequentially passed over the captured cells at 100 
fig/ml and 10 ul/min.
Although these results clearly indicated the ineffectiveness of the sandwich-based approach to 
the direct enhancement of SPR response signals, it has proved useful as the basis for an 
alternative evanescent-wave-based biosensor platform, that has been successfully used for the 
detection of E. coli 0157:H7 (DeMarco et al., 1999; DeMarco and Lim, 2002). It operated on 
the principle of ‘reporter molecule fluorescence’. A biotinylated capture antibody was 
immobilised onto a streptavidin-coated fibre-optic waveguide. This was then incubated with a 
cell sample from an enrichment culture and followed by the addition of a secondaiy, Cy5- 
labelled ‘sandwich’ antibody. Fluorescent excitation of the Cy5-labelled antibody was 
induced by the propagating evanescent wave. When used to detect L. monocytogenes, an 
appropriate detection limit of approximately 4 x 108 cells/ml was reported, following a twenty 
hour sample enrichment (Tims et al., 2001). It has been a major tenet throughout this thesis 
that enrichment is an essential component of any immuno-based detection system for L. 
monocytogenes. Although the sensitivity and specificity of the ‘reporter-based-fluorescence’ 
format could undoubtedly be improved upon by incorporating more suitable antibodies it has
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several weaknesses when compared to the direct SPR-based system described herein. The key 
limitations include a requirement for labelling (of both capture and sandwich antibodies), 
larger sample volumes, multiple washing steps and the need to prepare freshly derivatised 
waveguides between analyses.
5.2 .1 .11 A ssessm en t o f  n on -specific  b in d in g  o f  non-L . m on ocy togen es cells to  m A b2B 3-  
CM5 sen so r ch ip  su rfa ce
The monoclonal antibody mAb2B3 has been shown to specifically bind to the InlA protein 
(Sections 3.2.6.6 and 4.2.5), which itself, is exclusively present on the surface of pathogenic 
L. monocytogenes cells (Lebrun et al., 1996) and no significant inter-species cross-reactivity 
in ELISA has been demonstrated (Section 3.2.6.5). Nonetheless, given the extensive 
heterogeneity between ELISA and SPR-based analysis platforms, the system was challenged 
with a panel of related Listeria spp. and representative non -Listeria spp., of both the gram- 
negative and gram-positive varieties. Given that environmental and food samples 
contaminated with L. monocytogenes would be predicted to be colonised with related Listera 
spp. or at the very least, associated normal microflora, the ability to differentiate L. 
monocytogenes from these non-pathogenic species is critical.
When challenged individually with the selected panel of potential cross-reacting species at a 
similar concentration to that of the highest L. monocytogenes concentration tested (~1.1 x 109 
cells/ml), binding response levels were negligible in all cases (Figure 5.13). In fact none of 
the test strains generated a response above 8 RUs, which can be considered background.
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F igu re  5.13: Binding response of a representative sample of non-L. monocytogenes cells. 
Cell concentrations were adjusted to 1 x l ( f  cells/ml in PBS buffer prior to analysis. The 
overlayed, complete binding profile for each test strain is demonstrated (A), with the region 
corresponding to the final response values magnified and labelled (B). None of the strains 
tested generated a response value above 8 RUs.
5.2 .1 .12 A ssessm en t o f  n on-specific  b in d in g  o f  h ea t-in ac tiva ted  L . m on ocytogen es ce lls  to  
m A b2B 3-C M 5 sen so r  ch ip  su rface
A sample of L. monocytogenes cells was prepared in PBS at a concentration of 3.16 x 108 
cells/ml and passed over the mAb2B3-CM5 surface at 1 (il/min for 15 minutes, replicating a 
typical assay cycle. Samples from the same cell suspension, after having been held at 80 °C 
for 10 and 15 minutes, respectively, were also passed over the same test surface. Cells that 
had been heat-treated for 10 minutes demonstrated >80 % reduction in response generation, 
while 15 minute heat treatment resulted in total abrogation of a response level distinguishable 
above background (Figure 5.14). These results correspond with the ELISA profile for 
mAb2B3 outlined earlier (Section 3.2.6.4) and re-affirm that the L. monocytogenes-b'm&mg 
potential of mAb2B3 is dependent on favourable surface topography, facilitating InlA 
accessibility.
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Figure 5.14: Binding response profile ofL. monocytogenes cells following heat inactivation. 
Following treatment at 80 °C for 10 and 15 minutes, the response decreased from 317.1 RU 
(red) to 52.9 (green) and 4.9 (blue), respectively. This indicated a clear, inverse proportional 
relationship between degree of heat inactivation and absolute binding response levels.
It is noteworthy that, whereas the ELISA results demonstrated significant and substantial 
reduction in mAb2B3 binding-capacity following heat treatment of the L. monocytogenes 
cells at 80 °C for 10 minutes, the biosensor response was totally abrogated following just 15 
minutes heat-treatment. This reflects a key difference in the ELISA and biosensor assay 
formats. In ELISA, the antibodies are free to individually interact with any available and 
accessible, InlA proteins. The resulting colourmetric response is the net of multiple 
independent mAb2B3-InlA interactions on the L. monocytogenes cell. Using the Biacore, 
direct cell-binding assay, antibodies are not free to independently ‘seek-out’ and individually 
bind to any available InlA proteins. They are restricted to such an extent that a binding event 
is only reported if the proportion of accessible, surface-displayed InlA proteins (which itself is 
directly proportional to the clinical significance of the strain (Jacquet et al., 2004) is sufficient 
to generate the minimum cumulative threshold-avidity (Section 5.1) for whole-cell capture. 
This is an inherent advantage of the biosensor-based direct cell-binding strategy.
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5.2 .1 .13 C onstruction  o f  a  ca libra tion  cu rve  f o r  estim ation  o f  L . m on ocytogen es ce ll 
concen tration
A key objective of this Chapter was to demonstrate that specific and direct binding of L. 
monocytogenes cells to an immobilised ligand, in this case mAb2B3 antibody, could be 
monitored using SPR. In order to further substantiate this principle it was deemed necessary 
to demonstrate a clear dose-response relationship. Thus, a standard calibration curve of 
response in RUs versus L. monocytogenes cell concentration (cells/ml) was constructed across 
the range of cell concentrations defined in Section 5.2.1.9. It must be acknowledged that 
although the SPR-binding event was a true ‘real-time’ event, the actual sample analysis was 
quite tedious. Due to the requirement for pre-injection sample mixing, coupled with the 15 
minute injection time, meant that it took over 1 hour to obtain a single set of triplicate binding 
data for a given cell concentration. Thus, in order to obtain a set of binding results across the 
cell concentration range, it took over 14 hours of continual manning of the instrument. 
However, this probably reflects the fact that the instrument, in particular it’s sample handling 
and microfluidics components, were designed principally for smaller analytes.
In Section 5.2.1.9, it had been noted that the initial observations on cell-binding induced/cell 
concentration-dependent Req values indicated that higher cell concentrations were generating 
disproportionately higher responses. However, when the calibration curve data was fitted with 
a four-parameter equation, using BIAevaluation™ 3.1 software, it became clear that the 
relationship between the mean, absolute response and L. monocytogenes cell concentration 
was non-linear (Figure 5.15). The LOQD was estimated to be 1.85 x 107 cells/ml (Table 5.1), 
where, acceptability was defined as predicted values falling within 20 % of the true value (i.e. 
100 ± 20 % recovery). However, when plotted with double-logarithmic scaling, a curve-linear 
relationship was resolved (Figure 5.16). This is consistent with the findings of several 
independent researchers investigating similar, electrochemical-based biosensor approaches to 
detection of bacterial cells (O’Sullivan et ah, 1999; Park et al., 2000; Kim and Park 2003). 
Using this typical calibration, cell concentrations could reliably be determined down to ‘at 
least’ 1.23 x 107 cells/ml (Table 5.1). However, reliable quantification may be an overly 
restrictive criterion on which to assess the assay performance. Furthermore, quantification 
may not be an absolute prerequisite since, as already emphasised (Section 1.6), current 
legislation dictates that a specific ‘presence-or-absence’ test is required. Following optimised 
enrichment of suspected contaminated samples, it would be reasonably expected that the 
enriched test sample would contain cell concentrations in excess of 1 x 107 cells/ml. The cell- 
binding assay, as described, is capable of differentiating L. monocytogenes at this 
concentration from background noise and non-specific responses.
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Figure 5.15: Semi-logarithmic calibration curve for estimation of cell concentration. The 
mean binding responses were plotted against the corresponding L. monocytogenes cell 
concentrations. Each data point in the representative curve corresponds to the mean of a 
single set of triplicate sample analyses. The data was fitted equally well with a four-parameter 
equation and a 3rd order polynomial function (insert), according to Y=-2xlO~>(X/+2xlO'u' 
(X)2+ 1x1 (f’(X)+30.61.
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Figure 5.16: Double-logarithmic calibration curve for estimation of cell concentration. The 
log (mean binding responses) were plotted against the corresponding L. monocytogenes cell 
concentrations. Each data point in the representative curve corresponds to the mean of a 
single set of triplicate sample analyses. The data was fitted equally well with a four-parameter 
equation and a log-linear function (insert), according to 7= 0.345ln(X)-4.117. The ‘goodness- 
of fit’ is indicated by the narrow residual plot and low %2 value (5.71 x 10"4).
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Table 5.1: Typical calibration curve data.
C o n c e n t r a t i o n
(cells/m l)
M e a n  r e s p o n s e  
±  S D  (R U )
%
C V
A B
B a c k -
c a lc u la te d
v a lu e
% R E B a c k -
c a lc u la te d
v a lu e
% R E
1.23 x  107 34.80  ± 0.954 2.74 5.680  x  10b 46.19 1.1 6 6 x 10 ' 94.80
1.85 x l O 7 47.47  ± 2.51 5.30 1.562 x lO 7 84.46 1.863 x  10 ' 100.68
2.77  x  10 ' 62.87  ± 6.59 10.47 2.757  x  10 ' 99.52 2.790  x  10 ' 100.73
4.16  x  10 ; 90.30  ± 7.58 8.40 4.870  x  lO7^ 117.05 4 .5 8 9 x 10 ' 110.31
6.24 x  107 111.27 ± 3.02 2.71 6.480  x  107 103.84 6.050  x  10 ' 96.96
9.36  x  10 ' 163.55 ± 5.88 3.59 1.053 x  108 112.54 9.943 x  10 ' 106.23
1.41 x  10s 198.55 ± 6.04 3.04 1.320 x  10s 93.65 1.261 x  10s 89.46
2.11 x  10s 303.00  ± 6.98 2.30 2.140  x  10s 101.23 2.104  x  10* 99.72
3 .1 6 x 10" 411.13 ± 11.77 2.86 2.998  x  10* 94.86 3.013 x  10s 95.37
4.74  x  10s 636.30  ± 35.36 5.56 4.861 x  10s 102.56 4.980  x  10^ 105.07
1.07 x  109 1265.44 ± 52.30 4.13 1.069 x l O 9 99.88 1.075 x l O 9 100.48
‘A ’ denotes data extrapolated from the calibration curve in Figure 5.15. ‘B ’ denotes data 
extrapolated from the calibration curve in Figure 5.16. The data represents the mean of a 
single set of triplicate sample analyses.
In a further test of the robustness of the assay, sensor baseline responses were monitored over 
a typical 30 sample assay run (Figure 5.17). An average downward baseline drift of 3.09 x 10'
4 RU per assay replicate was noted. This was very small and was taken to indicate that the 
mAb2B3 surface was stable even over an extended range of sample analysis, with 
incorporated regeneration measures. This would obviously be an important consideration in 
terms of both commercial and routine analysis applications where the associated costs, 
necessitated by reagents, time and expertise involved in repeated pre-analysis surface 
preparation may otherwise be construed as prohibitive.
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Figure 5.17: Baseline-stability over a typical 30-sample assay. The small negative slope 
indicated a stable baseline with an average surface degeneration of 3.09 x 10'4 RU/replicate, 
following surface regeneration with 5 mM NaOH.
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5.2.2 B iacore-based  characterisa tion  o f  th e  m A b 2 B 3 -In lA  in teraction
Biacore was investigated in terms of its suitability for examining the binding characteristics of 
the mAb2B3-InlA interaction. It is universally agreed for such measurements to be considered 
reliable, the following should be observed:
1. Analyte and ligand must be pure and the concentration of analyte at least, must be 
known.
2. The smaller of the interacting molecules should be immobilised.
3. Analyte should preferentially be monovalent. When constrained to using bivalent 
analyte, an appropriate correction factor can be introduced, otherwise kinetic data is 
difficult to interpret and affinity measurements actually refer to avidity.
4. The immobilised ligand should be optimally oriented to ensure minimal stearic 
hinderence of analyte.
5.2.2.1 C haracterisa tion  o f  th e m A b2B 3-In lA  in teraction  u sin g  a  cova len tly-im m ob ilised  
rln lA -C M S  su rface
5 .2 .2 .1 .1  P re-con cen tra tion  o f  r ln lA  on to  th e  C M 5 sen so r  ch ip  su rface
The purity of the monoclonal antibody ‘mAb2B3’ had been confirmed by SDS-PAGE 
Western blotting and SEC-HPLC (Section 3.2.6.3) and its concentration was known, 
specifically. In addition, it was anticipated that eventually, the rInlA-mAb2B3 interaction 
could potentially be exploited in an inhibition assay for L. monocytogenes cells, with 
improved sensitivity. Thus, despite the fact that mAb2B3 is, quite obviously, a bivalent 
molecule it was selected as the analyte and rlnlA was chosen as the candidate ligand for 
immobilisation.
EVLAC-purified rlnlA protein in PBS was diluted 1/10 in 10 mM sodium acetate buffer across 
the pH range 3.6-5.5. Although the amine coupling reaction is known to proceed best at pH 
>4.0, pre-concentration at the lower pH values (3.6-3.8) was also assessed, bearing in mind 
the low predicted pi (4.9) of the rlnlA molecule. Optimal pre-concentration was achieved at 
pH 4.5 (Figure 5.18).
5 .2 .2 .1 .2  P repara tion  o f  r ln lA -C M S  sen so r  ch ip  su rface
IMAC-purified rlnlA protein in PBS was diluted 1/10 in 10 mM sodium acetate buffer, pH
4.5 and passed over a freshly EDC/NHS-activated CM5 chip surface. Unreacted active groups
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were ‘capped’ with 1 M ethanolamine (pH 8.5) and this was followed with a brief (30 second) 
pulse of 5 mM NaOH, to remove loosely (non-covalently) bound ligand and stabilise the 
baseline response. Appoximately 8000 RUs of rlnlA was efficiently immobilised onto the 
CM5 matrix (Figure 5.19). An equivalent level of a control protein (commercial IgG2a) was 
immobilised on an adjacent surface located in the flow cell immediately downstream of the 
rlnlA surface, to act as an on-line reference surface. Specific, reference-subtracted binding of 
mAb2B3 to the r!nlA-CM5 sensor chip surface was then confirmed (Figure 5.20).
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Figure 5.18: rlnlA pre-concentration analyses. Top; pre-concentration of rlnlA onto the CM5 
sensor chip surface across the pH  range 3.6-4.5. Bottom; pre-concentration of rlnlA onto the 
CM5 sensor chip surface across the pH  range 4.5-5.5. Maximum pre-concentration was 
observed at pH  4.5. Thus, 10 mM sodium acetate buffer at pH  4.5 was chosen as the 
immobilisation buffer for rlnlA onto the CM5 surface.
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Figure 5.19: Immobilisation IMAC-purified rlnlA onto the CM5 sensor chip surface. (A) 
EDC/NHS activation, (B) binding of mAb2B3, (C) capping of unreacted groups and (D), 
regeneration pulse of 5 mMNaOH. A final level of 8109.1 RUs covalently attached rlnlA was 
achieved.
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Figure 5.20: Surface saturation sensorgram (reference-subtracted) for the rInlA-CM5 chip 
surface. Protein A-purified mAb2B3, at a 1/50 dilution in HBS, was passed over the surface at 
10 fjl/min for 2 minutes. The saturated equilibrium response (Req) was estimated at 
approximately 282 RUs. This was significantly lower than the predicted Req value and 
indicated sub-optimal surface activity.
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5.2.2.1.3 E qu ilibrium  steady-sta te affin ity o f  m A b2B 3 f o r  am in e-cou pled  rln lA
The amount of rlnlA immobilised was quite high (8000 RUs) and would undoubtedly have 
prevented accurate kinetic determination of affinity data, ostensibly due to mass-transport 
limitation. However, because equilibrium measurements are unaffected by mass-transport or 
re-binding artefacts, high levels of immobilisation could be used to increase the binding 
response to appreciable/discemable levels for reliable estimation of steady-state affinity. 
Samples consisting of 200 (il of serial doubling dilutions of mAb2B3 ranging from 3.3 x 10“6 
to 1.29 x 10'8 M were individually passed over the rlnlA surface. To conserve antibody, 
samples of mAb2B3 were passed over the rlnlA surface at a reduced flow rate of 2 |j.l/mm. 
After the 40 min exposure equilibrium was approached and the equilibrium response (Req) 
was noted. Regeneration was achieved by stripping the rlnlA from the anti-His surface with 
two 30 second pulses of freshly prepared 5 mM NaOH. All sensorgrams were reference 
subtracted from a murine IgG-immobilised reference surface. To remove systematic 
anomalies a blank run consisting of HBS, that contained no mAb2B3, was subtracted from 
each of the test sensorgrams. The relationship between the steady state equilibrium binding 
response (Req) and the corresponding affinity Results were plotted as Req versus mAb2B3 
concentration and the data analysed using the BIAevaluation™ steady-state affinity model 
(Figure 5.21). The steady-state dissociation constant (KD) value was thus, calculated to be 
2.23 x 10'7 M. This represents the reciprocal of the association constant (KA).
Req =  — i Rmax (Equation 5.2)
KA.n.(CA)i. + \
Response value at equilibrium.
Steady-state equilibrium affinity association constant (M1). 
Steric hinderence factor and represents the average 
number of ligand sites occupied per analyte molecule. 
Injected analyte concentration.
Maximal response.
Where; Req
Ka
n
0cA)i
and Rmax
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Figure 5.21: Steady-state affinity model o f mAb2B3 binding to rInlA-CM5 surface. The Req 
values obtained following a 40 minute interaction period were plotted against their 
corresponding affinity-purified, mAb2B3 antibody concentrations. The Kn value was 
calculated by non-linear curve analysis, using a predefined steady-state affinity function 
provided in BIAevaluation ™ software. Assuming n=l, the apparent KD was estimated to be 
approximately 2.23x JO' M.
140
120
100
80
60
40
20
267

The estimated Ka value was lower than expected, given the demonstrated capacity to 
efficiently bind and retain cells at the sensor chip surface (Sections 5.2.1.5 and 5.2.1.9) and it 
prompted a closer inspection of the immobilised ligand activity.
It was possible to approximate the theoretical maximum binding response (Rmax) according to 
the following equation (Equation 5.3) and thus, estimate the relative surface activity.
Rmax = Ligand level x MW analyte x binding stoichiometry
MW ligand (Equation 5.3)
The immobilised ligand level was 8000 RUs (Figure 5.19). Thus, knowing that the molecular 
weights of mAb2B3 and rlnlA were 150 kDa and 80 kDa, respectively and assuming a 
saturated binding response of 280 RUs (Figure 5.20), surface activity was interpreted to be
3.6 %. This is just an estimate and it is acknowledged that had the mAb2B3 antibody been 
used at a higher concentration, lower flow rate and the interaction time extended, the 
experimental Rmax would have been greater, but not, however, to the extent that it would 
approach the theoretical maximum level.
It is possible that the sub-optimal immobilised ligand activity was a direct result of the 
random covalent nature of the amine coupling method leading to steric hindrance and 
abrogation of the intrinsic binding activity in mAb2B3 antibody that was cross-linked about 
the Fab region. In addition, on the basis of the pre-concentration observations (Figure 5.18), 
mAb2B3 immobilisation had been conducted at pH 4.5. This would be considered an 
average-to-high pH for typical amine coupling to a CM5 chip. Considering that the predicted 
pi of rlnlA is 4.92, it is entirely possible that impurities in the IMAC-purified rlnlA 
preparation were actually preferentially cross-linked at this pH. Thus, even if the impurities 
were present at very low levels and consequently, not apparent in SDS-PAGE analysis 
(Section 4.2.5.1), the low pH used could effectively pre-concentrate the impurity to a 
significant degree on the activated CM5 surface.
On the basis of he sub-optimal performance of the rInlA-CM5 chip surface, it was decided to 
investigate alternative means of directional non-covalent attachment of the rlnlA ligand to the
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sensor surface. In particular, exploiting the His-tag component was investigated for 
concomitant selective and oriented immobilisation of the rlnlA ligand at the sensor surface.
S.2.2.2 A n a lysis  o f  th e  o f  th e  m A b2B 3-In lA  in teraction  u sin g  N T A  ch ip  tech n ology
The benefits of NTA for specific binding of olioghistidine-containing molecules has earlier 
been highlighted (Section 4.2.5). This specific affinity chelation has been harnessed for 
Biacore-based analysis of His-tagged proteins (Nieba et ah, 1997; Jisa and Jungbauer, 2003), 
using an NTA-coated sensor chip (Gershon and Khilko, 1995).
The NTA chip was considered particularly suitable, since the rlnlA protein had been 
engineered to contain a C-terminal Hexa-Histidine tag (Sections 4.2.4 and 4.2.5). Thus, it 
should allow homogenous, oriented and regenerable immobilisation of rlnlA. While 
undesirable preferential immobilisation of ligand impurities has been cited as a shortcoming 
with random, covalent coupling (Section 5.2.2.1.3), even if the ligand preparation is not 100 
% pure, NTA preferentially specifically chelates only the oligohistidine-containing molecule.
5.2 .2 .2 .1  O ptim isa tion  o f  th e  N T A -lin k ed  r ln lA  su rface  opera tin g  con dition s  
The NTA chip operating conditions are generic and have been validated with respect to NTA 
surface activation and regeneration conditions (Nieba et al., 1997; Anon., Biacore, 2002). A 
typical biding cycle is depicted in (Figure 5.22). Firstly, the chelating capacity of the NTA 
was activated or ‘charged’, using a 500 fiM solution of NiC^ (Section 2.10.5). IMAC- 
purified rlnlA was then passed over the Ni2+-charged NTA and anchored to the surface via its 
C-terminal His-tag. This was predicted to render the rlnlA in the optimal orientation for 
exposure and steric accessibility of its epitope-bearing sequence, complementary to mAb2B3. 
Finally, mAb2B3 was passed over the chelated rlnlA surface, and the degree of specific 
binding observed.
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F igu re  5.22: Complete binding cycle for the mAb2B3-rInlA interaction using NTA sensor 
chip technology. (A) NiCl2 activation of NTA surface, (B) capture of His-tagged rlnlA, (C) 
binding of mAb2B3 to rlnlA and (D), regeneration using a 1 minute pulse of 400 pm EDTA 
(pH 8.3). A flow rate o f  20 fil/min was maintained throughout. Approximately 300 RUs of 
mAb2B3 was observed to bind ‘apparently’ to the captured rlnlA surface. The sensorgram 
represents raw, non-reference subtracted binding data.
S .2.2 .2 .2  N on -sp ec ific  b in d in g  p ro file  o f  N T A  ch ip  su rface
The binding profile outlined in Figure 5.22 was as expected. However, unlike the CM- 
dextranated CM5 chip surface, where suitable reference material can be immobilised onto 
adjacent, downstream flow cells prior to sample analysis, when using the NTA chip, the 
active ligand surface preparation is integrated into each sample analysis and it is not possible 
to incorporate a stable, control surface that is independent of the test surface. Thus, on-line 
reference subtraction was not possible and no information on the non-specific binding 
contributions was garnered from the sensorgram in Figure 5.22. In order to further resolve any 
non-specific binding processes, a series of exploratory experiments were undertaken.
Firstly, the non-specific binding potential of the unactivated NTA was assessed. This was 
conducted by sequentially injecting a 1/100 dilution of mAb2B3, and a 1/10 dilution of 
IMAC-purified rlnlA (in HBS), over the unactivated NTA and monitoring the respective

binding responses (Figure 5.23). It was clear that both mAb2B3 and rlniA exhibited 
negligible binding to the NTA matrix.
It was also necessary to check for non-specific binding of mAb2B3 to Ni2'-charged NTA. 
This was determined by comparing the response levels for a 40 (il injection of mAb2B3, 
diluted 1/100 in HBS and a blank injection, consisting of HBS buffer only (Figure 5.24). As 
expected, HBS did not elicit any apparent binding response. However, approximately 70 RUs 
of mAb2B3 were observed to bind the Ni2+-charged NTA. In view of the lack of suitable on­
line referencing function/facility, it was imperative that the degree of apparent non-specific 
binding be reduced, prior to further analysis or characterisation studies.
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Figure 5.23: Non-specific binding p ro file  o f rln lA  and mAh2B3 to NTA. A  1/10 d ilu tion  o f 
IM AC -purified  H is-tagged rln lA  (A) and a 1/100 d ilu tion  o f a ffin ity-pu rified  mAb2B3 (B), in 
H BS buffer, were sequentially passed over a fresh, unactivated NTA ch ip surface, fo r two 
minutes at 10 fil/m in. The binding response was neglig ib le in  both instances.
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Figure 5.24: Non-specific binding p ro file  o f mAb2B3 to N i2+-charged NTA. The ‘re d ’ 
sensorgram  corresponds to the NTA surface activated w ith N iC h  (A) and exposed to a 1/100 
dilu tion  o f mAb2B3 in  H BS fo r two minutes, at 10 fil/m in  (B). The ‘b lue ’ sensorgram  
represents the equivalent control response fo llow ing  a blank injection o f H BS buffer 
containing no mAb2B3. The difference between the test and contro l interactions was p lotted  
(green) and revealed 71.2 RUs o f non-specific binding ofm Ab2B3 to N i2+-charged NTA.
It was possible that mAb2B3 was actually binding to the Ni2'-activated NTA through 
histidine residues within its intrinsic amino acid composition, although this has not been 
frequently reported as an inherent complication. Moreover, the running buffer had been 
supplemented with 50 |iM EDTA, as recommended by Nieba et a l., 1997, to counteract non­
specific monovalent histidine interactions. It was assumed more likely, that the non-specific 
binding forces were ostensibly ionic in nature. In order to overcome these ionic contributions, 
the salt concentration was increased from 150 mM to 500 mM and the binding response of 
mAb2B3 with Ni2+-activated NTA was assessed across a range of pH values (Figure 5.25). 
The most pronounced non-specific responses were observed at the higher pH values tested, 
generated. This was not surprising, given that at higher pH values the protein would be 
expected to be less positively charged and thus interact to a greater degree with the Ni2+- 
charged NTA. It was concluded that a combination of 500 mM NaCl and a pH value of 6.25 
was most effective in combating non-specific binding.
272

1600
/
/
- A
pH 7.0 (0.15 M NaCI) 
pH 6.5 (0.15 M NaCI)
- pH 6.5 (0.50 M NaCI) 
-p H  6.25 (0 50 M NaCI)
- pH 6.0 (0.50 M NaCI)
100 
Time (s)
Figure 5.25: The effect o f p H  and sa lt concentration on non-specific binding o f mAb2B3 to 
N i'-ch a rg e d  NTA. A  1/2 d ilu tion  o f mAb2B3 in H BS buffer o f varying p H  and NaCI 
concentrations were passed over the N i2' -activated NTA surface at 5 jil/m in, fo r two minutes. 
H BS buffer at p H  6.25 and containing 500 m M N aC l substantially reduced the degree o f non­
specific binding to N i2 -charged NTA.
The specific interaction of mAb2B3 with Ni2+-NTA-anchored rlnlA in the optimised buffer, 
was ultimately confirmed by comparing the mAb2B3 binding response levels with those on a 
Ni2+-NTA surface to which, an unrelated His-tagged protein, designated rpl8 (Figure 5.26). 
This was a B ruce lla  abortus—derived protein that had been recombinantly expressed with a C- 
terminal His-tag, using the pQE60 vector cassette (provided by Lyndsey Dunne, DCU). There 
was no binding apparent on the Ni2+-NTA-anchored rpl8 surface. In fact there was a 
reduction in the baseline response level of approximately 100 RUs. This was due to 
dissociation of rpl8 from the Ni2-charged NTA surface, which was undoubtedly exacerbated 
under the low pH and high salt composition of the sample buffer. Thus, when this reference 
response was subtracted from the mAb2B3 response at the Ni2+-NTA-anchored rlnlA surface 
(-200 RUs), the effective specific response was approximately 300 RUs. Given, that the rlnlA 
capture level was approximately 900 RUs, this constitutes a specific surface activity of 
approximately 40 %. This was significantly greater than that achieved using direct covalent 
attachment of rlnlA (Section 5.2.2.1.2), however, it was still lower than anticipated, given that
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the rlnlA ligand was optimally oriented. This was perhaps a result of the low pH/high salt 
combination needed to combat non-specific elements. Thus, although this series of 
experiments demonstrated clearly specific binding of mAb2B3 to rlnlA, its usefulness was 
compromised by three significant weaknesses in the approach:
1. The somewhat harsh buffer conditions, necessary to elicit a verifiably specific 
response.
2. The associated low apparent surface activity.
3. The inability to incorporate an on-line reference subtraction component.
These are inherent weaknesses in the NTA chip technology and may explain the lack of 
published experimentation directly incorporating it. On the basis of these findings, it was 
concluded that the NTA chip was not the ideal surface for investigating the mAb2B3-rlnlA 
interaction.
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Figure 5.26: Optim ised, specific binding o f mAb2B3 to N i2+-activated NTA-anchored rln lA  
surface. A  1/2 d ilu tion  o f mAb2B3 in  H BS buffer (pH  6.25, 500 m M N aC l) was passed over 
rln lA  (red)- and rp l8  (blue)-captured surfaces. (A) N iC l2 activation, (B) binding o f H is- 
tagged ligand (rln lA  o r rp l8 ) at a flow  rate o f 10 pl/m in fo r two minutes, (C) binding o f 
mAb2B3, (D) bound leve l o f mAb2B3 and (E) NTA surface regeneration using EDTA. The 
insert shows a m agnified overview  o f the mAb2B3 binding interaction regions o f the 
respective sensorgrams. The interaction regions were overlayed and aligned using 
B lAeva luation™  software and the reference-subtracted ‘effective’ response was 
superimposed (green). The data c lea rly  demonstrate successful and specific binding o f 
mAb2B3 to rln lA , anchored to N i2 activated NTA v ia  its C -term inal H is-tag.
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5.2.2J Characterisation of the mAb2B3-rInlA interaction using an anti-His-tag antibody
ligand-capture approach
5.2.2.3.1 Pre-concentration of anti-His-tag antibody onto the CMS sensor chip surface
As a result of the inadequacies, revealed as inherent, when using the NTA methodology to 
controllably orient the rlnlA protein, it was decided to investigate the potential of using an 
anti-His-tag antibody to capture the rlnlA, via its C-terminal His-tag.
A recent survey of available anti-His-tag monoclonal antibodies has revealed a universally 
more specific propensity to bind oligihistidine tags, with a demonstrated lower tendency to 
non-specifically bind, isolated or clustered Histidine residues, occurring in the amino acid 
sequence of His-tagged proteins (Anon., Biacore, 2002). A BSA-free, anti-His-tag 
monoclonal antibody was sourced from Novagen (N70796), hereon referred to as ‘Nova-His’. 
It was essential that the antibody was free from BSA and other carrier or stabilising proteins 
so as to prevent more favourable coupling of the undesired contaminating protein over the 
antibody itself, leading to lower apparent coupling efficiency, concomitantly interpreted as 
sub-optimal specific surface ligand activity.
The Nova-His antibody was adjusted to 50 |ig/ml in 10 mM sodium acetate across the pH 
range 4.0-5.0 and the degree of pre-concentration was assessed as before (Section 2.10.1). 
Maximum pre-concentration was achieved in 10 mM sodium acetate buffer at pH 4.2 (Figure 
5.27).
2 7 6

Time (s)
Figure 5.27: Pre-concentration o f ‘N ova-H is’ onto the CM 5 sensor chip surface across the 
p H  range 4.0-5.0. Maximum pre-concentration was observed a t p H  4.5. Thus, 10 m M  sodium  
acetate buffer at p H  4.5 was chosen as the im m obilisation buffer fo r the Nova-H is antibody 
onto the CM 5 chip surface.
5.2.2.3.2 Immobilisation of anti-His-tag antibody onto the CMS sensor chip surface
It was important that maximum ligand coupling efficiency was achieved, to prevent the 
binding capacity of the Nova-His surface limiting the subsequent mAb2B3-rInlA interaction 
and also to reduce the net contribution of partial rlnlA dissociation from the observed 
mAb2B3-rInlA interaction. The immobilisation (Figure 5.28) was controlled manually and 
incorporated an extra EDC/NHS activation pulse, to maximise the % reactive ester formation. 
In addition, following an initial exposure to Nova-His antibody in immobilisation buffer (10 
mM sodium acetate, pH 4.2), a second ligand-binding pulse was incorporated to ensure the 
CM5 coupling capacity was fully exhausted. Coupling saturation was reached at 
approximately 8000 RUs. A control surface was prepared by immobilising a similar level of 
IgG2a control antibody in the flowcell immediately downstream of the Nova-His surface to 
facilitate on-line reference subtraction (Sections 2.10.3, 5.2.1.2 and 5.2.1.3).
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Figure 5.28: Im m obilisation o f ‘N ova-H is’ antibody onto the CM 5 sensor chip surface. The 
im m obilisation was contro lled  manually, so as to ensure that the injected solution o f ‘Nova- 
H is ’ antibody fu lly  saturated the coupling capacity o f the activated C M  dextran. This included 
an extra surface activation pu lse and a secondary im m obilisation pulse to achieve saturation.
(A) P re lim inary ED C/N H S activation pulse, (A ) secondary, complete ED C/N H S activation,
(B) prim ary binding o f ‘Nova-H is ’ antibody, (B ) secondary binding o f ‘N ova-H is ’ antibody
(C) capping o f unreacted groups and (D), regeneration pulse o f 5 m M H C l. The difference in 
‘bound m Ab2B3’ levels achieved fo llow ing  the prim ary (B) and secondary (B ) ligand  
injections was m inim al, ind icating maximum coupling. A  fin a l leve l o f 8109.1 RU s covalently 
attached ‘Nova-H is ’ antibody was achieved.
. •
.
When mAb2B3 was passed sequentially over the Nova-His and IgG2a reference surface, 
negligible binding was revealed (Figure 5.29), thus confirming the absence of significant non­
specific binding.
Time (s)
Figure 5.29: N on-specific binding p ro file  o f mAb2B3 on the Nova-H is surface. A  1/10 
d ilu tion  o f mAb2B3 in  H BS  was se ria lly  passed over both the N ova-H is (red) and contro l 
IgG2a (blue) surfaces. N eg lig ib le non-specific binding was demonstrated, as clearly  
demonstrated by the reference-subtracted p lo t (green).
Following capture of rlnlA (-450 RUs), subsequent, specific binding of mAb2B3 was 
successfully demonstrated (Figure 5.30). Although the positive binding interaction was 
clearly visible over the early part of the sensorgram, immediately following injection of the 
mAb2B3 sample, the response began to decrease after approximately five minutes. This can 
be attributed to the more rapid dissociation of rlnlA from the Nova-His surface. Although the 
on-line reference subtraction successfully prevented systematic deviations and peculiarities, 
the mAb2B3 binding region of the sensorgram actually represented a cumulative, non­
resolved plot of two steady-state interactions:
Ka1
Nova-His + rlnlA < ^  Nova-His-rlnlA
Kd1 
Ka2
Nova-His-rlnlA + mAb2B3 <  ^ Nova-His-rInlA-mAb2B3
Kd2
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In the interaction under investigation it was apparent that Kd i > K d i and thus, the more rapid 
dissociation of rlnlA from the Nova-His surface effectively masked the mAb2B3-rInlA 
binding response over an extended interaction period. The actual binding of mAb2B3 to rlnlA 
was resolved by subtracting a blank injection cycle (i.e. HBS containing zero mAb2B3). This 
second referencing step efficiently compensated for the negative contribution of K d i and 
revealed the surface-saturation response to be approximately 225 RUs. This reflected a 
specific surface activity of approximately 53 %, which was higher than that achieved using 
either direct covalent attachment (Section 5.2.2.1) orNTA capture (Section 5.2.2.2).
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Figure 5.30: Complete binding cycle sensorgram  fo r the m Ab2B3-rInlA interaction on the 
Nova-H is, anti-polyhistid ine-derivatised CM 5 surface. (A) Injection o f 10 pd o f rln lA , d iluted  
1/10 in  HBS. (B) A fter two m inutes o f buffer-flow, mAb2B3 was injected at 1.5 x  10 6 M  
across the surface, in HBS. The flow  rate used throughout was 5 fil/m in. The inset shows the 
norm alised, single online-referenced m Ab2B3-rInlA binding response (red), w ith the true, 
double-referenced response data, superim posed (green).
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5.2.2.3.3 Steady-state affinity of mAb2B3 on Nova-His-captured rlnlA surface 
The steady-state affinity profile for mAb2B3, binding to Nova-His-captured rlnlA, was 
investigated, using the optimised Nova-His capture approach and from the resultant binding 
data (Figure 5.31), a steady-state affinity model was plotted (Figure 5.32) and used to 
estimate the affinity constant (Ka), as previously described (Sections 2.10.6 and 5.2.2.1.3). 
The calculated equilibrium steady-state dissociation constant Kd value (1.93 x 10"7 M) was 
quite similar to that obtained using the covalently immobilised rlnlA approach (Section 
5.2.2.1.3). It was expected that since, in theory, the capture method facilitated homogenous, 
oriented immobilisation of rlnlA, with demonstrated improved surface activity, the observed 
Kd value would be, accordingly, enhanced. The fact that this was not realised, along with the 
pervading non-ideal surface activity across all three rlnlA immobilisation formats 
investigated, indicated that the IMAC-purified rlnlA may have been compromised by intrinsic 
heterogeneities.
In addition, although the data is not shown, numerous attempts to characterise the mAb2B3- 
rlnlA interaction by modelling the kinetic parameters were undertaken, yet they failed to yield 
data that could be adequately modelled. It is acknowledged that the universal applicability of 
ligand-capture immobilisation as a platform for kinetic interpretation of binding interactions 
is questionable (Quinn e l a l., 1999). Nonetheless, it was felt that, given the careful referencing 
steps incorporated, the data would at least facilitate modelling, even if the extrapolations 
derived from resultant models was not ideal. The total failure of the data obtained to fit the 
kinetic models, further reinforced suspicion of rlnlA heterogeneity at the chip surface.
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Figure 5.31: Overlayed steady-state sensorgrams depicting the binding p ro file s fo r mAb2B3 
to H is-tag-affm ity-captured rln lA  on an anti-H is-tag-im m obilised CM 5 surface (Nova-His). 
The top sensorgram  represents the data fo llo w in g  on-line reference subtraction. The bottom 
sensor gram  represents the same binding data, ‘double-referenced’ by subtracting the blank 
or ‘buffer on ly ’ data, in  order to compensate fo r rln lA  dissociation (from anti-H is-tag  
antibody) during the 40 minute binding interaction.
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Figure 5.32: Steady-state a ffin ity model o f mAb2B3 binding to H is-tag-affin ity-captured  
rln lA  on an anti-H is-tag-im m obilised CM 5 surface (Nova-H is). Req values were interpreted 
after a 40 minute interaction period  and fo llo w in g  double-reference subtraction, were p lotted  
against the ir corresponding affin ity-purified, mAb2B3 antibody concentrations. The Ko value 
was calcu lated by non-linear curve analysis, using a predefined steady-state a ffin ity function  
provided in  B lAevaluation ™ software. Assum ing n= l, the apparent K D was estim ated to be 
approxim ately 1.93 x  1O' M
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5.2.2.4 Non-denaturing PAGE analysis of IMAC-purifiedrlnlA
The deviations from ideal predictions, exhibited by the immobilised rlnlA surfaces prompted 
a closer investigation into the disposition of the purified rlnlA protein preparation. 
Preliminary characterisation of IMAC-purified rlnlA by SDS-PAGE and Western blotting 
(Sections 4.2.5) had revealed it to be predominantly pure and immunoreactive towards 
mAb2B3. A neat sample of the IMAC-purified rlnlA used in the Biacore experiments 
(Sections 5.2.1-5.2.3) was analysed by native, or non-denaturing PAGE (Section 2.3.3) across 
a range of gel acrylamide concentrations (7, 8, 9 and 10 % (w/v)), alongside molecular weight 
markers that ‘bracketed’ the known molecular weight of the His-tagged rlnlA protein. 
However, even without referring to a standard curve, it was clear from the electrophoretic 
mobility that the apparent molecular weight was in fact, substantially greater than that 
confirmed by sequence analysis (Section 4.2.4.2) and SDS-PAGE (Section 4.2.5.1). The gel 
depicted in Figure 5.33 is typically representative of the electrophoretic resolution pattern 
obtained across the four gel acrylamide concentrations investigated. This strongly suggested 
that the rlnlA protein was present, under the buffer conditions employed, as a multimeric 
compound. It has been demonstrated that even proteins that have been purified as monomeric, 
can, subsequently, multimerise over time and complicate SPR-based binding analysis (Van 
derMerwe et a l., 1993; Myszka, 1997).
5.2.2.5 HPLC analysis of IMAC-purified rlnlA
In order to further resolve the apparent multimeric nature of the IMAC-purified rlnlA, a neat 
sample in PBS was subjected to SEC-HPLC (Section 2.11.3). One major peak was observed 
and exhibited a retention time of 7.0 minutes (Figure 5.33). A series of molecular weight 
standards was also analysed under the same operating conditions. The retention time (Tr) of 
each standard was recorded, and divided by the time taken for a sample to elute in the column 
void volume (vo). A constant flow rate was maintained (0.5 ml/min) and this rendered Tr to 
be equal to ve. Thus, when the ve/vo values (Section 2.11.2) were plotted against the log of 
the molecular weight of the respective standard, a linear calibration curve was obtained. 
When the rlnlA sample retention time was substituted into the standard curve (Figure 5.34), 
the peak molecular weight was calculated to be approximately 308 kDa. This corresponded to 
approximately four times the confirmed molecular weight of monomeric rlnlA and thus, 
indicated that the IMAC-purified rlnlA was actually present as a tetramer. It is thus postulated 
that steric complications, elicited by the tetrameric configuration were responsible for die 
non-ideal behaviour of the rlnlA, when immobilised on the various sensor chip formats, 
notwithstanding the steps taken to ensure homogenous and oriented ligand immobilisation.
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Figure 5.33: Non-denaturing PA G E  analysis o f IM AC -purified  rln lA . The pu rified  protein in 
PB S  buffer was diluted 1/10 in  non-denaturing sample buffer and loaded onto the gel. The 
m olecular weight standard samples (bovine serum album in (BSA), carbonic anhydrase (CA) 
and chicken egg album in (CEA)) were chosen to bracket the pred icted m olecular weight o f 
rln lA . The ge l shown, consisted o f the lowest acrylam ide concentration investigated (i.e. 7 % 
(w/v)). Despite this, it  was clear that the rln lA  sample d id  not electrophoretically m igrate 
sign ifican tly from  the loading front. This was interpreted to indicate m ultim eric compound 
form ation.
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Figure 5.34: SEC-HPLC analysis of IMAC-purified rlnlA, A neat sample of the purified 
rlnlA, in PBS was applied to the HPLC column. A Phenomenex 3000 SEC column was used 
with PBS mobile phase at a flow rate of 0.5 ml/min and monitored by UV absorbance at 280 
nm. One dominant peak was observed (B) at 7.0 minutes retention. A number of smaller, 
shoulder peaks were evident (A, C, D, E, and F).
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Figure 5.3S: SEC -H PLC  standard curve o f ve/vo versus log lO (M r) fo r estim ation o f rln lA  
m olecular weight. The vo value was calcu lated using blue dextran and the data points 
obtained fo r the m olecular weight standards 0-am ylase (fi-A), 200 kDa; alcohol 
dehydrogenase (AD), 150 kDa; bovine serum album in (BSA), 66 kDa; carbonic anhydrase 
(CA), 29 kDa and cytochrome C  (CC), 12.4 kDa). The data was lin ea rly  resolved using a 
four-param eter equation.
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5.2.3 Characterisation o f  the mAbG94F8-p60 interaction using Biacore
The evidence garnered by ELISA and Western b lo t analyses in Section 3.2.2.3 had suggested 
that mAbG94F8 was specific fo r p60. However, this was subject to further confirmation. The 
Biacore system facilitated a more controllable analysis o f the various parameters affecting 
binding, in a range o f formats.
5.2.3.1 Confirmation of p60-specificity of mAbG94F8 using Biacore
The monoclonal antibody mAbG94F8 had been putatively designated ‘anti-p60\ based on 
prelim inary inhibition-ELISA  and Western blot analysis using L. monocytogenes culture 
supernatant-derived proteins (Sections 3.2.2.2 to 3.2.2.4). In addition, although a strong 
immunoreactivity was observed when rp60 was probed by Western blotting (Section 3.2.2.3), 
it  was not possible to correspondingly confirm  ‘non-reactivity’ towards LLO , due ostensibly 
to lack o f availab ility o f suitably pure native or recombinant LLO  protein. Confirm ation o f 
this distinction in reactivity was necessary due to the fact that both p60 and LLO  were present 
in L. monocytogenes culture supernatant (Section 3.2.1.2) and were o f equivalent, 
indistinguishable molecular weights.
Subsequent to this particular set o f experiments, a small quantity o f recombinant LLO  (r 
LLO ) was sourced and a sample was kind ly donated by Prof. Mauro Magnani (Centro di 
Biotecnologie, University o f Urbino, Italy). The rLLO  had been prepared as previously 
described (Giammarini et al., 2003). Due to the lim ited amount o f rLLO  available, it  was fe lt 
that im m obilising it  onto a sensor chip surface would enable the most judicious exploitation 
o f the protein fo r analysis.
5.2.3.1.1 Preparation of rLLO-CM5 sensor chip surface
Pre-concentration was not performed, as a means o f rationing the lim ited supply o f rLLO  
protein. However, since the predicted theoretical p i o f LLO  was 6.7 (based on the Genbank 
accession number AF253320, UniProt reference number Q9L5B9, using the ProtParam 
function at http://us.expasy.org/cgi-bin/protparam) and the protein was known to be stable in  
acidic environments, it  was fe lt that pH 4.5 would be adequate fo r pre-concentration and 
imm obilisation. In  order to ensure maximal covalent im m obilisation capacity was achieved, a 
‘double-activation’ step was incorporated. This entailed exposing the CM  dextran to 
EDC/NHS fo r tw ice the normal activation time (i.e. 14, rather than 7 minutes). 
Approxim ately 2047 RUs o f rLLO  was covalently immobilised (Figure 5.36).
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5.2.3.1.2 Assessment of mAbG94F8 binding to immobilised rLLO
The binding response of mAbG94F8 against immobilised rLLO, was compared with that of 
polyclonal anti-LLO. The latter was affinity-purified (Section 2.6.3) from rabbit polyclonal 
antiserum, kindly donated by Prof. Chakraborty and Dr. Daiji, University of Giessen, 
Germany. Affinity-purified mAbG94F8, in PBS, was diluted 1/10 in HBS buffer and fresh 
mAbG94F8 hybridoma supernatant was diluted 1/2 in HBS containing 1 M NaCl, to yield a 
final salt concentration of 0.5 M. The high salt was incorporated to minimise non-specific 
binding of heterogenous material from within the complex matrix of the cell culture medium. 
Both mAbG94F8 samples were individually, sequentially injected over the immobilised 
rLLO-CM5 surface and in both cases, binding responses were negligible (Figure 5.37). 
However, when the polyclonal anti-LLO antibody was passed over the surface, over 2000 
RUs of antibody bound. This confirmed that the activity of the immobilised rLLO protein had 
not been substantially compromised by the immobilisation procedure. Cumulatively, these 
results confirmed that mAbG94F8 was not active against rLLO, and when considered 
alongside the results in Section 3.2.2.4, confirmed that mAbG94F8 was indeed specific for 
p60 and not LLO.
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Figure 5.36: Immobilisation rLLO onto the CM5 sensor chip surface. (A) EDC/NHS ‘double­
activation (B) covalent binding of rLLO and (C), capping of unreacted groups. A final level 
of20447.0 RUs covalently attached rLLO was achieved.
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T i m e  ( s )
F igu re  5.37: B ind ing analysis o f putative anti-p60 m AbG94F8 and an ti-LLO  to rLL0 -C M 5  
surface. The sensorgram  depicts the raw, non-reference-subtracted binding responses 
obtained fo llow ing  sequential injection o f (A) a ffin ity-pu rified  mAbG94F8, at a 1/10 d ilu tion  
(~20 ng/m l) in HBS, (B) fresh  m AbG94F8 hybridom a supernatant, at a 1/2 d ilu tion  in  H BS  
(containing 0.5 M N a C l) and (C), an ti-LLO  po lyclona l antibody, at a 1/100 d ilu tion  in  HBS, 
across the rLLO -CM 5 surface. The flow  rate employed throughout was 10 pl/m in and surface 
regenerations (D, E  and F) were e lic ited  w ith 5 f il pu lses o f 10 m M  NaOH. S ign ifican t 
binding, was only demonstrated by the an ti-LLO  po lyclona l antibody (2326.4 RUs).
S.2.3.2 Preparation o f m AbG94F8-CM 5 sensor ch ip  surface
To facilitate the demonstration of specific binding of rp60 by mAbG94F8, the reverse 
configuration, with mAbG94F8 immobilised on the CM5 surface, was also investigated. Pre­
concentration was conducted, as routinely described (Section 2.10.1), across the pH range 
4.0-5.0 (Figure 5.38). Preliminary, exploratory experiments had indicated rp60 to be prone to 
non-specific binding (Paul Leonard, personal communication) and thus, to minimise the 
possibility of residual activated carboxyl groups, a ‘double-capping’ step was incorporated, 
whereby the period of exposure to capping reagent was doubled. Approximately 15800 RUs
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of mAbG94F8 was efficiently immobilised (Figure 5.39). A blank reference surface was 
prepared, for the purposes of on-line reference subtraction, by subjecting a downstream 
flowcell surface to an identical activation and capping procedure, with the ligand- 
immobilisation step omitted.
Time (s)
Figure 5.38: Pre-concentration o f mAbG94F8 onto the CM5 sensor chip surface across the 
pH range 4.0-5.0. There was no substantial improvement in pre-concentration from pH 4.6 to 
5.0 and, thus, 10 mMsodium acetate buffer at pH  4.7 was chosen as the immobilisation buffer 
for the mAbG94F8 antibody onto the CM5 chip surface.
291

45000
35000
25000
8  15000 K
1000 1500 
Time (s)
Figure 5.39: Im m obilisation o f m AbG94F8 onto the CM 5 sensor ch ip surface. The 
im m obilisation included an extended, ‘double-capping’ step, to m inim ise non-specific 
binding. (A) EDC/N H S activation, (B) covalent binding o f mAb2B3 (125 fig/m l in  10 m M  
sodium acetate, p H  4.7) (C) capping o f unreacted groups and (D), regeneration pulse o f 5 
m M H C l. The fin a l leve l amounted to 15793.6 RUs o f covalently attached m AbG94F8 was 
achieved.
5.2.3.3 Assessment of p60protein binding to immobilised mAbG94F8 
The specific activity of the mAbG94F8-CM5 surface, with respect to p60 protein was 
demonstrated by injecting fresh supernatant sample, from a L. monocytogenes culture at 
exponential growth in BHI broth, across the sensor surface. The supernatant was filtered 
using a 0.2 fim cut-off syringe filter to remove cells/particulate debris, before being injected. 
In addition, a neat sample of IMAC-purified rp60 was also injected across the surface. 
Following on-line reference subtraction, the overlayed binding interaction curves indicated 
response levels of approximately 64 and 634 RUs, respectively (Figure 5.40).
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F igu re  5.40: Sensorgram depicting binding o f p60 to im m obilised m AbG94F8. A  20 f il 
sample o f neat, IM AC -purified  rp60 (red) and sterile  filte re d  culture supernatant from  a L. 
monocytogenes l/2 a  culture in  B H I broth was injected over the m AbG94F8-CM 5 surface at a 
flow  rate o f 10 fil/m in. The broken lin e  indicates the baseline response. B ind ing responses o f 
633.7 and 64.1 were recorded fo r the rp60 and cultw 'e supernatant samples, respectively.
5.2.3.4 Im m obilisation o f rp60 onto the CM S sensor ch ip  surface 
The findings of Sections 5.2.3.1-5.2.3.3, above, which confirmed that mAbG94F8 was 
reacting with p60 and not LLO, were in agreement with cross-reactivity results outlined in 
Section 3.2.2.4. The latter indicated that mAbG94F8 reacted specifically with a 60 kDa 
protein, present in the supernatant of each of the representative L. innocua and L. ivanovii 
species’ tested. Although L. ivanovii produces a variant haemolysin, termed ‘ivanolysin’, L. 
innocua is a known non-haemolytic species.
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Thus, in terms of the principle objective of this thesis (i.e. the specific detection of L. 
monocytogenes), the mAbG94F8 antibody was not ideal, due to the lack of species specificity 
and the fact that it is predominantly secreted into the culture medium. Nonetheless, the ability 
to specifically detect p60 protein in enrichment media may have potential implications for the 
development of a ‘presumptive’ test platform as a reliable indicator of listerial contamination. 
With this in mind, it was deemed a useful exercise to investigate the possibility of employing 
the SPR-based biosensor to specifically detect listerial p60 protein. This was assessed in a 
series of exploratory, empirically optimised experiments.
Immobilisation was performed using the standard EDC/NHS covalent attachment process 
(Sections 2.10.2, 5.2.1.1 and 5.2.1.2). Due to the extreme basicity of rp60, with a predicted pi 
of -9.3, pre-concentration was not performed. Instead, immobilisation was conducted at the 
highest pi that is recommended as acceptable for EDC/NHS-mediated coupling. As this was 
significantly lower than 9.5, it was predicted to effectively preconcentrate the rp60 onto the 
CM-dextran matrix. An immobilised level of approximately 7500 RUs was achieved (Figure
5.41).
5.2.3.5  Preliminary assessment of binding to the rp60-CM5 sensor chip surface 
Given the high intrinsic pi of rp60 (-9.3), it was anticipated that it would exhibit a 
significantly positive charge in HBS running buffer (pH 7.4). Experimentally, this manifested 
as a strong, non-specific ionic preconcentration (-2297 RUs) onto the negatively charged, 
unmodified CM-dextran matrix, following a two minute injection of rp60 at 25 pg/ml (Figure
5.42). When the same sample was passed over the rp60-immobilised surface, there was also 
substantial, yet significantly less binding (-1080 RUs) apparent. The net reduction in overall 
non-specific binding was attributed to the rp60 immobilisation step which effectively blocked, 
or ‘capped’ most of the charged or reactive carboxyl moieties. The incorporation of a 
‘double-capping’ step (Figure 5.41) rendered it unlikely that substantial residual uncapped 
carboxyl groups were the main source of the non-specific pre-concentration of p60. It was felt 
most probable that rp60 was actually non-specifically ‘binding to itself. Thus, when an 
inhibition test was attempted, the antibody control (i.e. mAbG94F8 in HBS buffer, with no 
free rp60 antigen), generated a lower apparent binding response (105 RUs), than when 
incubated with excess rp60 protein (1080.1 RUs) (Figure 5.42). This could be interpreted as a 
combined response of individual non-specific binding of rp60 and specific binding of 
mAbG94F8 to available rp60 ligand on the chip surface. This would suggest that the 
mAbG94F8-rp60 interaction was not competitive in solution and re-affirm the suspicion of 
non-specific rp60-rp60 interaction. However, this assumption was in clear contradiction of the 
inhibition-ELISA outlined in Section 3.2.2.3, which clearly demonstrated that mAbG94F8
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was capable of binding p60, albeit, the non-recombinant, crude extract version, in solution. It 
is plausible that the exaggerated binding response was actually a cumulative response for 
successfully bound mAbG94F8-rp60 complex, binding to the immobilised rp60, 
predominantly via the non-specific rp60-rp60 interaction. It was difficult to definitively 
resolve the binding pattern demonstrated in Figure 5.42. However, what was clearly apparent 
was, that these non-specific contributions rendered the sensor format unreliable for detection 
of free p60.
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Figure 5.41: Immobilisation of rp60 onto the CM5 sensor chip surface. The immobilisation 
included a ‘double-capping’ step, to minimise non-specific binding. (A) EDC/NHS activation, 
(B) covalent binding of rp60 (100 fig/ml in 10 mMsodium acetate, pH 6.0) (C) capping of 
unreacted groups and (D), regeneration pulse of 5 mMHCl. A final level of 7543.8 RUs of 
covalently attached mAbG94F8 was achieved.
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Figure 5.42: Pre lim inary binding p ro file  o f m AbG94F8 to rp60-CM 5 surface. The colour- 
coded binding curves represent as fo llow s: (blue), a 1:1 m ixture o f rp60 d ilu ted 1/5 in  H BS  
and H BS buffer alone (effective rp60 d ilu tion  o f 1/10) injected across a blank, unm odified 
CM -dextran surface; (green), the same effective 1/10 rp60 solution injected across the rp60- 
im m obilised CM 5 surface; (pink), a 1/1000 d ilu tion  o f m AbG94F8 in  H BS injected across the 
rp60-im m obilised CM 5 surface and (red), a 1:1 m ixture o f rp60 d ilu ted 1/5 in  H BS and a 
1/500 d ilu tion  o f m AbG94F8 in  H BS injected across the rp60-im m obilised CM 5 surface. The 
flo w  rate used throughout was 10 jul/min and 20 f il o f each sample was injected. A ll curves 
were subjected to on-line reference subtraction and were overlayed, aligned and norm alised 
using BIAevaluation ™ software. Com parative binding response levels were taken 30 seconds 
after the end o f each sample injection and the values are indicated in  the inset box. 
Cum ulatively, the data suggests strong non-specific binding o f rp60 to CM -dextran and 
possib ly rp60 itself, also.
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5.2.3.6 The effect of salt concentration on binding to the rp60-CM5 surface
In an effort to reduce the contribution to non-specific binding, of the ionic interactions, a salt 
titration was conducted. NaCl concentrations of up to 0.5 M have been reported to reduce 
non-specific binding contributions in complex matrices such as urine and serum (Johansson 
and Hellenas, 2004). mAbG94F8 at a 1/200 dilution and rp60 at a 1/500 dilution were 
empirically selected for analysis, since at these respective dilutions, both analytes generated 
comparative net binding responses of between 200 and 250 RUs. Across the range of NaCl 
concentrations assayed, the degree of non-specific binding of free rp60 to the immobilised 
rp60-CM5 surface decreased gradually from -250 to -50 RUs (Figure 5.43). However, across 
the same salt concentration range, the specific mAbG94F8 binding response remained 
constant and was essentially, unaffected.
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Figure 5.43: Effect o f buffer N aC l concentration on binding to the rp60-CM 5 surface. 
m AbG94F8 at a 1/200 d ilu tion  (blue) and rp60 at a 1/500 d ilu tion  (purple), were passed over 
the rp60-CM 5 surface at 5 jul/m in fo r two minutes and the mean binding response level 
plotted. The data is the average o f trip lica te  measurements. The response levels were 
measured in  H BS buffer containing 0.150, 0.225, 0.300 and 0.500 M N aC l.
■  m AbG 94F8
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5.2.3.7 Immobilisation of rp60 onto the B1 sensor chip surface
The B1 sensor chip is equivalent to the generic CM5 sensor chip in terms of its hydrogel 
content, yet it contains 70 % less carboxyl groups. Therefore, it was postulated that the lower 
overall level of carboxylation would reduce the propensity for non-specific, cationic surface 
effects. Due to the reduced availability of available carboxyl groups and concomitant lower 
ligand immobilisation capacity, it was essential that the activation step of the immobilisation 
process was maximised. Thus, a ‘double-activation’ was employed and in addition, rp60 was 
used at twice the concentration (i.e. 200 Mg/ml) and twice the volume that was used with the 
CM5 surface, to ensure the surface immobilisation capacity was fully saturated. 
Ethylenediamine was used as a capping agent instead of ethanolamine as a final precaution 
against non-specific binding. The final level of immobilised rp60 was, as expected, low (2163 
RUs), yet it was sufficient for binding analysis (Figure 5.44). A comparable negative control 
surface was prepared by double-activation and diethylamine-capping of a downstream flow 
cell surface.
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Figure 5.44: Immobilisation of rp60 onto the B1 sensor chip surface. The immobilisation 
included a ‘double-capping ’ step, to minimise non-specific binding. (A) EDC/NHS activation,
(B) covalent binding of rp60 (200 ng/ml in 10 mMsodium acetate, pH 6.0) and (C), capping 
of unreacted groups with ethylenediamine instead of ethanolamine. A final level of 2162.5 
RUs of covalently attached rp60 was achieved.
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5.2.3.8 Optimisation of binding to the rp60-Bl sensor chip surface
The individual binding responses of mAbG94F8 and rp60 were compared (Figure 5.45) on 
the rp60-Bl chip, using HBS running buffer containing 0.5 M NaCl. When the raw response 
curves were compared with the responses on the blank, ‘capped’ B1 reference surface, there 
was a net binding response of 192.75 RUs generated by specific mAbG94F8 binding. 
Conversely, a negligible response of ~2.5 RUs was demonstrated when free rp60 was 
injected. This indicated that the rp60-Bl chip was indeed less susceptible to non-specific 
binding.
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Figure 5.45: Com parison o f m AbG94F8 (A) and free rp60 (B) binding to the rp60 -B l chip 
surface. The specific binding responses o f m AbG94F8 (left) at a 1/50 d ilu tion  in  HBS  
containing 0.5 M  N aC l and rp60 (right), at a 1/100 d ilu tion  were compared fo llow in g  a two 
minute injection at 10 fil/m in. The red, blue and green colour-coding refers to the rp60 -B l 
surface response, contro l surface response and the reference-subtracted response, 
respectively. The sensorgrams were overlayed, aligned and norm alised using 
BIAevaluation™ softw are. The net binding response e lic ited  by m AbG94F8 was 192.7 RUs, 
w hile that e lic ited  by free rp60 was neglig ible.
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In order to conclusively demonstrate the specificity of the mAbG94F8-rp60 interaction using 
the rp60-immobilised B1 sensor chip, the reference subtracted responses of mAbG94F8 
following pre-incubation at 37 °C in a 1:1 ratio with HBS alone and rp60, respectively, were 
compared (Figure 5.46). The clear reduction in net binding of mAbG94F8 was indicative of 
successful solution-phase inhibition and thus, confirmed that the complicated non-specific 
binding anomalies could be overcome by judicious buffer and surface optimisation.
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Figure 5.46: Solution-phase inh ib ition  o f m AbG94F8 binding to the rp60 -B l chip. The curves 
represent reference-subtracted binding response o f a 1/25 d ilu tion  o f m AbG94F8 fo llo w in g  
pre-incubation at 30 °C in  a 1:1 ra tio  w ith H BS buffer alone (red) and a 1/50 d ilu tion  o f rp60 
(blue), respectively. Samples were in jected for two m inutes at a constantflow  rate o f 5 ul/m in. 
The sensorgrams were overlayed, aligned and norm alised using BIAevaluation™  software. 
The difference in  Req response values (A) was approxim ately 277.77 RUs, and one minute 
after the end o f the injection the response difference was approxim ately 100 RUs (B). The 
reduction in  binding response c lea rly  indicates sign ifican t specific, solution-phase binding o f 
m AbG94F8 to rp60.
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5.3 Summary and conclusions
The principle aim of this chapter was to evaluate the potential of employing a SPR biosensor- 
based, approach to facilitate direct and label-free detection of L. monocytogenes. This 
incorporated further characterisation of the L. m onocytogenes-specific reagents described in 
Chapters 3 and 4.
The core achievement encompassed the demonstration of ‘real-time’ monitoring of direct 
binding of L. monocytogenes cells to the species-specific monoclonal antibody ‘mAb2B3\ It 
was found that optimal cell binding was achieved when mAb2B3 antibody was covalently 
attached, through amine-coupling, to a fully dextranated CM5 sensor chip hydrogel surface. 
Comparative analysis of these findings with recent reports in the literature revealed similar 
observations. Conversely, cells failed to bind efficiently to mAb2B3 antibody that was 
covalently linked to the equivalent non-dextranated, planar Cl sensor chip surface, despite the 
fact that this particular chip is actually marketed specifically for the detection of cells and 
other macromolecular entities. The binding levels achieved were comparable with those 
recently reported by Clyne and co-workers (2004), for specific capture of H elicobacter p y lo ri 
cells with a compatible receptor ligand, covalently attached to a CM5 sensor chip surface. 
However, no attempts had previously been made to explain the improved cell binding at the 
hydrogel surface. A critical explanation was thus postulated, that accommodated consensus 
thermodynamic and fluid dynamic perspectives. A central tenet was the substantial elasticity 
exhibited by the dextran polymer and intrinsic translational and rotational mobility, which it 
conferred upon the covalently attached ligand. This facilitated multiple bond formation 
between the ubiquitously distributed InlA protein, on the cell surface, and the immobilised 
antibodies, which was sufficient to overcome the avidity-threshold required for stable cell 
binding at the hydrogel surface. Correspondingly, the accessibility and constitutive expression 
of InlA on the L. monocytogenes cell surface, was viewed as a quintessential factor in the 
success of the direct cell binding strategy.
Subsequently, it was demonstrated that a number of representative L iste ria  spp., other than L. 
monocytogenes, and a selection of non-L iste ria  genus bacteria failed to elicit a binding signal. 
Similarly, binding of L. monocytogenes cells was totally abrogated following treatment of the 
cells at 80 °C for an extended period. The results mirrored those observed in the ELISA-based 
characterisation of the mAb2B3-Z. monocytogenes cell binding interaction, outlined in 
Chapter 3. These observations were interpreted as extremely significant, as they contribute to 
the possibility of reducing the false positive detection of non-pathogenic L iste ria  spp. and
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h e a t-k ille d , n o n -v ia b le /n o n -v ir u le n t  L. m o n o cy to g en es  c e l l s ,  w h ic h  are lim ita tio n s  a s s o c ia te d  
w ith  m a n y  o f  th e  cu rren tly  a v a ila b le  im m u n o - a n d  D N A -b a s e d  d e te c t io n  m e th o d s . T h e y  a lso , 
further re in fo r c e  th e  s ig n if ic a n c e  o f  th e  e x c lu s iv i ty  o f  In lA  to  L. m o n o cy to g en es , an d  th e  
a sso c ia te d  c e ll  to p o g ra p h y .
U s in g  th e  d irec t b in d in g  a s s a y  it  w a s  p o s s ib le  to  d e te c t  L. m o n o cy to g en es  c e l l s  at 
c o n cen tra tio n s  a p p ro a ch in g  1 x  107 c e l ls /m l. In  l ig h t  o f  sev era l rep orts th at b in d in g  o f  a  
se c o n d a r y  a n tib o d y  to  cap tu red  c e l l s  r e su lted  in  en h a n ced  r e sp o n se  s ig n a ls , a  sa n d w ic h -ty p e  
stra teg y  w a s  in v e s tig a te d , as a  m e a n s  o f  im p r o v in g  th e  se n s it iv ity . H o w e v e r , tw o  p o ly c lo n a l  
a n tib o d ie s , k n o w n  to  react w ith  L is te r ia  c e l l s ,  fa i le d  to  e l ic it  a n y  d is c e m a b le  s ig n a l  
im p ro v em en t w h e n  p a sse d  o v e r  cap tu red  L. m o n o cy to g en es  c e l l s .  T h is  particu lar  o b se r v a t io n  
m irrored  th e  f in d in g s  o f  L ath rop  an d  co -w o r k e r s , (2 0 0 3 ) .  F u rth erm ore, a s a lrea d y  a llu d ed  to , 
th e  th resh o ld  a v id ity  w a s  th e  p r in c ip le  lim it to  th e  a s s a y  se n s it iv ity . M o r e  s p e c if ic a l ly ,  
e f f e c t iv e  cap tu re  o f  c e l l s  a t th e  se n so r  su r fa ce  w a s  o n ly  p o s s ib le  w h e n  th en  th e  c e l l  
co n cen tra tio n  w a s  su f f ic ie n t ly  h ig h  to  sa t is fy  th e  c o m b in e d  th erm o d y n a m ic , f lu id  d y n a m ic  
and  in trace llu lar  ch a rg e  d e term in a n ts th a t d e fin e d  th e  a v id ity -tr e sh o ld . T h u s, it w a s  u n lik e ly  
that e v e n  su b stan tia l b in d in g  o f  se c o n d a r y  a n tib o d y  w o u ld  e n h a n c e  d e te c t io n  lim its  to  
s ig n if ic a n t ly  b e lo w  1 x  107 c e lls /m l.
T h e  sp e c if ic  b in d in g  o f  m A b 2 B 3  to  r ln lA  w a s  a ls o  c o n fir m e d  th ro u g h  S P R -b a se d  
ch a ra cter isa tio n  o f  th e  in teraction . V a r io u s  im m o b ilis a t io n  s tra teg ie s  w e r e  in v e s t ig a te d  w ith  
r e sp e c t  to  r ln lA . T h is  w a s  v ie w e d  a s  n e c e ssa r y , s in c e  th e  p ro jec ted  d e v e lo p m e n t  o f  a  
stan d ard ised  S P R -b a se d  c o m p e t it iv e  or  in h ib it io n  a ssa y  fo rm a t, pu rsu an t to  th is  resea rch , w a s  
e n v is a g e d  a s  a  m e a n s  o f  a c h ie v in g  g rea ter  se n s it iv ity . O p tim ise d  im m o b ilis a t io n  o f  r ln lA  w a s  
a ls o  req u ired  to  fa c ilita te  e s t im a tio n  o f  th e  stea d y -sta te  eq u ilib r iu m  a ff in ity  o f  m A b 2 B 3  to  
r ln lA . In itia lly , d irec t c o v a le n t  a tta ch m en t o f  r ln lA  to  a  C M 5  se n so r  c h ip  su rfa ce  b y  a m in e -  
c o u p lin g , w a s  fa v o u red  b e c a u se  o f  th e  s ta b le  and  rob u st c o v a le n t  lin k a g e  it  c o n ferred  and  th e  
‘r e -u s a b ility ’ o ffe r e d  u n d er c o n d it io n s  o f  o p tim ise d  sa m p le  b u ffer  an d  reg en era tio n  
c o n d it io n s .
S u rp r is in g ly , th e  e s t im a ted  ste a d y -s ta te  a ff in ity , a s r ep resen ted  b y  th e  ap p aren t K D, w a s  q u ite  
lo w  (2 .2 3  x  10'7 M ). H o w e v e r , th is  e s t im a te  w a s  in terpreted  ten ta tiv e ly , d u e  to  th e  fa c t  that th e  
ap p aren t su r fa ce  a c tiv ity  o f  th e  im m o b il is e d  r ln lA  w a s  c a lc u la te d  to  b e  m u ch  lo w e r  than  th e  
th eo re tica l p red ic tio n . T h is  w a s  a ttr ib u ted  to  th e  rand om  n atu re  o f  th e  im m o b ilis a t io n  stra tegy . 
T o  o v e r c o m e  th is  lim ita tio n , a  lig a n d  cap tu re  ap p roach  w a s  in v e s tig a te d . T h e  in itia l capture  
stra teg y  to o k  a d v a n ta g e  o f  th e  H is -ta g  th a t h a d  b een  in corp ora ted  at th e  r ln lA  C -term in a l an d  
a v a ila b le  N T A -b a se d  c h e la t in g  se n s o r  c h ip  te c h n o lo g y . U n fo r tu n a te ly , w ith  th e  N T A  se n so r
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c h ip  arran gem en t th ere  w a s  p erv a d in g  n o n -s p e c if ic  b in d in g  o f  m A b 2 B 3  to  th e  N i2+-ch a rg ed  
N T A  m atrix . M o s t  o f  th e  n o n -s p e c if ic  b in d in g  w a s  e f f ic ie n t ly  a b ro g a ted  u s in g  sa m p le  b u ffer , 
at p H  6 .2 5 , in  th e  p r e se n c e  o f  a  h ig h  sa lt  co n cen tra tio n  (0 .5  M ). H o w e v e r , s in c e  th e  N T A  ch ip  
arran gem en t d id  n o t  fa c ilita te  ‘o n - l in e ’ r e fe r e n c e  su b traction , it  w a s  regard ed  a s  u n re lia b le  fo r  
th e  d e term in a tio n  o f  a ff in ity  data . S u c h  c o m p lic a t io n s  are p ro b a b ly  th e  rea so n  w h y  th e  u se  o f  
N T A  se n s o r  c h ip s  is  in freq u en tly  rep orted  in  th e  literature.
In ord er to  o v e r c o m e  th e  lim ita tio n s  o f  th e  N T A -b a s e d  cap tu re  ap p roach , an  a ltern a tiv e  
stra teg y  w a s  in v e s tig a te d . T h is  en ta iled  th e  u se  o f  an  a n ti-H is -ta g  m o n o c lo n a l a n tib o d y , w h ic h  
w a s  im m o b ilis e d  to  a  C M 5  su rfa ce  th ro u g h  a m in e -c o u p lin g . T h is  w a s  n o t su b je c t  to  n o n ­
s p e c if ic  b in d in g  a rte fa cts  and  a ls o , fa c ilita te d  ‘o n - l in e ’ r e fe r e n c in g  o f  sen so rg ra m  data. 
H o w e v e r , th e  fo rm a t w a s  c o m p lic a te d  b y  th e  fa c t  th at r ln lA  r a p id ly  d is so c ia te d  fro m  th e  an ti- 
H is -ta g  su r fa ce . T h u s, ‘d o u b le -r e fe r e n c in g ’ h ad  to  b e  in corp ora ted  in  ord er to  r e s o lv e  th e  
c o m p le x  stea d y -sta te  eq u ilib r iu m  b in d in g  p r o f ile  rep resen ted  b y  th e  c u m u la tiv e  raw  
sen so rg ra m  data . T h e  a s so c ia tio n  co n sta n t w a s  e s t im a ted  to  b e  1 .93  x  1 O'7 M , w h ic h  w a s  
co m p a ra b le  w ith  th e  e s t im a te  o b ta in ed  u s in g  th e  c o v a le n t ly  im m o b ilis e d  r ln lA  su r fa ce . In  
a d d it io n , d e sp ite  ca re fu l a tten tion  to  en su re  o p tim a l o r ien ta tio n  o f  th e  r ln lA  m o le c u le , the  
c o n c o m ita n t im p ro v em en t in  ap parent a c t iv ity  o f  th e  cap tu red  lig a n d  w a s  s t ill su b sta n tia lly  
le s s  than  th e  p red ic ted  le v e l .
It w a s  c o n c lu d e d  th at th e  su b -o p tim a l a c tiv ity  w a s  c a u se d  b y  in h eren t a n o m a lie s  w ith in  th e  
r ln lA  m o le c u le . S u b seq u en t a n a ly s is  in d ic a te d  th at th e  r ln lA  h ad  a ssu m e d  a  m u ltim er ic  
d isp o s it io n  in  so lu tio n , s p e c if ic a l ly  a  te tra m er ic  co n fo rm a tio n . T h is  is  an is su e  th at w i l l  n e e d  
to  b e  ad d ressed  p rior to  in co rp o ra tio n  o f  th e  r ln lA  m o le c u le  in to  a n y  so lu tio n -p h a se  a s s a y  
form at.
A lth o u g h  it  h ad  n o t b e e n  p o s s ib le  to  c o n fir m  th e  s p e c if ic ity  o f  m A b G 9 4 F 8  fo r  p 6 0  p rote in  
u s in g  E L IS A , it  w a s  p o s s ib le  to  d o  th is  u s in g  B ia c o r e . It w a s  c le a r ly  d em o n stra ted  that 
m A b G 9 4 F 8  b o u n d  s p e c if ic a l ly  to  a  se n so r  c h ip  su r fa ce  w ith  rp 6 0  a tta ch ed  an d  n o t  to  o n e  w ith  
rL L O  attach ed . F u rth erm ore, pu rsu an t to  th e  s u g g e s t io n  th at th e  m A b G 9 4 F 8  a n tib o d y  co u ld  
p o te n t ia lly  b e  u se d  in  a  p resu m p tiv e  o r  in d ica to r  te s t  fo r  lister ia l p r e se n c e  (S e c t io n  3 .2 .2 .4 ) ,  
th e  p o s s ib il ity  o f  p er fo rm in g  su c h  a te s t  u s in g  th e  B ia c o r e  se n so r  w a s  in v e s tig a te d . D e sp ite  
th e  v e r y  h ig h  p i  e x h ib ite d  b y  p 6 0  an d  its  in h eren t ‘s t ic k in e s s ’, c o n d it io n s  w e r e  o p tim ise d  that 
fa c ilita ted  sp e c if ic  b in d in g  o f  p 6 0  to  b e  m o n ito r e d  in  rea l-tim e .
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C h a p t e r  6
O v e r a l l  S u m m a r y  a n d  C o n c l u s i o n s
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T h e  o v era ll a im  o f  th is  w o r k  w a s  to  d e v e lo p  a  m o n o c lo n a l a n tib o d y  su ita b le  fo r  u s e  in  an  
a ssa y s  fo r  th e  sp e c if ic  d e te c t io n  o f  Z. m o n o cy to g en es  c e l l s ,  a s  d e ta ile d  in  C h ap ters 3 , 4  an d  5.
In C h ap ter 3 , p re lim in a ry  s tu d ie s  fo c u s s e d  o n  th e  p ro d u c tio n  o f  a n tib o d ie s  to  en r ic h e d  p ro te in  
fra c tio n s  th at h ad  b e e n  d er iv ed  fro m  a c tiv e  cu ltu res  o f  p a th o g e n ic  L. m o n o cy to g en es .  T h e  fir st  
m o n o c lo n a l a n tib o d y  w a s  iso la te d  fo l lo w in g  im m u n isa tio n  o f  m ic e  w ith  an  e n r ich ed  L. 
m o n o cy to g en es  cu ltu re  su p ern atan t th a t had  b e e n  c r u d e ly  fra c tio n a ted . T h is  a n tib o d y  rea c ted  
s p e c if ic a l ly  w ith  a  6 0  k D a  p ro te in  p resen t in  th e  cu ltu re  sup ern atan t. It w a s  in it ia lly  u n c lea r  
w h eth er  th is  p ro te in  w a s  p 6 0  or  L L O . F o llo w in g  a  co m p a r a t iv e  a n a ly s is  o f  th e  a n tib o d y  
rea c tiv ity  to  ex tra ce llu la r  p ro te in s  d er iv ed  fro m  v a r io u s , rep resen ta tiv e  L is te r ia  sp p ., it w a s  
dem on stra ted  that th e  a n tib o d y  b o u n d  to  a 6 0  k D a  p ro te in  p resen t in  th e  su p ern atan t o f  L. 
m on ocy togen es , L. iv a n o v ii  an d  L. innocua. A lth o u g h  L. iv a n o v ii  is  k n o w n  to  p r o d u ce  a L L O  
h o m o lo g u e , L. in nocua  d o e s  n o t. M o r e o v e r , p 6 0  h o m o lo g o u s  p ro te in s  are p rev a len t  
th ro u g h o u t th e  g e n u s  an d  th u s , b in d in g  o f  th e  a n tib o d y  to  L. in nocua-  d er iv ed  6 0  k D a  
ex tra ce llu la r  p ro te in , w a s  tak en  to  in d ica te  th at th e  p ro te in  b e in g  r e c o g n is e d  w a s  in d e e d  p 6 0 .  
T h is  a ssu m p tio n  w a s  la ter  v e r if ie d  b y  co m p a ra tiv e  S P R -b a se d  a n a ly s is  o f  an tib o d y  b in d in g  to  
reco m b in a n t p 6 0 -  an d  reco m b in a n t L L O -im m o b ilis e d  se n s o r  ch ip  su r fa ces . D e s p ite  th e  c le a r  
c r o ss -r e a c tiv ity  w ith  L. in n ocu a-  and L. iv a n o v ii-d er iv ed  p ro te in s, it  w a s  su g g e s te d  th at th e  
a n tib o d y  c o u ld , p o te n t ia lly , b e  u se d  fo r  th e  p re su m p tiv e  d e te c t io n  o f  lis ter ia l c o n ta m in a tio n .
A  se c o n d  m o n o c lo n a l a n tib o d y  w a s  p ro d u ced  u s in g  a  m o re  ra tio n a l and  targeted  ap p roach . 
T h is  e n ta ile d  im m u n is in g  m ic e  w ith  a  k n o w n  L. m o n o cy to g en es  p a th o g e n ic ity  m arker p ro te in , 
in  th is  c a se , ‘M B ’. T h e  c e ll-m e m b r a n e -a n c h o r e d  In lB  p ro te in  w a s  p ro te in  iso la te d  u s in g  a  
cru d e, y e t , h ig h ly  e f f ic ie n t  ex tra c tio n  p r o to c o l. S u b se q u e n tly , a  m o n o c lo n a l a n tib o d y  w a s  
ra ised  a g a in s t th e  In lB -e n r ic h e d  ex tract. T h e  a n tib o d y  b o u n d  to  th e  ex tra c t in  b oth  in h ib it io n -  
E L IS A  and  W estern  b lo t  fo rm a ts. T h e  s p e c if ic i ty  o f  th e  a n tib o d y  for  In lB  w a s  further  
c o n firm ed  b y  d em o n stra tin g  b in d in g  to  a  reco m b in a n t v e r s io n  o f  th e  fu ll- le n g th  m atu re In lB  
p rotein . U n fo r tu n a te ly , th e  a n tib o d y  fa ile d  to  b in d  s tro n g ly  to  w h o le  L. m o n o cy to g en es  c e lls .  
In terestin g ly , th e  a n tib o d y  se e m e d  to  b in d  s lig h t ly  b etter  to  h ea t-trea ted  L. m o n o cy to g en es  
c e lls .  It w a s  th u s , p o stu la ted  th at, p erh ap s th e  a n tib o d y  b o u n d  to  a  r e g io n  o f  th e  fr e e  In lB  
p rotein  th at w a s  n o t  fr e e ly  a c c e s s ib le  in  th e  c e ll-b o u n d  form . T h is  w a s  a r ea so n a b le  
a ssu m p tio n , g iv e n  th e  c o m m o n  a sser tio n  th at In lB  rem a in s  p a rtia lly  b u ried  w ith in  th e  m ajor  
c e ll  w a ll  structure. H o w e v e r , it  w a s  su b se q u e n tly  r e v e a le d , th rou gh  e p ito p e -p r o filin g , th a t th e  
a n tib o d y  sp e c if ic a l ly  b o u n d  to  a s e q u e n c e  in  th e  o u term o st and , th u s , m o s t  e x p o se d  In lB
6.1 O verall su m m a ry  a n d  conclusions
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d o m a in . T h is  em p h a s ise d  th e  r o le  o f  th e  o v e r a ll c e l l  su r fa ce  to p o g ra p h y , in  d ic ta tin g  th e  
a c c e s s ib il ity  o f  th e  su r fa ce  a n tig en .
B a se d  o n  th e  in a b ility  o f  th e  a n ti-In lB  a n tib o d y  to  b in d  w h o le  L. m o n o cy to g en es  c e l ls ,  and  th e  
s ig n if ic a n t  c r o ss -r e a c tiv ity  o f  th e  a n ti-p 6 0  a n tib o d y  w ith  L. in n o cu a , it  w a s  n e c e s s a r y  to  a d o p t  
an a ltern a tiv e  stra tegy . M ic e  w e r e  im m u n ise d  w ith  w h o le  L. m o n o cy to g en es  c e l l s ,  rather th an  
iso la te d  c e ll-su r fa c e  or  ex tra ce llu la r  p ro te in s . D u e  to  th e  c o m p le x  nature o f  th e  w h o le  c e l l  
im m u n o g e n , it  w a s  a n tic ip a ted  th a t a  c o r r e sp o n d in g ly , h e te r o g e n e o u s  p o p u la t io n  o f  a n tib o d ie s  
w o u ld  resu lt. T h is  n e c e ss ita te d  th e  im p le m e n ta tio n  o f  a  n e g a t iv e  s c r e e n in g  fo rm a t, w h e r e b y  
h y b r id o m a  su p ern atan ts w e r e  sc r e e n e d  in  p a ra lle l, a g a in s t b o th  L. m o n o cy to g en es  c e l l s ,  and  a  
rep resen ta tiv e , p o o le d  se le c t io n  o f  n o n -p a th o g e n ic  L is te r ia  sp p . (L. w e lsh im eri, L. s e e lig e r i  
and L. in nocua). T h is  fa c ilita te d  e f f ic ie n t  is o la t io n  o f  an a n tib o d y  that d em o n stra ted  a  c lea r  
sp e c if ic i ty  fo r  L. m o n o cy to g en es  c e l ls .
F urther a n a ly s is  o f  th is  a n tib o d y  r e v e a le d  th a t it  b o u n d  to  an  ~ 8 0  k D a  p ro te in , s p e c if ic a l ly  
p resen t in  th e  so lu b il is e d  c e l l  w a ll  p ro te in  fra c tio n  o f  L. m o n o cy to g en es  c e l l s .  T h is  8 0  k D a  
p ro te in  w a s  p u ta t iv e ly  p o stu la ted  to  b e  In lA . H o w e v e r , co n fir m a tio n  o f  th is  a ssu m p tio n  
req u ired  further ch a racter isa tion . In th e  a b se n c e  o f  an  a v a ila b le  m e th o d  fo r  re lia b le  
p u r if ica tio n  o f  n a tiv e  In lA , a  r eco m b in a n t v e r s io n  w a s  h e te r o lo g o u s ly  e x p r e sse d  in  E. c o li  
(C h ap ter  4 ) . T h e  p ro te in  w a s  e f f ic ie n t ly  p u r if ied  v ia  an in co rp o ra ted  H is-ta g , u s in g  IM A C  
w ith  o p tim is e d  b u ffer  co m p o n e n ts . S p e c if ic  b in d in g  o f  th e  a n tib o d y  to  th is  p u r if ied  
reco m b in a n t p ro te in , c o n fir m e d  it s  c la s s if ic a t io n  a s an  a n ti-In lA  an tib o d y .
It w a s  a ls o  n o te d  th a t th e  a n tib o d y  d em o n stra ted  s ig n if ic a n t ly  g rea ter  b in d in g  to  L. 
m o n o cy to g en es  c e l ls  th a t h ad  b e e n  cu ltu red  in  L E B  m e d ia , rather th a n  in  B H I m ed ia . 
F u rth erm ore, fo l lo w in g  h ea t in a c t iv a tio n  o f  th e  L. m o n o cy to g en es  c e lls ,  th e  a b ility  o f  th e  a n ti-  
In lA  a n tib o d y  to  b in d  c e l l s  w a s  s ig n if ic a n tly  red u ced . T h u s , e v e n  th o u g h  In lA  is  e x p r e s s e d  
c o n s itu t iv e ly , at a  b a sa l le v e l in  v ir u le n t L. m o n o cy to g en es , e x tr in s ic  fa c to r s  a ffe c t  th e  ce llu la r  
to p o g ra p h y , w h ic h  in  turn  d ic ta te s  th e  a c c e s s ib il it y  o f  su r fa c e - lo c a lis e d  e p ito p e s . T h e  la ck  o f  
cro ss -r e a c tiv ity  o f  th is  a n tib o d y  w ith  n o n -p a th o g e n ic  L is te r ia  sp p . and  h e a t- in a c tiv a te d  L. 
m o n o cy to g en es  c e l l s  w a s  e x p lo ite d  in  an  in h ib it io n  E L IS A  fo rm a t fo r  s p e c if ic  d e te c t io n  o f  L. 
m o n o cy to g en es .
In C h ap ter 5 th e  a n ti-In lA  a n tib o d y  w a s  ev a lu a te d  in  term s o f  its  p o ten tia l a p p lica tio n  in  th e  
d e v e lo p m e n t  o f  a  S P R -b a se d  b io s e n so r  a s s a y  form at (B ia c o r e )  for s p e c if ic  d e te c t io n  o f  L. 
m o n o cy to g en es  c e lls .  T h is  fo rm a t w a s  s u c c e s s fu l ly  d em o n stra ted  to  fa c i l i te  d irect, la b e l-fr e e
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d e tec tio n  o f  L. m o n o cy to g en es  c e ll  b in d in g , in  rea l-tim e . It w a s  a ls o  p o s s ib le  to  v is u a lis e  th e  
reten tio n  o f  c e l l s  a t th e  se n so r  su r fa ce  b y  m e a n s  o f  S E M  a n d  A F M  im a g e  a n a ly s is . A v id ity  
e f f e c ts  w e r e  cru c ia l to  th e  c e l l  b in d in g  p r o c e s s  and  it  w a s  p r o p o se d  th at a  m in im u m  th resh o ld  
a v id ity  d eterm in an t rep resen ted  th e  m a in  lim it in g  fa c to r  to  e f f ic ie n t  c e l l  b in d in g . In itia lly , it  
w a s  so m e w h a t  su rp risin g  th at d irec t c o v a le n t  a ttach m en t o f  th e  m o n o c lo n a l a n tib o d y  y ie ld e d  
th e  m o s t  e f f ic ie n t  c e l l  b in d in g  a c tiv ity . T h e  p o s s ib le  a d v a n ta g e s  a ffo rd ed  b y  th is  
im m o b ilis a t io n  stra teg y  w e r e  c r it ic a lly  a s s e s s e d  in  co n ju n c t io n  w ith  c o m p a ra b le  c ita t io n s  in  
th e  literature. N o ta b ly , th e  s ig n if ic a n t  co n tr ib u to ry  e f f e c t  o f  th e  d ex tran  h y d r o g e l o n  c e l l  
re ten tio n  at th e  se n so r  su rfa ce  w a s  e m p h a s ise d . In  p articu lar, th e  e n h a n c e d  ro ta tio n a l and  
tra n sla tio n a l fr e e d o m  o f  th e  h y d r o g e l- te th e r e d  a n tib o d y  w a s  d e f in e d  a s a  h ig h ly  a d v a n ta g eo u s  
fa c to r  fo r  b in d in g  o f  c e l l s  and  m a c r o m o le c u la r  structures in  g en era l.
T h e  S P R -b a sed  c e l l  b in d in g  e x p e r im e n ts  r e f le c te d  th o s e  o b ta in e d  u s in g  E L IS A  (C h ap ter  3 ) ,  
in so fa r  as, n e g lig ib le  b in d in g  to  n on-Z . m o n o cy to g en es  c e l l s  a n d  h ea t- in a c tiv a ted  L. 
m o n o cy to g en es  c e lls ,  w a s  o b se r v e d . A  rep resen ta tiv e  ca lib ra tio n  c u r v e  w a s  co n stru cted  fo r  
d irec t b in d in g  a n a ly s is  o f  L. m o n o cy to g en es  c e l ls  fro m  w h ic h , a  l im it  o f  d e te c t io n  
ap p ro a ch in g  1.23 x  1 0 7 c e lls /m l w a s  e s t im a ted . D e s p ite  th e  fa c t  that th e  a n tib o d y  a ff in ity , a s  
d e term in ed  b y  eq u ilib r iu m  ste a d y -s ta te  m ea su rem en ts , w a s  n o t  e x c e p tio n a lly  s tro n g  (K d =  
1 .93  x  10'7 M )  th e  d e te c t io n  lim it w a s  a c tu a lly  s l ig h tly  lo w e r  th an  th e  l im it  d eterm in ed  u s in g  
E L IS A  (1 .8 5  x l O 7 c e lls /m l) .
It is  a c k n o w le d g e d  th a t n e ith er  o f  th e  a s s a y  form ats d em o n stra ted  rem ark ab le  se n s it iv ity  in  
co m p a r iso n  w ith  a v a ila b le  c ita t io n s  in  th e  literature. F or  e x a m p le , s im ila r  E L IS A -b a se d  c e ll -  
b in d in g  a s s a y s  rep ort lim its  o f  d e te c t io n  a p p ro a ch in g  o f  1 x  10 5 c e l l s /m l (E r ik s so n  e l a l., 
19 9 5 ; L eo n a rd  e t  a l ,  2 0 0 4 ) .  C o m p a ra b le  b io se n so r -b a se d  a s s a y s  v a iy  w i ld ly  in  th e ir  rep orted  
d e te c t io n  lim its . H o w e v e r , a ttem p ts to  im p r o v e  th e  s e n s it iv ity  o f  th e  L. m o n o cy to g en es  d irect  
c e l l  b in d in g  a ssa y , b y  u s in g  a  sa n d w ic h  fo rm a t th e  sen so r  c h ip  su rfa ce  w e r e  u n su c c e s s fu l, and  
it is  u n lik e ly  th a t th e  s e n s it iv ity  ca n  b e  en h a n ced , b a sed  o n  d irect, e v a n e sc e n t  f ie ld - lim ite d  
in terroga tion . N o n e th e le s s ,  it  is  a sser ted  th a t th e  a s s a y s  d e sc r ib e d  in  th is  resea rch  are in ten d ed  
fo r  th e  sp e c if ic  d e te c t io n  o f  L. m o n o cy to g en es  c e l l s  from  p r e -en r ich ed  sa m p le  cu ltu res. T h u s, 
it is  th e  a n tib o d y  s p e c if ic ity  th a t i s  th e  q u in te ssen tia l d e f in in g  cr iter ia  o f  th e  a s s a y  
p er fo rm a n ce . T h e  lim ite d  s e n s it iv ity  a c h ie v a b le  u s in g  S P R  w ith  r e sp e c t  to  lo w  c o n cen tra tio n s  
o f  w h o le  m ic r o o r g a n ism s (P o u r sh a f ie  e t  a l.,  2 0 0 4 )  is  a c k n o w le d g e d . H o w e v e r , it h a s  b e e n  
su g g e s te d  th a t a ll ‘rap id  m e th o d s ’ w i l l  l ik e ly  req u ire  p re -en r ich m en t to  a llo w  c e l l s  rea ch  
d e tec ta b le  n u m b ers (K a ra m o n o v á  e t  a l.,  2 0 0 3 )  an d  th is  is  a  p erv a d in g  te n e t  in  th e  
m e th o d o lo g ie s  an d  o p in io n s  e x p r e sse d  th ro u g h o u t th is  th e s is .
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C o n se q u e n tly , th e  k e y  m e r it  o f  th e  w o r k  d e sc r ib e d  h e r e in  re sts  in  th e  d em o n stra ted  s p e c if ic i ty  
o f  th e  a n ti-In lA  m o n o c lo n a l a n tib o d y  fo r  L. m o n o cy to g en es  c e l l s  an d  th e  s u c c e s s fu l  
in tegra tion  o f  th is  a n tib o d y  w ith  S P R -b a se d  b io s e n s in g  in stru m en ta tio n  to  fa c ilita te  r e lia b le  
d etec t io n  o f  L. m o n o cy to g en es  c e lls .  T h e se  re su lts  c le a r ly  e m p h a s ise d  th e  su ita b ility  o f  In lA  
as a  m ark er fo r  th e  s p e c if ic  im m u n o d e te c t io n  o f  L. m o n o cy to g en es . T h e  m a jo r  a d v a n ta g e  o f  
th e  S P R -b a se d  a s s a y  w a s , th at it  e x h ib ite d  a rap id  sa m p le -to -r e su lt  t im e  an d  o b v ia te d  th e  n e e d  
fo r  in term itten t w a sh in g  an d  sa m p le  m a n ip u la tio n  step s , su c h  a s are req u ired  in  tra d itio n a l 
im m u n o a ssa y  p la tfo rm s (e .g . E L IS A ).
F in a lly , a s  a  c lo s in g  c a v e a t, it  is  im p ortan t to  e m p h a s ise  th a t th e  m e th o d  d e sc r ib e d  h ere in , 
a lth o u g h  referred  to  as a  ‘r e a l- t im e ’ d e te c t io n  sy s te m , d o e s  n o t  purport to  o b v ia te  th e  n e e d  fo r  
a  p er io d  o f  en r ich m en t in cu b a tio n . O n  th e  con trary , it  is  f e l t  th at th e  n atu ra l fo l lo w -o n  to  th is  
w o rk  sh o u ld  fo c u s  o n  d e v e lo p in g  an  en r ic h m e n t p r o to c o l th a t w o u ld  o p t im is e  L. 
m o n o cy to g en es  s e le c t iv ity , In lA  e x p r e s s io n  and  c u lt iv a tio n  t im e , a s  a  lo g ic a l  c o m p le m e n t  to  
th e  S P R -b a sed  d e te c t io n  m e th o d . T h e  m a in  v ir tu es  o f  th e  sy s te m  o u tlin e d  a r ise  fro m  th e  
c u lm in a tio n  o f  th e  s p e c if ic ity  a ffo rd ed  b y  th e  m o n o c lo n a l a n tib o d y  an d  th e  rap id , o n e -s te p ,  
la b e l-fr e e , ‘sa m p le -to -r e su lt’ c o n firm a tio n , m a d e  p o s s ib le  u s in g  S P R  te c h n o lo g y .
F in a lly , it  i s  c o n c lu d e d  th a t th e  m o s t  l ik e ly  w a y  to  a c h ie v e  th e  r e q u is ite  s e n s it iv ity  an d  rap id  
sa m p le  a n a ly s is  w ith  r e sp e c t  to  L. m o n o cy to g en es  d e te c t io n , w i l l  b e  a  c u m u la tiv e  ap p roach  
u s in g  c la s s ic  m ic r o b io lo g ic a l, im m u n o lo g ic a l an d  b io se n so r -b a se d  te c h n iq u e s .
In term s o f  fu tu re  w o rk  a r is in g  fro m  th is  b o d y  o f  resea rch , a s s o c ia te  resea rch ers  h a v e  a lrea d y  
b eg u n  a ttem p ts to  g e n e t ic a lly  m o d ify  th e  a n ti-In lB  a n tib o d y  for  im p r o v e d  c e l l  b in d in g  a b ility . 
In  a d d it io n , n o v e l  la b e llin g  te c h n iq u e s  are b e in g  in v e s tig a te d , w ith  r e sp e c t  to  th e  a n ti-In lA  
an tib o d y , in  ord er  to  fa c ilita te  a  m o re  s e n s it iv e  E L IS A - and  f lu o r e sc e n c e -b a s e d  d e te c t io n  
form ats.
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